Epidemiology — Aging

Correlation of Serum Folate Levels with Glucose Levels in Gestational Diabetes Mellitus (GDM) in Relation to Vitamin B12 Levels

MAY O.O. KHIN, SIMON GATES, PONNUSAMY SARAVANAN, Coventry, United Kingdom

In non-pregnant type 2 diabetes, high serum folate levels have adverse effects on metabolic markers in vitamin B12 deficient setting, whereas folic acid supplementation can improve glycaemic control in some patients. This study aims to examine the association between serum folate levels and plasma glucose levels in normal and insufficient B12 (<150pmol/l) GDM. This retrospective study included GDM identified between 2009-2012 in a district general hospital, UK. All GDM received folic acid (40ug/day) as routine antenatal care. Serum folate, B12 and homocysteine were measured at 24-28 weeks and compared with glucose levels at diagnostic and postpartum OGTT.

Total of 188 pregnancy included, 60 GDM(31.9%) were B12 deficient and 31 GDM (17%) had high folate levels (>75ug/l). In both normal and B12 deficient GDM, plasma homocysteine had significant negative correlation with folate (r=-0.38 vs. -0.44), and not B12 levels. There was a significant inverse association between serum folate and fasting glucose levels at both diagnostic and postpartum OGTT. The association was significant in normal B12 GDM and not B12 deficiency, and was independent of age, BMI and parity. Our findings suggest that the effects of serum folate levels on fasting glucose levels may differ by vitamin B12 status and highlight the importance of normal vitamin B12 levels for folate to act on glycaemic levels.

Table. Pearson’s Correlation-Plasma Glucose Correlates with Serum Folate Levels.

<table>
<thead>
<tr>
<th></th>
<th>All GDM</th>
<th>Normal B12 GDM</th>
<th>B12 insufficient GDM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mid-pregnancy</td>
<td>Postpartum</td>
<td>mid-pregnancy</td>
</tr>
<tr>
<td>Fasting</td>
<td>-0.17(0.05)</td>
<td>-0.26(0.05)</td>
<td>-0.18(0.05)</td>
</tr>
<tr>
<td>2h postpartum</td>
<td>-0.14(0.05)</td>
<td>-0.19(0.05)</td>
<td>-0.18(0.05)</td>
</tr>
<tr>
<td>BMI</td>
<td>-0.22(0.01)</td>
<td>-0.23(0.01)</td>
<td>-0.03(NS)</td>
</tr>
<tr>
<td>Multiple regression for fasting glucose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All GDM</td>
<td>Normal B12 GDM</td>
<td>B12 insufficient GDM</td>
</tr>
<tr>
<td>Fasting</td>
<td>-0.04(0.05)</td>
<td>-0.04(0.05)</td>
<td>-0.04(0.05)</td>
</tr>
<tr>
<td>Adjusted R2</td>
<td>0.002(0.55)</td>
<td>0.05(0.55)</td>
<td>0.04(0.55)</td>
</tr>
<tr>
<td>NS=Not Significant.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sedentary Behavior Is Associated with Improved Cytokine Profile but Not with Glucose or Lipid Metabolism in Obese Pregnant Women

MIREILLE VAN POPPEL, MINAKSHI NAYAK, AKOS HEINEMMANN, MIRIAM PEINHAUPT, GERHOT DESOYE, Graz, Austria, Amsterdam, Netherlands

Sedentary behavior is an independent risk factor for the metabolic syndrome, but the role of sedentary behavior in the development of gestational diabetes is unclear. This longitudinal cohort study tested the hypothesis that less sedentary behavior is related to better insulin sensitivity, lipid and cytokine profile in obese pregnant women. Among 46 overweight and obese pregnant women, fasting blood was taken at 15, 24 and 32 weeks of gestation, and a 100 g oral glucose tolerance test was performed at 24 and 32 weeks. Fasting levels of glucose, insulin, total cholesterol, HDL, LDL, triglycerides were measured, as well as cytokines. Insulin sensitivity, first and second phase insulin response were calculated. Sedentary behavior was measured objectively using accelerometers. The relationship between sedentary behavior and metabolic outcomes were assessed using linear regression analysis. Women spent about 60% of their time sitting throughout pregnancy. In cross sectional analyses, an association of sedentary time at 15 and 24 weeks with increased total cholesterol and HDL was found. Changes in sedentary time were not associated with glucose metabolic or other lipid outcomes, but increased sedentary time was associated with lower CRP and leptin levels, and with higher adiponectin levels at 32 weeks of pregnancy. In conclusion, no consistent longitudinal relationship between sedentary habits of obese and overweight pregnant women with glucose or lipid metabolism was found. Increases in time spent sedentary in pregnancy were associated with improved cytokine profile. Whether increasing sedentary time is indeed beneficial for metabolism of overweight and obese pregnant women needs to be assessed in further studies.

Incidence of Mobility Loss and Subsequent Recovery by Diabetes Status, 1998-2010

BARIARA BARDENEHIER, JI LIN, XIACHUI ZHUO, MOHAMMED K. AU, TED THOMPSON, EDWARD W. GREGG, Atlanta, GA, North Wales, PA

Few studies have quantified the incidence of mobility loss or subsequent recovery associated with diabetes. We used generalized estimating equations to analyze prospective data from the Health and Retirement Study, a U.S. population-based sample of 11,141 adults aged ≥50 years with biennial visits from 1998 through 2010. Compared to non-diabetic persons, incidence of mobility loss was 75% higher (p<0.05) for diabetic men (226.4 vs. 138.8 per 1,000 PY) and 83% for diabetic women (34.6 vs. 18.9 per 1,000 PY). (Figure 1) Recovery from incident mobility loss was lower for those with diabetes than without, but was similar by sex (226.4 for non-diabetic women, 244.5 for non-diabetic men, 220.0 for diabetic women, 210.8 for diabetic men per 1,000 PY). (Figure 2) Incident mobility loss was higher among diabetic women than men, with little difference in recovery.

For author disclosure information, see page A810.
Changes in Hemoglobin A1c and Mortality Risk in Elderly People with Diabetes in the United States

M ED A E. PAVKOV, BARBARA BARDENHEIER, LINDA S. GEISS, Atlanta, GA

The association between hemoglobin A1c (A1c) change and mortality was assessed among persons with diabetes in the Health and Retirement Survey (HRS), a population-based survey of persons ≥50 years old. Two sequential A1c measurements were used to define pre-baseline change in A1c. The initial A1c was measured in 2003; a randomly selected half of this cohort had a second A1c measurement in 2006 and the remaining half in 2008. The period at risk started at the second A1c measurement (baseline) and ended at the date of death or final interview in 2012. Association between pre-baseline A1c change and mortality was explored by Cox regression models adjusted for sex, race/ethnicity, and baseline age, blood pressure, cystatin C, and self-reported comorbidities. Inverse probability weighting was used to reduce bias related to missing data. Results are weighted to represent the U.S. population aged ≥50 years with diabetes during 2006-2008. The study included 768 adults with diabetes (51% males) and pre-baseline A1c measurements (352 with A1c remaining <7%, 263 with A1c increasing to or remaining ≥7%, and 153 with A1c declining to <7%). During a median follow-up of 4.3 years (range 0.3 to 6.9 years) 187 participants died. At baseline, median age was 69.7 years (interquartile range [IQR] 62.7-77.5), median blood pressure 94.7 mmHg [IQR 86.0-103.2)], and median cystatin C 1.1 mg/L [IQR 0.9-1.5]. 88.1% were non-Hispanic white, 10.8% non-Hispanic black, and 1.1% Hispanic/other. Compared with participants with pre-baseline A1c remaining <7%, the adjusted hazard ratio for death was 1.5 (95% CI 1.03-2.3) in those whose A1c increased to or remained ≥7% and 1.4 (95% CI 0.9-2.2) in participants with declining A1c. In conclusion, in this cohort representative of the elderly population with diabetes, persistently high or worsening A1c increased the risk of death. A declining A1c was not associated with reduced mortality, possibly reflecting the high prevalence of comorbidities in this population.

Proximal Predictors of Discontinuance with Oral Antidiabetic Agents among the Elderly

BRUCE C. STUART, NICOLE BRANDT, CHARLEN E QUINN, XIAN SHEN, PAMELA ROBERTO, ELLEN LOH, SWAPNIL RAJPATHAK, XINGHUA HUANG, BRUCE C. STUART, NICOLE BRANDT, CHARLENE QUINN, XIAN SHEN, PAMELA ROBERTO, ELLEN LOH, SWAPNIL RAJPATHAK, XINGHUA HUANG, North Wales, PA

Persistence in oral antidiabetic (OAD) therapy is an ongoing clinical concern in treating type 2 diabetes (T2D). Empirical studies of OAD persistence are dominated by small-scale analyses that focus on static rather than dynamic differences between discontinuers and persistent users. Lacking evidence of time-varying prognostic factors for drug discontinuance, clinicians may miss important intervention opportunities. We assessed predictors of OAD discontinuance in a nationally representative 5% sample of Medicare beneficiaries with T2D enrolled in fee-for-service Part D drug plans (2006 - 2008) with discontinuers defined as OAD use in a 12 month baseline period followed by a minimum of 12 months of non-OAD use. Discontinuers (N=7,435) were compared to persistent OAD users (N=65,602) on a series of variables hypothesized to influence discontinuance including static variables (demographics, income, disability, comorbidity burden) and monthly observations for time-varying factors (OAD count, insulin, hospital/SNF admissions, ED visits, Medicare spending, discontinuance with ACEs/ARBs and statins, unique physicians seen, hypoglycemia, uncontrolled diabetes, first use and gaps in OAD therapy). We estimated linear probability models using stepwise regression to identify timing and strength of association to OAD discontinuance. Long-term OHA discontinuation was rare (10%). Static factors explained 1.2% of the variance in probability of discontinuance. Adding dynamic factors increased explained variance to 26% of which 20% was due to co-occurring factors in the OAD discontinuation month (multiple OADs, ACEI/ARB/statin discontinuation, insulin use, and unique physicians seen) and 4% was due to prognostic factors occurring in the second and third month prior to discontinuation (hypoglycemia, hospital discharge, OAD usage gap). In conclusion, dynamic factors proximal to OAD discontinuance were far stronger predictors of non-persistence than traditional static measures. Supported By: American Diabetes Association (7-13-CD-08 to A.Q.)
Epidemiology/Interventions

1477-P
An Out-of-Range (OOR) Glycemic Population Health Safety Measure

LEONARD POGACH, MIIRIAM MANEY, OXYSA YOROKA, CHU-LI NTENG, DAVID C. ARON, East Orange, NJ, Cleveland, OH

The ADA recommends a target A1c of 7.5%-8.0% or slightly higher in persons with decreased life expectancy or at risk for serious high glycemia. Our objective was to evaluate an OOR measure that assessed both over treatment (OT) [A1c<7%] or other cut points: <5.0%, <5.5% and undertreatment (UT) [A1c>9%]; cut points: 9.1-5.5%, >5.5% among high risk, largely elderly patients. This was a cross-sectional study of Veterans Health Administration patients in 2013. The study population was those that received insulin (I) or sulfonylurea (SU) and were considered at high risk for hypoglycemia (being 75 years or older, or with a serum creatinine ≥2.0 mg/dL, or having a diagnosis of cognitive impairment or dementia). The national average and facility specific performance for OOR, OT and UT was determined using the last A1c in 2013.

We identified 435,078 patients on I/SU, of whom 133,362 (30.6%) met the inclusion criteria at 130 facilities (average number of patients: 1,017; range 126 - 3,587). The mean age was 75.5 years. The A1c was OOR in 45.2% of patients: OT in 31% of patients (6% with A1c <6.0%, 16% with <6.5%), UT in 14.2% (4.7% with A1c >9.0-9.5%; 9.5% with >9.5%). Only 27.6% were in the range recommended by ADA (A1c 7.5-8.4%). The OOR measure ranged from 37.6% in the best performing decile (of the 130 facilities) to 53.5% in the worst performing decile. The ranges for OT and UT alone in best and worst performing deciles were 23.4%-41.2% and 9.7%-20.4%, respectively. Facility rankings for OT or UT were poorly correlated (Spearman’s rho = 0.44).

We conclude that nearly half of our study population of elderly or ill patients, most of whom would not be included in current HEDIS measures, were OT or UT, and therefore at risk for short term harms. There was significant facility level variation, and even the best performers had more than a third of high risk patients with OOR A1c. We propose that a single measure can be used to simultaneously address multiple ranges of glycemic control in a vulnerable population to improve monitoring of patient health safety.

Supported By: U.S. Department of Veterans Affairs (RPP12-492)

Clinical Inertia Affects Younger and Older Adults with T2DM Equally, With or Without CKD

W. DAVID STRAIN, PÄIVI M. PALDÁNIUS, Exeter United Kingdom, Basel, Switzerland

Clinical inertia (CI) is a multifactorial phenomenon with contributory factors from people with diabetes (PwD), their physicians, and the system in which they operate. The Time2DoMore program suggested that physicians believe older PwD and those with chronic kidney disease (CKD) are more susceptible to CI than younger patients with few comorbidities, resulting in lower expectations of adherence to lifestyle changes in older PwD. CI has less impact in clinical trials, presumably due to the placebo effect. The difference between routine care and this placebo effect in trials represents a correction of non-pharmacological aspects of CI. We used this method to demonstrate pre-existing CI in older cohorts, those with CKD, and older patients with CKD compared to a younger, non-CKD population.

Placebo-treated subjects (n=3081) from the vidaliglptin clinical trial program, comprising 25 studies, were stratified in a factorial design by age (<70 or >70 years) and with or without CKD (eGFR <60 mL/min). HbA1c change was assessed at 24 weeks (ANCODVA). Baseline HbA1c was similar across the groups (table). The placebo effect was comparable between groups in the base-case, and after adjustment for baseline HbA1c values.

We are able to demonstrate a consistent placebo effect across age groups and presence or absence of CKD, suggesting that the non-pharmacological component of CI in PwD may be independent of age and comorbidities.

**Table.**

<table>
<thead>
<tr>
<th></th>
<th>Younger, non-CKD</th>
<th>Younger with CKD</th>
<th>Older, non-CKD</th>
<th>Older with CKD</th>
</tr>
</thead>
<tbody>
<tr>
<td>m=278</td>
<td>m=304</td>
<td>m=338</td>
<td>m=263</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>54.4</td>
<td>60.6</td>
<td>73.3</td>
<td>74.7</td>
</tr>
<tr>
<td>Baseline HbA1c (%)</td>
<td>8.16</td>
<td>7.85</td>
<td>7.95</td>
<td>8.16</td>
</tr>
<tr>
<td>Placebo effect (%)</td>
<td>-0.27</td>
<td>-0.20</td>
<td>-0.25</td>
<td>-0.23</td>
</tr>
<tr>
<td>After adjustment for baseline HbA1c</td>
<td>-0.27</td>
<td>-0.20</td>
<td>-0.25</td>
<td>-0.23</td>
</tr>
</tbody>
</table>

Values are expressed as mean. All comparisons (ANCODVA) between groups: p>non-significant.

Supported By: Novartis

For author disclosure information, see page A810.

1478-P
Anti-Müllerian Hormone (AMH) Concentrations and Time to Menopause in Women with Type 1 Diabetes in the Epidemiology of Diabetes Interventions and Complications (EDIC) Study

CATHERINE KIM, RODNEY L. DUNN, BARBARA H. BRAFFETT, PATRICIA CLEARY, VALERIE ARENDS, MICHAEL W. STEFFES, MICHAEL LANHAM, JOHN F. RANDLE, HUNTER WESSELLS, ARUNA SARMA, DCT/EDIC RESEARCH GROUP, Ann Arbor, MI, Bethesda, MD, Rockville, MD, Minneapolis, MN, Seattle, WA

AMH is a measure of ovarian functioning and predicts response to assisted reproductive technologies as well as age at the final menstrual period (FMP). Cross-sectional studies suggest that insulin resistance may affect AMH levels. Relationships between AMH with age at FMP and insulin dose have not been examined among women with type 1 diabetes, who have ovulatory disorders more often than women without diabetes.

In EDIC, 202 women experienced natural menopause at the mean age of 50 (SD 4.3) years. In a random subsample of 50 women who underwent AMH sampling every 2 years prior to the FMP, logAMH declined linearly prior to the FMP. Therefore, in the remaining women, we performed only 2 AMH measurements prior to the FMP in order to yield values >0 and to represent a range of years prior to the FMP (mean of 10 and 6 years prior to the FMP). AMH coefficients of variation were 5.0% at 3.6 ng/mL and 1.7% at 8.5 ng/mL, and the lower limit of detection was 0.16 ng/mL.

AMH concentrations became undetectable ~1.0 year before the FMP (slope -0.26±0.01, p<0.001). In regression models, younger age at EDIC baseline (p=0.04) and lower insulin dose (per 0.5 units/kg/day) were associated with higher AMH (p=0.008), while randomization arm (p=0.8), body mass index (p=0.6), and HbA1c averaged over EDIC and the preceding Diabetes Control and Complications Trial (p=0.8) were not. Insulin dosing was not associated with more rapid declines in AMH (p=0.8).

These preliminary analyses suggest that AMH can be used to predict age at menopause among women with type 1 diabetes; higher insulin doses may be associated with lower AMH initially but AMH declines; and AMH was not associated with HbA1c over a narrow range. Additional investigation is needed to determine if these associations persist in adjusted models and if AMH predicts additional reproductive outcomes.

Supported By: U01DK094176, U01DK094157, DPDK098129

1480-P
Diabetes in the Baltimore Male Hip Fracture Patients Study

CHARLENE C. QUINN, MARC HOCBERG, DENISE ORWIG, ANN GRUBER-BALDINI, JAY MAGAZINER, Baltimore, MD

The link between type 2 diabetes (T2D), osteoporosis and fractures in older adults is not well understood. Twenty-five percent of U.S. hip fracture patients have diabetes. A prospective cohort study, frequency matched by sex, was conducted to determine whether sex differences exist across multiple outcomes after hip fracture among those 65 and older. The purpose of this secondary analysis was to compare characteristics of patients (n=338) with (n=27) and without (n=311) physician-diagnosed T2D at the time of fracture. In the primary study, participants were enrolled from 8 Baltimore hospitals and assessments done within 15 days of admission and at 2, 6, and 12 months post-assessment. Assessments included body composition measurements of bone mineral density (BMD), lean and fat mass, blood draw, and questionnaires. Data for this analysis came from inpatient medical charts and baseline measures. Participants were equal proportion males (49.4%) and females (50.6%), old (mean 80.9 years), mostly white (91.4%), educated (mean 13.1 years). Participants with T2D had higher BMI (26.6 vs. 24.7 kg/m2; p=0.057), lower self-reported Yale Physical Activity (275 vs. 3357 kcaL p=0.013), and more IADL impairments (2.30 vs. 1.97 p=0.062) than those without T2D. Participants with T2D also had significantly higher whole body BMD (0.80 vs. 0.75 g/cm2 p=0.028), total body fat (25.1 vs. 21.5 kg p=0.015) and total body mass (74.0 vs. 66.7 kg p=0.008). No significant differences were observed in history of osteoporosis and previous fracture, depression, and upper and lower extremity ADLs. In conclusion, participants with diabetes and hip fractures were different from typical older hip fracture patients but consistent with the general population with T2D.

Supported By: U01DK094176, U01DK094157, DPDK098129

Guided Audio Tour poster   ADA-Funded Research
Cognitive Dysfunction and Hypoglycemia in Older Adults with Type 1 Diabetes: Results from the T1D Exchange

MEDHA MUNSHI, TONYA D. RIDDLEWICK, NAOMI S. CHAYTOR, RICHARD E. PRATLEY, BRANDON ROBISON, JOHN B. BUSE, KELLEE M. MILLER, STEPHANIE N. DUBOSE, ROY W. BECK, Boston, MA, Tampa, FL, Seattle, WA, Orlando, FL, Idaho Falls, ID, Chapel Hill, NC

In this study, we aimed to evaluate the frequency of cognitive dysfunction among older adults with type 1 diabetes (T1D) and the factors associated with cognitive dysfunction.

This analysis includes 200 subjects between the ages of 60 and 86 years participating in a study of severe hypoglycemia in older adults with T1D (median age 68 years, median T1D duration 39 years, 47% female, 92% non-Hispanic white). Cognitive assessments included the Montreal Cognitive Assessment (MoCA) and the Trail Making Test part B (TMTB). Participants were given a blinded continuous glucose monitoring (CGM) sensor for 14 days. Spearman correlations were used to assess the association of hypoglycemia measures with cognitive scores.

Median (quartiles) MoCA score was 26 (24, 28) with 87 (44%) having a MoCA score ≥25. Median TMTB time was 95 (71, 120) seconds with 70 (36%) having a z-score<1.5. There was a weak, but statistically significant, association of poor MoCA and TMTB scores with increased hypoglycemia awareness (partial r=0.19 and 0.21, respectively). Neither MoCA nor TMTB were associated with fear of hypoglycemia, % CV values <$0 mg/dl or glycemic variation (Table). Cognitive dysfunction is highly prevalent in older adults with T1D and is associated with cognitive hypoglycemia awareness. Subsequent to a cognitive dysfunction should be tested for risk of unrecognized hypoglycemia in this population.

**Table.**

- **Hypoglycemia Unawareness**
  - Median (quartiles)
  - 34 (31, 35)
  - 0.75
  - 30.3
  - 43
  - 0.03

- **GDM %**
  - Median (quartiles)
  - 0.05 (0.05, 0.05)
  - 0.05
  - 0.06
  - 0.07
  - 0.07

- **CGM Coefficient of Variation (SD)**
  - Median (quartiles)
  - 0.31 (0.30, 0.31)
  - 0.30
  - 0.32
  - 0.30
  - 0.49

**Adjusted for Diabetes Duration, Education, Depression, Frailty.**

EVIDENCE OF A COMMON VARIANT IN CDCC71L-PKICS3 FOR SENSIBLE GLUCORECEPTOR FOR ACIDIFIED GLYCERYL END-PRODUCTS

PING AN, ALDI T. KRAJA, MARY K. WUJZYCKI, BHARAT THYAGARAJAN, JOSÉPH H. LEE,IVA MILJKOVIC, FANGSI SUN, E. WARWICK DAW, KAARE CHRISTENSEN, RICHARD MAYEUX, THOMAS T. PERLS, ANNE B. NEWMAN, MICHAEL PING AN, ALDI T. KRAJA, MARY K. WOJCZYNSKI, BHARAT THYAGARAJAN, JOSEPHINE MA ID, MITA K. WOJCZYNSKI, BHARAT THYAGARAJAN.

Purpose: Diabetes is known to be a risk factor for Alzheimer’s disease (AD). Voxel-based regional specific analysis system for Alzheimer’s disease (VSRAD) is the software of automatic image processing which enables statistical analysis of the degree of parahippocampal cortex atrophy and is widely used for early diagnosis of AD in Japan. Our previous study using VSRAD, presented at 7th ADA, has suggested that both hypoglycemia and hypoglycemia were related with the development of early AD in patients with diabetes. The purpose of this study is to assess the treatment related with the development of early AD.

Subjects and Methods: We studied 121 out-patients with type 2 diabetes over 60 years old (Age 71.1±8.9 years, male 58/female 63, HbA1c 6.9±1.0 %) before and after 5 years of oral diabetic treatment. We studied medication period of individual diabetic treatment during 60 months.

Results: 81 patients were treated with sulfonylurea (SU), 11 with non SU secretagogues, 27 with α-glucoside inhibitor (GLI), 45 with pioglitazone, 38 with metformin, 52 with dipeptidyl peptidase-4 inhibitor (DPP-4), 24 with glucagon like peptide (GLP-1) receptor agonist (RA), and 60 patients with insulin. The degree of atrophy advanced from 1.59±1.22 to 1.79±1.29 during 5-year study period. Compared with patients with little atrophy, 32 patients with more than 0.2 advanced degree showed significantly shorter period of treatment with GLP-1 RA (16.5±10.7 vs. 22.7±4.1 months, p=0.042). No significant difference was seen between the two groups with SU (62.8±3.6 vs. 57.7±4.3), non SU secretagogues (49.4±6.5 vs. 48.0±7.3), ex-GL (39.8±12.3 vs. 42.8±16.4), pioglitazone (38.5±14.7 vs. 57.8±24.0), metformin (52.9±16.6 vs. 45.3±20.6), DPP-4 inhibitor (21.65±9.5 vs. 23.7±4.3), and insulin (49.1±13.5 vs. 49.0±17.1 months).

Conclusion: Treatment with GLP-1 RA was suggested to be useful for prevention of the development of early AD in patients with type 2 diabetes.
Epidemiology—Cardiovascular Disease

1485-P

Glycemic Control in Skilled Nursing Facilities
RUSHAD PATEL, DENIS NIGMATULLINE, JAMES BENA, DO GYUN KIM, BARBARA MESSINGER-RAPPORT, M. CECILIA LANSANG, Cleveland, OH

Use of hypoglycemic agents for DM in elderly in skilled nursing facilities (SNF) has led to concerns about hypoglycemia, which might hamper efforts at controlling hyperglycemia. We studied frequency of hypo- and hyperglycemia and associated factors in SNFs. We reviewed charts from 2 SNFs. Events were defined as: hypoglycemia BG <70mg/dL, severe hypoglycemia 200mg/dL, and severe hyperglycemia >400mg/dL. Event-days were calculated. There were 203 subjects, mean age, big and A1cSD: 80.2±6.8y, 172.4±40.3mg/dL and 7.4±1.6. 61% were on insulin alone(0%), 67 on insulin + oral hypoglycemic agents (IOHA), the rest on OHA alone (OHA). Percentages of patients with at least one event are: 36.9% hypoglycemia, 3.4% severe hypoglycemia, 85.2% hyperglycemia, 14.8% severe hyperglycemia. Event-days are: 3.7% hyperglycemia, 0.1% severe hypoglycemia, 52.4% hyperglycemia, 1.16% severe hyperglycemia. Relative risks of hypo- and hyperglycemia based on medication are in Table 1.

Hypoglycemia rates were similar for I vs. IOHA vs. OHA. Among patients on insulin, there was greater risk of hypo- and hyperglycemia for basal+prandial+sliding scale compared to sliding scale alone; A1c 7.7 vs. 6.9% (p=0.059). Among patients on SU, risk of hypoglycemia was higher only if with insulin as well. Overall rates of severe hyperglycemia are low; hyperglycemia rates are high. The association of basal insulin with hypo- and hyperglycemia merits further investigation.

Table.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Relative Risk Hypoglycemia (95% CI)</th>
<th>Relative Risk Hyperglycemia (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin Use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Insulin Users</td>
<td>1.62(0.97,2.72)</td>
<td>1.57(1.38,1.79)</td>
</tr>
<tr>
<td>2. Insulin + Oral agents</td>
<td>1.47(0.82,2.63)</td>
<td>1.40(1.21,1.59)</td>
</tr>
<tr>
<td>3. Oral agents only</td>
<td>1.00(REF)</td>
<td>1.00(REF)</td>
</tr>
<tr>
<td>Insulin Type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Basal + prandial + sliding scale</td>
<td>1.65(1.14,2.37)</td>
<td>1.91(1.21,2.94)</td>
</tr>
<tr>
<td>2. Sliding scale only</td>
<td>1.00(REF)</td>
<td>1.00(REF)</td>
</tr>
<tr>
<td>Sulfonylurea (SU) use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SU with Insulin</td>
<td>2.05(1.44,2.91)</td>
<td>1.02(0.92,1.14)</td>
</tr>
<tr>
<td>SU without Insulin</td>
<td>1.32(0.72,2.31)</td>
<td>0.84(0.40,1.73)</td>
</tr>
<tr>
<td>Oral agents alone other than SU</td>
<td>1.00(REF)</td>
<td>1.00(REF)</td>
</tr>
</tbody>
</table>

1486-P

A Survey about Management Status of Type 2 Diabetes Mellitus in Elderly Diabetic Patients of China
CHEN PING, SUN LIN, TIAN HAOQI, LI PENGQI, JI MAOQI, HUANG BIN, ZHONG XIAOWEI, Chengdu, China

This study was aimed to investigate the management status of type 2 diabetes mellitus (T2DM) and diabetic complications in elderly diabetic patients of China, the characteristics of patients who achieved (or did not achieve) target treatment goals were also determined.

We conducted a multicenter survey, and collected data from elderly type 2 diabetes patients (60 years or older). Control criteria were defined based on the International Diabetes Federation 2013 Global Guideline for type 2 diabetes.

A sample of 2615 patients (male 1317, female 1298), age (60±8.2) years, and with a median disease duration of 7.3 years was included. All patients included were functionally independent. Clinical measures Target goals for hemoglobin A1c (HbA1c), blood pressure (BP), and low-density lipoprotein (LDL-c) were based on the latest IDF Guideline, including HbA1c < 7.5%, BP < 140/90mmHg and LDL-c<2.0 mmol/L. ABC goal referred to achievement of treatment targets for HbA1c, BP and LDL-c at the same time. The mean HbA1c, systolic BP, diastolic BP and LDL-c were 8.4%, 131.4mmHg, 76 mmHg, and 2.6mmol/L respectively. 36.7% patients achieved HbA1c target goal, 68.2% achieved BP target goal, 25.7% achieved LDL target goal and only 6.8% achieved ABC goal. In order to find independent risk factors associated with attainment of ABC goals, Logistic regression analysis was used in variables such as gender, age, history of diabetes and BMI. But all these variables were not associated with attainment of ABC goals significantly. In all patients, 31.3% of which had hypertension, 74.3% had dyslipidemia, 14.5% had coronary heart disease, 6.7% had cerebrovascular disease, 15.2% had diabetic retinopathy, 13.2% had nephropathy, 26.1% had diabetic peripheral neuropathy, and 2% had diabetic foot.

In conclusion, we used the latest standards and firstly examined the management status of T2DM in China’s elderly. The gap between guideline and current status reality in diabetic treatment in china was demonstrated to some extent.
Further adjustment for sex and co-morbidities did not attenuate this ratio. The ratio/death in T2D vs. non-diabetic subjects was 2.36 (2.09-2.66) (P<0.001).

Kingdom (BMI 30-34.9 vs. BMI >35kg/m2) also showed no significant difference in [95% CI]: 1.06 [0.86, 1.29], p=0.6). A subgroup analysis of obese patients in the hazard of CV events among insulin users (adjusted hazard ratio, aHR DPP-IV inhibitor vs. insulin respectively (39 vs. 42 events per 100 person-years) (P=0.28). Overall, the number of CV events was 171 vs. 231 for patients who added DPP-IV inhibitor vs. insulin respectively (39 vs. 42 events per 100 person-years).

Obesity and Cardiovascular Risk: Effects of Dual Therapy Intensification with a DPP-4 Inhibitor Compared with Insulin

ISKANDAR IDRIS, JIL MAMZA, RAJ MEHTA, RICHARD DONNELLY, Derby, United Kingdom

Large observational studies have raised concerns about the CV safety of insulin therapy in type 2 diabetes (T2DM) after monotherapy with metformin (MET) has failed to maintain glycaemic control. We therefore analysed the time to non-fatal acute myocardial infarction, non-fatal stroke or all-cause mortality in patients with T2DM who had their treatment intensified with a DPP-IV inhibitor or insulin following dual therapy failure with MET and SU. A retrospective cohort study was conducted in 8,554 patients who were newly treated with a DPP-IV inhibitor or insulin following dual therapy failure with MET and SU. The risk of the composite outcome (CV events) was compared between 2 treatment groups: MET+SU-DPP-IV inhibitor (reference group, n=3,654) and MET+SU+ insulin (n=1,584). Follow-up was 5 yrs (total of 988 person-yrs), and propensity score matching analysis and Cox proportional hazard models were employed.

Overall, the number of CV events was 171 vs. 231 for patients who added DPP-IV inhibitor vs. insulin respectively (39 vs. 42 events per 100 person-years). Compared to the reference group, there was no significant difference in the hazard of CV events among insulin users (adjusted hazard ratio, aHR [95% CI]): 1.06 [0.86, 1.29], p=0.6). A subgroup analysis of obese patients (BMI 30-34.9 vs. BMI ≥35kg/m2) also showed no significant difference in the incidence of CV events between the reference group and insulin [42 vs. 39 events per 100 person-yrs]. Therefore, in this large cohort study tracking outcomes in routine clinical practice, intensification of dual oral therapy by adding insulin is not associated with a higher or lower risk of CV events compared with adding a DPP-IV as the third oral agent.

1 Rounie CL et al. JAMA 2014;311:2288-2296.

Independent Predictors of Cardiovascular Disease (CVD) Events Identified in a Cohort of Type 2 Diabetes (T2D) Patients in China

XIAXIUNG CAI, DAHY HU, CHANGYU PAN, JIANPING WENG, GUIH EJI, SENLI SU, JUMING LU, HAIMING TIAN, GUANGWEI LI, DAJIN ZOU, DANNY ZHANG, HANJUNG ZHUO, LINONG JI, BEIJING, China, Guangzhou, China, X’an, China, Dalian, China, Chengdu, China, Shanghai, China, Berwyn, PA

The aim of this study is to determine the incidence of CVD complications in a large Chinese T2D cohort with high risk of CV disease.

This was a multi-center, prospective and longitudinal cohort study. Patients with high risk of CVD were enrolled and followed up for 3 years at every 6-month interval. The inclusion criteria were: 1) ≥40 years old; 2) T2D diagnosis ≥6 months; 3) with confirmed hypertension and dyslipidemia, and one or more other CVD risks (overweight, microalbuminuria/proteinuria, previous CAD or stroke history, and ≥65 years old). The primary endpoint was the composite of CVD events (defined as the first occurrence of acute myocardial infarction, stroke or death from cardiovascular causes). All statistical analyses were done using SAS 9.4.

In year 2011 to 2014, 4,722 patients from 68 hospitals were recruited and followed up. 45.2% were male and the mean age was 65.9 years old. The median duration of diabetes was 7.2 years. The 1-year, 2-year, and 3-year cumulative incidence rates of the composite of CVD events were 2.6%, 3.9%, and 6.2%, respectively. Multivariate Cox models showed that age ≥65 yrs (Hazard Ratio [HR]=2.19; 95% confidence interval [CI]: 1.54-3.12; P<0.001) and prior CVD history (HR=1.65; 95% CI: 1.25-2.19; P<0.001) were associated with the higher risk of the composite CVD events; while the adequate control of HbA1c≥7.0% (HR=0.68 [95% CI: 0.52-0.90]; p<0.001) and blood pressure <140/90 mmHg (HR=0.57; 95% CI: 0.43-0.75; P<0.001) were associated with lower risk of the composite CVD events. Adequate control of LDL-c<2.6% was not significantly associated with the outcome.

This was the first report on CVD outcome of T2D patients from prospective cohort study in Chinese individuals with T2D in China. Age and presence of CVD history were independent predictors of CVD complications; while adequate glycemic control and blood pressure control were associated with lower risks of CVD complications.

Supported By: National Library of Medicine; National Key Program of Clinical Science of China; Peking Union Medical College Hospital

Predictors and Outcome of Heart Failure Complicating Type 2 Diabetes: The Fremantle Diabetes Study

TIMOTHY DAVIS, WENDY A. DAVIS, Fremantle, Australia

There have been no detailed contemporary population-based studies of heart failure (HF) complicating type 2 diabetes (T2D). To investigate predictors/outcome of hospitalization or death from HF in T2D, we analyzed prospective data from the community-based longitudinal observational Fremantle Diabetes Study Phase I (FDS1) which included 1,296 representative T2D subjects recruited from 1983 to 1996. This cohort and FDS1 age, gender, and postcode-matched non-diabetic residents were followed, through validated data linkage, from recruitment to death or census at end-June 2012. At baseline, FDS1 patients had a mean±SD age of 64.0±11.3 yrs, 49% were female, and their median diabetes duration was 4.0 yrs. Of 1,185 patients without prior hospitalization for HF at entry, 373 (31.8%) were hospitalized/died of HF during 14,338 patient-years (12.1±6.2 yrs) of follow-up. In Cox proportional hazards modelling, independent predictors of HF hospitalization/death comprised sedentary lifestyle, central obesity, lower systolic blood pressure, higher serum triglycerides and urinary albumin/creatinine ratio, eGFR ≥90 ml/min, known ischemic heart disease, retinopathy and schizophrenia (P=0.046). The age-adjusted hazard ratio (95% CI) for HF hospitalization/death in T2D vs. non-diabetic subjects was 2.36 (2.09-2.66; P<0.001).

Further adjustment for sex and co-morbidities did not attenuate this ratio.

T2D patients were 4.8 yrs younger vs. non-diabetic controls at first HF event (P<0.001), and these patients were also 4.4 yrs younger at time of death (P<0.001). T2D more than doubles the risk of HF hospitalization/death. Renal hyperfiltration appears a novel risk factor while albuminuria/retinopathy may be surrogates for microangiopathy-related cardiomyopathy. HF complicating T2D presents relatively early and is associated with early death.

Supported By: Raine Foundation; University of Western Australia; Fremantle Hospital Medical Research Foundation

Incidence of Cardiovascular Disease and All-Cause Mortality in Subtypes of Type 2 Diabetes

DORIT VISTIÅ, DENNIS WITTE, ADAM TABÁK, ERIC BRUNNER, MIKA KIVIMÄKI, KRISTINE FERCH, Gentofte, Denmark, Aarhus, Denmark, London, United Kingdom

The oral glucose tolerance test (OGTT) is seldom used for diagnosis of diabetes in clinical practice, but the OGTT may identify asymptomatic patients with a poor prognosis, who would not be diagnosed by the simpler fasting glucose test. We compared the incidence of cardiovascular disease (CVD) events and all-cause mortality in individuals diagnosed with diabetes by fasting glucose only by or OGTT. We analysed data from 7,537 participants in the longitudinal British Whitehall II study (91.3% of White ethnicity). Diabetes diagnosed by OGTT was subdivided into diabetes by fasting glucose only (F-DM, n=86), 2-hour glucose only (2h-DM, n=172) or combined fasting and 2-hour glucose (F-2h-DM, n=107). Median follow-up time was 20.1 years for all-cause mortality and 17.5 years for CVD. In White participants, the 10-year rates of CVD (Figure 1A) and all-cause mortality (Figure 1B) were 2.4-folds higher in F-2h-DM (26.0 and 18.7; P<0.05) than in individuals with F-DM (6.8 and 6.6) or 2h-DM (15.3 and 7.8), but not different in the F-DM and 2h-DM groups compared with the diabetes free population (P=0.05). In non-Whites there were no differences in rates between diabetes groups, but the entire non-White population had a 72% higher rate of CVD than the entire White population. Diagnosis of diabetes based on OGTTs is more effective in predicting premature CVD and death than the use of fasting glucose only, at least in White individuals.
A Decision Tree for Predicting Coronary Artery Disease (CAD) in Type 1 Diabetes (T1D)

RACHEL G. MILLER, STEWART J. ANDERSON, TINA COSTACOU, TREYVOR J. ORCHARD, PITTSBURGH, PA

CAD risk is greatly increased in T1D, but the reasons for this increase are not well understood. Our objective is to use a tree-structured survival analysis (TSSA) to formally assess the presence of subgroups for CAD risk in the Pittsburgh Diabetess Complications (EDC) study of T1D.

ECD study participants diagnosed with T1D from 1986-1988 were included in the current analyses (n=473 free of CAD at baseline, mean T1D duration 15 yrs, age 23 yrs, 50% male) and followed for 25 yrs to ascertain CAD incidence (fatal CAD, MI, revascularization procedure/blockage ≥50%, ischemic ECG [MN codes 1.3, 4.1, 4.3, 5.1, 5.3, 7.1], or EDC physician diagnosed angina). TSSA was used to fit a regression tree for time to CAD event by determining optimal cut-points of baseline covariates to discriminate level of CAD risk.

There were 95 (23%) cases of incident CAD. In those with higher non-HDLc, longer T1D duration additionally improved CAD prediction. A small high-risk subgroup with low non-HDLc and low red cell count was identified. Further exploration of this group showed that they are all women with a relatively good profile of other CAD risk factors.

Our results suggest that there may be threshold effects of combinations of these risk factors on absolute CAD risk. Further study, including external validation in other T1D cohorts, is needed to better determine the prognostic utility of TSSA for CAD in T1D.

For author disclosure information, see page A810.

Supported By: R01DK034818
Results are shown in Table 1. These findings demonstrate that PAT is significantly associated with CAC prevalence and progression, independent of BMI and VAT.

Table 1. Multiple Logistic Regression of PAT on Prevalence and Progression of CAC.

<table>
<thead>
<tr>
<th></th>
<th>Model 1*</th>
<th>Model 2†</th>
<th>Model 3‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>OR (95% CI)</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>Prevalence of CAC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log PAT</td>
<td>2.9 (2.1, 4.0)</td>
<td>1.7 (1.2, 2.5)</td>
<td>2.2 (1.5, 3.3)</td>
</tr>
<tr>
<td>Progression of CAC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAT quartiles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1st</td>
<td>1.0 (1.0, 2.8)</td>
<td>1.6 (0.91, 2.7)</td>
<td>1.7 (1.0, 2.9)</td>
</tr>
<tr>
<td>2nd</td>
<td>1.1 (0.63, 1.9)</td>
<td>1.0 (0.56, 1.8)</td>
<td>1.1 (0.62, 2.0)</td>
</tr>
<tr>
<td>3rd</td>
<td>2.0 (1.1, 3.6)</td>
<td>1.7 (0.89, 3.3)</td>
<td>2.1 (1.0, 4.1)</td>
</tr>
</tbody>
</table>

*Adjusted for age, sex, diabetes, HDL, and hypertension; †CAC prevalence in progression model. ‡Model 1 + VAT.

Supported By: American Diabetes Association (7-13-CE-02 to A.C.A.)

Cardiovascular Safety of GLP-1 Receptor Agonists (GLP-1-RA) vs. Other Antidiabetic Agents in Routine Care

ELISABETTA PATORNO, BRENDAN EVERETT, ALLISON GOLDFINE, JUN LIU, ROBERT GYNN, SEOYOUNG KIM, BOSTON, MA

GLP-1-RA may reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). Among metformin users, we compared intensification with GLP-1-RA vs. other antidiabetic agents with regard to MACE risk. Within a large commercial U.S. health insurance database, we identified T2DM patients who intensified metformin with new use of GLP-1-RA, DPP-4 inhibitors (DPP-4i), sulfonylureas, or insulin between 2005 and 2013. Propensity score (PS) matched analyses were used to balance more than 100 baseline characteristics and evaluate MACE risk (i.e. hospitalization for non-fatal acute coronary syndrome, stroke, or cardiac revascularization) in 3 separate PS-matched cohorts (Table 1). Follow-up started on the day following intensification and ended at a MACE event, insurance disenrollment, or the end of a 365-day period. GLP-1-RA initiators had no significant difference in MACE risk vs. initiators of DPP-4i (Cox HR= 1.01, 95% CI = 0.81, 1.26) or vs. sulfonylureas (HR= 0.85, 95% CI = 0.66, 1.11), but had decreased risk vs. insulin initiators (HR= 0.72, 95% CI=0.65, 0.80). Sensitivity analyses censoring at treatment discontinuation produced consistent results. In this study, intensification with GLP-1-RA was associated with a lower MACE risk than insulin, but a similar risk to DPP-4i and sulfonylureas.

Table 1. Characteristics and Outcomes in 3 PS-Matched Cohorts.

<table>
<thead>
<tr>
<th></th>
<th>GLP1-RA (N=23,729)</th>
<th>DPP-4i (N=14,091)</th>
<th>Sulfonylureas (N=14,091)</th>
<th>GLP1-RA (N=17,763)</th>
<th>Insulin (N=17,763)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline characteristics</td>
<td>GLP1-RA (N=23,729)</td>
<td>DPP-4i (N=14,091)</td>
<td>Sulfonylureas (N=14,091)</td>
<td>GLP1-RA (N=17,763)</td>
<td>Insulin (N=17,763)</td>
</tr>
<tr>
<td>Age, Mean (SD)</td>
<td>59.5 (11.5)</td>
<td>59.2 (10.0)</td>
<td>58.4 (11.6)</td>
<td>56.7 (10.3)</td>
<td>56.7 (10.3)</td>
</tr>
<tr>
<td>Female, N (%)</td>
<td>11,129 (51.7)</td>
<td>7,914 (56.3)</td>
<td>7,906 (56.4)</td>
<td>12,071 (67.1)</td>
<td>11,269 (64.7)</td>
</tr>
<tr>
<td>Charlson comorbidity index, Mean (SD)</td>
<td>1.3 (0.7)</td>
<td>1.2 (0.6)</td>
<td>1.2 (0.6)</td>
<td>1.2 (0.7)</td>
<td>1.3 (0.7)</td>
</tr>
<tr>
<td>Outcomes</td>
<td>GLP1-RA (N=23,729)</td>
<td>DPP-4i (N=14,091)</td>
<td>Sulfonylureas (N=14,091)</td>
<td>GLP1-RA (N=17,763)</td>
<td>Insulin (N=17,763)</td>
</tr>
<tr>
<td>MACE, N (HR per 1000 person-years)</td>
<td>127 (1.0)</td>
<td>158 (1.0)</td>
<td>149 (1.0)</td>
<td>250 (2.5)</td>
<td>326 (17.7)</td>
</tr>
<tr>
<td>Hazard Rate (95% CI)</td>
<td>1.01 (0.8-1.25)</td>
<td>Ref.</td>
<td>0.85 (0.6-1.11)</td>
<td>Ref.</td>
<td>0.71 (0.50-0.94)</td>
</tr>
</tbody>
</table>
1501-P
Cardiovascular Risk Factors after Lifestyle Intervention in Prediabetes: Findings from the D-CLIP Trial

Lifestyle interventions to prevent diabetes may impact cardiovascular disease (CVD) risk factors. The Diabetes Community Lifestyle Improvement Program (D-CLIP) is a randomized, controlled, translation trial of lifestyle modification to prevent diabetes among overweight Asian Indians with impaired fasting glucose and/or impaired glucose tolerance in Chennai, India (n=599). We report (a) proportions achieving CVD risk factor goals (b) changes in HbA1c, systolic blood pressure (SBP), plasma triglycerides (TG), total cholesterol (TC), and low- and high-density lipoprotein (LDL, HDL) across trial groups. After three years, loss to follow-up was 9%. The proportion reaching 1 or 2 CVD goals was statistically greater in the intervention vs. control group at most time points (Table 1). At 6 months, mean reductions from baseline were greater in the intervention for HbA1c (difference between groups: 0.13%, t-test p=0.0002), TG (16.18 mg/dL, p=0.0007), TC (8.68 mg/dL, p=0.0044), and LDL (5.84 mg/dL, p=0.007) but not SBP (1.22 mmHg, p=0.2) or HDL (0.04 mg/dL, p=0.9). After 3 years, differences dissipated (HbA1c 0.09%, p=0.2; TG 1.93 mg/dL, p=0.9; TC 2.86 mg/dL, p=0.8; LDL 0.96 mg/dL, p=0.8). Comprehensive lifestyle programs to prevent diabetes can have beneficial effects on cardiometabolic factors in Asian Indians with prediabetes, but maintaining improvements remains a challenge.

Table 1. Percent of D-CLIP Participants Reaching and Maintaining CVD Risk Reduction Goals.

<table>
<thead>
<tr>
<th>Months Follow Up</th>
<th>Reached At Least One CVD Risk Reduction Goal</th>
<th>Reached At Least Two CVD Risk Reduction Goals</th>
<th>Reached Three CVD Risk Reduction Goals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>73.5% 68.5% 61.5% 57.5% 44.5% 26.3%</td>
<td>40.6% 33.6% 33.6% 29.3% 23.0% 13.1%</td>
<td>6.0 3.9 4.6 5.7 3.1 1.4</td>
</tr>
<tr>
<td>Control</td>
<td>62.8% 52.9% 47.1% 47.8% 33.1% 17.1%</td>
<td>25.3% 22.2% 21.2% 24.9 16.4% 8.5</td>
<td>3.1 3.1 2.7 2.7 1.0 1.0</td>
</tr>
</tbody>
</table>

*Group percentages are significantly different at p<0.05.
Supported By: International Diabetes Federation; Emory Global Health Institute

1502-P
Declining Hospitalization Rates for Hemorrhagic and Ischemic Stroke among U.S. Adults With and Without Diagnosed Diabetes, 1998-2012
Nilka R. Burrows, Yanfeng Li, Edward W. Gregg, Ann L. Albright, Linda S. Geiss, Atlanta, GA

Stroke hospitalization rates have declined among U.S. adults with diabetes but the trends by type of stroke compared to people without diabetes have not been evaluated. Using 1998-2012 Nationwide Inpatient Sample data, we estimated the number of discharges among adults aged ≥35 years with hemorrhagic stroke (HS) (ICD-9 430-432) or ischemic stroke (IS) (ICD-9 433-434) as first-listed diagnosis. ICD-9 250 listed as a secondary diagnosis was used to identify those with diagnosed diabetes. Rates were calculated using diabetic and nondiabetic population estimates from the National Health Interview Survey and age-adjusted to the 2000 U.S. standard population. Join-point regression was used to analyze trends and calculate an average annual percentage change (AAPC) in rates with 95% confidence intervals. In 2012, 236,735 discharges for stroke (82% of which were IS) were diabetes-related, and 490,435 discharges (74% of which were IS) were nondiabetes-related. From 1998 to 2012, in both populations, age-adjusted rates for HS decreased at a similar rate, from 1.4 to 1.1 per 1,000 diabetic population (AAPC = -1.6% [-2.0%, -1.0%]) and from 0.8 to 0.6 per 1,000 nondiabetic population (AAPC = -1.5% [-2.0%, -1.0%]) (both AAPCs <0.01). For IS, age-adjusted rates decreased from 10.0 to 7.0 per 1,000 diabetic population (AAPC = -2.6% [-4.0%, -1.2%]) and from 3.3 to 2.6 per 1,000 nondiabetic population (AAPC = -1.0% [-1.5%, -0.6%]) (both AAPCs <0.05). Hospitalization rates for HS and IS in both diabetic and nondiabetic populations have declined. However, the rate of decline for IS was greater in the diabetic population compared with the nondiabetic population (AAPC = -2.6% [-1.6%, -1.0%]). The declining trends may be due to a number of factors, including a reduction in prevalence of risk factors, new and or more aggressive treatment of cardiovascular risk factors, or other factors.
Continuous variables
categorized as short (have you EVER been told by a doctor or other health professional that you have diabetes or sugar diabetes?); and females answering "yes" to the question "Other than during pregnancy, have you EVER been told by a doctor or other health professional that you have diabetes or sugar diabetes?" were included in the analysis. Sleep duration was categorized as short (≤6 hours), normal (7-8 hours), or long (≥9 hours). Self-reported diagnosis of stroke was the main outcome of interest.

A total number of 27,223 self-reported diabetic patients (mean age (±SEM) = 36.9 (±0.03) years, and mean BMI (±SEM) = 30.4 (±0.04) Kg/m2; 50.3% female; 6.6% Asians, 15.3% Blacks, and 76.1% Whites) provided valid data for the analysis. Stroke was reported in 8.7% of short sleepers, 15.9% of long sleepers and 7.9% of normative sleepers (p < 0.05). Based on logistic regression analysis, adjusting for effects of age, gender, race/ethnicity, socioeconomic status, smoking, alcohol intake, physical activity and medical comorbidities, diabetic patients with both short sleep and long sleep had an increased odds of stroke when compared to normal sleep duration (OR=1.14, 95% CI: 1.11 – 1.18, p < 0.01; and OR=1.17, 95% CI: 1.17 – 1.19, p < 0.01, respectively).

In diabetic patients, abnormal sleep duration was associated with increased risk of stroke, and diabetic patients reporting long sleep duration had an almost twofold greater likelihood of having a stroke. Incorporating a sleep history into routine clinic visit examination may help healthcare providers optimize efforts to prevent or manage stroke in diabetic patients.

The Combined Effect of Visit-to-Visit Variability in HbA1c and Systolic Blood Pressure on the Incidence of Cardiovascular Events in Patients with Type 2 Diabetes

TOSHIOI TAKAO, YUTAKA MATUSYAMA, MACHI SUKI, HIROYUKI YANAGI-SAWA, MASATOSHI KIKUCHI, SHOU KAWAZU, Tokyo, Japan

Visit-to-visit variability in HbA1c or blood pressure (BP) is an independent predictor of diabetic complications. However, no study has examined the risk simultaneously. This study investigated the association between long-term visit-to-visit variability in HbA1c and systolic BP (SBP) and the incidence of cardiovascular disease (CVD) in patients with type 2 diabetes.

We retrospectively enrolled 650 patients with type 2 diabetes and no history of CVD, who first visited our hospital between 1995 and 1998 and had at least one hospital visit, with at least one visit per year. Patients were followed through June 2012, at the latest. The median follow-up period was 15.4 years.

CVD occurred in 85 patients. Multivariate Cox regression analysis showed that the coefficients of variation (CV) for both HbA1c and SBP were significant predictors of the incidence of CVD independent of the mean HbA1c and mean SBP. Patients were classified into four groups according to the median CV of HbA1c and SBP. Hazard ratios were highest for the high HbA1c CV and high SBP CV group, and significantly higher for the low HbA1c CV and high SBP CV group and high HbA1c CV and low SBP CV group than for the Low HbA1c CV and high SBP CV group, and significantly higher for the low HbA1c CV and high SBP CV group than for the Low HbA1c CV group and high SBP CV group (Table). Long-term visit-to-visit variability in both HbA1c and SBP represented a combined and additive risk for the incidence of CVD simultaneously.

<table>
<thead>
<tr>
<th>Table</th>
<th>Incidence of CVD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Model 1</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>P-value</td>
</tr>
<tr>
<td>Continuous variables</td>
<td></td>
</tr>
<tr>
<td>HbA1c CV</td>
<td>1.07 (1.01-1.13)</td>
</tr>
<tr>
<td>SBP CV</td>
<td>1.03 (1.01-1.19)</td>
</tr>
<tr>
<td>Categorical variables</td>
<td></td>
</tr>
<tr>
<td>Low HbA1c CV and low SBP CV</td>
<td>–</td>
</tr>
<tr>
<td>Low HbA1c CV and high SBP CV</td>
<td>1.99 (1.01-3.95)</td>
</tr>
<tr>
<td>High HbA1c CV and low SBP CV</td>
<td>2.37 (1.06-5.31)</td>
</tr>
<tr>
<td>High HbA1c CV and high SBP CV</td>
<td>2.93 (1.44-5.94)</td>
</tr>
</tbody>
</table>
Table 1. Characteristics.

<table>
<thead>
<tr>
<th>Predictor</th>
<th>All Fatal</th>
<th>Non-Fatal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>32</td>
<td>40</td>
</tr>
<tr>
<td>Pre-Diabetes</td>
<td>35</td>
<td>43</td>
</tr>
<tr>
<td>Diabetes</td>
<td>39</td>
<td>47</td>
</tr>
</tbody>
</table>

Table 2. Echocardiography Parameters.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Pre-Diabetes</th>
<th>Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>LV end-diastolic volume (EDV, mL)</td>
<td>14.7±4.6</td>
<td>13.5±4.8</td>
<td>12.4±7.7</td>
</tr>
<tr>
<td>LV end-systolic volume (ESV, mL)</td>
<td>4.2±1.9</td>
<td>4.0±1.8</td>
<td>4.4±2.5</td>
</tr>
<tr>
<td>LV ejection fraction (EF, %)</td>
<td>68±10</td>
<td>69±10</td>
<td>63±13*</td>
</tr>
<tr>
<td>Peak early diastolic E velocity (cm/ sec)</td>
<td>85±17</td>
<td>76±16</td>
<td>75±20*</td>
</tr>
</tbody>
</table>

Table 1.

Table 2.

Table 1.

Table 2.
1511-P
To Determine the Individual Effect of Age, Duration of Diabetes, BMI, and Hba1C on Parameters of Arterial Stiffness in Patients with Type 2 Diabetes
SABYASACHI SEN, AYTAN S. MAMMADOVA, LINDA WITKIN, WASHINGTON, DC
Arterial Stiffness (AS) has been used as a measure of vascular health. However, limited number of studies exist to determine which parameter of a patient has more effect on AS measures. The indices for measuring AS we are used are Augmentation Index (AgI), Augmentation Index Adjusted for heart rate (AgI-HR), augmentation pressure (AP) and Pulse Wave Velocity (PWV). We used the Pearson product-moment correlation as a statistical method for analysis. We analyzed 18 patients to investigate which of the above parameters affect AS most. Only one point was taken for this study. Subjects were enrolled with DM > 8 years, age 40-70, with HbA1c of 6-9 and BMI 25-39.9. We enquired: a) whether age or duration of DM has more impact on the AS and; b) whether BMI or HbA1c level has more impact on AS.

Results that we obtained: a) AgI in the group of patients with DM duration of 3-6 year and 6-9 year (P correlation [Pc] =0.83; 0.93; n= 10) has linear relationship with age, AI and age has a linear relationship of P=.075; 118 with DM duration 0-8 yrs; b) relationship between AP and age is linear, Pc =0.82; n=18; c) PWV c-f and year of DM in the group of people age 40-55 has a linear relationship with P= 0.93, n=5; d) HbA1c has direct effect on AI 75 in the patients with BMI 25-29.9. Pc = 0.89; n=18; AND HbA1c has linear impact on PWV c-f in the patients with BMI 25-29.9. P< 0.06; n=4. We summarize that: A) Arterial stiffness measures in diabetes subjects appear to be related and reproducible using multiple measurement indices. B) PWV appears to be more informative than FWA, C) age can affect AS more than duration of DM; D) Level of HbA1c has more effect on AS than BMI, particularly in patients with BMI 25-29.9. In conclusion, we note that AS measurement is a robust indicator of vascular health. Though diabetes is considered a CVD risk equivalent, age appears to play a bigger role in AS development. Degree of diabetes or HbA1c seems to impact more than BMI on AS particularly in overweight subjects.

1512-P
Testosterone, Cardiac Magnetic Resonance Imaging (CMR), and Cardiac Function in Men With Type 1 Diabetes in the Epidemiology of Diabetes Interventions and Complications Study (EDIC)
CATHERINE KIM, BARBARA H. BRAFFETT, PATRICIA CLEARY, JOINT BEBU, VALERIE ARENDS, MICHAEL W. STEFFES, HUNTER WESSELS, TREVOR J. ORCHARD, ARUNA V. SARMA, DCC/EDIC RESEARCH GROUP, Ann Arbor, MI; Bethesda, MD; Rockville, MD; Minneapolis, MN; Seattle, WA; Pittsburgh, PA
Low endogenous testosterone (T) levels are associated with increased risk of cardiovascular events, but the mechanisms are unclear. We examined the relationship between endogenous T and measures of cardiac function obtained upon CMR, as well as the relationship between T and subclinical atherosclerosis obtained upon carotid ultrasound. Participants were men in EDIC, the observational follow-up of Diabetes Control and Complications Trial (DCCT); 528 men had T measurements at year 10 of EDIC, CMR measurements at years 14/15, and cIMT at year 12. At EDIC year 10, the participants were 45±7 years old, had diabetes for 22±5 years, and had a time-weighted DCCT/EDIC mean HbA1c of 7.7±1.2%. Adjusted for low, levels of T were associated with lower end-diastolic volume index values (p=0.03) and with lower stroke volume index values (p=0.03). T was not associated with cIMT.

Lower endogenous T levels are associated with CMR measures but not with cIMT among men with type 1 diabetes. Additional analyses are needed to determine if low T contributes to cardiac dysfunction in men with type 1 diabetes, specifically, if BMI and insulin dosing confound the association between T and CMR measures.

1513-P
Study of Cardiovascular Risks in Adolescents—ERICA: Epidemiological Aspects of the Pilot
ANA MAYRA OLIVEIRA, ATILA OLIVEIRA, MARA SUELY SANTOS TEÓFILO CARNEIRO, CRISLAINNE CARNEIRO MARQUES SILVA, LORENA VENEZA MASCARENHAS, ALANNE LOUISE CARDOSO OLIVEIRA, ANA LUISA OLIVEIRA, ANTONIO CESAR OLIVEIRA, Feira de Santana, Brazil; Salvador, Brazil; Campinas, Brazil
The risk factors of cardiovascular (CV) diseases in youth is growing up. We aimed to determine the frequency of CV risk factors (obesity, elevated blood pressure [BP], dyslipidemia and dysglycemia) and association between obesity and insulin resistance [IR], dyslipidemia, dysglycemia and elevated BP in adolescents.

Methods: This is a cross-sectional study with Brazilian adolescents, selected by convenience, from public and private schools from five different cities, which formed the pilot study of the Study of Cardiovascular Risk Factors in Adolescents—ERICA. The measurements included: anthropometry, BP and laboratory tests.

Results: We analyzed 18 patients to investigate which of the above parameters affect AS most. Only one point was taken for this study. Subjects were enrolled with DM > 8 years, age 40-70, with HbA1c of 6-9 and BMI 25-39.9. We enquired: a) whether age or duration of DM has more impact on the AS and; b) whether BMI or HbA1c level has more impact on AS.

Results that we obtained: a) AgI in the group of patients with DM duration of 3-6 year and 6-9 year (P correlation [Pc] =0.83; 0.93; n= 10) has linear relationship with age, AI and age has a linear relationship of P=.075; 118 with DM duration 0-8 yrs; b) relationship between AP and age is linear, Pc =0.82; n=18; c) PWV c-f and year of DM in the group of people age 40-55 has a linear relationship with P= 0.93, n=5; d) HbA1c has direct effect on AI 75 in the patients with BMI 25-29.9. Pc = 0.89; n=18; AND HbA1c has linear impact on PWV c-f in the patients with BMI 25-29.9. P< 0.06; n=4. We summarize that: A) Arterial stiffness measures in diabetes subjects appear to be related and reproducible using multiple measurement indices. B) PWV appears to be more informative than FWA, C) age can affect AS more than duration of DM; D) Level of HbA1c has more effect on AS than BMI, particularly in patients with BMI 25-29.9. In conclusion, we note that AS measurement is a robust indicator of vascular health. Though diabetes is considered a CVD risk equivalent, age appears to play a bigger role in AS development. Degree of diabetes or HbA1c seems to impact more than BMI on AS particularly in overweight subjects.
Epidemiology/Genetics

3.1) in 2012. Mortality rates declined from 4.3 (95% CI 1.9-6.7) to 2.4 (95% CI 1.6-3.2) in men and from 5.0 (95% CI 2.8-7.1) to 2.6 (95% CI 1.8-3.5) in women. The decline is probably due to the increased prescription of statins. Future research should focus on gender-differences.

**Study of the Variability of Heart Rate in Type 2 Diabetes Mellitus Patients with Diabetic Autonomic Neuropathy**

AUGUSTO C. SANTÔMAURO JÚNIOR, BRUNA M.G. MASCARENHAS, REBECA E.M.B. RAMIRO, CAROLINE NAGAOKA, ANA TERESA M.G. SANTÔMAURO, FADLO FRAGIE FILHO, SANTO ANDRÉ, Brasí, São Paulo, Brazil

Diabetic autonomic neuropathy (DAN) is a severe and common complication of diabetes mellitus (DM). The balance between the sympathetic and parasympathetic nervous system, called autonomic balance, is an alternation of autonomic activity (sympathetic or parasympathetic) heart. From normal cardiac cycles considered normal, allows to extract indices that assess the prevalence of autonomic activity (sympathetic or parasympathetic) heart. Using the SDNN index, stratified patients into 3 cardiac risk groups: Group A - high risk - SDNN ≥ 50ms - sympathetic predominance (23 patients with SDNN = 136 ± 14), Group B - low risk - SDNN ≤ 50ms - parasympathetic predominance (37 with SDNN = 44 ± 14), and Group C - medium risk - 50 < SDNN < 100ms - sympathetic hyperactivity and reduced vagal tone can develop arrhythmias and sudden death. Analyze of the cardiac autonomic profile is an important element for cardiovascular (CV) stratification in type 2 DM (T2DM) with DAN.

The utilization of the Holter system, analyzing changes of the cardiac cycles considered normal, allows to extract indices that assess the prevalence of autonomic activity (sympathetic or parasympathetic) heart. From normal measured RR cycles (NN) in 24 hours, we removed indices such as the SDNN (standard deviation of all RR cycles). The lower this ratio, the higher sympathetic activity on the heart and therefore greater cardiac risk. In the study, 126 patients with T2DM performed Holter, 61 women (mean age = 54.3 ± 3.3). We excluded from the study patients on blockers and psychostimulants.

Using the SDNN index, stratified patients into 3 cardiac risk groups: Group A - high risk - SDNN ≥ 50ms - sympathetic predominance (23 patients with SDNN = 136 ± 14), Group B - low risk - SDNN ≤ 50ms - parasympathetic predominance (37 with SDNN = 44 ± 14).

The Holter is an easy way to assess cardiac risk. In this study we could stratify the CV risk in T2DM. The group A had higher risk for fatal arrhythmias. The data of the most recent clinical studies shows that neuropathy has been gaining attention as an important complication determining cardiovascular events.

**WITHDRAWN**

**How to Measure the Effect of Diabetes on Cardiovascular Events during a Clinical Trial? A Meta-analysis of 330,376 Patients from 47 Landmark Trials**

MICHEL P. HERMANS, SYLVIE A. AHN, MICHEL F. ROUSSEAU, Brussels, Belgium

Diabetes is known as a major cardiovascular risk factor. However, its influence on the rate of occurrence of cardiovascular (CV) events during a clinical trial that includes a sub-cohort of diabetics is rarely measured.

The purpose of this work was to determine the extent to which having diabetes at baseline, individually or at a sub-group level, increases as such residual CV risk over the course of a clinical trial.

We performed a meta-analysis of primary outcomes (PO) rates of key prospective trials, for which the baseline proportion of diabetics was reported, including studies having specifically reported CV outcomes within their diabetic subgroups.

Forty-seven studies, representing 330,376 patients (among whom 124,115 diabetics), were analyzed as regards the relationship between CV outcomes rates (including CHD) and the number of diabetics enrolled. Altogether, a total of 18,445 and 16,156 events occurred in the comparator and treatment arms, respectively. There were significant linear relationships between diabetes prevalence and both PO and CHD rates (%/year): y = 0.0299x + 3.12 [PO] (p = 0.0128); and y = 0.0531x + 1.54 [CHD] (p = 0.0094), baseline diabetes predicting PO rates between 3.12%/year (no diabetic included) and 6.11%/year (all patients diabetic); and CHD rates between 1.54%/year (no diabetic) and 8.85%/year (all patients diabetic).

Inclusion, the contribution of absolute and relative residual CV risk associated with the presence of diabetes at baseline during a clinical trial can be readily predicted from the linear equations relating diabetes prevalence to primary outcomes or CHD rates.

**Invasively Measured Aortic Blood Pressure Predicts Stroke in Diabetic Patients Followed in the Western Denmark Heart Registry during 2001-2012**

ESSEN LAUGESEN, SIBREN T. KNUDSEN, KLAVS W. HANSEN, NIKLAS B. ROSEN, LISSETE O. JENSEN, JAN RAVKILDE, LARS PEDERSEN, MORTEN MADSEN, HANS ERIK BØTKER, PER L. POULSEN, Aarhus, Denmark, Silkeborg, Denmark, Odense, Denmark, Aalborg, Denmark

Diabetic patients are at high risk of stroke. Office blood pressure (BP) conventionally is used to assess hemodynamic load on the cerebral circulation. The prognostic impact of invasively measured aortic BP, which more closely represents the hemodynamic cerebral burden, remains unknown.

Office BP, invasively measured aortic BP, and aortic pulse pressure (PP) were recorded in 3113 diabetic patients (median age 65 years [IQR: 58-71 years], 63% male) with stable angina pectoris undergoing elective coronary angiography during January 2001-December 2012. The association with incident stroke during follow-up was assessed using Cox regression analyses. The predictive power of aortic BP vs. office BP was assessed by Harrell’s C.

In total, 85 (2.7%) patients had a stroke during a median follow up period of 3.1 years [IQR: 1.5-5.1 years]. Aortic systolic BP and PP, but not office BP, were associated with incident stroke in both crude and adjusted analyses (Table). Harrell’s C increased non-significantly when aortic BP, compared to office BP, was used to predict stroke (Table).

We conclude that aortic systolic BP and aortic PP were associated with risk of incident stroke in diabetic patients. However, aortic BP did not significantly improve predictive power compared to office BP.
## EPIDEMIOLOGY—CARDIOVASCULAR DISEASE

### Table. Incident Stroke Per 10 mmHg BP Increase.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Hazard ratio</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihypertensive treatment</td>
<td>1.05</td>
<td>0.15</td>
</tr>
<tr>
<td>ACE/ARBs (%)</td>
<td>0.81</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Calcium channel blockers (%)</td>
<td>0.31</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diuretics (%)</td>
<td>0.54</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

### 1519-P

#### Individualized Treatment in Patients with Comorbid Type 2 Diabetes and Heart Failure: Insights from the DIALOGUE Registry

**Falk Ouarrak, Roland E. Schmieder,** and **Heart Failure: Insights from the DIALOGUE Registry**

Patients with type 2 diabetes (T2DM) and hypertension have an increased risk of heart failure (HF) and HF itself complicates the treatment and outcomes of diabetes. We aimed to assess treatment strategies and outcomes in this patient group.

**DIALOGUE** is a prospective, multi-center registry in patients ith both T2DM and hypertension. Heart failure was recorded at baseline (physician assessment) and patients grouped into those with or without HF.

Out of 8392 patients included, 1223 (14.3%) were diagnosed as having HF at baseline. Patients with HF were older and had a >3 year longer diabetes duration. They had a significantly higher comorbidity burden, with the increase in coronary heart disease and strokes being pronounced. Consequently, they probably due to the additional proven benefit in heart failure treatment.

**Model 3: Model 2 plus age, gender, smoking, previous stroke, antihypertensive treatment, lipid-lowering treatment, and atrial fibrillation.**

Supported By: Danish Diabetes Association; Danish Diabetes Academy

### 1520-P

#### Impact of Metabolic, Hemodynamic, and Inflammatory Factors on Target Organ Damage in Healthy Subjects

**Marie K. Blicher, Ruan Kruger, Thomas B. Olesen, Sara V. Greve, Torben Johansen, Michael H. Olesen, Odense, Denmark; Pitcheftston, South Africa; Glostrup, Denmark**

We tested to impact of metabolic, hemodynamic and inflammatory factors on target organ damage (TOD) defined as cardiac hypertrophy (CH), atherosclerosis, arteriosclerosis and microvascular damage (MD). In a population based cohort study of 2115 healthy subjects (1049 male 1066 female) with a mean age of 53±10.5 without known diabetes or cardiovascular disease we measured fasting plasma glucose (FPG), serum insulin, lipid profile, soluble urokinase receptor (suPAR), c-reactive protein (CRP), urine albumin/creatinine ratio (UACR), 24-hour ambulatory systolic (24hSBP) and diastolic blood pressure (24hDBP), left ventricular mass index (LVMI) by M-mode echocardiography, carotid plaques (CP) by ultra sound and carotid femoral pulse wave velocity (PWV).

We establish best model for association of LVMI, CP, PWV and UACR we used multiple linear regression analysis starting with inclusion of all variables without co-linearity taking away one non-significant variables.

**Model 1**

1. **Model 1 plus age, gender, smoking, previous stroke, antihypertensive treatment, lipid-lowering treatment,** and **atrial fibrillation.**

**Model 3: Model 2 plus extent of coronary vessel disease (0/diffuse without significant stenoses/1/2/3).**

Supported By: Novartis Pharma GmbH

### Table.

<table>
<thead>
<tr>
<th>Heart failure (n=1123)</th>
<th>No heart failure (n=7269)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>72.3±9.6</td>
<td>63.5±11.2</td>
</tr>
<tr>
<td>Diabetes duration (median months)</td>
<td>79.8</td>
<td>66.1</td>
</tr>
</tbody>
</table>

**Clinical variables**

- HbA1c (%)  
  - Model 1: 7.7±1.4  
  - Model 2: 7.8±2.2  
  - Model 3: 7.8±2.2  
  - p-value = 0.13

- 24hSBP (%)  
  - Model 1: 83.2±8.9  
  - Model 2: 8.5±2.8  
  - Model 3: 8.5±2.8  
  - p-value = 0.05

**Antidiabetic treatment**

- Metformin after BL (%)  
  - Model 1: 72.4  
  - Model 2: 76.1  
  - Model 3: ≤0.0001

- DPP-4 inhibitors after BL (%)  
  - Model 1: 62.4  
  - Model 2: 62.2  
  - Model 3: 0.90

- Sulfonylurea after BL (%)  
  - Model 1: 19.2  
  - Model 2: 17.3  
  - Model 3: 0.11

- Glitazones after BL (%)  
  - Model 1: 0.5  
  - Model 2: 0.5  
  - Model 3: 0.97

- Insulin, short acting (%)  
  - Model 1: 5.9  
  - Model 2: 4.0  
  - Model 3: <0.01

- Insulin, long acting (%)  
  - Model 1: 14.7  
  - Model 2: 12.3  
  - Model 3: <0.05

- Insulin, mixed (%)  
  - Model 1: 2.4  
  - Model 2: 1.5  
  - Model 3: <0.05

**Antihypertensive treatment**

- ACE/ARBs (%)  
  - Model 1: 87.1  
  - Model 2: 76.5  
  - Model 3: <0.0001

- Betablockers (%)  
  - Model 1: 67.1  
  - Model 2: 43.3  
  - Model 3: <0.0001

- Calcium channel blockers (%)  
  - Model 1: 33.7  
  - Model 2: 25.9  
  - Model 3: <0.0001

- Diuretics (%)  
  - Model 1: 66.8  
  - Model 2: 38.8  
  - Model 3: <0.0001

**Events during follow-up period**

- Death at 6 months (%)  
  - Model 1: 0.7  
  - Model 2: 0.1  
  - Model 3: <0.0001

- Death at 12 months (%)  
  - Model 1: 0.9  
  - Model 2: 0.2  
  - Model 3: <0.0001

*mean±SD.

**For author disclosure information, see page A810.**
Irisin and Vaspin as Novel Markers to Predict Metabolic Syndrome in Patients with Type 2 Diabetes

SHIWEILU, MINGMIND WANG, XIAOHUA LIU, JUN WANG, LIZHANG, SHUQUN ZHAO, KUI FU, TAIYUAN, China, Houston TX

Metabolic syndrome (MS) is a public health issue currently, for which insulin resistance and obesity are considered as the major causative factors. Energy metabolism dysfunctions with enhanced reactive oxygen species (ROS) production may contribute to the metabolic abnormality of adipose tissue in obesity and diabetes. Irisin, a newly identified myokine and adipokine, can increase energy expenditure and improve insulin sensitivity and glucose tolerance. Vaspin as an adipocytokine was identified with anti-diabetic, anti-hypertensive and anti-dyslipidemic treatment as co-variates (HR for SD increment 1.05, 95% CI: 0.96-1.04; p=0.004). This counterintuitive association was no longer observable in a model including age, sex, body mass index, smoking habit, estimated-glomerular filtration rate, albuminuria and anti-diabetic, anti-hypertensive and anti-dyslipidemic treatment as co-variates (HR for SD increment 1.08, 95% CI: 0.98-1.07; p=0.243, respectively). When the two cohorts were pooled and analyzed together, a clear association between target risk score and all-cause mortality was observed (HR for SD increment 1.05, 95% CI: 1.02-1.08, p=0.004). This counterintuitive association was no longer observable in a model including age, sex, body mass index, smoking habit, estimated-glomerular filtration rate, albuminuria and anti-diabetic, anti-hypertensive and anti-dyslipidemic treatment as co-variates (HR for SD increment 1.05, 95% CI: 0.96-1.04; p=0.852). In conclusion, in a real-life clinical set of patients with type 2 diabetes mellitus, the combination of recommended target values of established cardiovascular risk factors is not associated with all-cause mortality.

Guided Audio Tour: Diabetes Advances in Clinical Diagnosis and Screening (Posters: 1522-P to 1529-P), see page 13.

EPIDEMIOLOGY—CLINICAL—DIAGNOSIS AND SCREENING

Prediction of Incident Diabetes in the Jackson Heart Study Using Random Forests

RAMIN CASANOVIA, SANTIAGO SALDANA, SEAN SIMPSON, MARY B. LACY, ANGLA SUBAUSTE, CHAD BLACKSHEAR, LYNNE E. WAGENKNECHT, ALAIN BERTONI, Winston-Salem, NC, Providence, RI, Jackson, MS

Statistical models for prediction of incident diabetes are often based on a few variables selected by experts. Here we pursued two main goals: 1) Investigate relative performance of a machine learning method such as Random Forests (RF) and a logistic regression (LR) model for detecting incident diabetes, and 2) Uncover potential predictors of diabetes. The Jackson-Heart Study collected data at baseline and in two follow-up visits from 5,381 African Americans. We excluded those with baseline diabetes and no follow-up, leaving 3,833 for analyses. Over a mean 8-year follow-up, 584 participants developed diabetes. Diabetes was defined as current use of insulin or oral antidiabetic agent, self-report or physician’s diagnosis, fasting glucose > 126 mg/dl, or HbA1c > 6.5%. We used a LR model published by ARC (Schmidt et al., Diabetes Care 2005) which included BMI, waist circumference, systolic BP, age, sex, glucose, HDL cholesterol, triglycerides, and parental diabetes history. The RF model evaluated 95 variables (including those provided to the LR model) from demographic, anthropometric, blood biomarkers, medical history, and echocardiogram data. The dataset was partitioned into training and testing sets 100 times. Each training dataset included 400 participants who developed diabetes during follow-up and 400 who did not. Both RF and LR were estimated for the training sets; the testing sets were used to evaluate performance based on accuracy, sensitivity, specificity and area under the curve (AUC). We also used RF measures to rank the importance of the variables to the model. RF produced Accuracy = 77%, Sens. = 70%, Spec. = 76% and AUC = 0.81 (mean values) versus, for LR, Accuracy = 71%, Sens. = 67%, Spec. = 71% and AUC = 0.76. Among the top-ranked variables HbA1c, glucose, renin and waist were detected. This work shows the potential of RF for incident diabetes prediction and detecting subtle patterns in data. Our findings confirm well-known predictors of diabetes and suggest a role for renin in prediction of diabetes.

Supported By: 1R01HL117286-01 (to A.B.)

Novel Mutations in GCK and HNF1A-MODY in a Large Cohort of Brazilian Diabetic Families

LILIAN A. CAETANO, LUCAS S. SANTANA, ELISANGELA S. QUEDES, MARCIA NERY, ALEXANDER L. JORGE, MILNA G. TELES, Sao Paulo, Brazil

Maturity-Onset Diabetes of the Young (MODY) is the most common form of monogenic diabetes. To date, there are few cohorts investigated for MODY in Brazil. The aim of this study was to report novel mutations related to MODY 2 (GCK) and 3 (HNF1A) in Brazilian diabetic families and describe clinical characteristics of those patients. Recently, our group has initiated molecular screening for MODY using Sanger’s sequencing method. A total of 54 Brazilian families (102 subjects) were screened for GCK or HNF1A mutations: 26 families with clinical suspicion of MODY 2 and 26 families with MODY 3 phenotype. All exons and flanking intronic regions of GCK and HNF1A genes were studied. We found 10 GCK mutations (8 missense, 2 splice site) in 26 families (38%). Two of these variants were novel: c.580-3C>A/IVS5-3C>A and c.505A>G/p.K169E. HNF1A mutations were found in 5 families (18%): 2 missense, 1 nonsense and 2 frameshift-insertion. One was a novel mutation: c.1558+1T>C/p.E520*. 3 novel heterozygous mutations in GCK and HNF1A genes segregated in family members with diabetes phenotype. All variants were absent in healthy individuals databases (1k genomes, ESP-6500) and were predicted to be damaging using in silico analysis (Polyphen-2, MutationTaster, SIFT, HSF). In variant K169E, the substitution occurred in a codon already associated with MODY. All 3 subjects have diabetes onset before age of 25, BMI below 25, family history of diabetes, detectable fasting C-peptide (range 1.1-2.2 ng/mL) 3 years after diagnosis of diabetes, and negative beta cell pancreatic antibodies (GADA, IAA, IAA). In summary, we found 3 novel MODY mutations that are predicted to be pathogenic. Those genetic variants were present in subjects with clinical features of MODY. Since most of the MODY mutations are private, it is important to study different ethnicities. This is one of the largest cohorts of MODY patients in Brazil. Our molecular study has identified unpublished mutations, expanding the number of variants associated to this phenotype.

Supported By: CAPES, FAPESP

Guided Audio Tour Poster

ADA-Funded Research

For author disclosure information, see page A810.
The Influence of Fasting Status on the Relationship between A1C and Fasting Glucose: The Jackson Heart Study

MARY E. LACY, GREGORY A. WELLENNIUS, ADOLFO CORREA, ANNE E. SUMNER, SIMON LIU, XI LUO, JAMES G. WILSON, ANNIE GJELSVIK, CHARLES B. EATON, MERCEDES R. CARNEHONI, WEN-CHIH WU, Providence, RI; Jackson, MS; Bethesda, MD; Los Angeles, CA; Chicago, IL.

Current guidelines recommend the use of hemoglobin A1c (A1C) as a diagnostic and screening parameter for diabetes. Because of decreased pres-ence of HbA and shortened lifespan of red blood cells in those with sickle cell trait (SCT), A1C may systematically underestimate levels of glycemia in those with SCT, particularly African Americans (AA) who have a much higher prevalence of SCT than whites. This analysis examined the relationship between concurrent measures of A1C and fasting plasma glucose (FPG) among AA with and without SCT using data collected across 10 years (3 clinic visits between 2000 and 2010) on 3,221 participants from the Jackson Heart Study. Using generalized linear mixed models to account for correlation of repeated measures, we estimated the effect of SCT on the association between A1C and FPG. Overall, 270 participants had SCT (8.4%). Participants with SCT did not differ by sex, age, or hemoglobin levels. Using assays available from 2000-2010, at the same FPG, participants with SCT had A1C measures that were, on average, 0.32% lower than participants without SCT (95% CI: 0.28%-0.36%; p<0.01). Given the threshold of A1C ≥6.5% for diagnosis of diabetes, a difference in A1C of 0.32% at the same FPG represents a substantial difference that may result in under-diagnosis of diabetes among AA with SCT. It remains to be determined if newer A1C assays continue to present this diagnostic challenge.

The Effect of Fasting Status on 23 Cardiometabolic Biomarkers in 96,000 Subjects

STEPHEN A. VARVEL, LEILA GHAEDI, JAMES V. POTTALA, TIMOTHY E. GRAHAM, Richmond, VA; Salt Lake City, UT.

Fasting requirements for blood collection present practical challenges for clinicians during routine patient assessment. Better understanding of the effects of fasting would enhance clinical decisions about appropriate ordering of tests. De-identified data were obtained from blood samples collected from 99,860 individuals participating in 27 community-based surveys across 27 countries and compared prevalence of diabetes based on HbA1c ≥6.5% with prior definitions using fasting plasma glucose (FPG) ≥7 mmol/L or either FPG ≥7 mmol/L or post-prandial glucose (PPG) ≥11.1 mmol/L. Participants who reported prior diagnosis or treatment for diabetes were assigned to the diabetes group. We estimated sensitivity and specificity of HbA1c vs. FPG, PPG, or combined FPG and PPG among participants who did not have diabetes and pooled these using random-effect meta-analyses.

We used data from 74 population-based surveys (217,408 participants in 27 countries) and compared prevalence of diabetes based on HbA1c ≥6.5% with prior definitions using fasting plasma glucose (FPG) ≥7 mmol/L or either FPG ≥7 mmol/L or post-prandial glucose (PPG) ≥11.1 mmol/L. Participants who reported prior diagnosis or treatment for diabetes were assigned to the diabetes group. We estimated sensitivity and specificity of HbA1c vs. FPG, PPG, or combined FPG and PPG among participants who did not have diabetes and pooled these using random-effect meta-analyses.

Impact of Diabetes Definition on Global Surveillance of Diabetes Prevalence

GOODARZ DANAEI, Boston, MA

During the past few decades diabetes definition has changed several times including most recently by adding haemoglobin A1c (HbA1c) as a diagnostic test. HbA1c has the advantages that no fasting is needed and there are now handheld devices that facilitate its use in large population-based studies. However, the debate over usefulness of HbA1c and its optimal diagnostic cut-off continues. Prior studies were based on small cohorts and few covered different regions.

We used data from 74 population-based surveys (217,408 participants in 27 countries) and compared prevalence of diabetes based on HbA1c ≥6.5% with prior definitions using fasting plasma glucose (FPG) ≥7 mmol/L (or either FPG ≥7 mmol/L or post-prandial glucose (PPG) ≥11.1 mmol/L). Participants who reported prior diagnosis or treatment for diabetes were assigned to the diabetes group. We estimated sensitivity and specificity of HbA1c vs. FPG, PPG, or combined FPG and PPG among participants who did not have diabetes and pooled these using random-effect meta-analyses.

HbA1c-based prevalence of diabetes was on average 4% lower than those based on FPG alone and 16% lower than those based on FPG or PPG. FPG-based prevalence was on average 4% lower than that based on FPG or PPG. Pooled sensitivity of HbA1c ≥6.5% was 52.2% when compared with FPG and 36.2% when compared with PPG. Specificity of HbA1c ≥6.5% was 99.8% for both comparisons. Lowering the diagnostic threshold for HbA1c to 5.5% would increase the sensitivity of HbA1c vs. FPG to 82.8% while specificity would still be acceptable at 97.5%. HbA1c with the proposed 6.5% threshold performs relatively well in estimating diabetes population prevalence but would miss about half of the undiagnosed diabetes cases, making it unsuitable as a screening test. A lower threshold at 5.9% would increase the sensitivity while maintaining a high specificity.

Supported by: National Institutes of Health (1R01DK090435); UK Medical Research Council; UK Wellcome Trust

For author disclosure information, see page A810.
Progression to Diabetes among U.S. Medicare Fee-for-Service Enrollees
KAI MCKEEVER BULLARD, SHARON SAYDH, EDWARD W. GREGG, GIUSEPPINA IMPARETÀ, Atlanta, GA

In the U.S., nearly 40% of the population will develop diabetes (DM) in their lifetime, and almost 3 in 4 older adults have some form of dysglycemia. We examined time to progression to DM from normal- and prediabetic glycemic status among a nationally representative sample of Medicare fee-for-service (FFS) enrollees. We used data from 1,091 men and women without diabetes aged ≥ 65 years who were examined in the 1999-2004 National Health and Nutrition Examination Survey (NHANES), a nationally representative survey. Incident DM was ascertained using 1999-2007 Medicare claims records. We excluded individuals at baseline with self-reported diagnosed DM, fasting plasma glucose (FPG) ≥ 126 mg/dl, or HbA1c ≥ 5.7% or prediabetes (IFG, FPG 100-125 mg/dl; or, impaired A1c [IA1C], 5.7-6.4%). Progression to DM from time of NHANES examination date to first diagnosis was examined using cumulative probabilities and proportional hazards models. During a mean follow-up of 5.4 years, 144 participants progressed to DM, representing an overall incidence rate per 1000 person-years [PY] (95% CI): 22.6 (17.4, 27.8) in the general Medicare FFS population. At baseline, cases had higher prevalence of obesity, central obesity, physical inactivity, and hypertension than non-cases. DM incidence rates per 1000 PY were 11.0 (6.7, 16.4) for those with normoglycemia and 34.4 (25.2, 43.6) for those with prediabetes. The incidence rate for those with combined IA1C + IFG was 62.3 (40.0, 84.7). Adjusted hazard ratios (normal glycemic status = reference) with prediabetes. The incidence rate for those with combined IA1C + IFG was 2.04 fold predicted incident diabetes with a RR of 7.5 (95% CI: 1.8-30.6). The effect of age on the incidence of diabetes mellitus in the elderly is significant (RR=4.8, 95% CI 1.6-14) after additional adjustment for other confounding factors, including sex, age, family history of diabetes, smoking and others.

We conclude that the high AHr ligand binding activity in serum predicts the progression to T2D, suggesting a pathogenic role of AHr ligands, probably POPs. CALA assay might be useful as a diagnostic test predicting T2D.

Causal Factors for Development of Diabetes Mellitus over the Course of 10 Years in the Korean Genome and Epidemiology Study: Serum Aryl-hydrocarbon Receptor Binding Activity
HONG YUL LEE, WOOK-HA PARK, YOUNGMI K. PAK, NAM H. CHO, Seoul, Republic of Korea

Many epidemiologic studies showed serum levels of persistent organic pollutants (POPs) are linked to type 2 diabetes (T2D). Taking advantage of the fact that most of the POPs act by binding the aryl-hydrocarbon receptor (AHr), we developed a novel cell-based AHr ligand activity (CALA) assay for serum POPs and found serum AHr binding activity (AHr binding) is increased in T2D (Park WH et al. BioFactors, 2013). In this study we tested if AHr binding is predictive of future development of T2D. Total of 1,537 sera collected in 2008 from the Ansung cohort, a part of Korea Genome and Epidemiologic Study (KoGES) was tested. KoGES was started in 2001 and followed up to 2013 (Cho NH et al. Acta Diabetol, 2013). About half, or 919 cases, had normal glucose tolerance (NGT), 244 cases had impaired glucose tolerance (IGT), and 374 were diabetic (DM).

The mean AHr binding was significantly higher in those subjects who developed IGT or DM within 4 years than who remained NGT. Subjects with IGT or DM had higher AHr bindings than NGT. Many clinical parameters are associated with metabolic syndrome are quantitatively correlated with AHr bindings. From a ROC analysis, the estimated cut-off value of AHr binding predicting progression to DM within 4 years was 2.04 fold, with AHr binding area 82.1%, sensitivity 66.7%, and specificity 83.6%. In the Cox proportional hazards model, cutoff ≥2.04 fold predicted incident diabetes with a RR of 7.5 (95% CI 3.0-18.8) in the unadjusted model and increased risk remained highly significant (RR=4.5, 85% CI 1.8-14) after additional adjustment for other confounding factors, including sex, age, family history of diabetes, smoking and others.

We conclude that the high AHr ligand binding activity in serum predicts the progression to T2D, suggesting a pathogenic role of AHr ligands, probably POPs. CALA assay might be useful as a diagnostic test predicting T2D.
**EPIDEMIOLOGY—CLINICAL—DIAGNOSIS AND SCREENING**

**1532-P**

**Lifetime Risks for Type 2 Diabetes Mellitus: The Rotterdam Study**

SYMMEN LIETHART, THIJN W. VAN HERPT, MAARTEN J.G. LEENING, ALBERT HOFMAN, BRUNO H.C.H. STRICKER, MANDY VAN HOEK, ERIC SJURBRANDS, OS-CAR H. FRANCO, ABBAS DEHGHAN, Stuttgart, Germany

Data on the lifetime risk of type 2 diabetes and the use of blood glucose lowering medication are scarce. Little is known about the lifetime risk of type 2 diabetes in relation to measures of adiposity. We calculated lifetime cumulative incidences for diabetes and the use of blood glucose lowering medication adjusted for competing risk of death free of diabetes in 10,050 participants aged 45 years and older of the prospective population-based Rotterdam Study. Incident diabetes was diagnosed as fasting glucose level ≥7.0 mmol/L and/or the use of blood glucose lowering medication. All analyses were stratified by sex and anthropometric measures. The mean (SD) age of the population was 64.7 (9.7) years and 57.7% were female. During a mean follow-up of 7.9 (4.0) years, 828 participants developed diabetes and 1709 deceased. At the age of 45, the lifetime risk for type 2 diabetes was 31.3% (95% CI 29.3 to 33.3) (30.5% [27.5 to 33.5] for men and 31.9% [29.3 to 34.8] for women). The lifetime risk was lower with increasing age and declined to 6.9% (8.9 to 10.9) at age 85. Lifetime risks were increasing with body mass index (BMI) and waist circumference (WC) both in men and women. At age 45, those with a BMI ≥25 kg/m² had a lifetime risk of 18.8% (15.8 to 21.7), whilst 56.6% (46.7 to 66.6) of those with a BMI ≥25 kg/m² developed diabetes. In addition, those aged 45 with a WC ≥80 cm for women and ≥94 cm for men had a lifetime risk of 19.5% (16.0 to 23.1), whereas 60.9% (51.0 to 70.9) of those with a WC ≥108 cm for women and ≥122 cm for men developed diabetes. The lifetime risk for the use of oral antidiabetic medication was 28.5% (25.0 to 32.0), whereas 9.1% (7.8 to 10.3) became insulin dependent. In conclusion, almost one in three individuals aged 45 will develop type 2 diabetes and will be medication dependent during their remaining lifespan. Our study underscores the importance of lifestyle by showing the effects associated with obesity on lifetime risk of type 2 diabetes.

**1533-P**

**Longitudinal Trajectories of Glucose, Insulin Sensitivity, and Insulin Secretion during Development of Type 2 Diabetes in Japanese: Toranomon Hospital Health Management Center Study**

YORIKO HEIANZA, KAZUYA FUJIHARA, SHIGEKO HARA, OSAMU HANYU, KAZUMI HANYU, KAZUYA HARA, SHIGEKO KOBAYASHI, TETSURO ARAI, YASUJI ARASE, HIRONOHIK ISOHE, Akitaka Japan, Mito Japan, Tokyo Japan, Kyoto Japan

Evidence is limited about long-term trajectories revealed by assessments of insulin and glucose concentrations before development of type 2 diabetes (T2D). To clarify the time point of deteriorating insulin sensitivity and β-cell function during the development of T2D, we investigated 515 individuals without T2D using various measures of glucose and insulin concentrations during a 3-h oral glucose tolerance test over 10 y. Individuals who did not develop T2D (n=454) had consistently low mean fasting values (<67 mg/dL) and postprandial glucose concentrations at 30 min (<155 mg/dL), 60 min (<171 mg/dL), 120 min (<122 mg/dL) and 180 min (<87 mg/dL) over 10 y. Those who later developed T2D (n=61) had higher glucose concentrations at 0 to 120 min even 10 y before diagnosis than those who did not develop T2D; incident cases of T2D also experienced a sharp increase in these glucose measures 3 y before diagnosis. A large difference between cases and non-cases was observed for glucose measurements at 60 min over the total observational period while glucose concentrations at 180 min specifically deteriorated only 1-2 y before diagnosis. Interestingly, those who later developed T2D had constantly reduced insulinogenic index values as a marker of early insulin secretion and reduced whole body insulin sensitivity index levels; these values remained low and did not markedly increase in the late stage before diagnosis. A sharp increase in the homeostasis model assessment index of insulin resistance in the late stage before diagnosis predicted T2D. Results suggested that persons who later developed T2D had clearly elevated glucose concentrations at 60 min rather than other glucose measurements even 10 y before diagnosis. Those who developed T2D also had consistently reduced β-cell function and whole body insulin sensitivity over 10 y before diagnosis, values similar to those observed at diagnosis.

Supported By: Japan Society for the Promotion of Science

**1534-P**

**Family History of Diabetes, Presence or Absence of Metabolic Risk Factors, and 5-Year Incident Risk of Type 2 Diabetes in Japanese Men: Toranomon Hospital Health Management Center Study**

IGARASHI RISA, HEIANZA YORIKO, KIDANMA SATORU, HATTIA MAIKKO, SAITO KAZUMI, HANYU OSAMU, HARA SHIGEKO, KOBAYASHI TETSURO, ARASE YASUJI, SONE HIROHITO, Niigata, Japan, Tokyo Japan

A positive family history (FH) of diabetes is a risk factor for diabetes. We investigated the impact of the combination of FH and a number of metabolic risk factors on the development of diabetes in 8821 persons without diabetes at baseline examination. Diagnosis of diabetes was made by fasting glucose ≥126 mg/dL, HbA1c ≥6.5% or a self-reported history of clinician-diagnosed diabetes. FHs of grandparents, parents or siblings having diabetes were assessed by a questionnaire. Metabolic risk status was assessed by hypertension, dyslipidemia, low HDL cholesterol concentrations and impaired fasting glucose. A metabolically abnormal (MA) state was indicated by having any of these conditions. During a 5-year follow-up, 305 individuals developed diabetes. Compared with individuals with no FHs, those with parental FH had an odds ratio (OR) of 2.61 (95% CI 1.95, 3.45) for developing diabetes. Persons with a bi-parental FH had an OR of 6.65 (2.87, 15.43) for diabetes compared to those with no parental FH of diabetes. Persons with a FH in 2 generations (grandparents and parents) had an OR 4.76 (2.01, 11.32) compared to those without FHs in both generations. In comparison with no FH of diabetes, individuals with FHs in parents and siblings had an OR 5.05 (2.68, 9.52) for diabetes. We investigated the individual and combined effect of metabolic risk factors and FH clustering. MH persons with a FH of diabetes in ≥2 relatives (grandparents, parents, siblings) had an increased risk of developing diabetes with an OR 5.81 (2.72, 11.59) for diabetes compared with MH individuals without FHs. However, MH persons with a FH in only one relative did not have a significantly increased risk of diabetes (OR 1.35 (0.77, 2.38). Although the association of FH with developing diabetes varies according to the presence or absence of MA, we found that individuals with FHs of diabetes in parents or 2 generations were at high risk for developing diabetes.
Combined effects of SHBG and estradiol on incident T2D in male

distribution. Disease states were classified as normal (normal glucose tolerance & fasting glucose, n=623), isolated impaired fasting glucose (iIFG), n=220), and isolated IGT (iIGT, n=56). The associations of metabolites for normal vs. iIFG or iIGT were made using logistic regressions controlling for age, sex, and BMI. Odds ratios for a one SD change in the metabolite level, 95% confidence intervals, and p values (adjusted with a false discovery rate of 0.1) were calculated for each metabolite.

α-Hydroxybutyrate (AHB) was found to be the metabolite most strongly associated with iIGT (2.54 (1.86-3.48), SE-9) while having no significant association with iIFG. The second most strongly associated metabolite with IGT was linoleoylglycerophosphocholine (LGPC) (0.48 (0.35-0.66), SE-6) which was also modestly associated with iIFG (p=0.09). These analyses were replicated for α-HB and LGPC using an identical protocol in the Botnia cohort at baseline (normal n=1105, iIFG n=338, iIGT n=128). AHB was strongly associated with iIGT (2.03 (1.85-2.49), SE-11) with no significant association with IGT. LGPC also were strongly associated with IGT (0.49 (0.40-0.61), SE-11) and modestly associated with IIFG (1.17 (1.06-1.3), SE-3).

In summary, in two different cohorts totalling more than 3,000 nondiabetic subjects, AHB and LGPC were shown to be selective biomarkers of IGT with respect to normal or iIFG.
Elevated diabetes risk: diabetes risk score ≥ 5, HbA1c ≥ 5.8%, FBG ≥ 5.5 mmol/l, 2hBG ≥ 11.1 mmol/l; IIFG: isolated impaired fasting glucose: diabetes risk score ≥ 5, HbA1c < 5.8%, FBG < 5.5 mmol/l, 2hBG ≥ 11.1 mmol/l; TID: 2-hour blood glucose (capillary).
parameters for GA and A1C but not fructosamine, GA may be more likely to be used as a diagnosis test for glucose intolerance.

Table: Glucose Parameters in Lowest & Highest Quintiles of A1C, Glycated Hemoglobin & Fructosamine

<table>
<thead>
<tr>
<th>Glucose Parameters</th>
<th>Quintile</th>
<th>Lowest</th>
<th>Highest</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1C (mg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glycated Hemoglobin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fructosamine (mg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1543-P

Anthropometric Predictors of Type 2 Diabetes among White and Black Adults
Dale Hardy, Devita Stallings, Jane Garvin, Hongyan Xu, Francine Chapin, Susan Racette, Augusta, GA. St. Louis, MO, Tucson, AZ

We compared 6 anthropometric screening predictors for type 2 diabetes (T2DM) in white and black males and females, and determined optimal cut-points for a Body Shape Index (ABSI), body adiposity index (BAI), body mass index (BMI), waist circumference (WC), waist to height ratio (WHtR), and waist to hip ratio (WHR). We used a cross-sectional study design with baseline data (1987-1989) from the Atherosclerosis Risk in Communities study. Our analyses consisted of 15242 participants/1827 diabetes cases (5320/520 black females) aged 45-64 years. All anthropometric predictors were converted to Z scores. Logistic regression odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, physical activity, and family history of diabetes were used to present relationships. The Akaike Information Criterion and Receiver Operating Characteristic C-index were used to calculate best fit model indices. Multivariate odds ratios were highest for WHR (white females: OR=2.68; 95% CI:2.39-3.01) and lowest for ABSI (white males: OR=0.382 (0.365-0.398) and 0.833 (0.814-0.850), respectively. Sensitivity and specificity of HbA1c for diagnosis of pooled prediabetes and diabetes was 0.328 (95%CI 0.308-0.339) and 0.942 (0.936-0.948); when used only for the diagnosis of prediabetes: 0.382 (0.365-0.398) and 0.833 (0.814-0.850), respectively. Sensitivity and specificity of HbA1c used for diagnosis diabetes only was 0.704 (0.695-0.713) and 0.792 (0.777-0.807), respectively (table). In conclusion, HbA1c measurement is a significantly better tool for diagnosis of diabetes than prediabetes in a high risk population. Were it to be used for prediabetes screening or diagnosing, majority of individuals with this condition would be missed.

Table 1. Distribution of glucose intolerance conditions in the studied cohort.

<table>
<thead>
<tr>
<th>Diagnosis (according to FBG or HbA1c)</th>
<th>FBG (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;100 (normal)</td>
<td>461</td>
</tr>
<tr>
<td>100-125 (IFG)</td>
<td>185</td>
</tr>
<tr>
<td>&gt;125 (diabetes)</td>
<td>39</td>
</tr>
<tr>
<td>Total</td>
<td>685</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HbA1c (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5.7 (normal)</td>
</tr>
<tr>
<td>5.7-6.4 (prediabetes)</td>
</tr>
<tr>
<td>&gt;6.4 (diabetes)</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBG = fasting blood glucose</td>
</tr>
<tr>
<td>Supported By: Bayer Diabetes Care</td>
</tr>
</tbody>
</table>

1544-P

WITHDRAWN

1545-P

Prediabetes Screening in High Risk Population with HbA1c
Leszek Gwizdyiak, Elektra Symaninska-Gabalska, Maciej Pawlowski, Jerzy Loja, Lodz, Poland

Symptom-free prediabetes is an optimal time to introduce diabetes prevention measures. Therefore, an effective screening strategy for prediabetes is urgently needed. 5,276 diabetes-free individuals (2,963 women; 56%, aged 45-55 years, who had at least one risk factor for diabetes development took part in a nationwide diabetes screening programme. Participants had fasting blood glucose (FBG) repeatedly measured and HbA1c assessed with the point-of-care device A1cNow (Bayer, Germany). FBG was used for diagnosis of impaired fasting glucose (IFG, 100-125 mg/dl) or diabetes (>125 mg/dl) and served as “gold standard”. HbA1c 5.7-6.4% diagnosed prediabetes, >6.4% - diabetes (Table 1). Sensitivity and specificity of HbA1c used for diagnosis of pooled prediabetes and diabetes was 0.328 (95%CI 0.308-0.339) and 0.942 (0.936-0.948); when used only for the diagnosis of prediabetes: 0.382 (0.365-0.398) and 0.833 (0.814-0.850), respectively. Sensitivity and specificity of HbA1c used for diagnosis diabetes only was 0.704 (0.695-0.713) and 0.792 (0.777-0.807), respectively (table). In conclusion, HbA1c measurement is a significantly better tool for diagnosis of diabetes than prediabetes in a high risk population. Were it to be used for prediabetes screening or diagnosing, majority of individuals with this condition would be missed.

Table 1. Distribution of glucose intolerance conditions in the studied cohort.

<table>
<thead>
<tr>
<th>Diagnosis (according to FBG or HbA1c)</th>
<th>FBG (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;100 (normal)</td>
<td>461</td>
</tr>
<tr>
<td>100-125 (IFG)</td>
<td>185</td>
</tr>
<tr>
<td>&gt;125 (diabetes)</td>
<td>39</td>
</tr>
<tr>
<td>Total</td>
<td>685</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HbA1c (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5.7 (normal)</td>
</tr>
<tr>
<td>5.7-6.4 (prediabetes)</td>
</tr>
<tr>
<td>&gt;6.4 (diabetes)</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBG = fasting blood glucose</td>
</tr>
<tr>
<td>Supported By: Bayer Diabetes Care</td>
</tr>
</tbody>
</table>

1546-P

Investigation of Diabetes Risk in Troponin Negative Chest Pain Admissions
Amara Puttanna, Georgina Moritz, Sophie Harvey, Viraj Patel, Aditi Kumar, Lynn Affaraha, Diana Raskauskiene, Walsall, United Kingdom, Birmingham, United Kingdom, Dudley, United Kingdom

Patients admitted with chest pain are risk stratified and troponin blood tests are performed for those deemed at high risk. Usually cardiac disease is further assessed however this is not the case for metabolic disease despite a large proportion of these patients being at risk of diabetes.

We investigated whether patients admitted with troponin negative chest pain are at a greater risk of developing diabetes with a view to providing evidence for more rigorous screening in this subgroup.

We analysed a retrospective cohort of patients admitted with chest pain to a district general hospital between January to April 2009 and with a negative troponin test. Patients with pre-existing diabetes were excluded. Patients’ blood tests were analysed during the subsequent 5 years to establish further glycaemic testing and any abnormalities. American Diabetes Association (ADA) guidance on blood test values for diabetes and pre-diabetes were utilised.

257 patients (156 male, 101 female, mean age 56.2 years) were reviewed for 5 years post admission.

92 (35.8%) patients subsequently developed pre-diabetes; 83 patients had impaired fasting glucose (IFG), 8 patients had HbA1c in pre-diabetes range and 1 patient had impaired glucose tolerance according to ADA criteria.

Of the patients with pre-diabetes, 28 (34.4%) developed diabetes and of the 195 remaining patients without glycaemic abnormalities, 1 developed diabetes. This gave a relative risk of developing diabetes if troponin negative and having pre-diabetes of 50.

32.7% of our study population had impaired fasting glucose which is higher than previously suggested data in the general population. We also found that patients who developed diabetes were more likely to present with higher blood sugar levels (mean blood glucose 6.7 mmol/l vs. 6.5mmol/l, p = 0.05).
Our findings suggest that focused screening of troponin negative chest pain patients for diabetes or pre-diabetes is necessary to target patients in this "at risk" subgroup and reduce the healthcare burden.

1547-P
Fatty Liver Index (FLI) Is Independently Associated with Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) in Patients with Type 2 Diabetes
GIUSEPPINA MANZONI, FEDERICO MARTUCCI, MARIA GRAZIA RADAELLI, ALICE OLTOLINI, SILVIA PERRA, ELISABETTA DEVECCHI, GUIDO LATTUADA, GIULIANA PERSEGHIIN, Monza, Italy

NAFLD is independently related to CVD and CKD. Our aim was to assess whether FLI, a surrogate marker of NAFLD based on BMI, waist, GGT, fasting serum triglycerides, was associated with micro- and macro-vascular complications of type 2 diabetes. Among the 1,621 diabetic patients in stable clinical conditions who attended our secondary care diabetes clinic at least twice in 2012, FLI was obtained in 870 patients (whose features were not different than those of the entire population). Patients were segregated in three categories based on a FLI score lower than 30 (n=100), between 30-60 (n=213) and higher than 60 (n=557) as originally proposed. Age was higher in those with the highest FLI score but duration of the disease (9±8 years), insulin use, anti-diabetic, anti-cholesterol and anti-hypertensive drugs were not different with the exception of GLP1 receptor agonists, ARB and allopurinol which were more common in those with the highest FLI score.

Fasting plasma glucose, HbA1c, blood pressure, heart rate, uric acid, total cholesterol, HDL cholesterol, AST and ALT but not LDL-cholesterol were all higher in those with the highest FLI score regardless of drug therapy. CVD (24%, 46% and 37% in those with FLI lower than 30, between 30-60 and higher than 60 respectively; p<0.001), microalbuminuria (11%, 38%, 49%; p<0.0001), eGFR < 60 mL/min (12%, 26%, 23%; p=0.03), but not retinopathy (14%, 19%, 16%; p=0.65), were more prevalent among patients within higher FLI score and this association was independent of age, sex, duration of the disease, parameters of the metabolic syndrome and therapy. In conclusion, the demonstrated independent association of FLI with CVD and CKD in patients with long lasting type 2 diabetes supports the hypothesis of a prognostic role of fatty liver, to be assessed as a continuous variable, in the natural history of the disease.

1548-P
The Diagnostic Validity of NerveCheck: From Functional and Structural Damage of Small and Large Nerve Fibres to Neuropathic Pain GEORGIOS PONIRAKIS, MARIA ODRIOZOLA, IDAINIS NIKOLAOS PETROPOULOS, SHAZLI AZMI, MARYAM FERDOUSI, HASSAN FADAVI, UAZMAN ALAM, E. GRAHAM, SZILARD VOROS, EDDIEELLE, GUIDO LATTUADA, GUIDO LATTUADA, MIROS, SUZANNA ODRIOZOLA, J. VIDAL, R. GOMIS, ARIEL ODRIOZOLA, RAYAZ LOS, SHAZLI AZMI, MARYAM FERDOUSI, HASSAN FADAVI, UAZMAN ALAM, GEORGIOS PONIRAKIS, MARIA ODRIOZOLA, IOANNIS NIKOLAOS PETROPOULOS, ALICE OLTOLINI, SILVIA PERRA, ELISABETTA DEVECCHI, GUIDO LATTUADA, GIULIANA PERSEGHIIN, Monza, Italy

NerveCheck is a new device (cost $700) for QST assessment. We have assessed its reproducibility and diagnostic validity against established QST devices and its diagnostic ability to detect large (LFN) and small fibre neuropathy (SFN) as well neuropathic pain symptoms. 143 subjects (18 with painful, 55 with painless diabetic neuropathy and 70 controls) underwent QST assessment with NerveCheck; large fibre testing (vibration perception threshold (VPT) (Neurothesiometer), Sural Sensory Action Potential (SNAP)) and small fibre testing (cold (CPT) and warm perception threshold (WPT) (Neurothesiometer), Sural Sensory Action Potential (IENFD)).

The Diagnostic Validity of NerveCheck: From Functional and Structural Damage of Small and Large Nerve Fibres to Neuropathic Pain. NerveCheck showed a diagnostic efficiency of 86%, 79% and 71% for VPT, CPT and WPT, respectively for VPT (Neurothesiometer) and thermal sensation (TSA-II). The AUC of VPT for SNAP (82.2%) was significantly higher than for IENFD (60.5%, p=0.028).

There was a significantly greater nerve dysfunction in subjects with painful compared to painless neuropathy (VPT 2.51 vs. 5.01, p=0.008, CPT 3.17 vs. 4.72, P<0.005 and WPT 3.51 vs. 4.79, p=0.001).

1549-P
Exosomes-associated microRNA Profiling in Type 1 Diabetes MARTA GARCIA-COSTA, DARIO F. DI LAURIA, ARMANDO MENDEZ, CAMILLO RICORDI, MILOS M. M. A403

Type 1 diabetes (T1D) is a disease characterized by an autoimmune-mediated total or near-total destruction of the pancreatic beta cells, leading to a substantial or complete loss of insulin secretion. There is a need for biomarkers of T1D for assessment of the risk of developing the disease, for monitoring progression and the clinical response to treatments. Exosomes are microvesicles released by most of cell types and found in biological fluids including blood, saliva, and urine. Exosome miRNA profiling has emerged as a powerful tool to accelerate biomarker discovery. The goal of this study was to identify plasma exosome-derived microRNAs as new biomarkers and the consequent relation of those with T1D. We used a microarray containing 800 miRNAs in order to profile the exosome miRNA content of T1D patients (n=12) and gender and age matched control subjects (n=12). The microRNA array identified one up-regulated miR-25-3p (p=0.0014) and six down-regulated miRNAs miR-18-5p (p<0.015), miR-302-3p (p=0.0461), miR-378e (p<0.0001), miR-570-3p (p<0.0001), miR-574-5p (p=0.0002) and miR-579 (p=0.0013) in T1D patients compared to the controls. These results were validated by real-time PCR in an additional cohort of T1D patients and control individuals (n=17) per group that confirmed the significant down-regulation of miR-378e (fold change 1.75, p=0.0003), miR-570-3p (fold change 4.45, p<0.0001) and miR-574-5p (fold change 2.24, p=0.0458). The miRNAs identified that were differentially expressed in T1D patients versus healthy individuals were assigned to a possible target by informatics tools, showing that the majority of identified targets were involved in metabolic pathways. In conclusion, our study indicates that exosome miRNA profiling may provide potential biomarkers of T1D but also new insights in the disease.

1550-P
Application of New Cholesterol Guidelines to the Korean Adult Diabetic Patients BU KYUNG KIM, YOUNG SIK CHOI, SU KYOUNG KWON, HYEON CHANG KIM, KYOUNG HWA HA, DAE JUNG KIM, Buxan, Republic of Korea, Seoul, Republic of Korea

The 2013 guidelines of the American College of Cardiology and the American Heart Association (ACC-AHA) for the treatment of cholesterol expand the indication for statin therapy. The aim of this study is to evaluate how many diabetic patients have received appropriate statin therapy and to estimate how many patients would be indicate for statin therapy according to ATP-III and new ACC-AHA guideline in Korea. We analyzed the data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012. We estimated the number of diabetic patients who already had treated dyslipidemia and for whom statin therapy would be recommended according previous guideline and new guideline.

Of the total 1,975 diabetic patients, 377 (19.1%) were receiving drug for dyslipidemia. Among 1,598 patients who had not taken any medicines for dyslipidemia, 85.6% (1,048) would be indicated for statin therapy according to ATP-III guideline. When we apply to new ACC-AHA guideline, 94.3% (total=1,506, 72.8% (n=1,163) need moderate-high intensive and 21.5% (n=343) need moderate intensive) would be eligible for statin therapy. Among the total diabetic patients, as compared with the ATP-III guidelines, the new guidelines would increase the number of eligible for statin therapy 53.1% to 76.2%.

In present practical situation, many diabetic patients have not received appropriate statin therapy. The new ACC-AHA guidelines would increase the number of diabetic patients who would be eligible for statin therapy in Korea.

1551-P
New Fasting Index Improves Detection of Impaired Glucose Tolerance JAMES V. POTTALA, STEPHEN A. VARREL, DAWN L. THISELTON, TARA DALL, JOSEPH P. MCCONNELL, G. RUSSELL WARNICK, MACKIE SASINOWSKI, TIMOTHY E. GRAHAM, SULIARD VOROS, Richmond VA, Salt Lake City, UT

Oral glucose tolerance testing (OGTT) defines impaired glucose tolerance (IGT, i.e. 2-hour plasma glucose a 140 mg/dl post 75 gm oral glucose); however, OGTT is time-consuming, inconvenient, and difficult to perform in routine clinical practice. We sought to determine whether novel fasting
Epidemiology—Clinical—Diagnosis and Screening

1552-P Excess in Hemoglobin Glycation and Glycemic Variability in Obese Individuals without Known Dysglycemia

Paul Valens, Marwins Fyskedis, Amel Rezk, Isabela Banu, Camille Cussac-Pilegian, Sabrina Chiehe, Emmanuel Coisson, Bondy, France

We previously showed that, in obese individuals without known dysglycemia, age was a determinant of hemoglobin glycation. A mathematical relation has been proposed (ADAG) between HbA1c and mean glucose levels given by continuous glucose monitoring (CGM). We aimed to assess in overweight or obese patients the difference between the HbA1c level predicted by this relation and the measured HbA1c level and the determinants of this difference.

Seventy patients (age 46.5±14.3 years, BMI 35.2±6.8 kg/m²) without known dysglycemia had a CGM during 24h in stable condition. Mean glucose and MAGE (mean amplitude glycemic excursion) were calculated. Predicted HbA1c was calculated using the formula mean glucose=1.649*HbA1c-2.645 and compared to measured HbA1c (ΔHbA1c). An OGTT was performed.

Measured HbA1c was 5.1% to 7.4%. According to the ADAG 24 patients had prediabetes (fasting hyperglycemia and/or glucose intolerance) and 13 had diabetes. The population was separated into quartiles of measured HbA1c (Q1 to Q4). In each quartile, measured HbA1c was higher than predicted HbA1c (p<0.01 to <0.0001). ΔHbA1c increased significantly from Q1 to Q4 (6.0±3.23 to 7.7±3.04; 3.8±5.02 to 1.1±3.01%; p<0.038). In the overall population, ΔHbA1c correlated with age (r=0.536; p<0.0001) and MAGE (r=0.494; p=0.0001). In multivariate analysis ΔHbA1c remained associated with age, MAGE and HbA1c quartiles (p=0.002, 0.017, 0.006, respectively; adjusted R² of the model=0.43).

In obese individuals with normal or mildly elevated HbA1c levels and dysglycemia on OGTT for half of them, HbA1c levels are higher than predicted by mean glucose. This possible excess of hemoglobin glycation is determined in particular by 24-h glycemic variability.

1553-P Progression to Diabetes and Prediabetes among Nondiabetic Asian Indian Subjects Based on Baseline Glycated Hemoglobin Levels

Mohan Deepa, Rajendra Pradeepa, Ranjit Unnikrishnan, Coimbatore Subramaniam Shanthirani, Ranjit Mohan Anjana, Viswanathan Mohan, Chennai, India

We report on the 10-year progression to diabetes or prediabetes based on baseline glycated hemoglobin (A1c) in 975 adults aged ≥20 years from the baseline survey of Chennai Urban Rural Epidemiology Study (CURES) conducted between 2001-2003. We excluded individuals with self reported diabetes and those who were detected to have diabetes at baseline. Oral glucose tolerance tests and A1c estimations were performed at baseline, and after a median follow-up period of 8.9 years. On follow up, diabetes was diagnosed if fasting plasma glucose was ≥200mg/dl or 2hr post glucose was ≥200 mg/dl or A1c ≥5.5% [48 mmol/mol]. When subjects were stratified according to baseline A1c, the overall incidence rates of diabetes were 14.1, 30.1 and 54.6 per 1000 person-years and the age and gender adjusted hazard ratios (95% CI) for diabetes were 1.0 (reference), 2.0 (1.4-2.8) and 3.5 (2.4-5.1) for those with A1c ≥5.5% [37-41 mmol/mol] and 6.0-6.4% [42-46 mmol/mol], respectively. ROC curves showed that baseline A1c of 5.7% [39 mmol/mol] had 62% sensitivity, 66.2% specificity and AUC of 0.685 to predict development of diabetes.

Table 1.

<table>
<thead>
<tr>
<th>HbA1c Category (Baseline)</th>
<th>&lt;5.5%</th>
<th>5.5-5.9%</th>
<th>6.0-6.4%</th>
</tr>
</thead>
<tbody>
<tr>
<td>[-37 mmol/mol]</td>
<td></td>
<td>[-41 mmol/mol]</td>
<td>[-42-46 mmol/mol]</td>
</tr>
<tr>
<td>n</td>
<td>407</td>
<td>389</td>
<td>179</td>
</tr>
<tr>
<td>Cases of incident diabetes</td>
<td>49</td>
<td>103</td>
<td>77</td>
</tr>
<tr>
<td>Cases per 1000 person years</td>
<td>14.1</td>
<td>30.1</td>
<td>54.6</td>
</tr>
<tr>
<td>Hazard Ratio for Diabetes (95% CI, p value)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c Category</td>
<td>Model 1: Unadjusted</td>
<td>Model 2: Age and Gender Adjusted</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------</td>
<td>---------------------------------</td>
<td></td>
</tr>
<tr>
<td>&lt;5.5% (reference)</td>
<td>1.0</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>5.5-5.9%</td>
<td>2.0 [1.4-2.8, &lt;0.001]</td>
<td>2.0 [1.4-2.8, &lt;0.001]</td>
<td></td>
</tr>
<tr>
<td>6.0-6.4%</td>
<td>3.5 [2.5-5.2, &lt;0.001]</td>
<td>3.5 [2.5-5.1, &lt;0.001]</td>
<td></td>
</tr>
</tbody>
</table>

1554-P Prediction Model for Developing Impaired Glucose Tolerance: The Insulin Resistance Atherosclerosis Study (IRAS)

Carlos Lorenzo, Anthony J. Hanley, Marian J. Rewers, Andrew J. Karter, Steven M. Haffner, San Antonio, TX; Toronto, ON; Canada, Aurora, CO; Bainbridge Island, WA

We predicted that diabetes has attracted considerable interest. However, there are no prediction models for early worsening of glucose tolerance status. Therefore, we aimed to develop a prediction model for developing impaired glucose tolerance (IGT) using a stepwise forward selection procedure. A 75 g OGTT was administered at baseline and follow-up visits among 559 IRAS participants who had normal glucose tolerance at baseline. A total of 120 participants developed incident IGT during a mean follow-up period of 5 years. Insulin sensitivity index ($\tilde{S}$) and acute insulin response (AIR) were directly measured by the frequently sampled intravenous glucose tolerance test. Model fit was improved by adding AIR and $S$ (Model 3) to commonly used diabetes predictors (Model 1), but was not changed by homeostasis model assessment of insulin resistance (HOMA-IR) and β-cell function (HOMA-β cell) (Model 2). In addition to a greater area under the ROC curve, Model 3 added predictive value to Model 1. AIR was required for model improvement. In summary, insulin secretion is a stronger predictor of short-term progression to IGT than insulin resistance (as is true of diabetes). Direct measures of insulin sensitivity and secretion optimize the prediction of early worsening of glucose tolerance status. However, this is less practical in usual care settings.

Table. Models Predicting Progression to IGT Using a Stepwise Forward Selection Procedure.

<table>
<thead>
<tr>
<th>Independent variables</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hispanic vs. non-Hispanic white</td>
<td>1.21</td>
<td>0.450</td>
<td>1.20</td>
</tr>
<tr>
<td>- Family history of diabetes (yes vs. no)</td>
<td>1.43</td>
<td>0.008</td>
<td>1.43</td>
</tr>
<tr>
<td>- 2h glucose (×1 SD)</td>
<td>1.91</td>
<td>&lt;0.001</td>
<td>1.91</td>
</tr>
<tr>
<td>- Log HOMA-IR (×1 SD)</td>
<td>-</td>
<td>-</td>
<td>1.10</td>
</tr>
<tr>
<td>- Log HOMA-β cell (×1 SD)</td>
<td>-</td>
<td>-</td>
<td>-0.84</td>
</tr>
<tr>
<td>- Log AIR (×1 SD)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>- Log S (×1 SD)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Overall model</td>
<td>p-value</td>
<td>p-value</td>
<td>p-value</td>
</tr>
<tr>
<td>Area under the ROC curve</td>
<td>0.692</td>
<td>Ref.</td>
<td>0.695</td>
</tr>
<tr>
<td>Integrated discrimination improvement</td>
<td>- Ref.</td>
<td>0.001</td>
<td>0.509</td>
</tr>
<tr>
<td>Net reclassification improvement (%)</td>
<td>-</td>
<td>Ref.</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Age, sex, African American, waist circumference, and fasting glucose were not retained in any model.

* - Estimates of area under the ROC curve given by bootstrap method.

Supported By: National Heart, Lung, and Blood Institute; National Center for Research Resources

For author disclosure information, see page A810.
Serum Preadipocyte Factor 1 Concentrations and Risk of Developing Diabetes: A Nested Case-Control Study  
SEUNG-HWAN LEE, YEO-REE YANG, HAE KYUNG YANG, HYUK-SANG Kwon, YONG-Moon Park, Bong-Yun Cha, KUN-Ho Yoon, Seoul, Republic of Korea. Columbia, SC

Preadipocyte factor 1 (Pref-1) is a preadipocyte secreted protein that plays an inhibitory role in adipogenic differentiation and is also involved in the proliferation and differentiation of various precursor cells. It has been associated with various metabolic parameters, but with inconsistent results. This study aimed to determine whether Pref-1 could be a predictive marker for the development of diabetes in people without diabetes. A population-based, nested case-control study of individuals who progressed to diabetes (n=43) or prediabetes (n=345) and age, sex, and fasting plasma glucose (FPG) matched control participants who maintained normal glucose tolerance (n=389) during a 4-year follow-up was performed using data from the Chungju Metabolic disease Cohort Study. Circulating levels of Pref-1 were measured by ELISA assay. Baseline serum Pref-1 levels showed a stepwise decrease across the glucose tolerance status at follow-up. Individuals whose FPG level had increased or whose homeostasis model assessment of beta-cell function had decreased at follow-up showed significantly lower levels of Pref-1 compared to their control group counterparts. Adjusting for age, body mass index, FPG, serum insulin levels, systolic blood pressure, and triglycerides, the incidence of diabetes was nearly threefold higher in the lowest versus the upper three quartiles of circulating Pref-1 (relative risk, 2.794; 95% CI, 1.188-6.571; P=0.0198). Of note, these findings were significant in women but not in men. In conclusion, levels of circulating Pref-1 may be a useful biomarker for identifying women at high risk for developing diabetes.

Incidence of Childhood Type 1 Diabetes in Italy during 2004-2013  
VALENTINE CHIURINO, RICCARDO JESUTA, MARISA BEZAIA, MARELLA BUZZESE, GIUSEPPE D’ANNUNZIO, LUCIA FERRITO, ANNAPAOLOA FRONGIA, DARIO IAFUSCO, ANTONIO IANNINI, LORENZO IUGHERTI, FORTUNATO LOMBARDI, SILVANO PIFFER, SONIA TONI, STEFANO TUMINI, EDURA SKRAMI, FLAVIA CARLE, RIDI STUDY GROUP, Ancona, Italy; Ascoli, Italy; Lecce, Italy; Genova, Italy; Cagliari, Italy; Naples, Italy; Modena, Italy; Messina, Italy, Florence, Italy, Milan, Italy; Trento, Italy; Milan, Italy. 

Childhood type 1 diabetes has been shown an increase in Italy of 3.0% during 1990-2003. Aim of this study was to describe the incidence for type 1 diabetes in children 0-14 years in the same geographical area, during 2004-2013, according to gender, age and area of residence. Registry for type 1 diabetes mellitus in Italy (RIDI) is a coordination of local registries established in 1997. Eleven registries, distributed throughout the country, contributed to this analysis, covering more than 25% of the total Italian population. Cases were grouped into four macro-area of residence at diagnosis: North, Centre, South, and Sardinia. The incidence rates were age-standardized on the World Standard Population. 95% Confidence intervals (95% CI) were estimated assuming the Poisson distribution. In total, 12,557 cases were regarded as type 1 diabetes in the study period (2004-2013), with 2,958 cases in the last year of registry function, 2013. The incidence rates were 6.4 and 5.3 for males and females, respectively. The overall incidence was 6.5 (95% CI: 6.1-6.9) for males, and 5.4 (95% CI: 5.0-5.8) for females. For males, the incidence rate in the youngest age group (0-4 years) was 12.6 (95% CI: 11.6-13.7), while for females it was 11.2 (95% CI: 10.4-12.1). For older age groups, higher rates were observed only in females. The incidence rates for type 1 diabetes were higher in males than females in all age groups except for the age group 15-19 years. The overall incidence rates were higher in males than females, with a ratio of 1.2 (95% CI: 1.1-1.3) for the entire study period. The incidence rates were stable in males during the study period, with a slight increase in females. In conclusion, childhood type 1 diabetes in Italy has shown an increase in incidence rates during 2004-2013, with a higher incidence in males and the highest incidence rates observed in the youngest age group. The trend suggests a continuing increase in incidence rates, with a higher incidence in males than females. Further studies are needed to investigate the factors contributing to this increase, especially in females.
**EPIDEMIOLOGY—CLINICAL—DIAGNOSIS AND SCREENING**

**1559-P**

**Redefining Reactive Hypoglycemia from a Population Study**

JEAN HUANG, HORYNG-YEH OU, RUDRUDREE KARNCHRANASUW, WEI FENG, RAYNOLD SAMOA, LEE-MING CHUANG, KEN C. CHIH, DUANE CA, TAIWAN, TAIWAN, KANSAS CITY, KS, TAIPEI, TAIWAN

Whipple Triad currently serves as the standard for reactive hypoglycemia diagnosis. However, repeated hypoglycemia could induce automatic dysfunction causing unawareness of symptoms. Furthermore, the glucose level of reactive hypoglycemia is still undefined. We used the data from NHANES to redefine reactive hypoglycemia.

We included adult non-diabetic subjects (≥20 y/o) with data of fasting plasma insulin available from the NHANES 1999-2010. Diabetes was defined as established diabetes, fasting plasma glucose (FPG) ≥126 mg/dl, 2-hour plasma glucose (2hPG) ≥200 mg/dl or Hba1c ≥6.5%. Linear regression analysis was applied with the data of FPG and fasting plasma insulin (FPI) predicting the plasma glucose at zero insulin. Non-diabetic subjects with 2hPG ≥50mg/dl were examined for reactive hypoglycemia prevalence accordingly.

After excluding diabetic subjects, there are 11,483 subjects in the study (52.72% female, age 47±19 y/o, BMI 28.07±2.23 kg/m², A1c 5.3±0.4%, FPG 98±10 mg/dl, FPI 11.56±9.84 μU/ml, mean ± SD). With linear regression analysis, FPI=−13.0216+(0.2510×FPG), (r=0.2568; p<0.0001). When insulin secretion approaches near zero, plasma glucose was estimated to be 51.88mg/dl. Accordingly, 50mg/dl was chosen to define reactive hypoglycemia. Among the non-diabetic subjects, there were 1.11% subjects with 2hPG ≤50mg/dl. The subjects with 2hPG ≤50mg/dl are fewer female, younger BMI, lower fasting plasma glucose, higher insulin resistance, and with fewer glucose intolerant subjects (All p<0.001). The delta plasma glucose obtained from 2hPG subtracting FPG was -50±11 mg/dl in subjects with 2hPG ≤50mg/dl compared to 21±42 mg/dl in subjects with 2hPG >50mg/dl (p=0.0001).

From our observation, FPI approaches zero when FPG approaches 50 mg/dl, which we used as our definition of hypoglycemia. Prevalence of reactive hypoglycemia is 1.11%. Based on characteristics of the reactive hypoglycemia population, delta plasma glucose could be a good screening test for reactive hypoglycemia in non-diabetic subjects.

**1560-P**

**Self-Perceived Distress and Diabetes Risk among Young Men**

GILAD TWIG, HERTELZ C. GERSTEIN, EVA FRUCHTER, AVI SHINA, ARNON AFK, ESTELE DERAZNE, DORIT 12UR, TALI CUKIERMAN-YAFFE, DANIELA AMITAL, HOWARD AMITAL, AMIR TIRUSH, RANAN GAT, ISRAEL, HAMILTON, ON, CANADA, JERUSALEM, ISRAEL, MONTREAL, QUEBEC, AND BOSTON, MA

Our goal was to assess the effect of self-perceived emotional distress on T2D incidence among young adults.

Incident diabetes was assessed among 32,586 men (mean age 31.0±5.6 years) with no history of T2D from the prospectively followed young adults of the MELANY cohort (mean follow-up 6.3±4.3 years). Distress level was assessed repeatedly by asking participants, “Are you preoccupied by worries that affect your overall wellbeing?” as part of a computerized questionnaire. The association between reported distress and incident T2D was determined using time-dependent Cox proportional hazard model.

There were 732 cases of T2D during 206,382 person years. The prevalence of distress was 53% higher in men with T2D compared to 21±42 mg/dl in subjects with 2hPG <50mg/dl (p<0.0001). Prediabetes was present in 56% (IFG 10%, IGT 10.6%, IFG+IGT 5.3%, Hba1c alone 30.2%). Prediabetes by Hba1c, regardless of OGTT, was present in 47%. Patients with prediabetes by Hba1c alone were compared to those with IFG and/or IGT and normoglycemic controls for blood pressure (BP), plasma lipids, and insulin levels (BMI and age as covariates). Systolic and diastolic BP, VLDL, HDL, cholesterol, triglycerides, and fasting insulin for patients prediabetic by OGTT criteria were worse than normoglycemic values (P<0.05 or better), but did not differ between patients prediabetic by Hba1c alone and those with normoglycemia. VLDL was higher in Hba1c prediabetes compared to normoglycemia (26±0.9 vs. 22±0.7 mg/dl, P=0.012).

Further prominent differences were observed between prediabetic and normoglycemic patients by OGTT criteria in these Latino patients. Patients diagnosed with prediabetes by Hba1c alone do not differ from normoglycemic patients for most cardiometabolic variables, but may represent a stage on a continuum between normoglycemia and abnormal glucose tolerance.

**1562-P**

**Glycated Albumin May Be a Useful Indicator for Beta-Cell Dysfunction and Impending Diabetes in Prediabetic Condition**

SOO MIN HUNG, SANG YOOL RHEE, YOO-CHEDL HWANG, CHANG HEE JUNG, KWANG JUON KIM, BYUNG-WAN LEE, WON SEON JIN, CHEOL-YOUNG PARK, SANG MAN JIN, JAE HYEDIN KIM, JEONG-TAEK WOO. Seoul Republic of Korea

Prediabetes is known as a pre-clinical stage of increased risk for overt diabetes mellitus (DM) and cardiovascular disease. Because glycated albumin (GA) has been suggested to have more potential for assessing insulin secretory dysfunction and glycemic fluctuation than Hba1c, we studied the clinical significance of GA in this stage.

We enrolled 1,375 anti-diabetic drug naïve subjects in a retrospective, multi-center, cross-sectional manner. According to 75-g oral glucose tolerance tests (OGTTs), the subjects were separated into normal glucose tolerance (NGT), isolated impaired fasting glucose (i-IFG), isolated impaired
glucose tolerance (i-IGT), combined glucose intolerance (IGI), and DM groups. The clinical characteristics of these five groups were measured, including GA, insulin sensitivity index (HOMA2%-S), and insulin secretory index (HOMA2%B).

Mean GA was 11.6±1.4, 12.3±1.8, 12.3±1.9, 13.0±1.9, and 18.8±7.9 mg/dl in the NGT (n=295, 21.4%), i-IGT (n=257, 18.6%), i-IGT (n=103, 7.4%), CI (n=257, 18.6%), and DM (n=486, 34%) subgroups, respectively. After adjusting covariates, the adjusted mean GA levels were 12.2±0.1, 12.3±0.2, and 13.1±0.1 in the i-IGT, i-IGT, and CI subgroups, respectively; post-hoc analysis revealed that levels were significantly higher in the CI group (p<0.001). The Adjusted mean HbA1c levels were also significant, respectively, but were not distinguished from each subgroup by post-hoc analysis. Moreover, the correlation coefficients between GA and HOMA2%-S (r=0.567, p<0.001), and between GA and HOMA2%-B (r=0.013, p=0.325) were higher than those between HbA1c and HOMA2%-S, and between HbA1c and HOMA2%-B. And these results were remained significant after adjusting covariates. We suggest that GA might be a better indicator for screening impending diabetes and assessing β-cell dysfunction in prediabetic subjects.

Supported By: Republic of Korea Ministry of Health and Welfare (HI10C2020)

**1563-P**

Pancreatic Beta-Cell Function, Insulin Sensitivity, and Metabolic Phenotypes in Type 2 Diabetes at the Time of Diagnosis—The Verona Newly Newly diagnosed Type 2 Diabetes Study (VNDS)

MARCÒ DAURIZ, RICCARDO C. BONADONNA, MADELADELLA TROMBETTA, LINDA BOSSELLI, LORENZA SANTI, CORINNA BRANGERI, ISABELLA PICHIRI, CRISTIANO MOLINIO, ROBERTO MCCIULLI, STEFANO DEL PRATO, ENZO BONORA, Verona, Italy, Parma, Italy, Fka, Italy

Presence and frequency of beta cell (BC) dysfunction (BCD) and insulin resistance (IR) in patients with newly diagnosed type 2 diabetes mellitus (NDT2D) are imperfectly known, because previous studies used small cohorts and/or only surrogate indexes of BC function and IR. We assessed BC function and IR with state-of-art methods in the VNDS. In 712 GADA-negative, drug naive, consecutive Italian NDT2D patients we assessed: 1. standard parameters; 2. insulin sensitivity (IS) by the euglycaemic insulin clamp function by state-of-art modeling of prolonged (5 hours) OGTT-derived glucose/C-peptide curves. Thresholds for BCD and IR were the 25th percentiles of BC function and IS assessed with the same methods of the VNDS in Italian subjects with normal glucose regulation of the GEN-EYF (n=340) and GISIR (n=389) studies, respectively. In the VNDS, 89.9% [95% CI: 87.6 - 92.0%] and 87.8% [85.4 - 90.2%] patients had BCD and IR, respectively. Patients with only one defect were 19.7% [16.8 - 22.6%]. Isolated BCD and isolated IR were present in 10.9% [8.6 - 13.2] and 8.9% [8.8 - 11.0] patients, respectively. Coexistence of BCD and IR was observed in 78.9% [75.9 - 81.9%] of the patients. 1.4% [0.5 - 2.3%] of the patients had no detectable alterations in BC function and IS. Patients (19.7%) with only one metabolic defect had lower BMI, fasting glucose, HbA1c, triglycerides and BC function, and higher HDL-cholesterol and IS than patients with both BCD and IR (p<0.01 after Bonferroni’s correction). In conclusion, in NDT2D patients: 1. at least 75.9% have both BCD and IR; 2. At least 67.6% and 85.4% have BCD and IR, respectively. 3. At least 16.8% have only one defect and a significantly different (milder) metabolic phenotype compared to patients with both defects. These findings may be relevant to therapeutic strategies centered on the metabolic phenotype of the patient. ClinicalTrials.gov Identifiers: NCT0087980, NCT01852720

**1564-P**

Glycemic Status and Metabolic Features of Patients with Adrenal Incidentalomas With or Without Subclinical Cushings’ Syndrome

SOGEIKIM KIM, Bucheon, Republic of Korea

The aim of this study was to examine the clinical characteristics of adrenal incidentalomas discovered by computed tomography (CT) and to investigate glycemic status and metabolic features of subclinical Cushings’ syndrome (SCS) in patients with adrenal incidentalomas in a tertiary hospital in Korea. This retrospective study examined clinical aspects of 268 patients with adrenal incidentalomas discovered by CT at Soonchunhyang University Bucheon Hospital. Clinical data and endocrine function of the patient as well as historical findings were obtained from medical records, while the analytic characteristics were analyzed by laboratory and CT study. Hormonal tests for pheochromocytoma, Cushings’ syndrome, and aldosterone secreting adenoma were carried out. Most (n=218, 81.3%) cases were non-functioning tumors. Of the 50 patients with functioning tumors (16.7%), 19 (7.1%) were diagnosed with SCS, 13 (3.4%) with overt Cushings’ syndrome, 12 (4.5%) with primary aldosteronism, and 10 (3.7%) with pheochromocytoma.

Malignant tumors (both primary and metastatic) were rare (n=2, 0.7%). Body mass index, fasting glucose, Hba1c, and total cholesterol were significantly higher in patients with SCS in comparison with those with non-functioning tumor. The prevalences of type 2 diabetes mellitus and hypertension were significantly higher in patients with SCS compared to those with non-functioning tumors. Functioning tumors, especially those with subclinical cortisol excess, is commonly found in patients with adrenal incidentalomas although malignancy is rare. In addition, patients with SCS in adrenal incidentalomas have adverse metabolic and cardiovascular profiles.

**1565-P**

Serum Uric Acid: As a Strong and Independent Predictor of Metabolic Syndrome after Adjusting Body Compositions

TAE YU NUI, JI EUN JUN, SANG-MAN JIN, JI CHEDL BAE, KYU YON HUR, MYUNG-SHII MEON, KYU-YII MEON, JAE HYEON KIM, Seoul, Republic of Korea

Some observational studies have reported that serum uric acid (SUA) levels are one of the determinants of the metabolic syndrome (MetS). However, several previous studies reported combined results for men and women after adjusting for sex and there were few studies that body compositions were taken into account. Therefore, we performed this sex-specific follow-up study to investigate how the longitudinal effects of baseline SUA levels influence the incident MetS including body compositions as an adjusting factor in a large number of subjects. A total of 15,247 participants (9,291 men and 5,956 women) taking a medical check-up program without diagnosed MetS at baseline were enrolled. Separate analyses were performed for men and women including body compositions as a confounding factor. Cox proportional hazards models were used to quantify the independent association between SUA levels and incident MetS. During 68,709 person-years of follow-up, there were 4483 (3174 in men, 1309 in women) incident cases of MetS between 2006 and 2012. After full adjustment for multiple potential confounders, glucose metabolic confounders, lipid metabolic confounders and body compositions, SUA levels were significantly associated with incident MetS (per 1mg/dl, hazard ratio [HR]=1.076, 95% confidence interval [CI]: 1.034-1.120, p < 0.001) in men, HR=1.114, 95% CI: 1.015-1.222, p=0.023 in women, respectively. This study demonstrated that SUA levels are strong and independent predictor of MetS and this result remained after full adjustment for multiple associated confounders including body compositions, both men and women.

**1566-P**

Skin Advanced Glycation End Products (AGE) Fluorescence Identifies Abnormal Glucose Tolerance Independent of Levels of HbA1c and Soluble Receptor for Advanced Glycation End Products (sRAGE)

BHASKARAN SAROJAM REGIN, COMBATORRE SUBRAMANIAM SHANTHIRANI, ABHILIT SHINY, RAJENDRA PRADEEP, MOHAN DEEPA, JOHN MAYNARD, BHASKARAN SAROJAM REGIN, COIMBATORE SUBRAMANIAM SHANTHIRANI, India

Skin AGE fluorescence has been widely studied and linked to the development of diabetic complications. Recent studies suggest their utility in screening for abnormal glucose tolerance (AGT). Using Scout DS, a non-invasive, point-of-care (POC) diabetes screening device, we have recently demonstrated that SCOUT is an effective tool for AGT screening in Asian Indians. In this study, we evaluated the clinical utility of SCOUT in picking up AGT and analyzed its relationship with HbA1c (both by autoanalyzer and POC device) and serum levels of soluble receptor for advanced glycation end products (sRAGE). Subjects (n=139) without previous diagnosis of diabetes or impaired glucose tolerance in Chennai, India were subjected to oral glucose tolerance test (OGTT). They were classified as normal glucose tolerance (NGT) and abnormal glucose tolerance (AGT) which includes those with prediabetes or diabetes. Along with SCOUT DS score and Hba1c, circulatory levels of sRAGE were also measured by ELISA. SCOUT DS score was significantly (p<0.001) higher in subjects with AGT (n=42; 5±3.4 AU) compared to subjects with NGT (n=42; 5±3.3 AU). SCOUT DS score was positively correlated with BMI (r=0.404; p<0.001), fasting plasma glucose (r=0.285; p<0.001), post-prandial plasma glucose (r=0.483; p<0.001), autoanalyzer-based Hba1c (r=0.305; p<0.001) and POC-based Hba1c (r=0.347; p<0.001) and negatively correlated to sRAGE (r= -0.221; p<0.001). Logistic regression analysis revealed that the association between increased SCOUT DS score and AGT remained statistically significant (OR=1.47; p<0.001) even after adjusting for age, BMI, Hba1c and sRAGE levels. Our study underscores the clinical utility of SCOUT DS score as a non-invasive POC tool to identify the subjects at high risk for diabetes.

Supported By: Department of Biotechnology, Government of India

For author disclosure information, see page A810.
Concordance of Glucose-based and of HbA1c-based Diagnoses of Diabetes in Patients with Established Coronary Atherosclerosis: A Comparison between Men and Women

HEINZ DREKEL, DANIELA ZANOULIN, PHILIPPE REIN, ALEXANDER VONBANK, ANDREAS LEHRER, GERHARD NAERER, AXEL MEUDELIN, CHRISTOPH H. SAEI, Philadelphia, PA; Tresen, Liechtenstein; Feldkirch, Austria; Domling, Austria

Concordance between glucose based and HbA1c based diagnoses of diabetes differ between populations. Here, we aimed at investigating their concordance in men and in women with stable coronary artery disease (CAD).

We measured fasting glucose as well as HbA1c and performed standard 75g oral glucose tolerance tests in a consecutive series of 711 patients, 513 men and 198 women, who had angiographically proven coronary artery disease (CAD) but not previously diagnosed diabetes. Based on glucose values, diabetes was diagnosed with a fasting plasma glucose (FPG) ≥126 mg/dl or a postchallenge glucose ≥200 mg/dl 2 hours after the oral glucose load, based on HbA1c values diabetes was diagnosed with an HbA1c ≥6.5%.

Among men, 33 had diabetes based on fasting or postchallenge glucose values, of whom 26 also had diabetes according to the HbA1c criterion. Of the 480 men who did not have diabetes based on glucose values, 446 also did not have diabetes according to HbA1c criterion; among women, 3 had diabetes based on glucose values, of whom 2 also had diabetes according to the HbA1c criterion. Of the 195 women who did not have diabetes based on glucose values, 185 also did not have diabetes according to HbA1c criterion. Concordance of Glucose and HbA1c criteria was similar in men and women (92% and 94%, p=0.395). Applying glucose criteria as a standard, specificity, sensitivity, positive predictive value (PPV) and negative predictive value (NPV) of the HbA1c criterion for men were 78.8%, 92.9%, 43.3%, and 98.5%, respectively. For women, sensitivity, specificity, PPV and NPV of the HbA1c criterion were 66.7%, 94.9%, 16.7%, and 98.5%, respectively.

We conclude that concordance of glucose and HbA1c criteria among patients with stable CAD is high and is similar in men and women with CAD. However, for both sexes the sensitivity of the HbA1c criterion is poor in this patient population.

Weight Gain and Progression to Type 2 Diabetes in Korean Women with History of Gestational Diabetes Mellitus

JOON HO MOON, SODI HEON KKWAK, CHANG HO AHN, JIE EUN LEE, HYE SEUNG JUNG, SUNG HEE CHOI, SODI LIM, YOUNG MIN CHO, KYONG SOO PARK, NAM H. CHO, HAK C. JANG, Seoul, Republic of Korea; Seoul, Republic of Korea

We investigated the effects of longitudinal BMI change on the development of type 2 diabetes in Korean women with a history of gestational diabetes mellitus (GDM).

Women with a history of GDM or gestational impaired glucose tolerance (GIIT) were recruited and underwent a 75g oral glucose tolerance test at postpartum 6 weeks and annually thereafter. Changes in BMI were calculated between the initial postpartum visit and the last follow-up or at the onset of diabetes. The risk of diabetes was analyzed according to the tertiles of BMI change. A total of 416 subjects were included for analysis, with a median follow-up duration of 4.6 years. The BMI change in each tertile was -1.8, -0.2, and 1.6 kg/m², respectively. We observed an increased risk of incident diabetes as the tertile of BMI change increased (8.6%, 12.6%, and 16.9%, P=0.039). Postpartum BMI change was an independent predictor of diabetes in multivariate analysis (hazard ratio 1.19, 95% confidence interval 1.03-1.39, P=0.020). In the highest tertile group in which BMI increased, there was a significant deterioration in blood pressure, 2-hour glucose, insulin sensitivity, and lipid profiles.

This prospective study demonstrates that an increase in BMI during the 4-years of follow-up after parturition is significantly associated with an increased risk of diabetes and deterioration of metabolic phenotypes in Korean women with a history of GDM.

Table. Cumulative Incidence of Type 2 Diabetes and Changes of Metabolic Phenotypes by Postpartum BMI Change

<table>
<thead>
<tr>
<th>First tertile (n=139)</th>
<th>Second tertile (n=143)</th>
<th>Third tertile (n=136)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>-1.8 ± 1.1</td>
<td>-0.2 ± 0.3</td>
<td>1.6 ± 1.1</td>
</tr>
<tr>
<td>Fasting glucose (mg/dL)</td>
<td>5.4 ± 2.45</td>
<td>5.4 ± 1.3</td>
<td>10.6 ± 2.9</td>
</tr>
<tr>
<td>2-hour glucose (mg/dL)</td>
<td>5.1 ± 3.98</td>
<td>9.6 ± 4.69</td>
<td>26.2 ± 59.6</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>12.8%</td>
<td>19.2%</td>
<td>23.8%</td>
</tr>
<tr>
<td>Maternal index</td>
<td>0.0 ± 3.4</td>
<td>0.0 ± 3.4</td>
<td>-1.4 ± 3.2</td>
</tr>
<tr>
<td>Insulinogenic index</td>
<td>0.10 ± 0.52</td>
<td>0.03 ± 0.06</td>
<td>0.04 ± 0.50</td>
</tr>
<tr>
<td>Disposition index</td>
<td>1.0 ± 3.7</td>
<td>0.0 ± 2.6</td>
<td>0.8 ± 6.1</td>
</tr>
</tbody>
</table>

Support: Korea Healthcare Technology R&D Project, Ministry of Health and Welfare (A111929); Seoul National University Bundang Hospital (02-2010-0173)

For author disclosure information, see page A810.
Tracking Type 2 Diabetes Using Sparse Coding
AUREA C. RIBEIRO, ALLAN K. BARROS, EWALDO E. SANTANA, ROSEANE C. DI NIŻ, SÃO LUIS, BRAZIL

Tracking methods (TRACK) are used to diminish the drawbacks and costs related to the complications of type 2 diabetes (T2DM). Here we propose a noninvasive method for classification using sparse coding (SC). SC is a statistical technique to estimate the primary causes of the disease. Tests were conducted using the Brazilian database HIPERDIA, composed of 14 noninvasive medical markers of disease (HbA1c, 1-2-3-SBP, 3-DBP, 4-waist circumference (cm), 5-weight (kg), 6-height (cm), 7-family history, 8-smoking history, 9-physical inactivity, 10-overweight, 11-heart attack, 12-stroke, 13-other coronary heart diseases, 14-amputation). All possible combinations of these characteristics were tested and removed successively using a one-class SVM (SC). Table 1 shows the results for all combinations. It was observed that the removal of characteristics related to the age and high rates of body fat decreased the accuracy of the results, which was also observed for its influence on the disease. It is believed that the process of SC can attain the fundamental patterns of disease formation, minimizing the search space for the classifier. In this way, SC achieved results close to the physical results, because a high rate of body fat and old age is directly related to T2DM.

Aim: Polypharmacy is a common problem in diabetic patients and a significant barrier to the achievement of glycemic control. Since there are no data in our country regarding polypharmacy among diabetic patients we conducted this study in order to estimate the rate of polypharmacy among patients attending a diabetic outpatient clinic.

### Material and Methods

205 diabetic patients (98 women/107 men, mean age (± standard deviation, SD): 64.1±11.9 years, mean HbA1c: 7.5±1.5) were included in the study from January to May 2014. Data were collected by the medical files. Only chronic medications given for at least 1 month prior to the inclusion date, were recorded for each patient. Two types of polypharmacy were determined: polypharmacy defined as >5 drugs/day and >7 drugs/day.

### Results

Mean rates of polypharmacy >5 drugs and >7 drugs were 79.0% (95% CI = 72.6-85.2) and 54.1%, respectively. From the study patients, 82.9% were on oral antidiabetic medications (OAM) and 48.8% on insulin treatment. The majority of study patients were on an antihypertensive (96.6%) and lipid lowering medication (71.2%), followed by antipaleit, drugs (47.3%), H2 blockers and proton-pump inhibitors (22.4%), benzodiazepines (14.6%) and levothyroxine (12.2%). The number of drugs per patient varied from one to 13 while the mean number was 6.6±2.5. Regarding OAM, the number of drugs per patient varied from one to 4 while the mean number was 1.7±1.1. Regarding antihypertensive medication, the number of drugs per patient varied from one to 6 while the mean number was 2.1±1.5. Only, two independent variables for polypharmacy >5 drugs were found: age (odds ratio (OR): 1.08, 95% confidence interval (CI): 1.03-1.09, P<0.001) and OAM (OR: 2.59, 95% CI: 1.15-5.82, P=0.02). No significant associations were found between polypharmacy >5 and sex, HbA1c, duration of T2D, body mass index and insulin therapy.

Conclusions: Greek diabetic patients show high rates of polypharmacy with unknown implications for the achievement of therapeutic targets, especially for arterial hypertension and diabetes.
Potential Covariates and Pathophysiological Mechanisms Resulting in Elevated HbA1c Levels without Dysglycemia

STEVEN E. HANSON, Columbia, MO

Prior studies found an elevated mean HbA1c for Non-Hispanic Black (NHB) compared to Non-Hispanic White (NHW) populations without yielding a physiological mechanism. This study sought to use NHANES data to determine if covariates influence HbA1c levels but not other glycemic measures, and if any of these covariates are known to have differences for likelihood of exposure between racial groups. Once covariates were identified, potential physiological mechanisms related to these covariates were proposed and studied. NHANES data from 2002-2012 was analyzed using logistic regression to determine the odds ratio (OR) for HbA1c > 5.6% without dysglycemia (elevated FPG or OGTT) in non-diabetic subjects. Levels of cadmium in blood above the population mean were found to be significantly associated with elevated HbA1c levels without dysglycemia, and mean HbA1c for NHW with lower Cd exposure was less than those with higher Cd exposure. This was not true for NHB. Cd is known to impede acetylation, and N-acetyltransferase 2 (NAT2) is polymorphic with slow and rapid acetylator phenotypes with a distribution favoring rapid acetylation in NHW and slow in NHB populations. Acetylation may compete with glycation of the hemoglobin β-chain, so a subsample of NHANES subjects was evaluated for acetylator phenotype using caffeine metabolic data. In this subsample, slow acetylators were associated with lower HbA1c levels, which was the opposite of expectations. Further evaluation of this data found that CYP1A2 activity had a greater association with Cd level, and CYP1A2 was associated with decreasing NAT2 activity, thus Cd is suspected of acting through CYP1A2 to decrease NAT2 activity. Tobacco use is known to increase CYP1A2 activity and expose users to lead (Pb) and Cd. When controlling for both tobacco use and blood Pb levels in the statistical model, the significantly elevated OR for HbA1c > 5.6% with normoglycemia in NHB was ameliorated.


Relationship between Cigarette Smoking and the Risk of Proteinuria in New-Onset Type 2 Diabetes Men

KYOKO K. SATO, TOMOSHIGE HAYASHI, SHINICHIRO UEHARA, SHIGEKI KINUHATA, GINJI ENDO, KEIKO OUE, HIROSHI KAMBE, KUNIHIKO HASHIMOTO, KYOKO K. SATO, TOMOSHIGE HAYASHI, SHINICHIRO UEHARA, SHIGEKI KINUHATA, GINJI ENDO, KEIKO OUE, HIROSHI KAMBE, KUNIHIKO HASHIMOTO, Osaka, Japan

We prospectively examined the relationship between daily and cumulative cigarette consumption and the risk of proteinuria during the 11-years follow-up period in men with new-onset type 2 diabetes. Study subjects were 494 Japanese new-onset type 2 diabetes men aged 40-55 years, with normal estimated glomerular filtration rate (eGFR > 60 ml/min/1.73 m²) and no proteinuria who were not taking hypoglycemic or hypertensive medications at entry. Proteinuria was defined as 1+ or higher on urine dipstick. Daily cigarette consumption was divided into four groups: nonsmokers, past smokers, 1-24, and ≥25 cigarettes/day. Cumulative cigarette consumption was divided into four groups: nonsmokers, past smokers, 1-24, and ≥25 cigarettes/day. The incidence rates per 1000 person-years for nonsmokers, past smokers, 1-24, and ≥25 cigarettes/day were 25.4, 38.3, 46.6, and 54.1, respectively. After adjustment for age, BMI, systolic and diastolic blood pressure, HbA1c, daily alcohol consumption (nondrinkers, 0-22.9, 23.0-46.0, or ≥46.1 g ethanol/day), and regular leisure-time physical activity

For author disclosure information, see page A810.
Neuropathy Prevalence Compared with Other Complications in Longstanding T1DM: Preliminary Analysis of the Canadian Study of Longevity in Diabetes Cohort

ALAN M. FRIEDMAN, LEE E. LOVEBLUM, RANDY ROVINSKI, ELISE M. HALPERN, GENEVIEVE BOULET, DEVIRM ELEDEKULI, HILARY A. KEENAN, MICHAEL BRENT, NARIJANER PAUL, VERA BRIL, DAVID CHERNER, BRUCE A. PERKINS, TORONTO, ON, Canada, Boston, MA

T1DM subjects can survive for extreme duration without retinopathy or nephropathy. Though lifetime risk of neuropathy is thought to approach 100%, a small proportion of patients with longstanding T1DM were resistant to all complications. Retinopathy - and not symptomatic neuropathy - was the dominant complication indicating a need to better understand mechanisms that could promote resistance to specific complications.

Supported By: American Diabetes Association (1-03-CR-23, 1-06-CR-25 to V.N.);

Nonalcoholic Fatty Liver Disease Is Associated with Heart Valve Calcification in Type 2 Diabetes

ALESSANDRO MANTOVANI, MARCO DAURIZ, ISABELLA PICHIRI, MATTEO PERNIGO, CORINNA BERGAMINI, STEFANO BONAFACE, ENZO BONORA, GIOVANNI TARISIER, VERONA, Italy, Negrar, Italy

Aortic valve sclerosis (AVS) and mitral annulus calcification (MAC) are powerful predictors of adverse cardiovascular outcomes in patients with type 2 diabetes (T2D), but the aetiology of valvular calcification is uncertain. Nonalcoholic fatty liver disease (NAFLD) is an emerging cardiovascular risk factor commonly present in T2D patients, but its association with valvular calcification is unknown. We sought to investigate whether NAFLD is associated with AVS and/or MAC in T2D patients. We conducted a cross-sectional study by performing a conventional echocardiography and liver ultrasonography in a sample of 247 consecutive outpatients with T2D (79 men; mean age 68 years) free of known liver diseases, prior history of chronic heart failure and moderate-to-severe valvular heart disease. Overall, 139 (56.3%) patients had no calcification at both aortic and mitral valve (AVC-MC), 65 (26.3%) had one valve affected (AVC-MC), and 43 (17.4%) had both valves affected (MC). NAFLD was present in 175 (70.8%) patients and its prevalence markedly increased in patients with AVC-MC compared with either AVC-MC or AVC (68.1% vs. 83.1% vs. 80.4%, respectively; p<0.001). NAFLD was associated with AVC-MC (unadjusted-odds ratio [OR] 3.51, 95% CI 1.31-9.70, p<0.01). Adjustments for age, sex, smoking history, alcohol consumption, diastolic blood pressure, hemoglobin A1c, LDL-cholesterol, estimated glomerular filtration rate, use of hypoglycemic, lipid-lowering and anti-hypertensive medications and echocardiographic variables did not substantially attenuate the strong association of NAFLD with AVC-MC. We conducted a cross-sectional study. In conclusion, these results show for the first time that NAFLD is a strong and independent predictor of cardiac calcification in both aortic and mitral valves in patients affected by T2D. Further research is needed to better elucidate the mechanisms underlying this association.

Health Disparity in Zuni Indians as Reflected in Progression of Metabolic Risk Factors

VALLABH SHAH, D. GHAHATE, J. BOBELI, P. SANYI, T. FABER, Albuquerque, NM, Zuni, NM

The Zuni Indians are socioeconomically disadvantaged population faces a major public health challenge from growing health disparities. The Zuni Kidney Project (ZKP) has described the epidemiology of kidney disease and the subsequent investigation of Genetics of Kidney Disease in Zuni Indians (GKDZI) described the heritability of kidney disease and its intermediate phenotypes. Recently, through PCORI funded home-base kidney care (HBKC), we rescreeened 314 Zuni participants. In order to test the hypothesis that the metabolic risk factors including diabetes and chronic kidney disease would progress over time, we performed an analysis of subjects in HBKC who participated in both ZKP and GKDZI. Individuals (n=314) who participated in HBKC were studied at 3 time points at a mean interval of 8.6 years (range 2.5-13 years). 46% of this cohort was female; mean age at the 1st study point was 30.8 years. The table shows the progression of metabolic risk factors over time.

For author disclosure information, see page A810.
Epidemiology—Diabetes Complications

1583-P
Relationship between Diabetes Complications and Health Related Quality of Life among an Elderly Population in the United States
VINAY CHAUDHURI, KRANTHI S. GUTHIKONDA, STEPHEN L. SUGABASH, ERIC HAVENS, JONATHAN PEÑA, TRISTAN CORDER, TODD PREWITT, KATHLEEN M. O’CONNELL, Louisville, KY

Type 2 diabetes mellitus (T2DM) is associated with increased risk for morbidity and mortality. Health related quality of life (HRQOL) has become an increasingly important component of quantifying the health of patients. The objective of this study is to understand the relationship between complications of T2DM and self-reported HRQOL.

The Health Outcomes Survey (HOS), a cohort study spanning 2 years that is administered to a sample of Medicare Advantage members from all plans in the U.S. each year, includes a 4-question HRQOL instrument called Healthy Days. This instrument measures the number of physically and mentally unhealthy days (UHD) within the past 30 days. Using the results of the 2011-2013 HOS survey from the Humana Medicare Advantage population, members’ responses were matched to their claims data. Analysis of variance (ANOVA) was used to examine the correlation between the presence of complications and UHD. To measure the impact of the severity of complications a linear regression model was used to assess the association between the diabetes complication severity index (DCSI) and UHD.

Of the 12,105 people who completed the 2011-2013 HOS, 3,120 (25.3%) had T2DM (mean age=75.8 yrs, 54.0% female, mean UHD=11.3). Two individual complications associated with large increases in UHD were limb amputation (8.4 more UHD, p=0.002) and depression (7.9 more UHD, p=0.001). After controlling for age and gender, every one-point increase in the DCSI score was associated with an increase of 1.2 average UHD (p<0.0001). Increases in the number of HbA1c tests during the study period and HbA1c control (<8.0%) were associated with lower UHD, though not statistically significant.

Patients with more diabetes-related complications report worse HRQOL. There seems to be a significant opportunity to improve HRQOL of patients by improving targeted care and thereby preventing complications.

1584-P
Increased 10-Year Risk for Cardiovascular Disease Associated with Pooled Cohort Equation in Subjects with HbA1c Lower than 6.5%
EUN-JUNG RHEE, SE EUN PARK, CHEOL-YOUNG PARK, WON-YOUNG LEE, KI-WON OH, EUN-GYOUNG HONG, SUNG-WOO PARK, Seoul, Republic of Korea, Hwasung, Republic of Korea

In a new risk calculator, called “Pooled Cohort Equation,” has been released with a new cholesterol guideline. We calculated 10-year cardiovascular risk in non-diabetic Korean subjects with HbA1c lower than 6.5%. In 17519 participants (mean age 40 years, men: 79.3%) in a health screening program, 10-year risk for cardiovascular disease (CVD) was calculated with Pooled Cohort Equations (PCE). The subjects with underlying diabetes or HbA1c>6.5% were excluded from the study. In all subjects, HbA1c and fasting blood glucose (FBG) were measured and subjects were divided into four groups according to FBG and HbA1c levels: category I: FBG<100, 100 ≤ HbA1c<5.8, category II: HbA1c <5.5, 5.5 ≤ HbA1c<5.8, category III: HbA1c<6.5, 6.5 ≤ HbA1c<7.0, category IV: HbA1c≥6.5. Mean 10-year cardiovascular risk calculated by PCE was 2.9%. FBG and HbA1c showed significant positive correlation with 10-year CVD risk in bivariate correlation analyses (r=0.161, p<0.01; r=0.145, p<0.01). Mean 10-year CVD risk significantly increased as FBG increased in four groups from lower than 100 mg/dL to higher than 120 mg/dL (2.6, 3.3, 3.8, 4.1%, p<0.01 by one-way ANOVA test), and as HbA1c increased in four groups from lower than 5.5% to higher than 5.8% (2.4, 2.7, 3.0, 3.5%, p<0.01 by one-way ANOVA test). Risk for 10-year CVD risk being equal to or higher than 10% significantly increased from the 1st group to 4th group divided by FBG and HbA1c after adjustment for BMI and fasting insulin level (1.349, 1.955, 2.535 vs. 1.0 in the lowest FBG group; 1.846, 1.646, 4.019 vs. 1.0 in the lowest HbA1c group). 10-year CVD risk calculated by the new calculator significantly increased as the FBG and HbA1c increased even in Korean subjects without underlying diabetes.

1585-P
Phosphodiesterase Type 5 Inhibitor Use in Type 2 Diabetes Is Associated with a Reduction in All-Cause Mortality
SIMON G. ANDERSON, DAVID C. HITCHINGS, ANDREW W. TRAFFORD, ADRIAN H. HEALD, Manchester United Kingdom

Objectives: Phosphodiesterase type 5 inhibitors (PDE5i) are cardioprotective in animal models of acute myocardial infarction (MI) although few supporting clinical data are available. We sought to investigate whether PDE5i use in a cohort of patients with type 2 diabetes (T2DM), and therefore high attendant cardiovascular risk, was associated with altered mortality.

For author disclosure information, see page A810.

1586-P
Self-Report of Low Blood Sugar Symptoms among Adults with Diabetes 50 Years and Older in the United States
SHARON H. SAYDAD, BARBARA BARBARINEGER, LINDA S. GESS, JING WANG, Washington, DC, Atlanta, GA, Duluth, GA

Although there is an increased focus on preventing hypoglycemia events among adults with diabetes, few studies have looked at factors associated with hypoglycemia events outside of a hospital setting. We used data from the Health and Retirement Survey 2003 supplemental diabetes questionnaire that included questions related to low blood sugar. Diabetes participants (N=1628) responded to “How many days in the last month have you had symptoms of low blood sugar, such as sweating, weakness, anxiety, trembling, hunger, or headache?” Responses were categorized as 0 days, 1 to 3 days, 4 to 7 days, and 8 or more days. We aimed to determine the factors associated with low blood sugar symptoms (LBSS). Overall, 50.6% participants reported 0 days, 32.6% reported 1-3 days and 16.8% reported 4 or more days in the past month with LBSS. Greater frequency of LBSS was reported by women, adults 51-64 years, type 1 diabetes or type 2 diabetes taking insulin, participants reporting having a target A1c, visiting the doctor more frequently, more ER visits in the past year and self report of CVD. Race/ethnicity, education level, mean A1c, hypertension and use of sulfonylureas were not associated with increased LBSS. Adjusting for age, sex and duration of diabetes, the odds ratio for LBSS compared to 0 days was 3.6 (95% CI 1.4, 9.8) for adults with type 1 diabetes and 2.0 (95% CI 1.3, 2.9) for adults with type 2 diabetes taking insulin compared with adults with type 2 diabetes not on insulin. In adjusted analyses, visiting the doctor more frequently, more ER visits, proteinuria and CVD remained significantly associated with greater number of compared to 0LBSS while there was no significant association with being able to specify a target A1c. Among adult with diabetes, LBSS occur more frequently among women, younger older adults, those using insulin for treatment and those reporting poor CVD history. These groups may benefit from increased diabetes education to recognize and prevent hypoglycemia.

1587-P
Mortality in Youth-Onset Diabetes: The SEARCH for Diabetes in Youth Study
KRISTI REYNOLDS, JASMIN DIVERS, SCOTT ISOM, SHARON SAYDAD, JEAN M. LAWRENCE, DANA M. DABELEA, ELIZABETH J. MAYER-DAVIS, GIUSEPPINA INPERATORÉ, RONNY A. BELL, RICHARD F. HAMMANN, Pasadena, CA, Winston-Salem, NC, Atlanta, GA, Aurora, CO, Chapel Hill, NC

Few studies have examined mortality risk among youth with diabetes. We estimated all-cause mortality in youth with incident type 1 (T1D) and type 2 diabetes (T2D) diagnosed before age 20 yrs. T1D (n=8480) and T2D (n=1518) cases diagnosed from 1/1/02-12/31/08 were assessed for vital status through 12/31/10 using the National Death Index. Standardized mortality ratios compared observed vs. expected numbers of deaths based on age, sex, and race for the comparable general U.S. population. We used Cox proportional hazards regression to assess effects of demographics and diabetes type on mortality. Mean age at diagnosis was 10.7 yrs. During follow-up (mean 5.3 yrs) there were 41 deaths. Overall mortality did not differ significantly from expected (Table). However, compared to the general population, mortality was higher
among those with T2D, females, 15-19 yr olds, and NHBs. In Cox regression analysis, mortality was higher for NHVs vs. NHWs and those who were older at diagnosis. Although mortality was higher among those with T2D vs. T1D, the excess was accounted for by differences in age and race. Among youth with T1D, diabetes (n=11) was the most frequent underlying cause of death. Among youth with T2D, accidents/injuries (n=8) were the most frequent causes. Our results show excess mortality in youth with T2D, NHBs, females, and older youth with diabetes compared to the general population. Further study of mortality in youth with diabetes is warranted.

Table. Age-, Sex-, Race-Standardized Mortality Ratios (SMRs).

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>Male</th>
<th>Female</th>
<th>T2D</th>
<th>T1D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Hispanic White (NHW)</td>
<td>1.1</td>
<td>1.3</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Non-Hispanic Black (NHB)</td>
<td>1.3</td>
<td>1.3</td>
<td>1.2</td>
<td>1.3</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1.2</td>
<td>1.3</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Other</td>
<td>1.0</td>
<td>1.1</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Epidemiology—Diabetes Complications

1588-P Infection and Pathogen Burden among Medicare Beneficiaries with Diabetes, 2012

GLORIA L. BECKLES, MAN-HUEI CHANG, BENEDICT I. TRUUMAN, Atlanta, GA

Diabetes (DM) is associated with increased risk of mortality and morbidity from various infections and their complications. Infection is among the 10 most frequent indications for use of health care services and accounts for 2 of the top 3 conditions with the largest number of 30-day hospital readmissions among Medicare enrollees aged ≥65 years. In 2011, costs for 30-day-readmissions due to sepsisemia, pneumonia, and urinary tract infection totaled U.S. $3.3 2 billion. We analyzed data from the Centers for Medicare & Medicaid Services (CMS) to assess the frequency of receipt of medical care for infection among Medicare beneficiaries with DM in 2012.

We used the CMS chronic condition algorithm to identify beneficiaries with DM. We identified infections in persons with DM who had at least one reimbursement claim with the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9 CM) diagnosis code for a specific anatomic site or pathogen. We estimated the frequency of anatomic site with infection and pathogen burden among beneficiaries with DM.

Of the 10.3 million beneficiaries with DM in 2012, 82% were ≥65 years of age, 54% female, 28% minority racial-ethnic groups, and 39% had ≥3 comorbidities known to predict infection-related mortality. One in 5 (21%) beneficiaries (n=2.2 million) had at least one infection. Pneumonia (n=1,065,386), urinary tract, and blood were the most commonly involved anatomic sites, and skin was the most common site.

1589-P Effects of Hypertension and Diabetes on Myocardial Infarction, Stroke, and Mortality in the Chinese Population Participating in 23-Year Follow-up of Da Qing IGT and Diabetes Study

DUIHONG GONG, PING ZHANG, JINFENG WANG, YALI AN, EDWARD W. GREGG, BO ZHANG, HUI LI, YAN YAN HE, XING XIAOYAN, MICHAEL ENGELS, YING HU, PETER H. BENNETT, GUANGWEI LI, Beijing, China, Atlanta GA, Daqing, China, Phoenix AZ

Diabetes (DM) and hypertension (HTN) are risk factors for myocardial infarction (MI), stroke, and mortality, but little information is available on the long-term excess risks attributable to these factors in the Chinese population. We estimated the excess risks for DM and HTN alone, and in combination, from 23-year follow-up of the population-based Da Qing IGT and Diabetes Study.

In 1986, 110,660 adults aged 25-74 years were screened for newly diagnosed diabetes (DM) in Da Qing, China. 630 people with DM were identified and 519 with normal glucose tolerance (NGT) were selected for comparison. 285 with DM and 246 with HTN had HTN. In 2009, we tracked all study participants to compare their risks of first MI, stroke, and all-cause mortality. Diabetes and hypertension each lead to substantial excess risk for MI, stroke and mortality. The combination of the two further increases the risk of MI and mortality. Diabetes alone appears to increase the risk of MI and death more than HTN alone, whereas the risk for stroke is similar.

Table. Age-Sex-Adjusted Annual Incidence for MI, Stroke and All-Cause Mortality and Hazard Ratios.

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>Male</th>
<th>Female</th>
<th>T2D</th>
<th>T1D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Hispanic White (NHW)</td>
<td>1.1</td>
<td>1.3</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Non-Hispanic Black (NHB)</td>
<td>1.3</td>
<td>1.3</td>
<td>1.2</td>
<td>1.3</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1.2</td>
<td>1.3</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Other</td>
<td>1.0</td>
<td>1.1</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Hypoglycemia and Glycemic Variability Are Associated with Mortality in Non-Intensive Care Unit Hospitalized Infectious-Disease Patients with Diabetes Mellitus

SOICHI TAKEISHI, AKIHORI MORI, HIROMI KAWAI, NORITSUGU OHTUSA, NOBUYOSHI FUSHIMA, SHINTARO HAYASHI, TAKASHI SHIBUYA, SHUN ITO, TAKAYUKI YUMURA, HIROKI HACHIYA, Ichinomiya Japan

It has been reported that hypoglycemia and glycemic variability (GV) are associated with mortality in intensive care unit (ICU) patients. Reactive inflammatory biomarkers (RIB) and vital signs in infectious-diseases such as pneumonia have also been associated with mortality. However, it is not well known which factors—glycemic control, RIB, or vital signs—are most associated with mortality in non-ICU hospitalized infectious-disease patients with diabetes mellitus (Non-ICU-IP-DM). In this study, we investigated the association between those factors and mortality in non-ICU-IP-DM. We retrospectively analyzed 631 Non-ICU-IP-DMs who underwent glucose monitoring more than twice per day. We extracted RIB and vital signs data on the first day of glycemic control, and calculated hypoglycemia, GV (coefficient of variation (CV), standard deviation (SD)) and mean glucose level (MGL) from all glycemic values. We analyzed the association between those factors and mortality by using logistic multivariate regression analysis. We found a mortality rate of 10.1%, RIB and vital signs were not associated with mortality. However, hypoglycemia, CV, SD, and MGL were independent risk factors for increased mortality. Glycemic control (especially hypoglycemia and GV), rather than RIB or vital signs, is associated with mortality in Non-ICU-IP-DM.

Table. (n = 651) Mortality

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>1.02 (0.98-1.07)</td>
<td>0.34</td>
</tr>
<tr>
<td>Male sex, n</td>
<td>1.91 (1.81-4.49)</td>
<td>0.14</td>
</tr>
<tr>
<td>Body mass index (BMI), kg/m²</td>
<td>0.93 (0.83-1.03)</td>
<td>0.15</td>
</tr>
<tr>
<td>HbA1c (NGSP), %</td>
<td>0.64 (0.47-0.86)</td>
<td>0.0002</td>
</tr>
<tr>
<td>White blood cell (WBC), mg/dL</td>
<td>1.091 (1.01-1.09)</td>
<td>0.0001</td>
</tr>
<tr>
<td>C-reactive protein (CRP), mg/dL</td>
<td>1.03 (0.99-1.07)</td>
<td>0.22</td>
</tr>
<tr>
<td>Body temperature (BT), °C</td>
<td>0.61 (0.33-1.12)</td>
<td>0.11</td>
</tr>
<tr>
<td>Systolic blood pressure (SBP), mmHg</td>
<td>1.01 (0.99-1.03)</td>
<td>0.31</td>
</tr>
<tr>
<td>Diastolic blood pressure (DBP), mmHg</td>
<td>1.02 (0.98-1.05)</td>
<td>0.38</td>
</tr>
<tr>
<td>Heart rate (HR), minutes/minute</td>
<td>1.02 (0.99-1.05)</td>
<td>0.18</td>
</tr>
<tr>
<td>Arterial oxygen saturation (SpO2), %</td>
<td>0.84 (0.70-1.01)</td>
<td>0.06</td>
</tr>
<tr>
<td>Mean glucose level, mg/dL</td>
<td>1.07 (1.03-1.12)</td>
<td>0.0003</td>
</tr>
<tr>
<td>Standard deviation (SD), mg/dL</td>
<td>1.16 (1.03-1.29)</td>
<td>0.01</td>
</tr>
<tr>
<td>Coefficient of variation (CV), %</td>
<td>2.12 (1.06-4.17)</td>
<td>0.03</td>
</tr>
<tr>
<td>Hypoglycemia, n (%)</td>
<td>5.90 (2.19-15.94)</td>
<td>0.0004</td>
</tr>
<tr>
<td>t²</td>
<td>0.33</td>
<td></td>
</tr>
</tbody>
</table>

For author disclosure information, see page A810.
Lower urinary tract symptoms (LUTS) are commonly reported by men with diabetes. There is evidence that LUTS risk is heritable, and candidate gene studies have identified several potential risk variants. We aimed to identify genetic predictors of LUTS in men with type 1 diabetes (T1D) in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications using a genome-wide association study (GWAS). We characterized LUTS severity with the American Urological Association Symptom Index (AUASI) at EDIC year 17, using a standardized 7-item questionnaire that quantifies the presence and severity of the following symptoms: nocturia, frequency, urgency, weak urinary stream, intermittency, straining, and the sensation of incomplete emptying, with scores ranging from 0 to 35. Standardized definitions of LUTS were used (0-7: none/mild, ≥8 moderate/ severe). Genotyped were collected with an Illumina TM chip and imputed to the 1000 Genomes data. A GWAS with 474 controls and 156 cases was performed with a model adjusting for age, BMI, HbA1c, former DCCT treatment group, and diabetes duration. Age, but none of the other covariates, was significantly associated with LUTS in a logistic regression: p=3.0×10^−6, OR=1.09 (1.08-1.12). Genomic control lambda for GWAS was 1.02. Two regions reach suggestive significance: An intergenic region on chromosome 10 between a microRNA and SH2D4B (p=1.7×10^−6), OR=2.0 (1.8-5.0), and another on chr 2 in an intron of GPR39 (p=1.9×10^−6), OR=2.2 (1.6-3.0), MAF=25.3%. SNPs are involved in signaling. Our preliminary data demonstrates a potential role for a genetic contribution to LUTS in men with T1D. If validated in other cohorts, these SNPs could help risk stratify the large proportion of men with T1D who will develop significant LUTS.
**1595-P**

**Longitudinal A1C Patterns and Their Associations with Outcomes in Type 2 Diabetes**

NEDAL A. AARAPONG, YUE GAO, JENNIFER COOPER, JENNIFER Y. LIU, HOWARD H. MOFFET, ANDREW J. KARTER, ELBERT S. HUANG, Chicago, IL; Oakland, CA; Bainbridge Island, WA

Results from the United Kingdom-Prospective Diabetes Study suggest that achieving good A1C control early in type 2 diabetes reduces complications. However, little is known about A1C varies over time and how A1C patterns affect outcomes. We studied 28,016 patients with newly diagnosed type 2 diabetes from Kaiser Permanente Northern California from 1997-2001. Using latent growth mixture and Cox proportional hazard models, we categorized 10-year A1C patterns and examined their associations with time to post-10 year incident complications and death, adjusted for age, gender, race, hemoglobin, eGFR, 10-year average A1C, cardiovascular risk factors and comorbidity. We identified 5 A1C patterns: stable (81%), decreasing (5%), increasing (5%), inverse sine (4%) and sine (4%). Compared to stable, increasing, inverse sine and sine patterns were associated with increased microvascular disease (hazard ratio [HR], 1.17 [1.01-1.35]; 1.21 [1.05-1.41]), and the decreasing pattern was associated with increased death (HR, 1.28 [1.04-1.59]). Macrovascular disease risk did not differ by A1C pattern. During the first 10 years after diabetes diagnosis, the majority of patients have stable A1C levels. Those with non-stable A1C patterns had a greater risk of worse outcomes. In addition to achieving good A1C control, maintaining a stable A1C level may be an important goal for long-term outcomes.

**Association of New Plasma Biomarkers (TNFR1, Adrenomedullin, and Copeptin) with Rapid Renal Function Decline in French Type 2 Diabetes Patients**

PIERRE-JEAN SAULNIER, ELISE GAND, GILBERTO VELHO, KAMEL MOHAMMEDI, PHILIPPE ZAOUI, RONAN ROUSSEL, SAMY HADJADJ, PHILIPPE ZAOUI, MATHILDE FRATY, JEAN MICHEL HALIMI, STEPHANIE RAGOT, ROBIN ROUSSEL, SAMY HADJADJ, Poitiers, France, Paris, France, Grenoble, France, Tours, France

We assessed the predictive value of 3 biomarkers on renal function decline. Three recently-reported peptides were considered: mid-regional pro adrenomedullin (MR-proADM), copeptin and TNF receptor 1 (TNFR1). Patients with type 2 diabetes (T2D), estimated GFR<30ml/min at baseline and no history of renal replacement therapy were prospectively followed in a French hospital-based cohort. Biomarkers were measured on the same baseline plasma sample. Annualized GFR slope was individually determined by linear regression. Rapid renal function decline (RRFD) was defined by a decrease of ≥3 ml/min/1.73 m²/year. Using linear regression, we showed a significant association between RRFD and each of the biomarkers considered. The addition of MRI-proADM in the multi-adjusted model improved prediction of RRFD (IDI index = 0.0063, p<0.0001). In addition to the usual risk factors TNFR1 is an independent prognostic risk factor for RRFD in T2D patients.

**Systolic Blood Pressure Variability and Lower Extremity Amputation in Non-elderly Diabetic Veterans**

ELLY BUDIMAN-MAK, NOAM EPESTEIN, MEGHAN BRENNAN, ROYDEN STUCK, MARYLOUI GUHAN, ZHIPING HUO, NICOLAS EMANUELE, MIN-WOINDING SOHN, Hines, IL; Madison, WI; Charlottesville, VA

To examine the association between systolic blood pressure variability (SBPV) and lower-extremity major amputation (LEA). We hypothesize that excessive SBPV is associated with increased risk of LEA.

This is a nested case-control study of a cohort of individuals age ≥60 years with diabetes and an LEA in the U.S. Department of Veterans Affairs hospitals from 2003-2008. SBPV were based on all BP measures taken during a year before LEA. Conditional logistic regression was used to model LEA risk as a function of SBPV, mean SBP, demographic factors, and other known risk factors of LEA (e.g., PAD, foot ulcers, peripheral neuropathy, osteomyelitis, and history of vascular procedure). The cohort included 262,954 patients, 1129 experienced an LEA during follow-up. We randomly selected 3548 controls, matching on age, sex, race/ethnicity, and duration. The crude incidence rates were 8%, 16%, 32% and 41% in SBP Variability Quartiles 1 (lowest) - 4 (highest). Results from a logistic regression showed graded relationship between SBPV and major LEA. Compared to Quartile 1, odds ratios for Quarters 2 - 4 were 1.4 (95% CI, 1.01 - 2.07), 2.9 (95% CI, 2.02 - 4.07), and 3.2 (95% CI, 2.22 - 4.46) in a model with all covariates (P for trend <0.001).

This is the first study showing SBPV as significantly associated with increased risk of LEA in diabetes.
Clinical Course of Urinary Incontinence in Women with Type 1 Diabetes: Longitudinal Findings from DCC/T1DM

SARAH K. HOLT, QUENTIN CLEMONS, JAMES HOTALING, ALAN M. JACOBSON, BARBARA H. BRAFFETT, PATRICIA CLEARY, HUNTER WESSELLS, ARUNA SARMA, DCC/T1DM, Seattle, WA, Ann Arbor, MI; San Lake City, UT; Mineola, NY; Bethesda, MD; Rockville, MD

This study describes the long-term course of urinary incontinence (UI) in women with type 1 diabetes (T1DM). Longitudinal data from 604 females in the Epidemiology of Diabetes Interventions and Complications study defined UI annually over 7 years using a single question querying presence/absence of UI. At first year of longitudinal data collection mean age was 46 (±7) years and mean duration of diabetes was 26 (±5) years. Subjects were categorized into 4 groups: Never Reported UI (controls), Single Episode of ≥2 years duration, Intermittent UI for subjects moving between UI states at least twice, and Persistent UI for subjects never reporting regain of function (Figure 1). Adjusted logistic regression was used to estimate association of covariates with UI behavior groups at the time of the index report. Eligible cases had to have ≥2 years of follow-up from index report of UI and controls were matched by EDIC year. Over the study period prevalence of UI increased ≥18.1% to 32.4%. Single episode UI subjects did not differ from controls for measured clinical and demographic factors. Intermittent and persistent cases had higher BMI (p<0.01), longer duration of diabetes (p=0.01), higher insulin dose (p<0.001), and more likely to be parous (p=0.005), but did not differ with respect to Hemoglobin A1c. Within this T1DM cohort, UI is a dynamic state with remission linked to diabetic duration, BMI, and parity.

Figure 1. Heatmap of UI Status for DCC/T1DM Females Over Time

Prevalence and Factors Associated with Dental Loss among Ambulatory Patients with Diabetes

KENNETH E. IZUORA, ECHEOZNA EZEANOLUE, MICHAEL NEUBAUER, CIVON GEWELEBER, GAYLE ALLENBACK, GUODEN SHAN, GUILLERMO E. UMPHREZ, Las Vegas NV, Atlanta GA

Poor dental health is more prevalent among patients with diabetes compared to the general population. Dental loss is associated with periodontal disease (PDD) and several diabetes comorbidities. Understanding the prevalence and factors that impact dental loss in the diabetic population will aid with the development of new strategies for prevention and improved care.

For author disclosure information, see page A810.

In this cross-sectional study of diabetes patients presenting for routine clinic visit at a university medical center, subjects completed a 48-item investigator–administered questionnaire. Data was collected on demographics, duration and control of diabetes, dental care history, dental health status, and presence of microvascular (retinopathy, nephropathy or neuropathy) and macrovascular (heart disease or stroke) complications of diabetes.

Among 202 subjects enrolled, 100 were female, mean age: 58.9 ± 12.2 years, duration of diabetes: 15.6 ± 11.3 years, and A1c: 7.7 ± 1.6%. We found that 31 patients had no teeth, 32 had 1 - 16 teeth, and 126 had 17 - 31 teeth. Only 13 (6.4%) had all 32 of their teeth. Among those with teeth, 87.7% had survey responses suggestive of POD. Using multivariate linear regression, we found that presence of bone disease (history of, or treatment for osteoporosis) was associated with 22 times higher odds of having POD (p = 0.029). In addition, older age (p = 0.001), past or present smoking (p = 0.055), not flossing (p = 0.001) and presence of diabetic retinopathy (p = 0.002) were associated with fewer number of teeth. Current A1c did not predict presence of PDD or dental loss.

In conclusion, there is a need for developing innovative approaches to dental care among patients with diabetes given the high prevalence of periodontal disease and dental loss, and the strong correlation between periodontal disease and osteoporosis identified among our patients with diabetes.
EPIDEMIOLOGY—DIABETES COMPLICATIONS

Serum adiponectin was inversely associated with eGFR in SGR [β (SE) for 1 SD of adiponectin = -2.53 (0.69), p = 2.0*10⁻⁴] and in Foggia [β (SE) = -5.63 (1.66), p = 0.001] samples, as well as in the two studies combined [β (SE) = -3.46 (0.69), p = 6.0*10⁻⁴]. The association was somewhat new but still significant after adjusting for sex, smoking habits, BMI, diabetes duration, HbA1c, anti-diabetic, anti-hypertensive and anti-dyslipidemic treatments [β (SD) = -1.79 (0.73), p = 0.015]. For each adiponectin SD increment, the odds of having eGFR < 60 ml/min/1.73m² increased by 46% [OR = 1.46; 95% CI 1.24-1.71; p = 2.3*10⁻⁴] in SGR sample, 52% (OR = 1.52; 95% CI 1.19-1.94; p = 0.001) in Foggia sample, and 47% (OR = 1.47; 95% CI 1.29-1.68; p = 8.7*10⁻⁴) in the two studies considered together. Further adjustment for the above mentioned covariates did not change the observed association [OR = 1.38; 95% CI 1.16-1.69; p = 8.5*10⁻⁴].

This is the first report of an association between high serum adiponectin and low eGFR in a large study of patients with T2D of European ancestry. Such counterintuitive, paradoxical association deserve further attempts to be deeper understood.

Supported By: SDF-F0.DI.RN

1603-P

Cardiovascular Risk Factors and Cognitive Performance: A Diffusion Tensor Imaging Study

FREDDY ALFARO, VASILIDES-ARSENIOS LIOUTAS, DANIELA A. PMENTEL, WOO-KYOUNG YOO, VERA NDIKAV, Boston, MA, Anyang, Republic of Korea

Cardiovascular risk factors (diabetes mellitus type 2 [T2DM], hypertension, hyperlipidemia) are associated with worse cognitive performance in older adults. We aimed to determine the impact of cardiovascular risk factors on brain white matter microstructure and cognitive performance. 33 subjects with cardiovascular risk factors [age 65.3 ± 8.3, 57.6% female, 28 T2DM (duration 14.6 ± 8.5 years), 33 hypertensive, 28 hyperlipidemic and 23 age and education-matched nondiabetic normotensive controls completed a battery of cognitive tests (Hopkins Verbal Learning test [HVLT], Verbal Fluency test [VFl]). All patients received 3 T MRI diffusion tensor imaging. Brain global and regional volumes, white matter fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD) and axial diffusivity (AD) were calculated. Multiple regression analysis were performed adjusting for age, and for the presence of hypertension, hyperlipidemia and diabetes. Global and regional white and gray matter brain volumes were not different between the groups. The risk factor group had worse performance in verbal fluency, learning and memory, compared to controls (VF: t-score (p=0.0001), VF: #animals t-score (p=0.001), HVLT: Total recall t-score (p=0.0001), and HVLT: Delayed recall t-score (p=0.003)). We found a positive association between VF: #animals t-score and R angular gyrus diffusion tensor imaging (FA (p=0.0001), RD (p=0.0003), and AD (p=0.0001), radj 0.4), and a negative association with MD (p=0.003, radj 0.3), L1 (p=0.01, radj 0.3), and RD (p=0.0001, radj 0.3), independent of age, hyperlipidemia, hypertension diagnosis and HbA1c. The cardiovascular risk factor group had worse performance in verbal fluency, learning and memory. Semantic verbal fluency showed the strongest correlation with R angular gyrus diffusion tensor imaging metrics. Cardiovascular risk factors exert a long-term effect on brain structure manifesting as microstructural white matter abnormalities.

Supported By: National Institutes of Health—National Institute of Diabetes and Digestive and Kidney Diseases (SR20DK084463-02, 1R01AG0287601-A2, to V.N.); Harvard Clinical and Translational Science Center

1604-P

Emergence and Regression of Urological Symptoms in Men and Women with Type 1 Diabetes Mellitus

HUNTER W. WESSELLS, Seattle, WA

Urological complications associated with poor diabetes control are considered to be irreversible, however, longitudinal studies have not determined the cumulative emergence and regression of these complications. UroEDIC, an ancillary study of urological complications in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, was administered in 2003 and 2010. Participants who provided responses to an anonymized survey of sexual and urinary function at both time points were included (n=1059). Emergence, persistence and regression were assessed for lower urinary tract symptoms (LUTS), urinary incontinence (UI), urinary tract infection (UTI), female sexual dysfunction (FSD), and erectile dysfunction (ED). Item completion rates for each domain ranged from 92-99%. Mean age of the cohort in 2003 was 43 years. For subjects with a given urological complication at baseline, approximately two-thirds reported persistence and one-third showed regression of symptoms, with the exception of UTI (Table 1). Incident cases of urological complications led to an overall increase in prevalence at follow-up. Urological symptoms in patients with longstanding type 1 diabetes exhibit significant fluctuation over a seven-year interval. Further investigation into factors influencing regression of urological symptoms may offer potential for better management.

Supported By: U.S. Department of Veterans Affairs (IR11-077)

WITHDRAWN

1605-P

Do Prevention Quality Indicators (PQIs) Underestimate Preventable Hospitalizations (PhIs)?

CHIN-LIN TSENG, CRYSTAL SOROKA, MIRIAM MANEY, LEONARD POGACH, East Change, NJ

Agency for Health Research and Quality (AHRQ) PQIs have not been recently updated. We evaluated individual and combined rates of 5 AHRQ PQIs (metabolic decompensation (MD): short term, dehydration, and uncontrolled diabetes), lower extremity amputations (LEAs), and urinary tract infections), and 3 proposed PQIs (1E lower urinary infections [LEU], hypoglycemia [HYP]), and Acute Kidney Injury (AKII) among Veterans Health Administration patients (VHA) with diabetes in 2006. We combined VHA and Medicare records to identify patients with diabetes and determine PQIs; we then calculated PH rates (per 1,000 persons) and determine age and sex adjusted rates by race. Following the AHRQ definitions for PQIs, we used principal ICD9CM codes for the proposed PQIs: 1) LEU (Harrington C. 2000; excluding co-occurring LEAs); 2) AKI: diagnosis code 548.9, and 3) HYP (Sjöriver 2008). We used AHRQ technical specifications for current PQIs.

There were 975,677 individuals; 57% were 65 years or older, 57% men. Proposed PhIs comprised 48% of the AKII was the most common PH; lower extremity PHs increased by 41% by including LEU, and MD by 40% by including HYP. Blacks were more likely to incur all/AHRQ/proposed PhIs: 44/24/24 (per 1,000 persons) vs. 32/17/17 (whites) vs. 29/16/15 (Whites) based on age and sex adjusted rates.

Current PQIs do not capture about half of diabetes relevant Phs; development of additional PQIs should be considered.

Table. Diabetes Preventive Quality Indicators (PQIs), plotted among age, gender and race categories: Patients with Diabetes Mellitus (DM) (% of patients with DM)

For author disclosure information, see page A810.
First DM diagnosis or anti-diabetes drug dispense date was defined as the index date. Eligible patients had continuous coverage for 12 mo prior (baseline) and 4 y after the index date (follow-up). Both eyes were required to have a BCVA of ≥ 20/40 (Snellen equivalent; ≥0.7 ETDRS letter score) at baseline. Baseline and follow up BCVA data were extracted from electronic medical records. Noncompliant patients did not conduct dilated eye exams annually (DM with DR) or biennially (DM w/o DR). Associations between BCVA outcomes and dilated eye exams were investigated using multivariate logistic regressions. Among the 15,315 eligible patients (mean age ± SD: 66.8±11.5; 52% were female), Baseline mean (SD) BCVA ETDRS letter score of the worse-seeing eye was 79.0 ± 3.2. After 4 y, BCVA worsened to <20/40 (ETDRS letter score 68 or lower) in 22.7% of patients and <20/200 (ETDRS letter score 38 or lower) in 3.5% of patients. In all patients, having an annual eye exam was associated with a reduced risk of VA worsening vs. noncompliance (OR ratio [OR] (95% confidence interval [CI])=0.87 [0.78-0.97]). In patients w/o DR, having biennial exams was not associated with a reduced risk of VA worsening vs. noncompliance (OR=0.90 (95% CI: 0.77-1.05)). Older age, elevated hemoglobin A1C levels, and having other eye diseases (e.g. cataract or age-related macular degeneration) were associated with an increased risk of worsening BCVA. Annual eye exams were associated with a lower risk of worsening BCVA. This analysis emphasizes the importance of routine eye exams for patients with DM.

1608-P
Serum Uric Acid Levels Are Associated with High Risk of Diabetic Nephropathy Progress among Japanese Type 2 Diabetes Patients
YASUKI HAYASHINO, SHINTARO OKAMURA, SATORU TSUJI, HITOSHI ISHI, FOR THE DIABETIC STUDY GROUP, Agra, Japan
We studied a cohort of Japanese patients with type 2 diabetes from a large-scale registry, to determine the prospective association between baseline serum uric acid level and subsequent risk of development or progression of diabetic nephropathy. Longitudinal data were obtained from 2018 patients in the cohort with type 2 diabetes who were registered in a Japanese diabetes registry. To assess the independent correlations between baseline serum uric acid quartiles and either development or progression of diabetic nephropathy for 2 years, the Cox proportional hazards model was used and adjusted for potential confounders. Mean patient age, body mass index, and HbA1c level at baseline was 66.1 years, 24.6 kg/m2, and 7.5% (57.6 mmol/mol), respectively. Baseline serum uric acid levels with mean values of 3.6 mg/dl, 4.3 mg/dl, 5.8 mg/dl, and 7.3 mg/dl for the 1st to 4th quartiles, were significantly associated with urinary albumin-creatinine ratio at baseline (p = 0.001). The multivariable-adjusted hazard ratios (HRs) for developing diabetic nephropathy were 0.93 (95% confidence interval (CI) = 0.73-1.2; p = 0.526), 1.01 (95% CI, 0.74-1.38; p = 0.959), and 1.09 (95% CI, 0.73-1.63; p = 0.880), respectively, for the 1st, 3rd, and 4th quartiles as compared to the 2nd quartile of uric acid. We did not observe a significant association between baseline uric acid levels and development of nephropathy, while it was significantly associated with progression of nephropathy. Multivariable adjusted HRs for the progression from microalbuminuria to macroalbuminuria were 2.17 (95% CI, 1.15-4.18; p = 0.016), 3.04 (95% CI, 1.67-5.53; p = 0.001), and 3.56 (95% CI, 1.83-6.93; p = 0.001), respectively, for the 1st, 3rd, and 4th quartile of serum uric acid levels, as compared with the 2nd quartile. Low and high serum uric acid levels, independent of possible confounders, were associated with a subsequent risk of progressing, but not developing, diabetic nephropathy in type 2 diabetes patients.

1609-P
Validation of Serum Biomarker Panel for Prediction of Renal Function Decline in Type 2 Diabetes
HELEN C. LOCKER, BASSAM FARRAN, MARCO COLOMBO, SIBYLLE HESS, JULIA BROSNIAN, NEIL DALTON, FELIX AGAKII, PAUL M. MCKEESUE, HELEN M. COLLHOUN, ON BEHALF OF THE SUMMIT INVESTIGATORS, Dundee, United Kingdom, Edinburgh, United Kingdom, Frankfurt, Germany, Cambridge, MA, London, United Kingdom
The aim of this study was to validate a previously defined panel of 13 serum biomarkers plus creatinine that in combination with clinical factors improved prediction of renal function decline in individuals with type 2 diabetes and chronic kidney disease stage 3 above that based on clinical factors alone. We measured the biomarker panel in 429 samples from the Genetics Audit and Research TID registry, to determine the prospective association between baseline serum uric acid level and subsequent risk of development or progression of diabetic nephropathy. Longitudinal data were obtained from 2018 patients in the cohort with type 2 diabetes who were registered in a Japanese diabetes registry. To assess the independent correlations between baseline serum uric acid quartiles and either development or progression of diabetic nephropathy for 2 years, the Cox proportional hazards model was used and adjusted for potential confounders. Mean patient age, body mass index, and HbA1c level at baseline was 66.1 years, 24.6 kg/m2, and 7.5% (57.6 mmol/mol), respectively. Baseline serum uric acid levels with mean values of 3.6 mg/dl, 4.3 mg/dl, 5.8 mg/dl, and 7.3 mg/dl for the 1st to 4th quartiles, were significantly associated with urinary albumin-creatinine ratio at baseline (p = 0.001). The multivariable-adjusted hazard ratios (HRs) for developing diabetic nephropathy were 0.93 (95% confidence interval (CI) = 0.73-1.2; p = 0.526), 1.01 (95% CI, 0.74-1.38; p = 0.959), and 1.09 (95% CI, 0.73-1.63; p = 0.880), respectively, for the 1st, 3rd, and 4th quartiles as compared to the 2nd quartile of uric acid. We did not observe a significant association between baseline uric acid levels and development of nephropathy, while it was significantly associated with progression of nephropathy. Multivariable adjusted HRs for the progression from microalbuminuria to macroalbuminuria were 2.17 (95% CI, 1.15-4.18; p = 0.016), 3.04 (95% CI, 1.67-5.53; p = 0.001), and 3.56 (95% CI, 1.83-6.93; p = 0.001), respectively, for the 1st, 3rd, and 4th quartile of serum uric acid levels, as compared with the 2nd quartile. Low and high serum uric acid levels, independent of possible confounders, were associated with a subsequent risk of progressing, but not developing, diabetic nephropathy in type 2 diabetes patients.

1610-P
Burden of Urological Complications of Type 1 Diabetes Mellitus: Results from UroEDIC
HUNTER B. WESSELLS, Seattle, WA
This cross-sectional study assessed cumulative burden of sexual dysfunction, lower urinary tract symptoms (LUTS), urinary incontinence (UI) and urinary tract infection (UTI) in a cohort of men and women with longstanding type 1 diabetes (T1D). In 2010, participants in UroEDIC, an ancillary study of urological complications of T1D in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, completed an anonymized survey of sexual and urinary function. Primary outcome variables were designated a priori for each urological complication based on items derived from validated instruments (International Index of Erectile Function, Female Sexual Function Index, AUA Symptom Index and Sandvik Severity Scale). Survey item completion rates within complication domain ranged from 92-99%. In this cohort (n=1224) mean age was 51 years and mean diabetes duration was 29 years. Of the 580 women, 60% reported at least one of the following: LUTS (22%), Female Sexual Dysfunction (26%), UI (30%) and UTI (17%). Of the 644 men, 68% reported at least one of the following: LUTS (25%), Erectile Dysfunction (46%), Low Desire (41%) and Orgasmic Dysfunction (15%). Overlap of prevalent complications by gender is shown in Fig 1. Of the two-thirds of the cohort reporting a complication, half report two or more complications. Urological complications represent a substantial burden to the TID population and warrant future research.

1611-P
Prevalence and Risk Factors for Diabetic Foot in Overweight or Obese Patients with Type 2 Diabetes
RUYI ZHANG, HONG CHEN, HUA ZHANG, JIANMIN RAN, Guangzhou, China
This study was aimed to investigate the prevalence and risk factors for diabetic foot in overweight or obese patients with type 2 diabetes. From August 2011 to March 2012, 5241 subjects who were diagnosed as type 2 diabetes with BMI≥26 kg/m² were enrolled from 60 hospitals in Guangdong Province. Patients with diabetic foot was diagnosed by Wagner’s classification. Binary Logistic regression was used to analyze the risk factors for diabetic foot. In our Binary Logistic regression analysis, presence of diabetic foot was positively associated with age (OR=1.020, 95% CI 1.004-1.036), female (OR=1.784, 95% CI 1.142-2.787), the duration of diabetes (year) (OR=1.042, 95% CI 1.017-1.068), BMI(OR=1.224, 95% CI 1.156-1.296), HbA1c (OR=1.217, 95% CI 1.142-1.298), alcohol use (OR=3.657, 95% CI 2.337-5.723) and diabetic nephropathy (OR=1.768, 95% CI 1.152-2.622). The results suggested that prevalence of diabetic foot was relatively high in the overweight or obese patients with type 2 diabetes. For those overweight or obese patients with type 2 diabetes, especially the old female patients, it is important to control the plasma glucose, decrease the level of body weight, quit smoking and screen diabetes chronic complications such as diabetic nephropathy to lowering the risk of diabetic foot.
The Characteristics of Dyslipidemia and Hypertension in Elderly Patients with Type 2 Diabetes Mellitus

FULDEN SARAC, SUMRU E. SAVAS, SEFA SARAC, FEHMI AKCICEK, Izmir, Turkey

Diabetes mellitus is increasingly recognized as an essentially vascular disease, and a principal objective of diabetes care is prevention or reduction of cardiovascular risk. Our aim is to determine the characteristics of dyslipidemia and hypertension in elderly patients with type 2 diabetes mellitus (DM). Two hundred (160 female, 40 male) (mean age 72±16.7 yrs) elderly patients with type 2 DM were included in the study. The hypertensive phenotype was defined as systolic blood pressure (SBP) ≥140 or diastolic blood pressure (DBP) ≥90 mm Hg. National Cholesterol Education Programme guidelines were used for definition of dyslipidemia. Sociodemographic, clinical, and biochemical data were taken from medical records, retrospectively. Hypertensive phenotype was found in 50.3% of diabetic elderly patients. Mean levels of systolic and diastolic blood pressures were found to be 169±25.9 mmHg and 100.1±12.1 mmHg, respectively, in elderly patients with hypertension. Seventy percent of the hypertensive patients had isolated systolic hypertension. Hypercholesterolemia was found to be in 60.0%, low HDL cholesterol in 65.1%, high LDL cholesterol in 70.5%, and hypertriglyceridemia in 41.1% of the patients. High LDL-cholesterol was the most common dyslipidemia in combination (78.5%) in all patients. And also, isolated low HDL levels (8.1%) were found in male. There were positive correlations between hemoglobin A1C and LDL-cholesterol levels (r=0.490, p<0.01) and TSH levels (r=0.500, p<0.05) in male. However, a positive correlation between postprandial glucose and triglyceride levels was found in female patients (r=0.400, p=0.01). Isolated systolic hypertension was most common hypertension pattern in elderly diabetic patients. Dyslipidemia patterns such as hypercholesterolemia, low high-density lipoprotein and high low-density lipoprotein levels, and hypertriglyceridemia were common in diabetic elderly.

Risk for Bone Fractures in Men and Women with Type 1 Diabetes

VIRAL N. SHAH, CHIRAG S. SHAH, JANET K. SNELL-BERGEVIN, Aurora, CO, Karinika India

Fracture risk in men and women with type 1 diabetes (T1D) is not well studied. Therefore, a systematic review and meta-analysis of observational studies were conducted to assess the association between T1D and fractures.

Data were selected from Medline and Embase and “Abstracts” from annual scientific meeting of various diabetes and bone and mineral societies. Published studies reporting fracture risk in subjects with T1D in comparison with subjects without diabetes between 1990 and July, 2014 and abstracts from various annual meeting (2005 onwards) were also included for this meta-analysis.

Fourteen studies that met inclusion criteria reported 2,066 fracture events among 27,300 subjects with T1D (7.6%) and 136,579 fracture events among 4,364,125 subjects without diabetes (3.1%). The pooled relative risk (RR) of any fracture in subjects with T1D was 3.16 (95% CI: 1.51-6.63, p<0.002) [Figure]. Women with T1D had four times higher risk and men with T1D had two times higher risk for any fractures compared to subjects without diabetes. The pooled RR of hip fractures and spinal fractures were 3.78 (95% CI: 2.05-6.96, p<0.001) and 2.69 (1.71-4.32, p<0.001), respectively, among subjects with T1D.

Our meta-analysis suggests that both men and women with type 1 diabetes might have an increased risk for any fractures. A large prospective epidemiological study is needed to confirm our findings.
**1616-P**  
**Neutrophil-Lymphocyte Ratio and C-Reactive Protein Levels Are Increased in Patients with Diabetic Kidney Disease**  
LYDIA A. WONG, GEORGE J. MACISSAC, JAS-MINE SEAH, SARA BAGAR, MICHELE CLARKE, FELICITY PYRLIS, RENATA LIBIANTO, SCOTT BAKER, JETHRO WU, ELIF I. EKINCI, Heidelberg West, Australia, Melbourne, Australia, Heidelberg, Australia

The neutrophil-to-lymphocyte ratio (NLR) and high-sensitivity C-reactive protein (CRP) are reliable measures of systemic inflammation. We hypothesized that a higher NLR and CRP are associated with an increase in albumin excretion rate (AER) and reduced glomerular filtration rate (GFR) in diabetes.

504 patients with type 1 or type 2 diabetes attending Austin Health Diabetes Clinics were recruited in a prospective study. NLR was calculated by dividing total neutrophil count by total lymphocyte count.

NLR values were significantly higher for patients with albuminuria (AER>200μg/min) compared to patients with normoalbuminuria (p<0.01, Fig. 1), as well as in patients with eGFR>60/ml/1.73m² compared to patients with eGFR<60/ml/1.73m² (p<0.01, Fig. 1). CRP levels were significantly lower in patients with normoalbuminuria compared to those with albuminuria (p<0.02, Fig. 1), but were not related to eGFR.

Higher NLR values are independently associated with reduced eGFR and increased AER in patients with diabetic kidney disease. Higher CRP levels are only associated with increased AER, with no relationship to eGFR. Whether these findings represent cause, effect, or association, awaits the lower in patients with normoalbuminuria compared to those with albuminuria (p<0.05). As compared to the normal level of serum zinc group, the subjects in the group with low serum zinc level were more likely to have a longer duration of diabetes, poorer glucose control, worse β cell function.

**Epistemiology—Nutrition**

**1617-P**  
**Association between Serum Zinc Level and Microvascular Complications in Type 2 Diabetes**  
YINGYING LU, JIE ZHAO, XUEYAO HAN, XIANGHAI ZHOU, JING WU, LINONG JI, Beijing, China

Purpose: The aims of our study were to compare serum zinc level in diabetic patients with and without microvascular complications, to investigate the association between zinc level and each microvascular complication and identify clinical and biochemical characteristics related to low level of serum zinc.

Methods: This is a non-interventional, cross-sectional study. We included the hospitalized T2DM patients in our hospital from May 30, 2013 to March 31, 2014. We firstly compared the serum zinc levels between patients with at least one microvascular complication and those without any complications. We also assessed associations between serum zinc level and microvascular complications. We further compared the characteristics between people with high and low serum zinc level.

Results: The study involved 412 patients, 271 with one or more microvascular complications and 141 without microvascular complications. There was a linear relationship between serum zinc level and the number of microvascular complications. The serum zinc level was significantly lower in patients with microvascular complications than patients without (P<0.01). Patients with more microvascular complications had lower serum zinc level. In the regression analysis, we found that lower serum zinc level was the independent risk factor for the presence of diabetic nephropathy (OR=0.89, 95%CI=1.04-1.11, p<0.05). As compared to the normal level of serum zinc group, the subjects in the group with low zinc levels had a longer duration of diabetes, higher hemoglobin A1C, higher prevalence of hypertension, higher prevalence of any forms of microvascular complications, lower C-Peptide level.

Conclusions: Lower serum zinc level in T2DM patients was associated with more microvascular complications. Low serum zinc level is an independent risk factor for diabetic nephropathy. T2DM patients with low serum zinc level were more likely to have a longer duration of diabetes, poorer glucose control, worse β cell function.

**1618-P**  
**The Association between Breastfeeding and Insulin Sensitivity among Youth with Diabetes**  
NATALIE S. THE, ARCHANA P. LAMICHANE, CHRISTINA M. SHAY, SHANSHAN WANG, DANA DABELEA, JEAN M. LAWRENCE, JAMIE L. CRANDELL, TESSA L. CRUME, ELIZABETH MAYER-DAVIS, Greenville, SC, Chapel Hill, NC, Aurora, CO, Pasadena, CA

There is mounting evidence that infant feeding practices are associated with later health outcomes. However, the association between breastfeeding and insulin sensitivity (IS) is unclear, with some studies showing a protective effect while other studies report no association. Further, existing studies have been exclusively conducted in healthy populations, and have not considered youth with diabetes. Participants included in our analyses were youth with type 1 diabetes (T1D; n=1,751; mean age at diagnosis 8.6±2 years) and type 2 diabetes (T2D; n=204; mean age at diagnosis 13.8±2.6 years). These data were collected as part of the SEARCH for Diabetes Youth and the SEARCH Nutrition Ancillary studies (SNAS). Mothers of participants were asked to report infant feeding practices, including breastfeeding initiation and duration. IS was estimated using an equation validated for youth with diabetes, which includes waist circumference, A1C and triglycerides levels. Nearly 70% of participating T1D and T2D were ever breastfed in comparison to 35% of participants with T2D. Among participants with T1D, IS was higher in those who had longer duration of breastfeeding (mean IS: never breastfed 9.8±3.58; breastfed < 6 months 10.5±3.5; breastfed ≥ 6 months [10.7±3.4; p<0.001]) in the unadjusted analyses. However, stepwise linear regression analyses showed the association was no longer significant after adjustment for confounders (model 1: adjusted for socio-demographic factors [β=0.006; p=0.5]; model 2: adjusted for socio-demographic factors and diabetes related characteristics [β=0.02; p=0.1]).

Interactions of breastfeeding with HLA risk alleles and age at diagnosis were not significant (p>0.10). Among participants with T2D, breastfeeding was not significantly associated with IS in either unadjusted (β=0.003; p=0.8) or adjusted models (model 1: β=0.01; p=0.2; model 2: β=0.01; p=0.2). In our cohort of youth with diabetes, breastfeeding was not associated with improved IS in later life.  

Supported By: 2R01DK077949-05

**1619-P**  
**Food Insecurity Is Associated with Poor Glycemic Control among Young and Young Adults with Type 1 Diabetes Mellitus**  

Food insecurity, i.e. limited or uncertain availability of nutritionally adequate and safe foods, has been associated with poor glycemic control, medication underuse, less physical activity, and poorer diet quality among adults with type 2 diabetes, but there are no studies examining food insecurity among U.S. youth and young adults with type 1 diabetes (T1D). Using data from two centers (Washington and South Carolina) in the SEARCH for Diabetes in Youth Study, we evaluated the association between food insecurity and glycemic control among participants ages 3 to 27 years with T1D. During SEARCH visits, parents or adult participants completed surveys including the Household Food Security Survey Module (HFSSM), which asks about conditions and behaviors typical of households unable to meet basic food needs. Participants’ HbA1c was measured. The HFSSM yields a standardized score from 0-10, which was dichotomized as food secure (≥2.2) or insecure (<2.2). Of the 196 participants (mean age 15.5 years, T1D duration 77.8 months, and 44.6% Medicaid), 8.1% lived in food-insecure households.
Mean HbA1c was 9.8% for participants living in food-insecure households vs. 8.3% for those living in food-secure households (p=0.009). In a linear regression model adjusted for age, gender, race/ethnicity, health insurance, parent or participant education, T1D duration, and study site, participants from food-insecure households had 0.93% higher HbA1c (95% CI: 0.27, 1.60) vs. peers from food-secure households. In adjusted logistic regression, participants from food-insecure households had 3.95 higher odds (95% CI: 1.85, 9.44) of poor glycemic control, i.e., HbA1c ≥ 9.5%, vs. peers from food-secure households. Our findings suggest that food insecurity may be an important correlate of poor glycemic control. If our results are confirmed by longitudinal studies, targeted efforts should be developed to identify and alleviate household food insecurity among youth and young adults with T1D.

Supported By: University of South Carolina; Seattle Children’s Research Institute

## Additional Studies

### 1620-P

**Diet Quality during Pregnancy and Risk of Gestational Diabetes: The Healthy Start Study**

**ANNE P. STARLING, ALLISON L. SHAPIRO, JILL KAAR, TESSA L. CRUMME, KATHERINE A. SAUER, DEBORAH H. GLUECK, BRANDY M. RINGHAM, ANNA MARIA SIEGA-RIZ, DANA DABELEA, Aurora, CO, Chapel Hill, NC**

Poor diet quality during pregnancy may increase the risk of adverse pregnancy outcomes, with consequences for both maternal and offspring health. This study examined whether diet quality in early and mid-pregnancy was associated with gestational diabetes (GDM) or impaired glucose tolerance (IGT). Participants were 1090 ethnically diverse pregnant women enrolled in Healthy Start, a pre-birth prospective cohort study. Dietary intake was assessed using Automated Self-Administered 24-hour dietary recalls prior to 27 weeks of pregnancy (the median gestational age at GDM screening). Participants completed at least 1 and up to 6 dietary recalls, and a glucose challenge test and/or oral glucose tolerance test (OGTT). A USA Healthy Eating Index (HEI) score was calculated for each participant (range 1-100). GDM (n=50) was defined as either a clinical diagnosis in the prenatal medical record, or 2 abnormal values on a 3-hr, 100g OGTT, using Carpenter-Coustan criteria. IGT (n=102) was defined as a positive result (≥6.1m mg/dl) on a 1-hr, 50g oral glucose challenge test, and/or 1 abnormal value on the 3-hr OGTT, in the absence of GDM. Multinomial logistic regression, adjusted for potential confounders, was used to estimate associations between HEI score and risk of GDM or IGT. Total HEI score ranged from 30 to 87 (mean: 60, SD: 11). The optimal HEI cutoff for predicting GDM was calculated using Youden’s index. Relative to women with HEI greater than or equal to 64, women with HEI less than 64 (63% of participants) had a higher risk of GDM (adjusted OR: 2.19, 95% CI: 1.05, 4.57), independent of daily energy intake and maternal pre-pregnancy body mass index (BMI). There was no evidence of a statistical interaction between BMI and diet quality in their associations with GDM.

There was no significant association between HEI<64 and IGT. Our data suggest that improving dietary quality in early and mid-pregnancy may reduce the risk of GDM, independent of maternal obesity.

Supported By: National Institutes of Health (DK078488 to D.O. [DK56390])

### 1621-P

**Serum Nonesterified Fatty Acid (NEFA) Concentration Is Associated with Longitudinal Progression of β-Cell Dysfunction: Prospective Metabolism and Inlet Cell Evaluation (PROMISE) Cohort**

**LUKE W. JOHNSTON, CHRISTINE LEE, STEWART B. HARRIS, RAVI KETNARAKAN, BERNARD ZINMAN, RICHARD P. BAZINET, ANTHONY J. HANLEY, Toronto, ON, Canada; London, ON, Canada**

Higher NEFA concentrations are associated with incident type 2 diabetes (T2DM), however limited longitudinal data exist regarding the impact of NEFA on the progression of metabolic disorders underlying T2DM. Our aim was to study the longitudinal associations of NEFA with 6-yr changes in insulin sensitivity (IS), β-cell function, and glycemia.

Adults at risk for diabetes in PROMISE had glucose and insulin measured from an oral glucose tolerance test (OGTT) at 3 visits over 6-yrs (n=478). Fasting NEFA were analyzed at baseline with thin layer chromatography and gas liquid chromatography coupled to flame ionization detector. The inverse of HOMA-IR (HOMA-IS) and the Matsuda index assessed IS. The Insulinosgenic Index over HOMA-IR (IGIR) and the Insulin Secretion-Sensitivity Index-2 (ISSI-2) assessed β-cell function. Generalized estimating equations were adjusted for waist, physical activity, alcohol, and sex. IS and β-cell function decreased over 6-yrs (all p<0.001; Fig. A & B). Higher NEFA were associated with an increased risk for dysglycemia (RR=1.25 (1.03 to 1.52) per SD). Although NEFA were not associated with either IS measure, higher NEFA independently predicted declines in IGIR and ISSI-2 over time (both p<0.01, Fig. C). Our findings suggest NEFA influence T2DM risk primarily through β-cell dysfunction.

Fig. A: Insulin sensitivity (IS) declines over 6 years

Fig. B: β-cell function (ISSI-2) declines over 6 years

Fig. C: Forest plot of the results from the generalized estimating equations

Outcome variables Beta Coefficients (95% CI)

HOMA-IS

IGIR

ISSI-2

-0.05 (-0.11 to 0.01)

-0.04 (-0.11 to 0.02)

-0.07 (-0.12 to 0.01)

-0.1 (-0.16 to 0.05)

Supported By: Canadian Diabetes Association; Canadian Institutes of Health Research

### 1622-P

**Individual Serum Saturated Fatty Acids and Markers of Chronic Subclinical Inflammation: The Insulin Resistance Atherosclerosis Study (IRAS)**

**INGRID D. SANTAREN, STEVE M. WATKINS, ANGELA D. LIESE, LYNNE E. WAGENKNECHT, MARIAN REVERS, STEVE M. HAFFNER, CARLOS LORENZO, ANTHONY J. HANLEY, Toronto, ON, Canada; West Sacramento, CA, Columbia, SC, Winston-Salem, NC, Aurora, CO, San Antonio, TX**

Despite longstanding dietary recommendations for reduced saturated fatty acid (SFA) intake, recent evidence has highlighted distinct effects of individual circulating SFA on cardiometabolic outcomes, with potential protective effects of odd and longer-chain SFA. Less is known, however, regarding the impact of individual SFA on subclinical inflammation. This study aimed to cross-sectionally investigate the associations of individual SFA with inflammation markers in 624 white, African American, and Hispanic adults, aged 40-69 y from IRAS. Serum SFA were analyzed using gas chromatography. Clinical measures included fasting serum pro-inflammatory markers, adiponectin, and oral glucose tolerance tests. For outcomes, we used Principal Components (PC) Analysis of pro-inflammatory markers, yielding 2 PCs (PC 1: fibrinogen, CRP and white cell count; and PC 2: PAI-1 and TNF-α). In multiple linear regression models adjusted for demographic and lifestyle variables, waist circumference, and glucose tolerance status, 15:0 and 22:0 were negatively associated, while 14:0 and 16:0 were positively associated, with PC 2. Further, 20:0 was positively, and 14:0 and 16:0 were negatively associated with adiponectin (Figure). In conclusion, lower circulating odd and longer-chain, and higher even-chain SFA, were related to worsened subclinical inflammation status.

Figures: Standardized beta coefficients and 95% CI from multiple linear regressions of serum SFA on markers of subclinical inflammation (A-PC 1: fibrinogen, CRP and white cell count; B-PC 2: PAI-1 and TNF-α) and C-Adiponectin adjusted for demographics, lifestyle, dietary and metabolic variables.

Supported By: Banting and Best Diabetes Centre, Dairy Farmers of Canada; National Heart, Lung, and Blood Institute

For author disclosure information, see page A810.
Dietary Acid Load and Type 2 Diabetes Mellitus: Pooled Results from Three Prospective Cohort Studies

JESSICA C. KIEFTE-DE JONG, YANPING LI, MIU CHEN, GARY C. CURHAN, JOHN P. FORMAN, OSCAR H. FRANCO, FRANK B. HU, Rotterdam, Netherlands; Boston, MA

Low grade metabolic acidosis, which is related to a Western diet, may be associated with the development of type 2 diabetes mellitus (T2DM). We aimed to assess the association between dietary acid load and T2DM.

We studied 67,419 women from the Nurses’ Health Study (1994), 84,483 women from Nurses’ Health Study II (1999) and 35,585 men from the Health Professionals Follow-up Study (1996) free from diabetes, cardiovascular disease and cancer at baseline. Diet was assessed by validated food-frequency questionnaires every four years. Two indices of dietary acid load were used: (1) energy-adjusted estimated net endogenous acid production (NEAP) and (2) energy-adjusted animal protein to potassium ratio (A/P). Incident cases of T2DM were identified through validated questionnaires.

We documented 15,179 cases with T2DM during 3,976,093 person-years of follow-up. After adjustment for potential confounders, including socio-demographic, medical and lifestyle factors, and BMI, higher NEAP and higher A/P were significantly associated with an increased risk of T2DM (Pooled Hazard Ratio (HR); 95% Confidence Interval (CI): 1.28; 1.21-1.35; P-for trend<0.001 and HR: 1.30; 95% CI: 1.23-1.38; P-for trend<0.0001 for the high- est vs. lowest quintile of NEAP and A/P, respectively). The associations between NEAP and A/P and the risk of T2DM did not substantially differ among those who were overweight or obese compared to those with normal weight or between those with high or low adherence scores on the Alternate Healthy Eating Index (P for interaction<0.05).

In conclusion, this study suggests that high dietary acid load is prospectively and independently associated with a higher risk of T2DM. Further studies are needed to establish whether diet-induced low grade metabolic acidosis is a causal mechanism for the development of T2DM.

Supported By: European Foundation for the Study of Diabetes

Alcohol Drinking and 4-Year Changes in Fasting Glucose in the Guangzhou Biobank Cohort Study

LIN XU, C.Q. JIANG, C.M. SCHOOLING, K.K. CHENG, T.H. LAM, Guangzhou, China, Guangzhou Biobank Cohort Study

Moderate alcohol drinking is associated with a lower risk of type 2 diabetes (T2DM), whereas heavy drinking is not, but findings from small-scale randomized controlled trials of moderate drinking are mixed. We examined the association of baseline alcohol use (never, former, occasional, moderate and heavy and >210 gram of ethanol per week for men and >140 gram per week for women) with changes in fasting plasma glucose and risk of incident T2DM (Pooled Hazard Ratio (HR)); 95% Confidence Interval (CI): 0.88; 0.83-0.94; P=0.004 for the high-est vs. lowest quintile of alcohol intake respectively) in a Chinese population. The associations between alcohol and changes in fasting plasma glucose and risk of T2DM did not substantially differ among those who were overweight or obese compared to those with normal weight or those with high or low adherence scores on the Alternate Healthy Eating Index (P for interaction<0.05).

In conclusion, this study suggests that heavy alcohol use was associated with a lower risk of T2DM (-43% (95% CI -64% to -10%)), although occasional, light and former drinking were not. In conclusion, heavy alcohol use was associated with a lower risk of T2DM (-43% (95% CI -64% to -10%)), although occasional, light and former drinking were not. Further analysis is needed to establish whether alcohol use influences glucose metabolism in anaphylaxis variables, such as the 6-year study population. All models are adjusted for age, sex, and diabetes status (P-value from linear mixed models).

Supported By: American Diabetes Association (17-13-CD-10 to J.K.S-B.)

Changes in Macronutrient Intake and Achievement of ABC goals in Adults with Type 1 Diabetes

LINDSEY M. DUCA, RACHEL M. SIPPL, CATHERINE CHARTIER-LOGAN, GREGORY L. KINNEY, DAVID M. MAASHS, JANET K. SNELL BERGEN, Aurora, CO

Despite therapeutic advances, few patients with type 1 diabetes (T1D) achieve the ADA’s ABC goals (A1c<7%, B: BC<130/80mmHg, C: LDL-c<100mg/dl). Diet may contribute to suboptimal ABC control. We hypothesized changes in nutrient intake would impact ABC changes over 6 years in T1D adults.

Dietary intake was assessed by a validated food-frequency questionnaire at baseline in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study (n=652, age 38 ± 9 years), then at 2.5 ± 0.5, and 6.2 ± 0.6 years of follow-up. Linear mixed models were used to examine how HbA1c, SBP and LDL-c changed over time in relation to changes in dietary macronutrients.

Baseline and 6-year total fat intake (35.5% vs. 36.0%) and saturated fat intake (12.7% vs. 12.8%) did not differ. Protein intake remained similar at baseline vs. 6 years (19.2% vs. 19.6%), but carbohydrate intake decreased (46.6% vs. 43.2%, P=0.002). Increased total and saturated fat intake was associated with an increase in HbA1c and LDL-cholesterol, and increased protein intake was associated with reduced SBP. Changes in carbohydrate intake were not related to the ABC goals (Table). Increased intake of fat and saturated fat was associated with worsening of lipids and glycemic control and increased protein intake with lower SBP, whereas a decrease in carbohydrate intake was observed in the cohort but was not associated with changes in achievement of ABC goals.

Table.

<table>
<thead>
<tr>
<th>Change in HbA1c</th>
<th>Change to SBP</th>
<th>Change to LDL-cholesterol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>6 years</td>
<td>Baseline</td>
</tr>
<tr>
<td>Protein (%)</td>
<td>-0.09</td>
<td>-0.03</td>
</tr>
<tr>
<td>Energy (%)</td>
<td>-29.1</td>
<td>-30.7</td>
</tr>
<tr>
<td>Carbohydrate (%)</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Fat (%)</td>
<td>3.1</td>
<td>3.8</td>
</tr>
</tbody>
</table>

Meta-analyses were performed of randomized trials examining the influence of sugar, milk and total energy intake (TEI) on fasting plasma glucose (FPG) concentrations. Sugar was the total amount of mono and disaccharide carbohydrates present in diets. Milk was any liquid milk product. Random effect models were applied to estimate changes in FPG during trials corresponding to changes in the amount of sugar, milk or total energy intake. Results are expressed as change in FPG (mmol/L) per month with 95% CIs.

29 trials were retrieved on sugar conducted in adults and in children, 8 on sugar sweetened beverages that allocated 848 subjects in 21 groups and 21 on sugar from solid foods that allocated 768 subjects in 46 groups. Incremental intake of 100 g/d of sugar was associated with a non-significant 0.10 mmol/L (0.02, 0.21; p=0.11) increase in FPG. Liquid or solid sugar had the same effect on changes in FPG. A model restricted to 12 trials including 28 groups that also reported TEI showed that when TEI was taken into account, an increment of 100 g/d in intake of sugar was associated with a non-significant 0.06 mmol/L (0.010, 0.020; p=0.39) decrease in FPG, while an incremental intake of 400 kcal (i.e., the energy of 100 g of sugar) was associated with a significant 0.29 mmol/L (0.11, 0.46; p=0.004) increase in FPG.

Seven trials were performed on milk intake in adults: 507 subjects were allocated to 20 groups. Compared to comparison groups, significant increases in FPG of 0.11 mmol/L (0.02, 0.19; p=0.0001) were observed in milk groups. A model restricted to the 3 trials including 7 groups that also reported TEI showed that when TEI was taken into account, allocation to milk groups was associated with a non-significant 0.04 mmol/L (0.010, 0.07, 0.16; p=0.23) increase in FPG, while an incremental intake of 100 kcal/d was associated with a borderline significant 0.04 mmol/L (0.000, 0.08; p=0.06) increase in FPG.

Changes in FPG are driven by changes in total energy intake and not by changes in amounts of specific nutrients. Implications for public health are obvious.
EPIDEMIOLOGY—NUTRITION

1627-P

Adherence to Low-Carbohydrate Dietary Pattern and Long-Term Risk of Type 2 Diabetes among Women with a History of Gestational Diabetes: A Prospective Cohort Study
WEI BAO, SHANSHAN LI, JORGE E. CHAVARRO, DEIRDE K. TOBIAS, YEIYI ZHU, FRANK B. HU, Rockville, MD, Boston, MA
Women with a history of gestational diabetes mellitus (GDM) are at high risk of developing type 2 diabetes mellitus (T2DM) after pregnancy. Carbohydrate restriction may improve short-term glycemic control in patients with GDM, but its long-term impact on the risk of T2DM is unknown. We aimed to examine the association among 4346 women with a history of GDM from the Nurses’ Health Study II cohort, as part of the Diabetes & Women’s Health Study. These women were followed up from 1991 to 2011. Low-carbohydrate-diet (LCD) scores were calculated from validated food-frequency questionnaires that were collected every four years, including overall LCD score based on intakes of carbohydrate, total protein and total fat, animal LCD score on intakes of carbohydrate, animal protein and animal fat, and vegetable-based LCD score on intakes of carbohydrate, vegetable protein and vegetable fat. A higher LCD score indicates a closer adherence to a low-carbohydrate dietary pattern. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). We documented 703 incident T2DM cases during up to 20 years of follow up. After adjustment for age, race/ethnicity, parity, family history of diabetes, and other lifestyle factors, the HRs (95% CIs) of T2DM comparing the highest versus the lowest quartiles were 1.84 (1.46-2.32) for overall LCD score (p for trend = 0.008), 1.77 (1.40-2.26) for animal LCD score (p for trend = 0.003), and 1.03 (0.82-1.31) for vegetable LCD score (p for trend = 0.48). The associations may be partly explained by BMI. In conclusion, among women with a history of GDM, a low-carbohydrate dietary pattern, particularly with high protein and fat intake mainly from animal-source foods, is associated with higher T2DM risk, whereas a low-carbohydrate dietary pattern with high protein and fat intake mainly from plant-source foods is not associated with the risk.

Supported By: Eunice Kennedy Shriver National Institute of Child Health and Human Development

1628-P

Meta-analysis of Sugar-Sweetened Beverage Intake and Interactions with Genetic Loci Related to Fructose Metabolism on Measures of Fasting Glucose and Insulin in 5 Cohorts
NICOLA M. MCKEOWN, JINTAO MA, ALEXIS FRAZIER-WOOD, ROZENN LEMAITRE, HASSAN M. DASHITI, UD OJUUE, T.C. KEPPELE, L. SERIS, ET AL., ERIELE ANDERS, MIKA HUHELMA, VERA MIIKILÄ, JOSE C. FLOREZ, DENIS RYBIN, JOSEÉ TAO HUANG, YAN ZHENG, GEORGE A. BRAY, FRANK M. SACKS, LU QI, HOWARD D. SESSO, LU WANG, JULIE E. BURING, MA, Boston, MA

Objective: We examined interactions between weight-loss diets and genetic variants predisposing to diabetes on insulin resistance in a randomized controlled trial.

Support for disclosure information, see page A810.
Research Design and Methods: Data were analyzed in the Preventing Overweight Using Novel Dietary Strategies (Pounds Lost) trial. Diabetes genetic risk score (GRS) was calculated based on 36 diabetes single nucleotide polymorphisms (SNP) in 730 (80% Whites) overweight or obese adults.

Results: We found that dietary protein significantly modified the diabetes genetic associations with fasting insulin, HbA1c, HOMA-B, and HOMA-IR (P for interaction < 0.02, 0.04, 0.01, and 0.05, respectively) at 2 years in Whites, after adjustment for age, sex, ethnicity, baseline body weight, weight change, and baseline genotype phenotype. The low-GRS was associated with greater decreases in fasting insulin (P<0.04), HbA1c (P<0.0001), and HOMA-IR (P<0.00) among participants with low-protein diet. Opposite genetic effects on changes in fasting insulin (P<0.03), and insulin resistance (P<0.08) were observed among high-protein diet group.

Conclusions: Our data suggest that individuals with low diabetes genetic risk might experience greater benefits in improving insulin resistance when consuming a low-protein weight-loss diet, while high-protein diet may be more beneficial for those with high genetic risk.

Supported By: National Heart, Lung, and Blood Institute (H27798, H272024, H203494) Boston Obesity Nutrition Research Center (DK82820), National Institute of Diabetes and Digestive and Kidney Diseases (DK091718, DK002083)

---

**1632-P**

**Dietary Protein Intake and Risk of Type 2 Diabetes in U.S. Men and Women**

**VASANTI S. MALIK, YANPING LI, DEIRDRE K. TOBIAS, AN PAN, FRANK B. HU,**

**Boston, MA, Singapore**

Dietary proteins are known modulators of glucose metabolism. However, longitudinal studies evaluating the association between protein intake and risk of type 2 diabetes (T2D) are sparse and whether type of protein differentially affects long-term risk of T2D is uncertain.

We aimed to investigate the association between total, animal and plant protein and incident T2D in U.S. men and women.

We prospectively followed 72,192 women from the Nurses’ Health Study (1984-2004), 92,088 women from the Nurses’ Health Study II (1991-2009) and 40,722 men from the Health Professionals Follow-up Study (1986-2008) who were free of diabetes, cardiovascular disease and cancer at baseline. Diet was assessed using a validated food frequency questionnaire updated every 4 years. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs.

During 4,146,216 person-years of follow-up, we documented 15,580 incident cases of T2D. In pooled multivariate models, intake of percent energy from total and animal protein was associated with 39% (31%, 48%) and 49% (40%, 59%) increased risk for T2D respectively, comparing extreme quintiles. Associations were attenuated after adjusting for BMI (HR 95% CI). 1.07 (1.01, 1.17) and 1.13 (1.05, 1.21) comparing extreme quintiles for total and animal protein, respectively. Intake of percent energy from vegetable protein was associated with a moderate decreased risk for T2D (0.51 [0.94, 0.88] comparing extreme quintiles in the fully adjusted model including BMI. Substituting 5% of energy from vegetable protein for animal protein was associated with 18% reduced risk for T2D and substituting 1 serving per day of vegetable protein foods for animal protein foods was associated with 10-21% reduced risk for T2D.

Higher intake of total and animal protein was associated with increased risk of type 2 diabetes (T2D), while higher intake of vegetable protein was associated with a modest reduced risk. Substituting vegetable protein for animal protein was associated with reduced risk for T2D.

---

**1633-P**

**U-Shaped Association between Plasma Manganese Concentration and Type 2 Diabetes in Adults**

**ZHILEI SHAN, SUJING CHEN, LIANQAI KAIEN, LIEGANG LIU, Wohuan China**

Both manganese and manganese-dependent mitochondrial superoxide dismutase (MnSOD) polymorphisms are elucidated to be associated with the activity of MnSOD and type 2 diabetes (T2D). The objective was to investigate the association of plasma manganese with newly diagnosed T2D and whether the association could be modified by MnSOD polymorphisms. We aimed to investigate the association between plasma manganese and newly diagnosed T2D and risk for T2D, while higher intake of vegetable protein was associated with a modest reduced risk. Substituting vegetable protein for animal protein was associated with reduced risk for T2D.

Results: We found that dietary protein significantly modified the diabetes genetic associations with fasting insulin, HbA1c, HOMA-B, and HOMA-IR (P for interaction < 0.02, 0.04, 0.01, and 0.05, respectively) at 2 years in Whites, after adjustment for age, sex, ethnicity, baseline body weight, weight change, and baseline genetic phenotype. The low-GRS was associated with greater decreases in fasting insulin (P<0.04), HbA1c (P<0.0001), and HOMA-IR (P<0.00) among participants with low-protein diet. Opposite genetic effects on changes in fasting insulin (P<0.03), and insulin resistance (P<0.08) were observed among high-protein diet group.

Conclusions: Our data suggest that individuals with low diabetes genetic risk might experience greater benefits in improving insulin resistance when consuming a low-protein weight-loss diet, while high-protein diet may be more beneficial for those with high genetic risk.

Supported By: National Heart, Lung, and Blood Institute (H27798, H272024, H203494) Boston Obesity Nutrition Research Center (DK82820), National Institute of Diabetes and Digestive and Kidney Diseases (DK091718, DK002083)

---

**1634-P**

**Association between Mediterranean Diet, Metabolic Health, and Obesity among U.S. Adults**

YONG-MOON PARK, KYUNGDO HAN, TERESA T. FUNG, SUSAN E. STECK, JIAJIA ZHANG, LINDA J. HAZLETT, ANWAR T. MERCHANT, Columbia SC, Seoul, Republic of Korea, Boston, MA

Evidence on the relation between Mediterranean diet (MD) and metabolic health is scarce. Data came from 5,631 adults aged 20-90 years (2,376 men and 3,255 women) without a history of cancer from the NHANES III, 1988-1994. Mediterranean Diet Scores (MDS) were created to assess the adherence to MD using food frequency questionnaires, supplemented by the 24-hr dietary recall data. Metabolic health was defined if subjects had fewer than two metabolic abnormalities (systolic/diastolic ≥130/85 mm Hg, triglycerides ≥150 mg/dL, HDL-cholesterol <40 mg/dL in men or <50 mg/dL in women, fasting glucose ≥100 mg/dL, HOMA-IR ≥90th pct, hsCRP >90th pct). Metabolically unhealthy normal weight (MUNW, 18.5 ≤ BMI < 25 kg/m²) and metabolically healthy obese (MHO, BMI ≥ 30 kg/m²) individuals were identified. With increasing MDS, there was lower prevalence of MUNW in men and women of higher prevalence of MHO in men and women (Figure). Lower MDS was associated with MUNW only in women (tertile 2 vs. 1, OR 0.98 [95 CI 0.95-1.37], tertile 3 vs. 1, 0.49 [0.31-0.80], whereas higher MDS was associated with MHO only in men (tertile 2 vs. 1, 1.03 [0.66-1.60]; tertile 3 vs. 1, 1.89 [1.19-3.02], after adjusting for age, race, education, income, smoking, physical activity, history of cardiovascular disease, BMI, and energy intake.

Adherence to MD is associated with metabolic health among both normal weight and obese individuals in a representative U.S. population.

---

**1635-P**

**In Peru, Lower Risk of Obesity at Higher Altitudes Extends to Adolescents: A Cross-Sectional Study**

**ORISON D. WOOLCOTT, CESAR GUTIERREZ, OSCAR A. CASTILLO, ROBERT M. ELASHOFF, DAKRO STEFANOVSKI, RICHARD N. BERGMAN, Los Angeles, CA, Lima, Peru**

Background: We recently reported a significant inverse association between obesity and altitude in the adult population of the United States, adjusting for several covariates. It is of great interest from a public health perspective whether this relationship develops earlier in life, and in other countries.

Methods: We examined the association between altitude and obesity in the adolescent population of Peru, a country with topographic, socioeconomic, cultural, and ethnic features differing from those of the United States. We utilized data publicly available online from the Food and Nutrition National Center of Peru, CENAN, for 2009-2010, the last period for which data is available. The CENAN used a nationally representative sample selected by the National Home Survey. Body weight and height were measured on-site using standardized methods. Final dataset included 7,618 adolescent subjects (14-19 years old). Odds ratios were estimated using binary logistic regression with clustered robust standard errors, adjusting for risk factors and potential confounders, including age, sex, physical activity, out-migration rate, urbanization, and latitude.

Results: The odds ratios for obesity were as follows: 1.00 between 0−499 meters (reference category), 1.71 (95% confidence interval 1.29 to 2.26) between 500−1,499 m, 0.62 (0.45 to 0.86) between 1,500−2,999 m, and 0.29 (0.17 to 0.50) at ≥3,000 m.
Conclusions: In Peruvian adolescents, living at higher altitude per se appears to be associated with reduced odds of having obesity. These findings suggest that geographical elevation is an important factor linked to obesity not only among adults but also among adolescents. The environmental explanation for this interesting relationship, which was also reported for adults, is unknown, but could yield important information regarding the pathogenic environmental causes of obesity per se.

Supported By: National Institutes of Health; Alexander von Humboldt Foundation; University of California, Los Angeles Clinical and Translational Science Institute

Mortality and Days at Hospital in Offspring of Diabetic Mothers: Danish Population-based Cohort Study with 8 to 36 Years Follow-up

Guided Audio Tour: Diabetes—From Soup to Nuts (Posters: 1638-P to 1643-F) see page 13.

Metformin Reduces Prostate Cancer Disparity in Men with Type 2 Diabetes?

CHEN-PIN WANG, DONNA LEHMAN, YUI-WING LAM, JOHN KUHN, DEVAL-INGA MAHALINGAM, STEVEN WITTMAN, JAVIER HERNANDEZ, CARLOS LORENZO, JOHN DOWNS, SARA E. ESPINOZA, AMELIE RAMIREZ, San Antonio, TX

Hispanics are at higher risk for type 2 diabetes (T2D). T2D is associated with increased risk for high grade prostate cancer (PCa). The Diabetes Prevention Program suggested that metformin (METF) might modulate T2D risk due to the TCF7L2 polymorphism, which plays a role in the pathogenesis of T2D in Hispanics. This study assesses in men with T2D, whether 1) PCa incidence differs by Hispanic origin, and 2) METF is associated with ethnic difference in PCa incidence.

The retrospective study cohort consisted of 77,951 male veterans with T2D but no prior cancer or liver diseases, nor thiazolidinediones or insulin use during 2003-2013. Cox proportional hazard model was used to compute the hazard ratio (HR) of PCa associated with Hispanic, and compare HR associated with METF use for Hispanic vs. non-Hispanics, adjusting for covariates and propensity scores of METF use.

Mean follow-up was 6.4±2.8 years; 5424 (7%) were Hispanics; 13811 (17%) were Black; mean age was 67.8±8.8 years; mean AIC was 6.5±0.9%, 4070 (5.2%) had a PCa diagnosis; 38.9% used METF, 86.6% used statin; 13.4% used finasteride. PCa incidence was 40% greater in Hispanics (HR=1.40, p<0.01). METF use alone was associated with 35% PCa incidence reduction in Hispanics (HR=0.65, p=0.01) but not in non-Hispanics (HR=0.92, p=0.10). METF+statin was associated with similar PCa incidence reduction between Hispanics and non-Hispanics (p=0.83); HR=0.39 (p=0.01) in Hispanics; HR=0.57 (p=0.01) in non-Hispanics. METF+finasteride was associated with similar PCa incidence reduction between Hispanics and non-Hispanics (p=0.48); HR=0.57 (p=0.01) in non-Hispanics; HR=0.76 (p=0.04) in Hispanics.

In insulin naïve men with T2D: 1) PCa incidence was higher in Hispanics; 2) METF alone could be more effective for PCa prevention in Hispanics vs. non-Hispanics; 3) METF in combination with finasteride or statin could be equally effective for PCa prevention in both ethnic groups. Prospective studies in multi ethnic groups are needed to confirm if METF reduces ethnic difference in PCa risk.

Supported By: National Institutes of Health (R21CA161180)

The percentage of days spent at hospital from 7-28 days were 14.6% vs. 10.0% (p<0.05). The percentage of days spent at hospital from day of birth to death, emigration, or December 31 (GD). Vital status was collected from Statistics Denmark. Percentage of days categorized as pre-gestational IDDM (n=524) or gestational (n=171) diabetes in women with diabetes (DM) in a Danish County from 1976-2003. They were categorized as ODM or GD. While acute insulinogenic index (0.9±0.7 vs. 0.5±0.5 vs. 0.2±0.2, p<0.001) and HOMA-IR (89.1±57.0 vs. 108.5±60.8, p<0.001) significantly decreased, HOMA-IR (2.3±0.9 vs. 3.0±1.8 vs. 4.3±3.0, p<0.001) increased according to the glucose intolerance, NIG, prediabetes and T2DM by order. Prediabetes with high PP30 showed significantly lower HOMA-IR (80.1±57.0 vs. 108.5±60.8, p<0.001) and acute insulinemic index (0.34±0.28 vs. 0.59±0.56, p<0.001) than prediabetes with low PP30. However, prediabetes with high PP30 and overt T2DM had similar glycermic parameters including HOMA-IR, insulinogenic index and HOMA-IR as well as BMI and lipid profile. 19.9% of prediabetes with low PP30 and 34.3% of prediabetes with high PP30 progressed to T2DM (p=0.001).

Prediabetes with high PP30 (>200mg/dl) showed β-cell dysfunction and insulin resistance similar to T2DM. This study suggested that prediabetic subjects with high PP30 should be considered as proactive management for diabetes and diagnostic criteria for considering the value of PP30 should be reflected.

Supported By: National Institutes of Health; Alexander von Humboldt Foundation; University of California, Los Angeles Clinical and Translational Science Institute

Effect of Lifestyle Interventions on Glucose Regulation among Adults without Impaired Glucose Tolerance or Diabetes: A Systematic Review

XUANPing ZHANG, GIUSEPPINA IMPERATORE, WILLIAM THOMAS, YILING J. CHEN, FELIPE LOBelo, KERI NORRIS, HEATHER M. DEVLIN, MOHAMMED K. ALI, STEPHANIE GRUSS, BARBARA BARDENHEIER, PYONE CHO, ISABEL GARCIA DE QUEVEDO, UMA MUDALIAR, JINAN SAADDINE, LINDA S. GEISS, EDWARD W. BREGG, Atlanta, GA

The effectiveness of lifestyle interventions (LI) for diabetes (DM) prevention among persons with impaired glucose tolerance (IGT) is well established but...
whether LI is similarly effective in preventing pre-DM among persons without IGT is unclear. We conducted a systematic review to assess effectiveness of LI on glycemic indicators among adults (≥18 years) without IGT or DM. Sixty-seven studies met the inclusion criteria (randomized controlled trials of LI that reported: fasting plasma glucose [FFG]; hemoglobin A1C [A1C]; fasting insulin [FI]; or homeostasis model assessment–estimated insulin resistance [HOMA-IR]). LI included physical activity, diet, or their combination with follow-up at 12 months. We divided studies to two groups: 1) normal glycemia, defined as mean FPG ≤5.5mmol/L or A1C ≤5.5%; and 2) high normal, defined as FPG ≥5.5mmol/L or A1C ≥5.5%. We synthesized results as a whole and by glycemic status groups using random-effect models. We applied results from meta-analyses to data from the 2005-2012 National Health and Nutrition Examination Survey, and used Monte Carlo Simulation models to estimate potential decreases in the prevalence of pre-DM in the U.S. Compared to usual care, LI achieved significant reductions in FPG (-0.14mmol/L [95% CI, -0.19, -0.09]), A1C (-0.05% [-0.08, -0.02]), percent change in FI (+5.26% [20.22, +10.31]), percent change in HOMA-IR (-22.66% [-29.43, -15.88]), and percent body weight (-3.84% [-4.56, -3.12]). Similar effects were observed among both groups (FFG: -0.14mmol/L [95% CI, -0.19, -0.09]; A1C: -0.05% [-0.08, -0.02]; percent change in FI: +5.26% [20.22, +10.31]; percent change in HOMA-IR: -22.66% [-29.43, -15.88]; and percent body weight: -3.84% [-4.56, -3.12]).

Prevalence of Acute Kidney Injury (AKI) Is Underestimated Using Administrative Data

CHIN-LIN TSENG, ORSYSA SORIOKA, JEAN-PHILIPPE LAFRANCE, LEONARD FUGACH, East Orange, NJ, Montreal, QC, Canada

Patients with diabetes have an increased risk for AKI compared to those without. However, the magnitude of this potentially preventable event may differ based upon the method used to ascertain AKI. Our objective was to evaluate the rate of AKI hospitalizations (AKI-Hs) using administrative codes (ICD9CM) vs. laboratory (serum creatinine) values.

We analyzed Veterans Health Administration (VHA) inpatient records in 2006. Patients with diabetes were identified based on two ICD9CM codes or prescription of diabetes specific medications. We calculated the number of AKI-Hs and compare two approaches (APPs) of AKI derivation. AKI-Hs were defined by the principal diagnosis code 584.9 (APP 1). We also defined AKI-Hs using combination of ratio and difference from two serum creatinine values (APP 2; Lafrance 2010): the creatinine value within the first 2 days of a hospital admission and a lowest baseline creatinine value within prior 3 months of discharge of the same admission). We excluded AKI-Hs occurring with dialysis within prior 3 months of admissions.

There were 975,677 VHA diabetes patients incurring 156,813 hospital admissions. The number of AKI-H was 2,637 (3 per 1,000 persons) for APP 1 and 27,148 (28 per 1,000) for APP 2. For comparison of two approaches, we limited the admissions to the 95,379 that had both ICD9CM codes and two serum creatinine values qualified for application of APP 2. This led to 1,773 (843 [39%] reduction) AKI-Hs for APP 1. Of the 95,379 admissions, 29% were AKI-Hs based on either APP; 5% of them were AKI-Hs from both APPs, and 34% were from APP 2 only. Similar statistics were observed across various age, sex, and race groups and CKD stages 1-5, with Whites, P < 0.001; while NtproBNP levels were similar between White and Hispanic, Asian-American, Hispanic-American individuals, P=0.014 and P=0.180, respectively. In the DPP cohort, African-Americans had lower NtproBNP levels compared with other racial groups. Further studies should examine the cardio-metabolic implications of lower NtproBNP levels in African-Americans.

The Joint Asia Diabetes Evaluation (JADE) Program—A Quality Improvement Program to Treat to Multiple Targets

ANDREA LUK, ERIC LAU, RISA OZAKI, ALICE KONG, RONALD C. MA, CHRISTINE M.L. KWAN, AMY W.C. FU, PETER C. TONG, WING-YEE SO, JULIANA C.N. CHAN, HONG KONG JADE STUDY GROUP, Hong Kong, China

Diabetic complications are preventable although clinical inertia and poor self management often lead to suboptimal quality of care.

In 2007, we designed the web-based Joint Asia Diabetes Evaluation (JADE) Program with protocols, risk engines, decision support and personalized reports for detecting silent risk factors and promoting shared decision-making.

In 2007-2014, 21313 diabetic patients (mean±SD: age: 58.5±12.2 years, male: 54.6%; type 1 diabetes: 2%; median [IQR] duration: 7 (2-13) years) underwent structured assessment at 5 nurse-led Diabetes Centres in Hong Kong guided by the JADE Program. Six quality indexes were defined as Atlantis, blood pressure (BP) ≤130/80 mmHg, LDL-C ≤2.6 mmol/L, non-smoking status, use of renin-angiotensin-system (RAS) inhibitors and statins. After 1.25 (1.01-2.02) years, 7502 (35%) patients had repeat assessment with significant improvement in those who were previously not at target: 26% attained Atlantis (1136/4343); 26% BP<130/80 mmHg (1156/4459); 45% LDL-C<2.6 mmol/L (1643/3842); 18.5% smoking cessation (162/877); 11.6% started RAS inhibitors (579/5015); 17.6% started statins (905/5017) with 72-78% attaining all additional targets or remained stable. There was also improved self care with 38.6% started to perform self-blood-glucose-monitoring (664/1721), 71.9% adhered to balanced diet (586/615) and 24.5% increased physical activity (566/3819). Overall, 20.2% had at least 3% reduction in body weight, 39.1%: 4 mmol/L reduction in systolic BP, 15% 1 mmol/L reduction in LDL-C and 22.6% 0.5% reduction in A1c, which were expected to translate into long term clinical benefits.

The use of the JADE Program combining logistics, information technology and team-based care reduced clinical inertia, improved self care and increased attainment of multiple treatment targets.

For author disclosure information, see page A810.
Maternal Pregravid Obesity Accelerates the Timing of Pubertal Onset in Daughters

AI KUBO, LAWRENCE H. KUSHI, CEZILE A. LAURENT, LOUISE C. GREENSPAN, CHARLES F. QUEENSBERRY, ASSAMIRA FERRARA, Oakland CA, San Francisco, CA

Early puberty is associated with a variety of chronic conditions including metabolic syndrome and cancer, therefore identification of modifiable risk factors is essential. Fetal origins of accelerated pubertal development have not been well studied. We investigated whether in utero exposure to maternal gestational diabetes (GDM) and prepregnancy obesity are associated with timing of pubertal onset in a multiethnic population.

This cohort study included 12,222 female members of Kaiser Permanente Northern California (KPN) age 6-11 y, who were also born at one of the KPN facilities. Pubertal onset was assessed using pediatrician-based pubertal maturation (Tanner) staging. Outcomes were ages of transition from breast stage 1 to 2+ (BR2+) or pubic hair stage 1 to 2+ (PH2+). Maternal glucose levels, height, and weight at AFP test were obtained from the electronic health record (EHR). A proportional hazards model with interval censoring was used for analysis, adjusting for maternal age and race/ethnicity.

Having a mother who was overweight (body mass index (BMI) 25-29.9 kg/m²) or obese (BMI ≥30) was associated with earlier transition to BR2+ [hazard ratio (HR)=1.32, 95% confidence interval (CI) 1.19-1.47; HR=1.42 95% CI 1.26-1.60, respectively, vs. BMI <25]. Maternal obesity was also associated with earlier transition to PH2+ [HR=1.42 95% CI 1.25-1.62 for BMI <30; HR=1.26 95% CI 1.10-1.41 for BMI ≥30]. These associations were attenuated when adjusted for gender and the pre-pubertal age- and sex-specific BMI percentile, but remained significant [HR for BR2+=1.16 95% CI 1.02-1.32; HR for PH2+=1.19 95% CI 1.04-1.31, BMI ≥25 vs. <25]. There was no association between the presence of GDM and timing of pubertal onset.

Maternal obesity is associated with higher risk of earlier pubertal onset in girls, independent of their own obesity status. These results suggest the importance of monitoring obesity among pregnant women to prevent over-accelerating pubertal maturation in girls, which may in turn prevent their long-term sequelae.

 Supported By: KL2TR001115-02

Ethnic Differences in Body Composition and Adipokine Results from the MSALA and MESA Studies

ARTI SHAH, NANDRATHA R. KANDOLA, FENG LIN, MATTHEW ALLISON, JOHN JETTING, DAVID M. HERRINGTON, KIANG LIU, ALKA M. KANAYA, San Francisco, CA, Chicago, IL, San Diego, CA, Nashville, TN, Winston-Salem, NC

Possibly due to less favorable body composition and adipokines, South Asians (SA) have higher rates of type 2 diabetes (T2DM) compared to other ethnic groups. Studies comparing body composition in US to other race/ethnic groups are lacking. Currently, we performed a cross-sectional analysis of two community-based cohorts, Mediators of Atherosclerosis in South Asians Living in America (MSALA) and Multi-Ethnic Study of Atherosclerosis (MESA) using harmonized data. Generalized linear models were developed to assess ethnic differences in ectopic fat, lean mass, and adipokine (Table). *p-value <0.01 for pairwise comparison to SA.

All models were adjusted for age, sex, site, alcohol use, smoking, and BMI. Additionally, ectopic fat models were adjusted for exercise, hypertension, DM, androgens (Table). Liver attenuation models were adjusted for exercise, hypertension, DM, total mass models were adjusted for exercise, and the adipokine model was adjusted for visceral fat and intermuscular fat area. Compared to the other ethnic groups, SA had greater intermuscular and visceral fat, and lower liver density, lean muscle mass, and adipokine. SA have a less favorable body composition and adipokine profile compared to other groups independent of BMI, lifestyle and metabolic factors. Investigation of whether these differences account for higher DM and cardiovascular disease prevalence in U.S. SA is warranted.

Supported By: National Institutes of Health (R01HL109309)
Outcomes among Patients with Type 2 Diabetes (T2D): Receiving Basal Insulin with Mealtime Insulin or Exenatide BID: A Retrospective Study Using Real-World EMR Data

KATHLEEN LANG, HIEP NGUYEN, HUANHUANG, ELISE KAUFMAN, PHILIP LEVIN, Cambridge, MA, Wilmington, DE, Baltimore, MD

Mealtime insulin and exenatide twice daily (ExBID) are effective as add-on therapies to basal insulin for T2D patients in randomized clinical trials. This retrospective cohort study used electronic medical record (EMR) data to evaluate analogous real-world outcomes.

Adult patients with T2D who initiated mealtime insulin or exenatide BID as an add-on to basal insulin between Jan 1, 2008 and Mar 31, 2013 were identified in a U.S. EMR database, with the date of first prescription defined as index date. Patients were followed for 12-months before (baseline) and 6-months after index. Outcomes included glycemic control (percent with A1C<7%), change in A1C, incidence of hypoglycemic events, and change in body weight. Multivariate regressions adjusted for differences in baseline demographic characteristics and potential confounders.

1,152 ExBID patients (mean±SD age 59±10.4y, 55.0% female) and 23,891 mealtime insulin patients (mean±SD age 61±13.3y, 51.2% female) were identified. Mean baseline A1C was 6.7% and 6.9% (p=0.001) for mealtime insulin and ExBID patients, respectively. During follow-up, mean A1C was 8.1% and 7.9% (p=0.001) for mealtime insulin and ExBID patients, with 25.7% and 29.8% achieving control (p=0.006). Weight decreased with ExBID and increased with mealtime insulin (-3.1 vs +1.0 lb; p<0.001). Patients initiating ExBID were less likely to have a hypoglycemic event than mealtime insulin (2.5% vs. 5.7%; p<0.001). In multivariate models, ExBID patients were more likely to achieve glycemic control (OR=1.2, p=0.01) and had a similar change in A1C during follow-up (LS mean=-0.27 ExBID; -0.29 mealtime, p=0.74).

In a real-world setting basal insulin plus ExBID was as effective as basal insulin and meal bolus insulin treatment in reducing A1C, but was associated with less weight gain and less hypoglycemia. This study supports use of basal-exenatide treatment in T2D as an alternative to basal-meal bolus therapy.

Supported By: Eunice Kennedy Shriver National Institute of Child Health and Human Development

ESRD Outcomes Research and Policy Evaluation, Division of Policy, Planning, and Evaluation, U.S. Renal Data System, Atlanta, GA

End-stage renal disease (ESRD) was diagnosed in 921,363 patients with chronic kidney disease from 2000 to 2012. The incidence of ESRD at 2012 was 340.3 per million population, lower than in previous years. The incidence of ESRD was 285.8 per million population in patients <65 years of age and 490.1 per million in patients ≥65 years of age. The difference between the two groups was significant (p<0.001). The number of prevalent patients on dialysis was 541,090 as of 12/31/2012. The number of prevalent ESRD patients on dialysis decreased in 2012 for both men (185.9% decrease) and women (17.0% decrease). The most frequent cause of ESRD was diabetes (43.1% of prevalent patients). The prevalence of diabetes among prevalent patients increased from 38.3% in 2000 to 43.1% in 2012. Other prevalent causes were hypertension (25.7% of prevalent patients) and glomerulonephritis (17.2%). The prevalence of ESRD by race was highest among African Americans (32.9% of prevalent patients) and lowest among Asians (18.7%). The prevalence of ESRD by sex was higher in men (27.5% of prevalent patients) than in women (21.2%). The prevalence of ESRD increased with age and was highest among patients ≥85 years of age (55.3% of prevalent patients). The most common complication was cardiovascular disease (42.3% of prevalent patients). The prevalence of cardiovascular disease increased from 37.5% in 2000 to 42.3% in 2012. The prevalence of gastrointestinal complications (16.3% of prevalent patients) and infections (12.1% of prevalent patients) also increased from 2000 to 2012. The prevalence of heart failure (20.5% of prevalent patients) and osteoporosis (18.3% of prevalent patients) was highest among patients ≥85 years of age. The prevalence of heart failure decreased from 27.5% in 2000 to 20.5% in 2012, while the prevalence of osteoporosis increased from 15.7% in 2000 to 18.3% in 2012. The prevalence of diabetes was highest among patients with ESRD (43.1%) and was lower among patients with chronic kidney disease (27.1%). The prevalence of diabetes decreased from 2000 to 2012 for both men (40.8% to 39.0%) and women (30.0% to 29.6%). The prevalence of hypertension was highest among patients with ESRD (25.7%) and was lower among patients with chronic kidney disease (22.2%). The prevalence of hypertension increased from 2000 to 2012 for both men (22.1% to 23.4%) and women (19.2% to 20.6%). The prevalence of glomerulonephritis was highest among patients with ESRD (17.2%) and was lower among patients with chronic kidney disease (9.1%). The prevalence of glomerulonephritis increased from 2000 to 2012 for both men (16.6% to 17.6%) and women (9.0% to 9.9%). The prevalence of cardiovascular disease was highest among patients with ESRD (42.3%) and was lower among patients with chronic kidney disease (31.5%). The prevalence of cardiovascular disease increased from 2000 to 2012 for both men (38.5% to 42.3%) and women (26.7% to 28.1%). The prevalence of gastrointestinal complications was highest among patients with ESRD (16.3%) and was lower among patients with chronic kidney disease (10.8%). The prevalence of gastrointestinal complications increased from 2000 to 2012 for both men (14.7% to 16.5%) and women (10.1% to 11.7%). The prevalence of infections was highest among patients with ESRD (12.1%) and was lower among patients with chronic kidney disease (7.8%). The prevalence of infections increased from 2000 to 2012 for both men (10.5% to 11.6%) and women (7.1% to 7.8%). The prevalence of heart failure was highest among patients with ESRD (20.5%) and was lower among patients with chronic kidney disease (15.7%). The prevalence of heart failure decreased from 2000 to 2012 for both men (22.8% to 21.7%) and women (18.4% to 17.8%). The prevalence of osteoporosis was highest among patients with ESRD (18.3%) and was lower among patients with chronic kidney disease (14.9%). The prevalence of osteoporosis increased from 2000 to 2012 for both men (15.4% to 16.3%) and women (13.2% to 14.4%).
Weight Loss Strategies and Changes in Body Weight among Subjects with Type 2 Diabetes (T2D) in the U.S.

YING WANG, JANICE LOPEZ, VIVENNE ZHU, SUSAN C. BOLGE, MARCIA RUPNOW, ROBERT A. BAILEY, PAUL E. STANG, Titusville, NJ, Ellicott City, MD, Rantan, NJ.

This analysis seeks to understand weight loss strategies, weight changes, attitudes and behaviors in subjects with T2D. We used the 2005-2012 U.S. NHANES data to identify subjects with self-reported T2D diagnosis. Body weight data included measured and self-reported current body weight and height, self-reported weight the prior year, and self-reported desired weight. Analyses were weighted to account for the stratified, multistage probability sampling design and survey nonresponse.

Of the 2,266 subjects identified with T2D, 2,187 (93%) had data to calculate weight change from the prior year. The overall prevalence of overweight/obesity (body mass index ≥ 25 kg/m²) was 86% (95% confidence interval 84%-88%) in present year, and 88% (95% CI 86%-90%) the prior year. Figure 1 shows the prevalence of various weight loss strategies, and % body weight lost among subjects who were overweight/obese the prior year. Many diet-related methods were used, with average weight lost<5%.

Two most “effective” methods reported (smoking, taking laxatives/vomiting) are also potentially harmful. Overweight and obese persons would have to lose about 8% and 24%, respectively, to reach their desired weight.

This study highlights the T2D weight issues, and challenges facing patients and clinicians in seeking to manage it.
In conclusion, in the outpatient diabetes centers the patients with longstanding, poorly controlled insulin treated T2DM should be rigorously assessed towards malignancies, particularly breast cancer in women and colorectal cancer in men.

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>1.09 (1.52-2.21)</td>
<td>N/S</td>
</tr>
<tr>
<td>≥ 27.5</td>
<td>1.09 (N/S)</td>
<td></td>
</tr>
<tr>
<td>≥ 25.0 - 27.4</td>
<td>1.09 (N/S)</td>
<td></td>
</tr>
<tr>
<td>≥ 30.0 - 34.9</td>
<td>1.09 (N/S)</td>
<td></td>
</tr>
<tr>
<td>≥ 35.0</td>
<td>1.09 (N/S)</td>
<td></td>
</tr>
</tbody>
</table>

DHEAS and fasting glucose -0.06 (0.92) -0.10 (0.56) -0.08 (0.32) -0.06 (0.71)

Testosterone and fasting glucose -0.06 (0.92) -0.10 (0.56) -0.08 (0.32) -0.06 (0.71)

Testosterone and 2-hour glucose -0.07 (0.93) -0.10 (0.56) -0.08 (0.32) -0.06 (0.71)

SHBG and fasting glucose -0.06 (0.92) -0.10 (0.56) -0.08 (0.32) -0.06 (0.71)

SHBG and 2-hour glucose -0.01 (0.93) -0.07 (0.56) -0.06 (0.32) -0.07 (0.71)

Supported By: American Diabetes Association (1-05-CD-12, 1-07-JF-30 to K.M.); National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Child Health and Human Development; National Institute on Aging; Office of Research on Minority Health and Health Disparities; Office of Research on Women’s Health; Indian Health Services; Centers for Disease Control and Prevention; U.S. Global Change Research Program; National Center for Research Resources; Bristol-Myers Squibb; Lipton; Parke-Davis
Biomarkers for Insulin Resistance and 10-Year Risk of Diabetes: Evaluation of a Novel 92-Protein Assay in Two Large Swedish Community Cohorts

CHRISTOPH NOWAK, JOHAN SUNDSTRÖM, LARS LIND, ERIK INGELSSON, TOVE FALL, ÖIPALA, SWEDEN

Insulin resistance (IR) is a major precursor and pathogenic component of type 2 diabetes (T2D) but difficult to measure in the clinical setting. To identify new biomarkers for IR and T2D, we used a novel 92-protein proximity extension assay for cardiovascular and inflammatory markers.

Proteomic profiles of blood samples from non-diabetic elderly Swedish community residents in two longitudinal cohorts (PIVUS n=887, ULSAM n=606; mean age 73.2±0.53 yrs, 30.3% female) were assessed using the Olink Proseek Multiplex CVD 96x96 panel. Outcomes were baseline HOMA-IR, 10-yr incident T2D, and 5-yr risk for worsening fasting glucose category (<5.6 mmol/l, 5.6-6.9 mmol/l, and ≥7 mmol/l or T2D). Linear (HOMA-IR), logistic (5-yr prediction), and Cox regression analyses (10-yr T2D prediction) were adjusted for confounder factors (age, sex, BMI, waist circumference, C-reactive protein, and comorbidity) and multiple testing (5% false discovery rate).

At baseline, 15 out of 85 proteins that passed quality control were associated with HOMA-IR in the training sample (PIVUS), five had confirmed positive associations in the validation sample (ULSAM): leptin, tissue plasminogen activator (t-PA), renin, interleukin-1 receptor antagonist (IL-1RA), and hepatocyte growth factor (HGF). Only IL-1RA predicted 10-yr incident T2D (adjusted HR for a log2-scale unit increase 1.35, 95% CI 1.02-1.80). In unadjusted analyses, IL-1RA (HR 1.39, 95% CI 1.08-1.74), t-PA (HR 1.42, 95% CI 1.12-1.71) predicted 5-yr worsening in glycaemic state. These associations were no longer significant after confounder adjustment.

Proteomic profiling is valuable for IR/T2D biomarker discovery. The identified risk markers relate to recently implicated pathways in T2D pathogenesis, including endothelial dysfunction, ectopic hepatic lipid accumulation, and imbalance between pro- and anti-inflammatory cytokines.

Use of Health Information Technology and Access to Medical Care among Persons With and Without Diagnosed Diabetes

CHUH-FANG CHOU, KAI MCKEEVER BULLARD, JIJIAN B. SAADDINE, JOHN CREWS, GIUSEPPINA IMPERATO, ANN L. ALBRIGHT, Atlanta, GA

Health information technology (HIT) may be effective in improving access to care and quality of care. However, the proportion of U.S. adults (aged ≥18 years) with/without self-reported diabetes (DM) using HIT to access medical care is unknown. We used data from 14,096 adults with/without DM in the 2009, 2011, and 2012 U.S. National Health Interview Survey. We assessed use of HIT to access medical care by: use of the internet for setting appointments; communicating with health care providers; and refilling prescriptions. We calculated adjusted prevalences of HIT use from logistic regression models, controlling for socio-demographic and health status. Adults with DM reported higher age-adjusted prevalences of refilling prescriptions online (11.4% [95% CI: 9.4-13.7] vs. 5.3% [5.6-6.1]) and communicating with health providers online in the past year (7.8% [6.1-10.0] vs. 5.3% [5.0-5.5]) than those without. There was no statistical difference in the age-adjusted prevalence of setting appointments online between those with/without DM (5.3% [3.9-7.1]) vs. 4.2% [4.0-4.4]). The adjusted association between DM status and refilling prescriptions and communicating with health providers online differed by selected demographics. For example, among adults with DM, those aged 18-39 y were more likely to refill prescriptions online than those aged 40-64 y (14.3% [11.3-17.9] vs. 9.6% [8.4-11.0%]) among adults without DM, adults aged 18-39 y were less likely to refill prescriptions online than those aged 40-64 y (6.0% [5.6-6.4] vs. 7.0% [6.7-7.4]). Diabetes status is associated with HIT use. Among those with diabetes, younger and those with private insurance are more likely to use HIT. Given the potential of HIT to benefit large numbers of people, interventions to motivate people with diabetes to use internet for their medical care needs might be considered.

The Temporal Relationship between Diagnosis with Diabetes and Development of Depression: A Registry-based Analysis of the Working-Age Population in Denmark 1996-2010

BRYAN CLEAL, ULRIK HAAGEN NIELSEN, INGRID WILLAING, RICHARD I.G. HOLT, GEOTEH, DENMARK, HOLTE, DENMARK, SOUTHAMPTON, UNITED KINGDOM

The study investigated the temporal relationship between diagnosis with diabetes (Source: Danish Diabetes Register) and first purchase of prescribed antidepressants (Source: Register Medicinal Product Statistics) as a proxy for incident depression. We excluded individuals taking antidepressants in the year prior to baseline. People with diabetes of working age (19-58) were followed for five years after diagnosis. As a proxy of socioeconomic status, subjects were stratified according to occupational status.

Table. Odds Ratios for Dysglycemia in Pregnancy According to Number of Healthy Prenatal Behaviors.

<table>
<thead>
<tr>
<th>Healthy behaviors</th>
<th>Normal n (%)</th>
<th>Dysglycemia n (%)</th>
<th>Unadjusted OR (95% CI)</th>
<th>Adjusted OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>34 (5.2%)</td>
<td>8 (7.5%)</td>
<td>1.00 (ref)</td>
<td>1.00 (ref)</td>
</tr>
<tr>
<td>1</td>
<td>218 (33.3%)</td>
<td>40 (37.1%)</td>
<td>0.78 (0.34, 1.81)</td>
<td>0.71 (0.37, 2.22)</td>
</tr>
<tr>
<td>2</td>
<td>222 (35.9%)</td>
<td>41 (38.7%)</td>
<td>0.79 (0.34, 1.82)</td>
<td>0.86 (0.36, 2.19)</td>
</tr>
<tr>
<td>3-4</td>
<td>180 (27.5%)</td>
<td>17 (16.0%)</td>
<td>0.80 (0.16, 1.00)</td>
<td>0.44 (0.17, 1.17)</td>
</tr>
</tbody>
</table>

p for trend 0.03 0.04

Supported By: National Institutes of Health (R01DK076648, UL1TR001082, P30DK065595, T32DK078588)
9.9% of people with diabetes developed depression within 5 years of the diagnosis of diabetes, of whom 24.1% did so in the first year. Thus, a significantly greater proportion developed depression within the first year. Overall, incident depression in the first year is the same for all occupational groups. After five years differences between the different occupational categories emerge, with those of lower socioeconomic status having the highest incident. Conversely, those of high socioeconomic status who develop depression are more likely to do so in the first year after diagnosis. The data indicate that diagnosis of diabetes precipitates depression across the workforce, but those with high occupational status have better resilience/coping skills that allow them to adapt better to the demands of diabetes.

Changes in Cancer Mortality among U.S. Adults with Diabetes, 1990-2011

YILING J. CHENG, GIUSEPPINA IMPERATORE, DIANNA J. MAGLIA NO, BENDIUX CARSTENSEN, KAI M. BULLARD, BARBARA H. BARDENHEIER, LINDA S. GEISS, EDWARD W. GREGG, Atlanta, GA, Phahnian Australia, Gentofte, Denmark

Although mortality in persons with diabetes has decreased, there are evidences that the incidence of certain cancers and related mortality are increased in people with diabetes (DM). It is unclear whether overall cancer mortality has changed among U.S. adults with DM. To examine whether cancer mortality is higher in people with diabetes, we used data from 33,442 adults aged ≥20 yrs with self-reported DM who participated in the 1988-2008 U.S. National Health Interview Survey. Participants were linked to the National Death Index to determine vital status up to 2011. Cancer deaths were classified according to underlying or contributing cause of death. We compared cancer mortality rates of 5 consecutive time periods (1990-1994, 1995-1999, 2000-2004, 2005-2009, and 2010-2011).

During a mean follow-up of 12.5 years, 11,445 adults with DM died. From 1990-1994 to 2010-2011, age-standardized all cause death rates (per 1000 person-years and 95% CI) declined from 23.4 (20.3, 26.5) to 19.4 (17.8, 20.9), and underlying cancer death rates declined from 3.7 (2.8, 4.7) to 3.0 (2.4, 3.7). The age- sex- race-ethnicity-adjusted hazard ratios of underlying cancer mortality for the 5 time periods were 1.0 (1990-1994 used as a reference), 0.9 (0.7, 1.1), 0.9 (0.7, 1.2), 0.8 (0.6, 1.1), and 0.7 (0.6, 0.9), respectively. When classified according to either underlying or contributing cause, cancer death rates decreased by 27% (6%, 42%), and the death rate for selected cancer (combined liver and intrahepatic bile ducts, pancreas, endometrium, colon and rectum, breast, and bladder) decreased by 40% (9%, 60%) (both p < 0.05). Among U.S. adults with diabetes, cancer mortality rates are declining.

Characterizing the Prehospital Response to Diabetic Emergencies

ROBERT KAUFMAN, Montreal, QC, Canada

Pre-hospital diabetes-related emergencies represent an important part of the continuum of diabetes care. Understanding the prevalence of these emergencies is crucial to understanding the efficacy of patient education and home rescue medications. Using the National Emergency Medical Services Information System (NEMSIS) 2011 Public Release dataset, an analysis was conducted to determine the approximate number of diabetes-related 911 calls encountered by pre-hospital EMS each year. Given the database’s 11,317,115 primary 911 responses (estimated to represent 40-45% of the actual total responses in the U.S.), it was estimated that 916,273 responses (3.64%) of all calls to 911 were diabetes-related, based on dispatch complaint, provider impressions, and/or relevant Medicare condition code. Of these diabetes-related calls to 911, 669,270 (73.94%) resulted in transport to the hospital. Furthermore, as many as 222,991 (33.32%) of those transports received only Basic Life Support (BLS) level care, meaning that invasive treatments such as IV or IM treatments weren’t initiated until reaching the emergency department based on various scope of practices for BLS personnel. The NEMSIS database, however, did not allow for differentiation between hyperglycemia- and hypoglycemia-related emergencies, as the database lacked blood glucose level measurements. Records with BGL measurements was obtained from the North Carolina Office of Emergency Medical Services (NC OEMS). Of the 430,823 runs included in the NC OEMS data, 41,174 were found to be diabetes-related (9.65%), and 16,551 (40.19%) of
Prevalence of Diabetes among Patients of Safety Net Clinics

MARYBETH MCBRUNE, JUDITH POTTEN, SHEILA McCANN, KEN MAYER, TRISHA VAKAROS, GREGORY A. NICHOLS, Portland, OR; Miami, FL; Boston, MA.

The demographic and socioeconomic characteristics of underserved populations are associated with increased risk of diabetes. Our objectives were to calculate the prevalence of diabetes in three networks of safety net clinics and describe the characteristics of these vulnerable patients.

The Accelerating Data Value Across a National Community Health Center Network (ADVANCE) project is a Clinical Data Research Network comprised of the OCHIN Community Health Information Network, the Health Choice Network, and Fenway Health. Together, these three systems combine data from 97 Federally Qualified Health Center systems with 744 clinics serving approximately 1.6 million safety net patients, many of whom are uninsured. Using electronic medical record data that included visit diagnoses, laboratory results and pharmaceutical orders, we identified 273,635 adult OCHIN patients aged ≥20 years who had at least two visits to a participating clinic in 2012/2013. We defined diabetes as the presence of any two diagnostic events including a clinician-recorded diagnosis of diabetes (ICD-9-CM 250.xx), a diagnostic laboratory value (HbA1c ≥5.7%, fasting glucose ≥126mg/dl, random glucose ≥200mg/dl, or a prescription for an anti-hyperglycemic agent. We calculated diabetes prevalence overall and by age, sex, race/ethnicity and body mass index (BMI) categories.

Overall, diabetes was present in 14.8% of the study population. Prevalence was highest among older adults (30.5% of those ≥65 years) and race/ethnicity minority groups (19.9% among Hispanics, and 22.0% among non-Hispanic Blacks). Approximately 50% of the total population was obese. Among patients with diabetes, 72% of whites and 70% of non-Hispanic Blacks were obese, compared with 64% of Hispanics. The prevalence of diabetes among safety net patients is greater than in the general population, a difference that is driven by a larger proportion of minorities and greater obesity rates. Hispanics had higher rates of diabetes among those overweight but not obese.

The SWEET SPOTS Study: A Real-World Interpretation of the 2012 ADA Position Statement Regarding Individualized A1c Targets

STEPHENSON, NELLA BIESZK, MICHAEL GRABNER, WENHUI WEI, NICOLE BONINE, JUDITH J. ADA Position Statement Regarding Individualized A1c Targets

15 years, and 13% endocrinologists) and who were linked to 125 patient profiles (42% female, mean age 57 years, mean A1C 7.2%), 83% were somewhat aware of the position statement prior to the intervention and most (61% primary care physicians and 56% endocrinologists) believed it would impact how they set A1C targets. The educational intervention resulted in more stringent or looser goal-setting for lower or higher risk patients, respectively, but changes were not statistically significant. The proportion of physician-assigned targets that were within ADA-recommended ranges increased significantly.

This study found that although physicians treating T2DM are aware of the 2012 ADA position statement and state that it may influence treatment goals, patient-specific A1C targets were not significantly impacted. Further research into optimizing physician education regarding individualized A1C targets in T2DM patients is warranted.

Supported By: Sanofi U.S.

For author disclosure information, see page A810.

Assessment of Kidney Dysfunction with Cystatin C- and Creatinine-based Estimated Glomerular Filtration Rate and Predicting Future Type 2 Diabetes among Japanese: Toranomon Hospital Health Management Center Study

YUKIRO HEANZU, SHIGEKO HARU, SATORU KIDAMA, KAZUMI SAITO, SHIRO TANAKA, ISAMU HANYU, TETSURO KOBAYASHI, YASUJI ARASE, HIROHITO SONE, Naipata, Tokyo, Japan; Kyoto, Japan.

Although the prognostic value of the serum cystatic C level compared with the serum creatinine level has attracted attention worldwide, whether early stages of kidney dysfunction assessed by the estimated glomerular filtration rate from cystatin C measurements (eGFRCysC) rather than from creatinine measurements (eGFRCre) would more precisely reflect the risk of developing T2D has not been clarified. We therefore compared the risk of developing T2D associated with renal dysfunction indicated by eGFRCysC or eGFRCre measurements. Studied were 2,131 Japanese individuals without T2D. Hazard ratios (HRs) for the development of T2D over 3 to 5 y were calculated across categories of eGFRCysC and eGFRCre, respectively. Results showed that reduced levels of eGFRCysC were associated with a step-wise increase in the cumulative incidence rate of T2D (log rank test, p=0.007). We did not find such associations across eGFRCre categories. In comparison with the eGFRCysC >85th percentile group (>17.4 mL/min/1.73m2), the lowest group, which was the eGFRCysC <15th percentile group (<86.2 mL/min/1.73m2), had an adjusted HR of 2.30 (95% CI 1.13, 4.68) for T2D. Compared with the eGFRCysC >85th percentile group, the lowest eGFRCre group (15th percentile) had an HR of 1.19 (0.63, 2.24) for T2D. On the other hand, individuals with eGFRCre ≤60 mL/min/1.73m2 had a significantly increased risk of developing T2D. We also found that clustering of both low eGFRCysC and low eGFRCre further elevated the HR for T2D in comparison with the presence of either. In conclusion, the early stage of kidney dysfunction assessed by eGFRCysC rather than by eGFRCre would be a marker for predicting the development of T2D. Although mildly-to-moderately reduced levels of eGFRCre would also reflect a high risk of developing T2D, eGFRCysC in earlier stages of kidney disease might influence the development of T2D.

Supported By: Japan Society for the Promotion of Science

Short-Term Total Variability in Nontraditional Biomarkers of Hyperglycemia in Older Adults

CHRISTINA M. PARRINELLO, PAMELA LITSEY, DAVID COUPER, JOHN H. ECKFELDT, JOSEF CORESH, ELIZABETH SELVIN, Baltimore, MD; Minneapolis, MN; Chapel Hill, NC.

The short-term variability in nontraditional biomarkers of hyperglycemia is relatively uncharacterized. We included 174 ARIC participants (mean age, 76 years; 37% male; 27% black) who had two blood samples collected in 2011-13, 6 weeks apart. We compared 6-week variability in fasting glucose, HbA1c, fructosamine, glycated albumin, and 1, 5-anhydroglucitol (1, 5-AG) in persons with (n=61) and without diagnosed diabetes (n=113). We calculated the within-person coefficient of variation (CVw, intraclass correlation coefficient [ICC]), and Spearman’s rank correlation coefficient [r]. For all biomarkers, 6-week within-person variability, as measured by CVw, was greater in persons with diagnosed diabetes (67% of whom took glucose-lowering medication at visit 5). HbA1c had the lowest variability in persons with and without diabetes (CVw=4.1% and CVw=3.4%, respectively), and was comparable to that of fructosamine and glycated albumin (Table). In persons with diabetes, the correlation of repeat measurements of 1, 5-AG was high (both ICC and n=0.93) but the within-person variability was also high (CVw=20.7%) (Table). In persons without diabetes, HbA1c and nontraditional biomarkers of hyperglycemia track well over 6 weeks. In persons with diabetes, 1, 5-AG is highly variable, consistent with its biology as a marker of glucose excursions.


**Epidemiology**—Other

### Table

<table>
<thead>
<tr>
<th>Variable</th>
<th>Male (M)</th>
<th>Premenopausal (in/home use)</th>
<th>Postmenopausal (in/home use)</th>
<th>Premenopausal (PWN)</th>
<th>Postmenopausal (PWN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Beta</td>
<td>p-value</td>
<td>Beta</td>
<td>p-value</td>
<td>Beta</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>0.10</td>
<td>0.27</td>
<td>0.40</td>
<td>0.04</td>
<td>0.09</td>
</tr>
<tr>
<td>Glucose</td>
<td>0.01</td>
<td>0.07</td>
<td>-0.08</td>
<td>0.36</td>
<td>0.02</td>
</tr>
<tr>
<td>Alcohol</td>
<td>1.23</td>
<td>0.10</td>
<td>1.01</td>
<td>0.01</td>
<td>0.19</td>
</tr>
<tr>
<td>Smoking</td>
<td>0.18</td>
<td>0.95</td>
<td>1.96</td>
<td>0.72</td>
<td>1.01</td>
</tr>
<tr>
<td>Urinary tract</td>
<td>0.05</td>
<td>0.55</td>
<td>0.18</td>
<td>0.68</td>
<td>0.36</td>
</tr>
<tr>
<td>Menarche</td>
<td>0.03</td>
<td>0.08</td>
<td>-0.03</td>
<td>0.72</td>
<td>-0.08</td>
</tr>
<tr>
<td>Waist</td>
<td>0.01</td>
<td>0.09</td>
<td>0.09</td>
<td>0.13</td>
<td>0.07</td>
</tr>
<tr>
<td>BMI</td>
<td>-0.16</td>
<td>0.59</td>
<td>0.04</td>
<td>0.09</td>
<td>0.40</td>
</tr>
<tr>
<td>Waist: Hip</td>
<td>0.08</td>
<td>0.90</td>
<td>0.79</td>
<td>0.98</td>
<td>24.28</td>
</tr>
<tr>
<td>Insulin</td>
<td>0.33</td>
<td>0.02</td>
<td>11.53</td>
<td>&lt;0.01</td>
<td>8.088</td>
</tr>
<tr>
<td>Fasting insulin</td>
<td>0.66</td>
<td>0.69</td>
<td>6.30</td>
<td>-0.10</td>
<td>0.21</td>
</tr>
<tr>
<td>Met. vs. Met.</td>
<td>4.62</td>
<td>0.01</td>
<td>12.83</td>
<td>&lt;0.01</td>
<td>8.30</td>
</tr>
</tbody>
</table>

For author disclosure information, see page A810.

These treatment effects did not produce consistent effects on diabetes incidence. Among M-PLB, each 10-unit increase in SHBG at 1 year was associated with a lower risk of diabetes at 3 years (HR 0.88, 95% CI 0.77, 0.97). SHBG changes were not associated with decreased diabetes risk in any other group.

In the DPP, ILS, but not MET, was associated with favorable changes in SHBG. SHBG changes were associated with reduced diabetes incidence in M-PLB only. Further study is needed to understand moderators of SHBG and effects of SHBG modification.

Supported By: National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Child Health and Human Development; National Institute on Aging; Office of Research on Minority Health and Disparities; Office of Women's Health; Indian Health Services; Centers for Disease Control and Prevention; U.S. Global Change Research Program; National Center for Research Resources; Bristol-Meyers Squibb, Lipta, Parke-Davis

### Differences in Contribution of Beta Cell Function and Sarcopenia in Developing Diabetes Mellitus between Old and Young Adults

\[ EUNRUI\ Y,\ YEUL\ YANG,\ LEE-KYUNG\ KIM,\ BO\ KYUNG\ KOO,\ MIN\ KYONG\ MOON,\ Seoul,\ Republic\ of\ Korea\]

Although the prevalence of diabetes in the elderly population has been growing, very few have focused on clinical characteristics of elderly-onset diabetes mellitus. We aimed to investigate the difference in contributing factors in developing diabetes between old and young adults. We analyzed data from the 2008 - 2010 Korean National Health and Nutrition Examination Survey (KNHANES). In this nationwide survey, selected samples were weighted to represent the entire Korean population. We selected subjects with recent-onset diabetes (duration <5 years) and classified them according to age: elderly (age ≥75 years), usual (45 - 64 years), and early-onset group (25 - 39 years). The homeostasis model assessment of insulin resistance (HOMA-IR) and \( \beta \)-cell function (HOMA-B) were used to estimate insulin resistance and \( \beta \)-cell function, respectively. Sarcopenia was defined by appendicular skeletal mass/weight (% less than 1 SD below the gender-specific mean for healthy young adults using dual-energy X-ray absorptiometry. Subjects with elderly-onset diabetes showed a significantly better HOMA-B (means [standard error] 82.4 [6.1%]) compared with those of the usual [61.2 [7.9%]] and early-onset [63.1 [6.4%]] groups (P = 0.002). Elderly-onset group had significantly higher insulin resistance compared to the usual-onset group (HOMA-IR: means [standard error] 5.8 [0.7] vs. 4.4 [0.2]; P = 0.017). Prevalence of sarcopenia in each group was 66.0% in elderly-, 40.6% in usual- and 40.6% in young-age group. In the multivariate analysis, sarcopenia was significantly associated with the risk of diabetes in elderly-onset group odds ratio 2.11, 95% confidence interval 1.18 - 3.76; P = 0.011) but not in the other age groups. Subjects with elderly-onset diabetes has significantly higher \( \beta \)-cell function compared to subjects with younger age-onset diabetes. Sarcopenia might be more important contributing factor in developing diabetes mellitus in old adults.
for non-familial alter T2D (OR 1.32, p= .09). Adjusting for genetic risk attenuated the familial ego-alter T2D association (OR 1.40, p= .05) but marginally strengthened the non-familial ego-alter T2D association (OR 1.38, p= .05).

We found that T2D risk was shared across social ties, with a greater effect across familial than non-familial ties. Though obesity is known to be shared among social contacts, shared T2D risk was independent of shared obesity. Further analyses that account for ego education and interactions of genetic risk with relationship type are needed to fully characterize T2D risk in social networks.

1673-P
Risk for Type 2 Diabetes among Low Income Adults in the U.S. by Insurance Status
RUI LI, DELIANA KOSTOVA, KAI M. BULLARD, Atlanta, GA
The National Diabetes Prevention Program (NDPP) is an alliance of public and private organizations that aims to achieve wide-scale implementation and coordination of evidence-based lifestyle intervention programs to prevent type 2 diabetes in the United States. State health departments are working to increase the number of Medicaid enrollees participating in NDPP programs. Using data from 2,619 non-pregnant adults aged 20-64 years with family income at or below 138% Federal Poverty Line who were not on Medicare in the 2007-2012 U.S. National Health and Nutrition Examination Surveys, we estimated the proportions of low income adults at high risk for type 2 diabetes by self-reported insurance status: those having Medicaid coverage, those currently uninsured persons who would be potentially eligible for Medicaid or subsidized private insurance under the Affordable Care Act (hereafter called “those eligibles”), and those having private insurance. At high risk for diabetes was defined as meeting the American Diabetes Association (ADA) criteria for screening for type 2 diabetes (persons age ≥45 years, or body mass index ≥25 kg/m² plus ≥1 additional risk factor). We also estimated prevalence of prediabetes in a fasting subsample (n=950), defined as those with fasting plasma glucose (FPG) level 100-125 mg/dl or elevated A1C level 5.7%-6.4%. Among adults on Medicaid (n=526), 47.2% (95% confidence interval 36.6 - 57.8%) had prediabetes and 72.8% (61.7-81.5%) were at high risk for diabetes. Among eligibles (n=1,270), 37.8% (31.3-44.2) had prediabetes, and 67.0% (95% CI 63.9-70.1) were at high risk. Among privately-insured low-income adults (n=823), 28.7% (20.1-37.4) had prediabetes and 55.2% (45.5-65.0) were at high risk (p=0.05 compared with those on Medicaid and eligibles). Our results indicate that a large proportion of U.S. adults on Medicaid or potentially eligible for Medicaid or subsidized private insurance were at high risk for diabetes and could likely benefit from diabetes primary prevention efforts.

1674-P
The Rate of Growth in Diagnosed Diabetes Prevalence in U.S. Counties Stopped between 2004-2008 and 2008-2012
LINDA S. GEISS, TED THOMPSON, KAREN KIRTLAND, JI LIN, SUNDAH SHREST-HA, ANN L. ALBRIGHT, EDWARD W. GREGG, Atlanta, GA
A recent study using nationally representative data suggested that the rate of increase in the prevalence of diagnosed diabetes in U.S. adults leveled off or slowed in 2008. We used publicly available county estimates of diagnosed diabetes prevalence (based on state representative survey data of adults aged ≥18 years [http://www.cdc.gov/diabetes/atlas/countydata/County_List/Indicators.html]) to examine whether a slowing or leveling off is also evident across 3143 U.S. counties. For each county, we estimated the average annual percentage point change (APPC) in age-adjusted prevalence within two time periods - 2004-2008 and 2008-2012. To estimate APPC, we used multilevel regression that included random effects by county and year. Cubic splines were used to smooth the estimates over time. The distribution of county APPCs for 2008-2012 is to the left of the 2004-2008 distribution (Figure), indicating that the growth in prevalence was lower in 2008-2012 than in 2004-2008. The median APPC for counties in 2008-2012 (0.16) was half the median APPC in 2004-2008 (0.33). Southern and Appalachian counties which had high rates of diabetes and high APPCs in 2004-2008 tended to have low APPCs in 2008-2012. In summary, our county level data suggest a potential slowing in the diabetes epidemic which is particularly encouraging for counties known to be disproportionately burdened by diabetes.

1675-P
Excess Risk of Dying from Infectious Causes in Those with Type 1 and Type 2 Diabetes
DIANNA J. MAGLIANO, JESSICA L. HARDING, KERRYN COHEN, RACHEL HUX-LEY, WENDY DAVIS, JONATHAN SHAW, Melbourne, Australia, Queensland, Australia, Perth, Australia
To investigate infection-related mortality in individuals with type 1 and type 2 diabetes. A total of 1,108,996 individuals with diabetes who were registered with the Australian Diabetes register between 2000 and 2010 were linked to National Death Index. Mortality outcomes were defined as infection-related death (ICD 10 codes: A99-B99), pneumonia (J12-J18), septicemia (A40 & A41), and osteomyelitis (M88). Standardised mortality ratios (SMRs) and 95% confidence intervals (CI).

During a median follow-up of 6.7 years, there were 2,819, 2,164, 1,248 and 147 deaths from infection-related death, pneumonia, septicemia, or osteomyelitis, respectively. Crude mortality rates from infections were 0.147 and 0.431 per 1000 person-years in type 1 and type 2 diabetics, respectively. For pneumonia in type 1 diabetes, SMRs were approximately 5 and 6 in males and females, respectively while the excess risk was around 20% for type 2 (both sexes). For septicemia, SMRs were approximately 10 and 2 for type 1 and type 2 diabetes, respectively, and similar by sex. For osteomyelitis in type 1 diabetes, SMRs were 16 and 58 in males and females, respectively, and around 3 for type 2 diabetes (both sexes).

Although death due to infection is rare, we confirm that diabetic patients have an increased mortality from a range of infections, compared to the general population, and that the increased risk appears to be greater for type 1 than type 2 diabetes.
Nearly half of newly diagnosed patients did not reach stringent HbA1c control target in this population after one-year treatment. The study demonstrates the gap between the guideline recommendations and the actual management. Lifestyle changes and medication optimizations need to be set as priority in newly diagnosed T2DM patients.

Supported By: Bristol-Myers Squibb

EPIDEMIOLOGY—OTHER

1679-P

Prevalence of Thyroid Dysfunctions in Prediabetes

IHIAN SATMAN, HARICA BOLTÊPE, FARUK ALAGÖZ, NEVIN ÖNCÇAĞ, KUBİLAY KARŞIDAĞ, TEMEL YILMAZ, YILDIZ TUTUNCU, SİBEL KALACA, NESE C. OZBEY, TÜRDEP-II STUDY GROUP, İstanbul, Turkey

Using data from the recent adult population-based survey in Turkey (n=26,499, 63% female) we aimed to evaluate the thyroid status of individuals with different categories of prediabetes including Isolated IFG (n=3,123), Isolated IGT (n=1,663), Combined IFG+IGT (n=1,705), and High Risk A1C (n=6,696).

Although the mean (SEM) concentrations of FT4 and TSH did not differ across the groups, in the combined IFG+IGT group the mean Anti-Tg level was numerically and Anti-Tg level was remarkably higher than the other groups (p<0.003). This was not changed when the data were adjusted for age, gender, BMI, lipids, and known thyroid diseases. Anti-Tg levels were positively correlated with OGTT-2hPG and negatively correlated with fasting insulin.

The prevalence of overt and subclinical hypo and hyperthyroidism, and positive Anti-Tg and Anti-Tg antibodies are shown in the Table.

Table.

<table>
<thead>
<tr>
<th>Prediabetes Category</th>
<th>Prevalence of Thyroid Dysfunctions (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>Overt</td>
<td>Subclinical</td>
</tr>
<tr>
<td>Isolated IFG</td>
<td>0.5</td>
</tr>
<tr>
<td>Isolated IGT</td>
<td>0.8</td>
</tr>
<tr>
<td>Combined IFG+IGT</td>
<td>0.6</td>
</tr>
<tr>
<td>High Risk A1C</td>
<td>0.5</td>
</tr>
</tbody>
</table>

In terms of individual dysfunctions, there was no difference across the prediabetes categories except higher frequency of positive Anti-Tg in “IFG+IGT” (p<0.001). However, of the combined IFG+IGT group. 21.6% had at least one thyroid dysfunction, and this was significantly higher than in the other categories (Isolated IFG: 17, Isolated IGT: 17, and High Risk A1C Group: 17%, p<0.001).

In conclusion, thyroid diseases are common among persons with prediabetes. Anti-Tg but not Anti-Tpo is associated with glucose metabolism. Combined IFG+IGT category may be the most vulnerable group.

Supported By: Scientific and Technological Research Council of Turkey; Society of Endocrinology and Metabolism of Turkey; Istanbul University

1678-P

Pregnancy-induced Hypertension and Postpartum Hypertension on the Risk of Diabetes among Gestational Diabetes Women

XIAOJING YUAN, HUIKUN LIU, LEISHEN WANG, SHUANG ZHANG, JINHONG LENS, HUIQIANG TIAN, LU JI, JIAAKKO TUOMILEHTO, GANG HU, Baton Rouge, LA, Tianjin, China, Boston, MA, Helsinki, Finland.

Women with a history of pregnancy-induced hypertension or gestational diabetes mellitus (GDM) have a higher risk for postpartum diabetes. We aimed to examine the association of pregnancy-induced hypertension and postpartum blood pressure with postpartum diabetes risk among women with a history GDM. We conducted a population-based study among 1283 GDM women at 1-5 years after delivery in Tianjin, China. Logistic regression or Cox regression was used to assess the associations of pregnancy-induced hypertension and postpartum blood pressure with postpartum pre-diabetes and diabetes risks. GDM women who had a history of pregnancy-induced hypertension but did not use antihypertensive drugs during pregnancy had a 4.2-fold higher risk (95% CI: 2.13-8.47) of developing diabetes compared with those who were normotensive in index pregnancy. Compared with GDM women who had normal blood pressure at postpartum, hypertensive women at postpartum were 3.55 times (95% CI: 1.76-7.13) and 2.97 times (95% CI: 1.75-5.05) more likely to develop diabetes and prediabetes, respectively. The odds ratios of postpartum diabetes and prediabetes associated with each 10mmHg increase in systolic blood pressure were 1.27 (95% CI: 1.06-1.54) and 1.20 (95% CI: 1.06-1.35). Each 10mmHg increase in diastolic blood pressure contributed to a 1.52-fold higher risk (95% CI: 1.20-1.91) for postpartum diabetes and a 1.42-fold higher risk (95% CI: 1.22-1.65) for postpartum prediabetes. For women with prior GDM, hypertension during the index pregnancy and postpartum were risk factors for postpartum type 2 diabetes.

Supported By: European Foundation for the Study of Diabetes; National Institute of Diabetes and Digestive and Kidney Diseases (R01DK070790)

1677-P

Association of Payment Source with Emergency Department Use by Patients with Diabetes in the United States

KEIKO ASAO, JOYCE M. LEE, LEI WANG, MEHMET KUCAK, LAURIA N. MCEWEN, WILLIAM H. HERMAN, JAMES E. BAILEY, KEIKO ASAO, JOYCE M. LEE, LEI WANG, MEHMET KUCAK, LAURIA N. MCEWEN, WILLIAM H. HERMAN, JAMES E. BAILEY, Memphis TN, Ann Arbor, MI

Accurate population-based estimates of Emergency Department (ED) use by patients with diabetes is important for understanding the healthcare burden. We used data from the 2009 and 2010 National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) to examine the likelihood of ED visits by patients with diabetes according to payment source. We analyzed Patient Record Forms completed by trained surveyors that provided information on patient sociodemographic factors, diagnoses, and medical care from medical records. We selected patients ≥8 years of age with diabetes as ascertained by the question “Does the patient have diabetes?” Among 22,261 visits (15,010 from NAMCS and 7,251) from NHAMCS made by patients with diabetes, we identified 5,700 ED visits in the surveys, estimating 21.8 million (S.E. 1.4 million) ED visits made by patients with diabetes in the U.S. over two years. Mean ages (±SD) were 58.0 (± 0.3) and 62.2 (±0.3) for patients making ED and non-ED visits, 57% and 54% of the patients were female, respectively. Using a univariate logistic regression model, odds of ED visits among patients with self-pay was 6.9 times higher (95% CI: 5.2, 9.2) compared to those with private insurance. Similarly, odds of ED visits among those with Medicaid were 3.5 times (2.8, 4.2) and Medicare 1.7 times (1.5, 2.0) higher compared to those with private insurance. After adjusting for age, sex, race/ethnicity, income, education, region, and rural/urban status, the odds of ED visits for those with self-pay, Medicaid, and Medicare compared to those with private insurance remained significant: odds ratio 5.4 (4.7, 6.2), 2.5 (2.1, 2.8), and 1.8 (1.6, 2.0), respectively. In conclusion, payment source is a strong predictor of the likelihood of ED visits. Other research suggests that this effect is mediated by differences in access to or quality of outpatient care.

For author disclosure information, see page A810.
to resuming metformin. However, little evidence supports this practice. We are conducting a retrospective cohort study of patients at the San Francisco Veterans Affairs Medical Center to determine if there is a change in kidney function in patients on metformin with estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m² who receive IV contrast. Of the 35 patients identified thus far, mean age is 71±8 years, 31 (89%) are male, and 18 (51%) are Caucasian. Mean pre-contrast creatinine (Cr) was 1.29±0.13 mg/dL and post-contrast Cr was 1.25±0.14 mg/dL; p=0.14 (overall t-test). Mean pre-contrast eGFR was 54±6 ml/min/1.73m² and post-contrast eGFR was 59±19 ml/min/1.73m²; p=0.04 (overall t-test). To assess whether IV contrast and pre-contrast Cr (or eGFR) were associated with a change in kidney function, generalized linear models were developed. Covariates included age, sex, ethnicity, body mass index, diabetes duration, hemoglobin A1c, presence of albuminuria, hypertension, cardiovascular disease, heart failure, cirrhosis; and use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, and non-steroidal anti-inflammatory drugs. In fully-adjusted models, there was no significant change in Cr; β-coefficient -0.67 (95% confidence interval [CI] -1.37 to 0.02), p=0.06. And there was no significant change in eGFR; β-coefficient -0.67 (95% CI -1.73 to 0.40), p=0.22. Findings should be confirmed in larger studies. Our findings suggest that the current practice of holding metformin for two days after IV contrast should be re-evaluated as there was no significant change in kidney function even in a higher risk group of outpatients on metformin who received IV contrast.

The Effect of IV Contrast on Renal Function in Patients on Metformin with Decreased eGFR

APTI SHAH, CODY MCHARGE, ISABEL ELAINE ALLEN, DONALD CHAU, JUDY YEE, ROBERT J. RUSHAKOFF, San Francisco, CA

Given the concern for acute kidney injury (AKI) with intravenous (IV) contrast and theoretical risk of lactic acidosis with metformin use in the setting of AKI, the Food and Drug Administration mandates that metformin be discontinued for two days post-contrast and kidney function retested prior

Antiplaque Agents for Primary Prevention of Stroke and Myocardial Infarction in Japanese Diabetic Patients with Carotid Artery Plaque

SAYAKA FUKUSHIMA, JUN OGINO, SATOKO SAITO, KANAKO TASHIMA HORIE, NORIKO YOSHIDA, CHIHRO YONEYA, YUIKE SAKUMA, TAKENORI HARUKI, YOSHIFUMI SUZUKI, NAOYUKI HASHIMOTO, Yachie, Japan Asahi, Japan

Low-dose aspirin is recommended for primary prevention of cardiovascular disease (CVD) in patients with diabetes mellitus (DM) who are considered at high risk in U.S. but not in Europe. Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial showed that aspirin was not effective for primary prevention of CVD in patients with DM in Japan. The use of aspirin therapy in DM patients for primary prevention of CVD remains controversial. Reports of the use of antiplaque agents (APA) for primary prevention of CVD or stroke (S) in DM patients who have carotid artery plaques (CAP) are limited. We therefore retrospectively investigated the association between APA and myocardial infarction (MI) or S in DM patients with CAP.

We evaluated 246 Japanese DM patients (men 140, age 64±10 years) with at least one CAP detected by carotid artery ultrasound from 2007 to 2012. We excluded patients with a past history of CVD or S. The median follow-up period was 3.7 years. In patients on APA, there were no significant differences in the occurrence of MI or S, or either MI or S compared with patients who were not taking APA as determined by the Kaplan-Meier method. On the other hand, in patients with carotid arterial stenosis (CAS) of 40% or above, those on APA had a significantly lower incidence of S and either MI or S (log-rank p=0.046 and p=0.040, respectively). The follow-up period and family history of either MI or S were significantly associated with occurrence of either MI or S on univariate logistic regression analysis, and both remained significantly associated with either MI or S follow-up months, p=0.006; family history, p=0.005) on multivariate logistic regression analysis. MI significantly correlated with maximum intima-media thickness (p=0.005) and HA1c (p=0.007), and S significantly correlated with the follow-up period (p=0.031).

We conclude that APA is effective for primary prevention of S and MI in DM patients with CAS.

Predictors of Remission of Type 2 Diabetes following a Short-Term Intensive Metabolic Intervention

NATALIA MCINNES, ADA SMITH, ZUBIN PUNTHAKEE, DIANA SHERIFALI, KUMAR BALASURAMANIAN, STEPHANIE HALL, HERTZEL C. GERSTEIN, Natalia, Canada

Recent evidence suggests that short-term intensive treatment with insulin or oral diabetes medications can induce remission of early type 2 diabetes. We analyzed predictors of diabetes remission following a short-term intensive metabolic intervention comprising lifestyle interventions, insulin glargine, metformin and acarbose.

Eighty three patients with type 2 diabetes diagnosed within 3 years prior to enrollment were randomized to either an 8-week intensive metabolic interven-
Epidemiology

Prevalence of OSA

The prevalence of OSA [apnea-hypopnea index (AHI)] screened using an overnight in-home monitoring device (Watch-PAT200) was conducted to determine the prevalence of OSA and the AHI independently predicted the chance of having a poor glycemic control [median HbA1c (IGR) 7.21 (6.74-8.11) vs. 6.78 (6.23-7.43%), p=0.05] than the no-OSA group. After adjusting for age, sex, BMI, diabetes duration and insulin use, higher AHI was independently associated with higher HbA1c level (p=0.03). In summary, OSA in Asian type 2 diabetes patients is highly prevalent, similar to that of the Western population. Severity of OSA is independently associated with poor glycemic control.

Supported By: Ramathibodi Hospital

Nonalcoholic Fatty Liver Disease but Not Alcohol-associated Fatty Liver Disease Is a Significant Risk Factor for the Onset of Impaired Fasting Glucose among Men

TERUJI MIYAKE, TERU KUMAGI, SHINYA FURUKAWA, SHIN YAMAMOTO, YASUKI TODO, MASASHI HIROIKA, YUIISHI TOKUMOTO, KEITARO KAWASAKI, HIRIKAKI NUNI, OSAMU YOSHIDA, TETSUJI NIIYA, MASANORI ABE, BUNZO MATSUURA, YOICHI HIIASA, Toon, Japan, Matsuyama, Japan

Background: Fatty liver is associated with glucose intolerance and hepatic insulin resistance. The effect of alcohol consumption on the onset of glucose intolerance is controversial, and no previous studies have showed that fatty liver predicts the onset of glucose intolerance according to the amount of alcohol consumption. This study examines the potential relationship between fatty liver disease and the onset of impaired fasting glucose as stratified by the amount of baseline alcohol consumption.

Methods: We enrolled 6,403 persons (3,194 men and 3,209 women) between 18-80 years old who had -2 annual check-ups from 2003-2010. After excluding persons with fasting plasma glucose levels at or below 100 mg/dl and those who were currently taking anti-diabetic agents, the remaining 5,924 subjects were classified into two groups based on alcohol consumption: less than 20 g/day (non-alcoholic group) and more than 20 g/day (alcohol-associated group). The onset of impaired fasting glucose was defined as fasting plasma glucose ≥10 mg/dl during the observation period. Fatty liver was identified by ultrasonography.

Results: In the non-alcoholic group and the alcohol-associated fatty liver disease group, 5.5% and 6.7% of the men, and 1.6% and 3% of the women developed impaired fasting glucose (IFG), respectively. Fatty liver was positively associated with the onset of IFG in males with non-alcoholic fatty liver disease (NAFLD) (adjusted hazard ratio, 2.755; 95% CI, 1.873-3.788, P = 0.001) after adjusting for previously reported risk factors for IFG. However, males with alcohol-associated fatty liver disease and females with either type of fatty liver disease did not show any such association.

Conclusions: NAFLD but not non-alcoholic fatty liver disease among men is a significant risk factor for the onset of impaired fasting glucose, suggesting the need to consider additional etiologies of fatty liver disease in clinical practice.

Obstructive Sleep Apnea (OSA) in Asian Type 2 Diabetes Patients: Prevalence and Impact on Glycemic Control

SIRIMON REUTRAKUL, NANTAPORN SWARASANDON, HATAKARN NIMITPHONG, NARICH CHRAKALAWAN, SUNEE SAETUNG, BOONSONG ONGPHIHDHANAKUL, Bangkok, Thailand

OSA is a risk factor of insulin resistance and type 2 diabetes. The prevalence in T2DM patients ranged from 58-86%, mostly in Western countries. OSA severity correlated with glycemic control in some studies. The data in Asian population are lacking. With a growing diabetes epidemic in Asia, we conducted a cross-sectional study to determine the prevalence of OSA and its impact on glycemic control in Asian T2DM patients.

Eighty-one patients were interviewed for their diabetes history. Medical records were reviewed for most recent HbA1c values, medication use, and history of retinopathy or nephropathy (eGFR=60 or albuminuria). OSA was screened using an overnight in-home monitoring device (Watch-PAT200). Patients’ mean age was 57.1±11.3 y and mean BMI was 27.9±5.3 kg/m2. The prevalence of OSA (apnea-hypopnea index (AHI) ≥5) was found to be 77.8%, with 32.8%, 24.6%, and 14.8% had mild (AHI 5-15), moderate (AHI 15-30) and severe OSA (AHI≥30), respectively. The OSA group had a significantly higher BMI (29.0±4.8 vs. 25.4±3.4 kg/m2, p=0.01), longer diabetes duration (11.5±8.6 vs. 5.9±4.8 y, p<0.01) and poorer glycemic control (median HbA1c (IGR) 7.21 (6.74-8.11) vs. 6.78 (6.23-7.43%), p=0.05) than the no-OSA group. After adjusting for age, sex, BMI, diabetes duration and insulin use, higher AHI independently predicted the chance of having a poor glycemic control (HbA1c ≥7%) (1.67, 95% CI 1.006-1.132, p=0.03). Each one point increase in AHI corresponds to a 6.7% increase in chance of having a HbA1c ≥7%. In addition, a robust regression analysis adjusting for the same covariates revealed that higher AHI was independently associated with higher HbA1c level (p=0.03).

In summary, OSA in Asian type 2 diabetes patients is highly prevalent, similar to that of the Western population. Severity of OSA is independently associated with poor glycemic control.

Supported By: Canadian Diabetes Association; Population Health Research Institute; McMaster University (to N.M.)

Missing Oral Antihyperglycemic Drug Data in Large Claims Databases

MOMA CAI, KIMBERLY G. BRODVCIZ, YONG CHEN, CYNTHIA J. IRWIN, ALAN M. BROOKHART, ANNE MCNEILL, Chapel Hill, NC, North Wales, PA

Missing and misclassified data is an important limitation of claims databases. Missing prescription data has become an increasing concern since the inception of low-cost generic programs in 2006, as patients may obtain inexpensive prescriptions outside of their pharmacy benefit. This study examined the potential for missing data in initiators of oral anti-hyperglycemic drugs in Marketscan claims data. Patients with type 2 diabetes Mellitus (T2DM) having apparent new prescriptions of thiazolidinedione (TZD) were compared to those with new prescriptions of metformin (MET) therapy. Unlike MET, TZDs are usually used as monotherapy for T2DM and are not part of low-cost generic programs. Frequency of hemoglobin A1c (A1C) tests in the year prior to treatment initiation were summarized for new users of TZD monotherapy, TZD combination therapy, and MET monotherapy for the entire study period (2004-2012), and in 2004-2007 and 2008-2012. If new users of TZD monotherapy were true monotherapy users, we expected similar patterns of A1C testing between TZD and MET monotherapy groups. We identified 208,436 new TZD users, aged 25-64, of whom 159,924 (76.7%) were monotherapy users; 84,407 new users of MET were identified. In the year prior to treatment initiation, 21.7%, 14.7%, and 11.9% of TZD monotherapy, combination therapy, and MET monotherapy, respectively, received 3 or more A1C tests. Time trends also show greater discrepancy between therapy groups in 2008-2012 (27.4%, 17.2%, and 12.4% for TZD monotherapy, TZD combination, and MET, respectively) compared with 2004-2007 (17.4%, 13.1%, and 10.8%). For MET monotherapy, TZD combination therapy, and MET monotherapy users, some TZD monotherapy new users identified in claims data may have been on prior treatment for TZD. This potential for misclassification needs to be further explored.

For author disclosure information, see page A810.

Nonalcoholic Fatty Liver Disease but Not Alcohol-associated Fatty Liver Disease Is an Important Risk Factor for the Onset of Impaired Fasting Glucose among Men

Nonalcoholic fatty liver disease (NAFLD) not alcohol-associated fatty liver disease among men is an important risk factor for the onset of impaired fasting glucose (IFG), respectively. Fatty liver was positively associated with the onset of IFG in males with non-alcoholic fatty liver disease (NAFLD) (adjusted hazard ratio, 2.755; 95% CI, 1.873-3.788, P = 0.001) after adjusting for previously reported risk factors for IFG. However, males with alcohol-associated fatty liver disease and females with either type of fatty liver disease did not show any such association.

Conclusions: NAFLD but not non-alcoholic fatty liver disease among men is a significant risk factor for the onset of impaired fasting glucose, suggesting the need to consider additional etiologies of fatty liver disease in clinical practice.
Of approximately 17 million patients in the EMR database, 1,606 had an ICD-9-CM diagnosis indicating LD and no evidence of HIV (prevalence: 94/1,000,000). Upon detailed review of physician notes by two clinical experts, 3 patients were classified as having congenital generalized LD, 41 were classified as familial partial LD, 5 as acquired partial LD, and the remainder as localized LD or unable to be classified due to non-specific physician notes. Among the 49 with congenital generalized or partial forms of LD (prevalence: <1/1,000,000), 72% had high triglyceride values (>200 mg/dL), and 69% had a diagnosis of type 2 diabetes.

Through a detailed review of EMR data and physician notes, over 80% of patients with a diagnosis indicating LD could not be classified due to non-specific physician notes. Efforts aimed at training physicians to recognize and properly document lipodystrophic syndromes and to standardize coding of these syndromes in EMR data would be beneficial to understanding the true prevalence of these unique syndromes.

Metformin Use and Breast Cancer Stage At Diagnosis
ILIANA C. LEGA, KINWAIH FUNG, LORRAINE L. LIPSICOMBE, Toronto, ON, Canada

Metformin use may be associated with a reduction in breast cancer risk and mortality among women with diabetes. Some studies have suggested that metformin may also impact breast cancer stage and molecular subtypes; however results from these studies have been inconsistent and limited by small sample sizes and incomplete drug data. The objective of our study was to examine the association between metformin use and breast cancer stage in older women with diabetes. We used population-based data from Ontario, Canada to identify women over age 68 who were diagnosed with breast cancer between 2007 and 2013. Using multivariable logistic regression models adjusting for demographic factors, comorbidity, and mammography, we explored the association between metformin within three years of breast cancer diagnosis with the likelihood of early (I-II) vs. late stage (III-IV) breast cancer. We also explored the association between metformin use and estrogen receptor (ER) status, tumour size and lymph node status. Among 3125 women with diabetes and breast cancer, mean age at breast cancer diagnosis was 77.2 (67-84) and mean duration of diabetes was 9.0 (0.0-27.0) years. Prior to cancer diagnosis, 1519 were metformin users and 1606 were non-metformin users. There was no significant association between metformin use and stage of breast cancer (adjusted OR 0.96, 0.78-1.17), and this finding did not change for cumulative use of metformin. We also found no association between metformin use and likelihood of an ER- tumour, presence of positive lymph nodes or larger tumour size. In conclusion, we did not find an association between metformin use and breast cancer stage or subtype among older women with diabetes. Our findings do not support a role for metformin use in reducing the growth or aggressiveness of breast tumors before diagnosis in women with diabetes. However, these findings are limited to older women, and further research may be warranted to explore this association among younger women or those with shorter duration of diabetes.

Supported By: Ontario Institute for Cancer Research (Canada)
Reductions in Hemoglobin and Packed Cell Volume over 3 Years in UKPDS Patients with Newly Diagnosed Type 2 Diabetes

RUTH L. COLEMAN, RURY R. HOLMAN, Oxford United Kingdom

Diabetes increases the risk for developing anemia by 2-3 fold, compared to those without diabetes and similar renal function. We examined hemoglobin (Hb) and packed cell volume (PCV) changes over three years in UK Prospective Diabetes Study (UKPDS) patients with newly-diagnosed type 2 diabetes randomized to diet, sulfonylurea, metformin or insulin therapy. Of 4299 patients, 2727 remained on monotherapy at three years and had the requisite data (Table 1). Paired t-tests were used to examine univariate changes from baseline for Hb & PCV. Multiple regression models, adjusting for baseline age, sex, ethnicity, HDL-cholesterol, triglyceride, urine albumin, eGFR and Hb or PCV values were also performed, with diet as the reference group.

Hb levels fell significantly by 1.5%, 2.4%, 4.9% & 1.7% with diet, sulfonylurea, metformin and insulin therapy respectively, as did PCV levels 1.8%, 2.7%, 5.0% & 2.2% respectively. After adjustment, a statistically greater fall in Hb was seen only with metformin, but falls in PCV remained statistically greater with sulfonylurea, metformin and insulin.

Hb and PCV levels fell over three years with diet, sulfonylurea, metformin and insulin therapies, but to the greatest extent with sulfonylurea. The extent to which these changes reflect time related reductions following diagnosis of diabetes, and possibly B12 associated impact with metformin, needs to be determined.

Table 1. Risk Factors of CKD Presence and Severity in T2DM.

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Hemoglobin Baseline Variable</th>
<th>Three Year Difference</th>
<th>95% Lower Confidence Interval</th>
<th>95% Upper Confidence Interval</th>
<th>P-value Adjusted</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diet</td>
<td>Hb (g/dl)</td>
<td>15.08 -0.23 -0.32 -0.14</td>
<td>&lt;0.0001</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>PCV (%)</td>
<td>44.76 -0.81 -1.08 -0.54</td>
<td>&lt;0.0001</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Sulfonylurea</td>
<td>Hb (g/dl)</td>
<td>15.11 -0.37 -0.44 -0.31</td>
<td>&lt;0.0001</td>
<td>n.s.</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>PCV (%)</td>
<td>44.73 -1.21 -1.42 -1.00</td>
<td>&lt;0.0001</td>
<td>0.0042</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Metformin</td>
<td>Hb (g/dl)</td>
<td>14.88 -0.71 -0.88 -0.54</td>
<td>&lt;0.0001</td>
<td>0.0001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>PCV (%)</td>
<td>44.19 -2.22 -2.65 -1.78</td>
<td>&lt;0.0001</td>
<td>0.0001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Insulin</td>
<td>Hb (g/dl)</td>
<td>15.02 -0.26 -0.34 -0.18</td>
<td>&lt;0.0001</td>
<td>n.s.</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>PCV (%)</td>
<td>44.57 -0.96 -1.20 -0.72</td>
<td>&lt;0.0001</td>
<td>0.0001</td>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>

Regional Differences in Diabetes Prevalence by Age and Urban/Rural Setting

KATHERINE OURTOSOVA, LEONOR GUARIGUATA, UTE LINNENKAMP, JOAO DA ROCHA FERNANDES, NAM H. CHO, LYDIA E. MAKAROFF, Brussels, Belgium; Suwon, Republic of Korea

The prevalence of diabetes has been increasing for many decades, along with increases in life expectancy and urbanization. In order to predict future diabetes prevalence, it is essential to closely examine the relationship between diabetes prevalence and urbanization.

As a component of the 2014 update of the IDF Diabetes Atlas 6th Edition, a literature search of studies reporting age-specific prevalence for type 1 and 2 diabetes was conducted and the Analytic Hierarchy Process used to systematically select studies for inclusion. Logistic regression was applied to generate smoothed age-specific prevalence estimates for adults 20-79 years which were then applied to UN population estimates for 2014. From the 173 studies that were used for the Atlas estimates, only 26 studies from 25 countries contained data for rural and urban territories reported separately. The age profiles of diabetes prevalence were compared for those countries with rural/urban data using with 95% confidence intervals.

There was a wide heterogeneity in the association between urbanization and diabetes prevalence. In 13 out of 25 countries assessed, there was no significant difference in diabetes prevalence between urban and rural settings by age (I) and diabetes prevalence. In 7 countries diabetes prevalence was significantly higher in urban settings, compared to rural settings, between the ages of 20 and 15 (India, Nepal, Philippines, Saudi Arabia, Sri Lanka, Thailand, and Tunisia). In 5 countries diabetes prevalence was significantly higher in urban environments between 40 and 70 years (Bangladesh, China, Oman, Samoa, and Turkey).

This analysis found that in 52% of the countries analysed, there was no significant difference in diabetes prevalence by age in urban and rural settings. In countries where a difference was found, the diabetes prevalence was higher in urban settings, compared to rural settings.

Supported By: AstraZeneca Pharmaceuticals, LP

For author disclosure information, see page A810.
ies not adjusting for smoking (SRR=1.08 95% CI 0.95, 1.24). There was no significantly increased risk of lung cancer among diabetic patients in studies conducted in North America (SRR=1.02 95% CI 0.89, 1.19), Europe (SRR=1.01 95% CI 0.88, 1.17) or Asia (SRR=1.10 95% CI 0.93, 1.31).

22 studies investigated the association between diabetes treatments and lung cancer. The risk of lung cancer was increased among patients with diabetes treated with any type of insulin (SRR=1.20 95% CI 1.03, 1.41) and remained unchanged when the analysis was restricted to observational studies (SRR=1.20 95% CI 1.01, 1.43). The risk of lung cancer among glargine users, the focus of ten studies, was not increased (SRR=1.04 95% CI 0.91, 1.18) and this persisted when restricted to observational studies (SRR=1.02 95% CI 0.88, 1.19). Risk of lung cancer among patients prescribed non-glargine insulin had an increased risk of lung cancer (SRR=1.50 95% CI 1.10, 2.04). Risk of lung cancer was reduced among users of Thiazolidinediones (TZD) (SRR=0.67 95% CI 0.54, 0.85) but not metformin (SRR=0.94 95% CI 0.73, 1.22).

The risk of lung cancer is not increased among patients with diabetes compared to healthy subjects. Those diabetic patients prescribed glargine do not have an increased risk of lung cancer although users of other insulins have a significantly increased risk. TZD users have a decreased risk of lung cancer while there is no significant protection conferred by using metformin.

Birth Weight and Subsequent Risk of Type 2 Diabetes and Hypertension across Two Generations in Chinese Females

Mingling Chen, Hong Fang, Hua Zhang, Yulie Yan, Baidong Yang, Guoyou Gu, Wanghong Xu, Shanghai, China

To compare the trans-generational associations of birth weight with subsequent risk of type 2 diabetes and hypertension, we conducted a cross-sectional survey among 10324 females from 3888 families in Shanghai, China, during the period of November 2012 and January 2013. Self-reported information on birth weight, birth length, gestational week, and diagnosis of type 2 diabetes and hypertension were obtained by in-person interviews using a structured questionnaire. A positive association was observed between maternal and daughters’ birth weight, with 1 kg increase in maternal birth weight linked with an average of 0.335 kg (95% CI: 0.307-0.363) elevated birth weight in the female offspring. Maternal diabetes was also related with an average of 0.062 kg (95% CI: 0.019-0.104) increase in birth weight and a higher risk of subsequent type 2 diabetes in their daughters (OR: 3.173, 95% CI: 1.943-5.174). Maternal hypertension was not associated with birth weight of their daughters, but nearly quadrupled the subsequent risk of hypertension in their female offspring (OR: 3.639, 95% CI: 2.886-4.922). Although no significant association was observed between birth weight and prevalence of type 2 diabetes or hypertension in the subjects aged 20 years or above, path analysis and mediation analysis showed that offspring’s birth weight, as a mediator of maternal and daughters’ diabetes status, explained 2.8% of the association, but didn’t mediate the association between maternal and daughters’ hypertension status. Our findings suggest that different mechanisms may underlie the trans-generational associations of birth weight with subsequent risk of type 2 diabetes and hypertension in Chinese females.

Supported By: Program for Academic Leader of Public Health in Shanghai (GWDTR201204)

Lifestyle Modification Is Equally Effective in Nonobese and Obese Asian Indians with Prediabetes in Reducing the Incidence of Type 2 Diabetes

Ambady Ramachandran, Arun Nanditha, Chamukkutthan Snehala, Atha, Jagannathan Ram, Arun Radhavan, Samith A. Shetty, Vinitha Ramchandran, Chennai, India

The effectiveness of lifestyle modification (LSM) in prevention of type 2 diabetes (T2DM) was mainly attributed to benefits of weight reduction in the western studies in which mostly obese participants were included. In Asian Indians, with relatively lean body mass index (BMI) the effectiveness was independent of appreciable weight loss. The objective of this analysis was to assess whether baseline body mass index (BMI) influenced impact of LSM on incidence of diabetes among Asian Indians with impaired glucose tolerance (IGT). Data of two Indian Diabetes Prevention Programmes were combined in the analysis (2006 and 2013; n=709), Propotion of obese (BMI≥25 kg/m2) participants was more than that of non-obese (BMI<25 kg/m2) individuals (410 [57.8%] vs. 299 [42.2%]). Incident diabetes was diagnosed in 227 out of 709 participants during the total follow-up period, 68 and 139 in the intervention and control group respectively (relative risk reduction: 39% (HR: 0.61; 95% CI: 0.46-0.79); P=0.0001). The effect of intervention on the incidence of diabetes was similar in each BMI stratum (BMI≥25; HR: 0.60 (95% CI: 0.39-0.91); P=0.015, BMI<25; HR: 0.61 (95% CI: 0.43-0.87); P=0.006). Cox regression model showed that the lower beta cell compensa-
tion at baseline (HR: 0.900 (95% CI: 0.988-0.994); P<0.0001) and intervention (HR: 0.56 (95% CI: 0.37-0.85); P=0.007) significantly influenced the development of diabetes. Baseline BMI did not influence the outcome. To summarize, the mechanism of action of lifestyle intervention in Asian Indians is independent of baseline BMI.

Supported By: India Diabetes Research Foundation

Influence and Pneumococcal Vaccination Rates among Greek Diabetes Patients between 2003-2013 and Its Influence on Their Morbidity and Hospitalization

Alexios Sotiropoulos, Anastasios G. Koutsouvasilis, Paraskevi Vergidou, Anna Grozou, Ourania Apostolou, Dimitrios Panagiotou, Theodoros Peppas, Anastasia Katojodi, Stavros Bisousoulos, Elias Tsimidou, Nikia, Greece

Diabetic patients are particularly susceptible to influenza and pneumococcal infection. The aim of this study was to estimate the vaccination rates in Greek diabetes patients between 2003 and 2013 along with its influence on morbidity, hospitalization, duration and outcome of hospitalization. 1998 type 2 diabetes mellitus patients (930 in 2003 and 508 in 2013) were eligible in this study. All patients answered a questionnaire about vaccination between October and December and two months after appropriate counsel on immunization. All respiratory infections and consequent hospital admissions were recorded by telephone interviews two months after the end of the vaccination period. More patients had received the influenza vaccine in 2003 (62.1% vs. 52%, P=0.033) while more patients had received the pneumococcal vaccine in 2013 (39.4% vs. 16.1%, P=0.012). In 2013 more patients had received both vaccines compared to patients in 2003 (23.6 vs. 14.7, P=0.028). The probabilities of respiratory infection were notably higher in the absence of influenza vaccination (OR=4.14, 95% CI: 1.931-8.037, P=0.001) and pneumococcal vaccination (OR=2.87, 95% CI: 1.163-6.388, P=0.005) in 2013, significantly correlated only with the influenza vaccination in 2003 (OR=3.17, 95% CI: 1.071-9.56, P=0.033). The duration of hospitalization was longer in patients without any vaccination in 2013 (OR=2.874, 95% CI: 1.188-6.538, P<0.0001) while the presence of complications or death during hospitalization was correlated with the absence of any vaccination in 2013 (OR=2.458, 95% CI: 1.221-4.984, P<0.0001).

The rate of influenza vaccination among Greek diabetes patients has declined through time. Diabetes patients without any vaccination present higher morbidity and more hospital admissions while the duration and the outcome of hospitalization are correlated with the compliance to the vaccination programme.

Effects of Telmisartan on Insulin Sensitivity in Hypertensive Patients: A Meta-analysis of Randomized Controlled Trials

Takafumi Tsuichya, Kuniakazu Morita, Shido Okamoto, Shintaro Sakurai, Kenichirou Hori, Tomoko Terawasa, Rika Naruse, Kenji Harata, Kohzo Takebayashi, Toshihiko Nukai, Koshigaya Japan

The angiotensin II type 1 receptor blocker (ARB), telmisartan has a possible effect on the activation of the peroxisome proliferator activated receptor gamma (PPAR-γ) that is an essential regulator of lipid and glucose metabolism. Since a PPAR-γ agonist, thiazolidinedione, is an insulin sensi-
tizer, we have evaluated the impact of telmisartan on insulin sensitivity by a meta-analysis in hypertensive patients. Studies were identified through electronic searches and included if they met the following inclusion criteria: (i) randomized controlled trials that compared telmisartan with a placebo or other antihypertensive agents in adults; (ii) reporting homeostatic model assessment of insulin resistance (HOMA-IR); (iii) having a trial duration of at least 12 weeks that assessed clinically relevant doses of 20 to 80 mg/day telmisartan. HOMA-IR was analyzed as weighted mean differences (WMD) under a random effects model. A total of 17 comparisons met inclusion criteria, which included 1,283 study participants, 644 treated with telmisartan and 639 treated with comparator drugs. In a meta-analysis, telmisartan significantly reduced HOMA-IR among all studies (WMD = -0.71, 95% confidence interval [CI], -1.18 to -0.26). HOMA-IR was also decreased significantly compared with calcium channel blockers (CCBs) (WMD = -0.70, 95% CI, -1.17 to -0.23) but not with other ARBs (WMD = -0.75, 95% CI, -1.66 to 0.15). Publication bias was not found in the analysis (P=0.87). In a meta-regression analysis, telmisartan has a greater efficacy on HOMA-IR in groups
with smaller mean values of baseline age (P<0.05), higher of base line fasting
insulin levels (P<0.01) and longer duration of the telmisartan treatment
(P<0.05). The present meta-analysis suggests that telmisartan can improve
the insulin resistance index. Further molecular and biological studies are
needed to elucidate these potentially beneficial effects of telmisartan on
insulin resistance.

 Substance Use among Adolescents and Young Adults With and Without Diabetes
LAUREN E. WISK, ELISSA R. WEBTZMAN, Boston, MA

Extant literature on whether substance use differs among youth with/ 
without diabetes is mixed, and we lack nationally representative epidemiolo-
logic profiles of these behaviors during adolescence and young adulthood,
periods of peak risk.

We analyzed national data from the Panel Study of Income Dynamics
(Child Development & Transition to Adulthood Supplement) from 1997-2011
to investigate tobacco, alcohol, and marijuana use during the period of ado-
lescence (12-18) and young adulthood (19-26). Our sample included 54 youth
with type 1 or 2 diabetes, 1679 youth with other chronic conditions, and 411
youth with no conditions. Multivariable results adjusted for age, gender,
race/ethnicity, socioeconomic status, and psychological distress.

Prevalence of tobacco smoking was 39.1% for youth with diabetes, 51.8%
for youth with other conditions, and 49.4% for youth with no conditions.
Adolescents with diabetes were significantly less likely to report being ever
(AOR=0.25, p<0.01) or regular smokers (AOR=0.08, p<0.03) than those with
or without other conditions in adjusted analyses.

High levels of ever or binge drinking were reported by youth with diabetes
(75.6% & 24.6%, respectively) and substantial levels of marijuana use were
reported (53.3%) though these levels were not different than those of their
peers. Youth with diabetes reported marijuana initiation at younger ages
(14.1 years) compared to youth with or without other conditions (15.8 & 15.3
years, respectively), although differences did not persist after adjustment.

In a nationally representative cohort, substance use levels were substan-
tial among youth with diabetes, although risks for smoking were lower and
those for drinking and marijuana use no different than those among other
youth. Youth with diabetes may initiate substance use comparatively early.
Hence, improved assessment, monitoring, and intervention for risk behav-
iors among this group are warranted.

Supported By: Agency for Healthcare Research and Quality (2T32HS000063-20);
National Institute on Alcohol Abuse and Alcoholism [TR01AA02193-01]; Conrad N.
Hilton Foundation

Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated with an Increased Risk of Acute Pancreatitis in High-risk Type 2 Diabetic Patients: A Nationwide Cohort Study
CHIA-HSUIN CHANG, YI-CHENG CHANG, JOU-WEI LIN, SHU-TING CHEN, MEI-
SHU LAI, LEE-MING CHUANG, Taipei, Taiwan

Safety data about the risk of acute pancreatitis associated with dipeptidyl pepti-
dase-4 (DPP-4) inhibitor use in high risk type 2 diabetic patients with
prior history of pancreatitis or hypertriglyceridemia was limited. Here we
conducted a retrospective cohort study analyzing Taiwanese National Health In-
surance claim database. The risk associated with sitagliptin was compared
to that with acarbose, a second-line antidiabetic drug prescribed in patients
with similar diabetes severity without known effect on pancreatitis. A total
of 8,526 sitagliptin initiators and 8,055 acarbose initiators who had hyper-
triglyceridemia and received fibrates therapy or prior hospitalization history
for acute pancreatitis were analyzed for the risk of hospitalization due to
acute pancreatitis with adjustment for baseline propensity score.

In the crude analysis, sitagliptin was associated with a decreased risk of
acute pancreatitis (HR 0.74; 95% CI: 0.72-0.75) compared to acarbose
in diabetic patients with prior pancreatitis hospitalization history or hypertrig-
lyceridemia. The association was abolished after adjusting for propensity
score quintiles (adjusted HR 0.95; 95% CI: 0.79-1.16). Similar results were
found separately in either patients with prior hospitalization history of acute
pancreatitis (adjusted HR 0.97; 95% CI: 0.76-1.24) or those with hypertrig-
lyceridemia (adjusted HR 0.86; 95% CI: 0.51-1.43). No significant associa-
tion was found with different duration or accumulative doses of sitagliptin. In
the stratified analysis, no elevated risk was found for men or women, and for
those aged ≤ or ≥ 60 years.

We concluded that use of sitagliptin was not associated with an increased
risk of acute pancreatitis in high-risk patients with hypertriglyceridemia or
with past history of acute pancreatitis.

For author disclosure information, see page A810.

Diabetes and Prediabetes in a Cohort of Korean Employees
JIWON R. LEE, HSIN-CHIEH YEH, SOOHUN CHO, Yongin, Republic of Korea, Bal-
timore, MD

Asians tend to develop diabetes at younger ages and lower body mass
index (BMI). Identifying individuals at high risk and provide interventions
are imperative for prevention. We conducted a prospective study to char-
acterize diabetes risk factors and examine the associations between the
Korean diabetes screening score (ranged 0 to 11; validated and calculated
using age, family history, hypertension, waist circumferences, smoking, and
alcohol drinking) and incident diabetes and prediabetes in a cohort of 12,370
Korean employees aged ≥20 who joined in the Samsung Health Initiatives in
2002-3. Diabetes and prediabetes were defined by physician diagnosis and/
or fasting glucose. At baseline, the mean age was 34.5 (3.9) years; 96.5%
were men; 64.2% had BMI ≥23 kg/m²; 42.7% were current smokers; 33.3%
had at least one drink per day; 15.6% had hypertension; and 46.8% had
elevated diabetes risk scores (≥5 points). After 6 years of follow-up, 919
workers (7.4%) developed diabetes and 3,125 workers developed prediabe-
ettes (32.8%). Compared to employees with risk score=4, the odds ratios
of incident diabetes and prediabetes in employees with risk scores ≥5 and ≥8
were significantly elevated. After adjustments for additional covariates, the
associations attenuated but remained significant for incident prediabetes
(Table 1). Health promotion including weight loss and smoking cessation is
needed for this employee population.

<table>
<thead>
<tr>
<th>Odds ratio of incident diabetes</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-7 vs. ≤4</td>
<td>1.34 (1.15-1.58)</td>
<td>1.29 (1.10-1.59)</td>
<td>1.26 (1.07-1.50)</td>
</tr>
<tr>
<td>≥8 vs. ≤4</td>
<td>1.82 (1.27-2.51)</td>
<td>1.29 (0.88-1.90)</td>
<td>1.16 (0.78-1.71)</td>
</tr>
</tbody>
</table>

Table 1. Odds Ratios of Incident Diabetes & Prediabetes.

Clinical Differences in Patients Receiving Antidiabetic Drugs With and Without a Diagnosis of Diabetes in U.S. Electronic Health Records (EHR)
DONNIE P. FUNCH, ANTHONY P. NUNES, STEPHEN M. EZZY, ROBERT V. GATELY,
BAVILYN S. CARBERY, DAVID D. DORE, Waltham, MA

Studies of antidiabetic drugs (AD) often rely on diagnostic codes to iden-
tify the study population, excluding patients with no recorded DM diagnosis.
We examined clinical differences between treated patients with and with-
out a diagnosis of DM among a random sample of 1,000,000 patients in the
Humedica Research Database (2007-2013), a de-identified EHR database in
the U.S. Among initiators of any AD, we identified DM diagnoses in the 12
months prior to drug initiation. Patients with other indications for AD therapy
were removed. Of the 23,351 initiators, 64% had type 2 DM (T2D), 53% were
female and 13% under 45. The most common drugs at initiation were insulin
and metformin. Almost 30% had no DM diagnosis in the prior year (Table 1).
This group was more likely to be pre-diabetic based on HbA1c levels. The
baseline prevalence of comorbidities was lower for those with no DM di-
agnosis and those with type 1DM (T1D). Patients in all 4 categories were
similar on common lab tests. On average, all groups except T1D had BMI
differences were statistically significant for incident prediabetes
(Table 1). Health promotion including weight loss and smoking cessation is
needed for this employee population.

For author disclosure information, see page A810.
### Table 1. Select Characteristics for Categories of DM Diagnosis.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Linagliptin (N=2820)</th>
<th>Sitagliptin (N=18491)</th>
<th>Saxagliptin (N=8100)</th>
<th>Metformin (N=72694)</th>
<th>Sulfonylureas (N=33868)</th>
<th>Dibiguanide (N=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, Mean (SD)</td>
<td>59.30 (10.8)</td>
<td>54.40 (11.8)</td>
<td>53.00 (10.6)</td>
<td>51.30 (10.3)</td>
<td>52.00 (10.3)</td>
<td>51.00 (11.5)</td>
</tr>
<tr>
<td>Females, N (%)</td>
<td>17,549 (67)</td>
<td>76,618 (81)</td>
<td>34,068 (81)</td>
<td>133,044 (81)</td>
<td>133,044 (81)</td>
<td>26 (67)</td>
</tr>
<tr>
<td>Charlson comorbidity index, Main</td>
<td>1.90 (1.1)</td>
<td>1.90 (1.1)</td>
<td>1.90 (1.1)</td>
<td>1.90 (1.1)</td>
<td>1.90 (1.1)</td>
<td>1.90 (1.1)</td>
</tr>
<tr>
<td>Ischaemic heart disease, N (%)</td>
<td>1294 (9)</td>
<td>7123 (9)</td>
<td>3892 (9)</td>
<td>14,543 (9)</td>
<td>14,543 (9)</td>
<td>489 (9)</td>
</tr>
<tr>
<td>Congestive heart failure, N (%)</td>
<td>432 (3)</td>
<td>262 (3)</td>
<td>179 (3)</td>
<td>6491 (3)</td>
<td>6491 (3)</td>
<td>55 (3)</td>
</tr>
<tr>
<td>Male/female ratio</td>
<td>0.46 (1.6)</td>
<td>0.46 (1.6)</td>
<td>0.46 (1.6)</td>
<td>0.46 (1.6)</td>
<td>0.46 (1.6)</td>
<td>0.50 (1.6)</td>
</tr>
<tr>
<td>Mean BMI (SD)</td>
<td>25.3 (5.8)</td>
<td>25.3 (5.8)</td>
<td>25.3 (5.8)</td>
<td>25.3 (5.8)</td>
<td>25.3 (5.8)</td>
<td>25.3 (5.8)</td>
</tr>
</tbody>
</table>

**Supported by:** Optum Life Sciences

### 1706-P

**Association between Diabetes and Depressive Symptoms in Postmenopausal Women: Findings from the 2009 Taiwan National Health Interview Survey**

ELISABETTA PATORNO, CHANDRASEKAR GOPALAKRISHNAN, OLESYA ZORINA, MARIA BOTA, ALICE KOECHLIN, JULIO ROSENSTOCK, PETER BOYLE, SEONUNG BAE, KEE TONG CHONG, SEONGHAN, REPUBLIC OF KOREA, SNUED, REPUBLIC OF KOREA, SAWON, REPUBLIC OF KOREA

Diabetes is a worldwide public health problem and its prevalence in Asia is rapidly growing. So it would be very important to find proper biomarker to predict future prediabetes and diabetes. We performed this study to find which adipokines could be strong predictor for future glucose alterations.

A total of 1,000 participants were recruited from the Ansung cohort (prospective, community-based rural cohort) in Korea. All subjects underwent a 75-g oral glucose tolerance test and eight kinds of adipokines (PAI-1, Resistin, IL-6, Leptin, MCP-1, TNF-α, RBP4, and Adiponectin) were measured by the Human serum Adipokines LINCOplex kit (Linco Research, St. Charles, MO, U.S.) at baseline examination. Excluding subjects who were diagnosed with type 2 diabetes (T2D) at baseline and were not followed up, 571 subjects were enrolled and regularly examined at every 2 years for 10 years. At baseline, 241 participants were NGT and 330 participants were pre-diabetes. At 10 years, 120 in subjects with NGT have developed prediabetes, and 455 in subjects with pre-diabetes have developed T2D. In multivariate logistic regression analysis, the NGT group with the highest tertile of RBP4 levels was 5.07 times (95% CI 1.70−15.09, P=0.026) more likely to develop T2D than those in the lowest tertile. The subjects with lower tertile levels of adiponectin had more than threefold risk for development of prediabetes than those with the highest tertile.

The NGT group with the highest tertile of RBP4 levels was 5.07 times (95% CI 1.70−15.09, P=0.026) more likely to develop T2D than those in the lowest tertile. The prediabetes groups with the highest tertile of RBP4 or Resistin levels were 1.87 and 2.85 times (95% CI 1.00−3.51, P=0.051, and 95% CI 1.49−5.43, P=0.001) more likely to develop T2D than those in the lowest tertile, respectively. Increased serum PAI-1, RBP4, resistin or decreased adiponectin levels were independent risk factors for progression to prediabetes or T2D in the non-diabetic people.

### 1707-P

**Characteristics and Medication Adherence of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Linagliptin and Other Diabetes Medications (Nonsulinin) in Routine Care**

ELISABETTA PATORNO, CHANDRASEKAR GOPALAKRISHNAN, OLESYA ZORINA, SEBASTIAN SCHNIEWEISS, DOROTHEE BARTELS, JIN LUI, JOHN SEEGER, BOSTON, MA, INGEHEIM, Germany

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor marketed for T2DM treatment. Limited information is available regarding the characteristics of patients initiating linagliptin and their adherence to treatment in routine care settings. Within a large, nationwide U.S. health insurance database (Optum Cliformatics), we identified T2DM patients initiating linagliptin or other diabetes medication (non-insulin) from May 2011 through June 2012. The patient characteristics at baseline are described in Table 1. The patients were followed for adherence measures for up to 12 months. Along with meglitinides, linagliptin initiators had the greatest burden of comorbidities (Table 1). Linagliptin and saxagliptin initiators had the highest proportion of days covered (PDC) at 77.5% and 78.5%, and greater persistence of therapy at 12 months (P12), 51.3% and 49.8%, respectively. The lowest adherence measures were observed among initiators of meglitinides (PDC 64%, P12 22.6%), glitazones (PDC 68.9%, P12 28.4%) and GLP-1 receptor agonists (PDC 68.3%, P12 33.6%). These patterns of adherence were similar after propensity score matching and in another U.S. commercial health insurance database (MarketScan), suggesting the differences in adherence measures are not due to patient or health insurer characteristics.

### 1708-P

**The Predictability of Adipocytokines for Developing Prediabetes and Type 2 Diabetes**

CHANG HU AHN, YOUN JI KIM, EU JEDONG KU, KYOUNG YEON JUNG, KYEONG SEOK PARK, JI EUN LEE, SEOI LIM, KYONG SOO PARK, HAK C. JANG, NAM H. CHOI, SUNG HEE CHOI, Seongnam, Republic of Korea, Suwon, Republic of Korea

The NGT group with the highest tertile of RBP4 or Resistin levels was 5.07 times (95% CI 1.70−15.09, P=0.026) more likely to develop T2D than those in the lowest tertile. The prediabetes groups with the highest tertile of RBP4 or Resistin levels were 1.87 and 2.85 times (95% CI 1.00−3.51, P=0.051, and 95% CI 1.49−5.43, P=0.001) more likely to develop T2D than those in the lowest tertile, respectively. Increased serum PAI-1, RBP4, resistin or decreased adiponectin levels were independent risk factors for progression to prediabetes or T2D in the non-diabetic people.
risks of bladder cancer. Of 16 meta-analyses of metformin, 11 demonstrated a significantly reduced risk of cancer (all cancers, breast, colorectal).

Meta-analyses published in 2014 have contributed to the understanding of the associations between diabetes, diabetes therapies and cancer risk but some have severe methodological deficiencies and their findings should be taken with caution. Nevertheless, the clearest association was between the increased risk of colorectal cancer in diabetes subjects and the increased risk of colorectal cancer among those prescribed insulin compared to other anti-diabetic medications.

**1710-P**

*International Comparison of Smoking and Metabolic Control in Patients with Type 1 Diabetes (T1D)*

SABINE E. HOFER, KELLEEM MILLER, JULIA M. HERMANN, ROY W. BECK, REINHARD W. HOLL, DAVID M. MAATHS, Innsbruck, Austria; Tampa, FL, Ulm, Germany; Aurora, CO.

Smoking may potentiate the risk of micro- and macro-vascular complications in T1D. We assessed smoking status in patients with T1D at 18 years with <1 year T1D duration in the T1D Exchange (T1DX) registry in the U.S. (n=10 589) and the DPV registry in Austria and Germany (n=9 826). Smoking status (current, former and non-smokers) and its relationship with metabolic outcomes were compared between and within each registry.

Current smoking status was defined by smoking at least one cigarette per day; former-smokers reported smoking in the past, while non-smokers never smoked. For sub analysis, age groups (gr. 1: 18-<26 years, gr. 2: 26-<50 years and gr. 3: ≥50 years) were considered.

In DPV current smoking rates (adjusted for age and gender) were higher compared with the T1DX registry (21.4% vs. 9.7%), while the % of former smokers was lower (5.1% vs. 18.0%) although the % of non-smokers was equal (70%) in both registries. Current smokers were higher in DPV in all age groups. Previous smokers were similar in age group 1 and 2, but higher in the T1DX registry in gr. 3 (5.3% vs. 35.2%).

HbA1c was significantly higher in smokers in both registries (DPV 8.5% vs. 7.9%; T1DX 8.6% vs. 7.9%, p<0.0001).

In conclusion, patients with T1D who smoke had significantly higher HbA1c. The high number of smokers in DPV is a concern. Anti-smoking policy and smoking cessation programs established in the U.S. seem to be successful strategies to reduce smoking.

**1711-P**

*First-Line and Intensified Treatment with Glucose Lowering Drugs in 232,797 Swedish Type 2 Diabetes Patients*  

JAN W. ERIKSSON, JOHAN BOUGEDARD, DAVID NATHANSON, THOMAS NYSTROM, MARCUS THURESSON, ANNA NOHRHAMMAR, Uppsala, Sweden; Oslo, Norway; Stockholm, Sweden

The aim was to investigate first-line and subsequent drug treatment for all type 2 diabetes (T2D) in Sweden. All individuals dispensed for the first time with any glucose lowering drug during 2006-2013, n=232,797, were identified in the national prescription registry. Patients with type 1 diabetes or gestational diabetes were excluded. Cox survival models adjusted for age and gender were used to estimate likelihood for treatment intensification during up to 7 years of follow-up. In 2013, annual incidence and prevalence of drug-treated T2D was 368/100,000 and 4.4%, respectively, i.e. suggesting that they are greater than reported by the Swedish National Diabetes Registry.

For author disclosure information, see page A810.

**1712-P**

*Smoking Cessation before Diabetes Occurrence Reduces Liver Cancer Mortality in Men: A Prospective Cohort Study*

CHHEN-HSIEH CHIANG, Yunlin, Taiwan

Limited evidence exists regarding diabetes and timing of smoking cessation for deaths from hepatocellular carcinoma (HCC). This research aimed to investigate the association between diabetes, smoking habits, and timing of smoking cessation relative to diabetes in a prospective cohort. We consecutively followed a total of 29,206 men aged 40 to 94 years receiving health screening from 1 January 1998 to 31 December 2008. Non-diabetic quitters were defined as quitters who had quit smoking before having diagnosis of diabetes. There were 186 deaths from HCC ascertained by validated death certificates and the national death registry. Diabetes (adjusted hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.53 to 3.64) was positively associated with deaths from HCC. Never-smokers had a lower adjusted risk of HCC deaths compared to current smokers (HR, 0.46; 95% CI, 0.32 to 0.68). Diabetic participants with anti-diabetic agents had a similar risk of deaths from HCC compared to diabetic participants without anti-diabetic agents. Among all ever-smokers with current or past smoking habits (n=14,514), non-diabetic quitters (HR, 0.41; 95% CI, 0.20 to 0.84) had decreased deaths from HCC compared to diabetic smokers. However, diabetic quitters (HR, 0.86; 95% CI, 0.31 to 2.34) and non-diabetic smokers (HR, 0.55; 95% CI, 0.29 to 1.08) were observed to have a similar risk of deaths from HCC to diabetic smokers. The reduced risk of HCC deaths in non-diabetic quitters versus diabetic smokers remained significant in lag-time sensitivity analyses, applied to check for reverse causation. In conclusion, diabetes was positively associated with deaths from male liver cancer independently of chronic hepatitis B. To be associated with reduced liver cancer mortality, men should keep never smoking or quit smoking preceding diagnosis of diabetes.

**1713-P**

*Serum Fatty Acid Proportions Are Related to Development of Metabolic Syndrome in Japanese Male Workers*

AIKIKI HATA, YOSUKE SHIKAMA, NAKANO AKI, AKAYO TAMURA, TAKAKO ICHIHARA, TAKAKO MINAGAWA, YUMI KUWAMURA, MAKOTO FUNAKI, TOKUSHIMA, Japan

Serum fatty acids (FA), such as saturated FAs, are known to be responsible for the development of metabolic syndrome (MetS). However, most reports are from cross-sectional studies, which compared serum FA proportions between healthy subjects and subjects with MetS, and the role of serum FAs in the development of MetS remains unclear. In addition, available prospective cohort studies proving a causal association between serum FA proportions and MetS...
EPIDEMIOLOGY—OTHER

Alcohol and Marijuana Use among Youth with Diabetes
ELISSA R. WEITZMAN, SHARON LEVY, Boston, MA.

For youth with diabetes, alcohol and marijuana use may jeopardize health and self-care, yet knowledge and assessment of these behaviors are limited.

To inform care, we measured use of alcohol and marijuana by youth with diabetes and tested associations with knowledge and guidance. We collected cross-sectional data from consented youth aged 9-18 years in care for type 1 diabetes (T1D) using a structured online assessment. Eligible youth had diabetes for a 1 year and spoke English. We analyzed data in SAS using descriptive statistics and regression controlling for age, sex, and race. The Boston Children’s Hospital IRB approved the research.

Of 100 participants (65% response), 43% were female, mean age 16 years (± 2.08 years). Average age of alcohol/marijuana initiation was respectively 15.8±13.5 years. Older age was associated with use (p < 0.01 for both). Among 83 high school (HS) youth, 36%±26% reported past year alcohol/marijuana use respectively; 24% reported using both. 23% of HS youth reported they drank in the past 90 days, of which 67% reported binge drinking. When asked if alcohol could interfere with their medications, 44.3% of HS youth answered “no” (incorrect) or “I don’t know;” 54.6% answered thus when asked if alcohol could interfere with their labs. Among HS youth, 71% reported being asked by their care team in the past year about their drinking, while 53%, 49% and 41% reported being told that alcohol use was not healthy, could make their disease worse, and could interfere with their medications, respectively. Knowledge and guidance were not consistently related to use though answering incorrectly about alcohol/lab interactions was associated with binge drinking (p<0.01). Among past year marijuana users: 35% reported substituting it for alcohol and perceiving alcohol as riskier; 24% perceived that marijuana helped their symptoms.

Alcohol and marijuana use are prevalent among youth with T1D. Knowledge about interactions between alcohol and medications/lab tests is poor. Education and screening are warranted to ameliorate risk.

Supported By: National Institute on Alcohol Abuse and Alcoholism (1R01AA021913-01) Conrad N. Hilton Foundation

The Association between Visit-to-Visit Variability of Fasting Plasma Glucose and All-Cause Mortality in Chinese Type 2 Diabetic Patients
YINAN LIU, BAODONG YAO, HONG FANG, YULIE YAN, YANPING ZHAO, YUE CHEN, Shanghai, China; Ottawa, ON, Canada.

Diabetes is associated with long-term complications that include cardiovascular and kidney disease and is an important cause of mortality worldwide. The importance of visit-to-visit glycemic variability in diabetes remains unclear. This study aimed to assess the relationship between visit-to-visit variability in fasting plasma glucose (FPG) and all-cause mortality in Chinese type 2 diabetic patients.

From Jan 2007 to Dec 2007, 6,847 type 2 diabetic patients with at least four records of FPG in the first year during regular follow-up were included in this analysis. They were followed through Nov 2014. The data were obtained from Electric Health Recording (EHR) of Shanghai Minhang District of China. Glycemic variation were calculated using standard deviation and coefficient of variation of FPG (FPG-SD and FPG-CV respectively), and Cox proportional hazards regression model was applied to estimate the effect on all-cause mortality adjusting for other related risk factors. 11.94% (n=818) of the cohort died during an average of 6.2 years follow-up, resulting in a mortality rate of 19.43 per 1000 person-years. The mean FPG-SD was 0.9 mmol/L. After multivariate adjustment, hazard ratios for the second (0.37 to 0.66 mmol/L), third (0.6 to 1.15 mmol/L) and fourth (>1.15 mmol/L) versus first FPG-SD quartile (0.37 mmol/L) were 0.90 (0.74, 1.11), 1.00 (0.84, 1.26) and 1.39 (1.15, 1.68), respectively (p=0.001). The mean FPG-CV was 0.12. Multivariable hazard ratios for the second (0.56 to 0.10), third (0.10 to 0.19) and fourth (>0.15) versus first FPG-CV quartile (<0.05) were 0.89 (0.67, 1.16), 1.12 (0.87, 1.47) and 1.36 (1.12, 1.64) (p<0.001).

High level of glycemic variability is associated with an increase of all-cause mortality, and both FPG-SD and FPG-CV may be independent predictors of all-cause mortality in Chinese type 2 diabetic patients. Supported By: Shanghai Municipal Commission of Health and Family Planning

Association of Plasma Vanadium with Impaired Glucose Regulation in Adults
CHEN SJUNG, ZHILEI SHAN, TAOPING SUN, HONGFEI MA, LIEGANG LIU, Wuhai, China.

Vanadium compounds have shown beneficial effects on glucose metabolism in animal and clinical studies, but there are few epidemiologic evidences. Our previous study has recently shown that plasma vanadium levels declined in type 2 diabetes (T2D). The current study aimed to examine the association of plasma vanadium levels with impaired glucose regulation (IGR) and plasma heme oxygenase-1 (HO-1), a stress-responsive protein. A cross-sectional study was conducted involving 176 IGR and 824 normal glucose tolerance (NGT) individuals. An oral glucose tolerance test was performed to assess IGR. Plasma vanadium and HO-1 was measured by inductively coupled plasma mass spectrometry (ICP-MS) and ELISA, respectively. Plasma vanadium levels were lower in IGR group than in NGT group (p<0.01). The odds ratios (95% confidence interval) for IGR across the increasing plasma vanadium quartiles were (reference), 0.53 (0.28-1.00), 0.41 (0.21-0.81) and 0.07 (0.02-0.34), respectively, after multivariate adjustment including lifestyle factors, body mass index and family history of diabetes. Plasma HO-1 concentrations significantly decreased across quartiles of plasma vanadium levels (p<0.01). In a linear regression model, a 1-unit increase in vanadium was associated with a decrease in HO-1 (β coefficient: 0.21 ± 0.07, P < 0.005). Our results suggested that plasma vanadium concentrations were inversely associated with IGR and plasma HO-1 levels in Chinese adults.

Integrating Structured and Unstructured Data in EHR for Stratification and Characterization of Diabetics
ISA K. KIRK, CHRISTIAN SIMON, SIREN BRUNAK, Copenhagen, Denmark; Kongens Lyngby, Denmark.

The recent explosion of data from Electronic Health Records (EHR) have opened new paths for characterizing complex diseases and stratifying patients. Diabetes is such a disease where large efforts and resources are put into understanding its etiology and best treatments.

In this study we analyzed EHRs from a Danish diabetes center, which consisted of 14,018 T1D and T2D patients spanning 12 years and constituting almost 5.4M journal entries. For both describing patients and mapping between unstructured (text) and structured (typed values) data we used ICDO10 diagnosis codes. The codes from the unstructured data were found using an in-house developed text-mining pipeline, while the other codes were extracted directly from the structured data.

We stratified patients by implementing both a data-driven approach based on cosine similarities of the patients diagnosis codes vector, and a hypothesis approach based on sex and longitudinal HbA1c levels for characterizing well and unregulated diabetics.

By comparing ICDO10 codes between the unstructured and structured data, we found only a small overlap. When investigating the differences we verified that the structured data lacked information that was not directly related to diabetes, but could be relevant when determining treatment strategies. For instance, no ICDO10 codes for cancer were found in the structured data, and we thus propose a necessity for integrating both types of data when analyzing EHRs.

We were able to cluster patients into descriptive categories using ICDO10 codes. We found a clear division of T1D and T2D patients, and when comparing the average HbA1c levels for patients in the clusters with the clusters found using HbA1c levels, we saw sub-clusters with higher average HbA1c levels, indi-
Epidemiology/Poster Session

1719-P

Metabolic Syndrome among Hispanics Living in a Midwestern City: Data from LILA (Latinos Living in Louisville Area) Study

ASHRPEET KAUR, SATIHYA S. KRISHNASAMY, Louisville, KY

Metabolic syndrome (MetS) is associated with increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (DM). CVD is one of the leading causes of mortality in the Hispanic population, which is the largest and fastest growing ethnic minority in the U.S. We studied the prevalence of MetS and attributes in 53 adult men and women aged 19 to 83 years who attended the Hispanic community health fair, Louisville, Kentucky. The updated 2006 International Diabetes Federation (IDF) and ATP-III criteria were used to define MetS. Mean age (±SD) was 49.8 ± 12.4 (range 19 to 83 years) and mean BMI was 31.2 ± 11.3 kg/m² (range 20 to 46). A high prevalence of MetS (69.8%) and central obesity (85.2% with IDF criteria and 86.7% based on ATP-III criteria) was found as compared to NHANES data for the U.S. population (22.9%) and International Diabetes Foundation (IDF) criteria were used to define the Hispanic community health fair, Louisville, Kentucky. The updated 2006 and attributes in 53 adult men and women aged 19 to 83 years who attended the Hispanic community health fair, Louisville, Kentucky. The updated 2006 International Diabetes Federation (IDF) and ATP-III criteria were used to define MetS. Mean age (±SD) was 49.8 ± 12.4 (range 19 to 83 years) and mean BMI was 31.2 ± 11.3 kg/m² (range 20 to 46). A high prevalence of MetS (69.8%) and central obesity (85.2% with IDF criteria and 86.7% based on ATP-III criteria) was found as compared to NHANES data for the U.S. population (22.9%) and International Diabetes Foundation (IDF) criteria were used to define the Hispanic community health fair, Louisville, Kentucky. The updated 2006

Table: Frequencies of Components of Metabolic Syndrome in the Study Population

<table>
<thead>
<tr>
<th>Component</th>
<th>Total (n=53)</th>
<th>Women (n=26)</th>
<th>Men (n=27)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MetS - IDF</td>
<td>37 (69.8%)</td>
<td>18 (69.2%)</td>
<td>19 (70.4%)</td>
</tr>
<tr>
<td>MetS - ATP-III</td>
<td>37 (69.8%)</td>
<td>17 (65.4%)</td>
<td>20 (74.1%)</td>
</tr>
<tr>
<td>Hypertension by history</td>
<td>11 (20.8%)</td>
<td>4 (15.4%)</td>
<td>7 (25.9%)</td>
</tr>
<tr>
<td>DM by history</td>
<td>6 (11.3%)</td>
<td>2 (7.7%)</td>
<td>4 (14.8%)</td>
</tr>
<tr>
<td>Hyperlipidemia by history</td>
<td>11 (20.8%)</td>
<td>6 (23.1%)</td>
<td>5 (18.5%)</td>
</tr>
<tr>
<td>*WC - IDF criteria</td>
<td>40 (90.6%)</td>
<td>25 (96.2%)</td>
<td>15 (55.6%)</td>
</tr>
<tr>
<td>*WC - ATP criteria</td>
<td>39 (73.6%)</td>
<td>21 (80.8%)</td>
<td>18 (66.7%)</td>
</tr>
<tr>
<td>Blood pressure criteria</td>
<td>24 (45.3%)</td>
<td>11 (42.3%)</td>
<td>13 (48.1%)</td>
</tr>
<tr>
<td>Fasting blood glucose criteria</td>
<td>24 (45.3%)</td>
<td>9 (34.6%)</td>
<td>15 (55.6%)</td>
</tr>
<tr>
<td>Triglycerides criteria</td>
<td>28 (52.8%)</td>
<td>16 (61.5%)</td>
<td>12 (44.4%)</td>
</tr>
<tr>
<td>HDL criteria</td>
<td>30 (56.6%)</td>
<td>14 (53.8%)</td>
<td>16 (59.3%)</td>
</tr>
</tbody>
</table>

*WC = Waist circumference.

For author disclosure information, see page A810.

Guided Audio Tour: The Epidemiology of Type 1 Diabetes (Poster: 1720-P to 1728-P), see page 15.

1720-P

Bidirectional Association between Diabetes and Gout: The Singapore Chinese Health Study

AN PAN, GIM GEE TENG, JIAN-MIN YUAN, WOO PIAY KOH, Singapore, Singapore, Pittsburgh, PA

Studies suggest that gout is associated with increased risk of type 2 diabetes (T2D), while T2D was inversely related to incident gout. However, no cohort study has investigated the T2D-gout bidirectional association simultaneously. We analyzed data from the Singapore Chinese Health Study (SGHS), a cohort of 63257 Chinese aged 45-74 years at recruitment (1993-1998). Self-reports of diagnosed diabetes and gout were enquired at follow-ups (1998-2004) and II (2006-2010). We included participants free of cardiovascular disease or cancer at follow-up I and with complete data for both follow-ups. For the analysis of T2D to gout (analysis I), those with prevalent gout were further excluded (final n=31137). For the analysis of gout to T2D (analysis II), those with prevalent diabetes were also excluded (final n=29868). Cox regression models were used to estimate relative risks (RRs) with adjustment for demographic and lifestyle factors, including BMI and history of hypertension. Mean age at follow-up I was 60.5 (SD 7.3) years, and mean follow-up was 6.9 (SD 1.3) years. In the analysis I, diabetes was associated with a 23% lower risk of developing T2D (IRR 0.77; 95% CI 0.60-0.97). No significant interaction was found with sex, BMI or hypertension status. In the analysis II, gout was associated with 35% increased risk of developing T2D (IRR 1.35; 95% CI 1.12-1.63), while the association disappeared after adjustment for hypertension and BMI (IRR 1.00; 0.83-1.21). Significant interaction was found with BMI (Pinteraction=0.04) and hypertension (Pinteraction=0.007), and the association was marginally significant in adults with BMI <24 kg/m² (1.30; 0.95-1.78) and significant among non-hypertensive participants (1.37, 1.02-1.84), but not in their counterparts. Our results provide compelling evidence that diabetes is associated with a lower risk of incident gout, while gout was positively related to diabetes among normal weight and non-hypertensive adults.

Guided Audio Tour: The Epidemiology of Type 1 Diabetes (Poster: 1721-P to 1728-P), see page 15.

1721-P

Elective Cesarean Section and Risk of Childhood Type 1 Diabetes—A Nationwide Cohort Study

TINE D. CLAUSEN, THOMAS BERGHOLT, FRANK ERIKSSON, STEEN RASMUSSEN, NIELS KEIDING, ELLEN LOEKKEGAARD, Billund, Denmark, Copenhagen, Denmark, Hvidovre, Denmark

Delivery by elective cesarean section has been proposed to be a risk factor for childhood type 1 diabetes, but results from studies are diverging. Increasing rates of cesarean section, as well as expanding research indicating a serious influence of the gut microbiota on future health, emphasize the need for large-scale studies to evaluate the clinical consequences of delivery by cesarean section in the general population. In this Danish Nationwide cohort study we followed all singletons born during 1982-2010 and assessed the risk of childhood type 1 diabetes with onset before the age of 15 years by Cox regression. Four nationwide registers provided information on mode of delivery, outcome and confounders. A total of 1,760,336 singletons contributed 20,436,684 person-years, during which 4,404 were diagnosed with childhood type 1 diabetes. The risk of childhood type 1 diabetes was increased in children delivered by elective cesarean section compared with vaginal delivery when adjusted for year of birth, parity, sex, parental age and education and paternal type 1 diabetes diagnosed before childbirth (HR 1.17; 95% CI 1.04 to 1.32), but not when adjusted for maternal type 1 diabetes (HR 1.07; 95% CI 0.95 to 1.21). However, childhood type 1 diabetes tended to be more prevalent in offspring of mothers with type 1 diabetes when delivered by elective cesarean section (HR 1.22; 95% CI 0.99 to 1.53) and not when delivered by emergency cesarean section, which was not associated with childhood type 1 diabetes. Paternal type 1 diabetes was elevated access to diagnostic tools. Managing type 2 diabetes (T2D) involves adherence to dietary instructions and such instructions may also affect the diabetic risk factors in individuals with whom a patient with T2D shares daily life with. Thus, not achieving glycemic control could be associated with increased diabetic risk in individuals sharing household with the patient with T2D.

Therefore, to assess the association of glycemic control in patients with T2D and diabetic risk factors in their house mates, measurements of HbA1c, fasting plasma glucose (FPG), hypertension, anthropometry, dietary intake, smoking status and alcohol intake were obtained from 45 rural Ugandan patients with T2D and their 155 housemates.

Twenty-four patients (53.3%) did not reach their individual glycemic target according to ADA/EASD criteria. Compared to individuals from households with good glycemic control, individuals from households with a patient with poor glycemic control had higher levels of FPG and a higher weekly intake of staples (5.8 mmol/l vs. 5.5 mmol/l and 27.1 vs. 25.4, respectively, p = 0.05 for all tests). No differences were seen between the two groups of households in relation to HbA1c, hypertension, anthropometric measures, physical activity, oil intake, alcohol intake or smoking (p > 0.05 for all tests).

All models were adjusted for sex, age, socio-economic status, education and patient time lived with T2D.

The results suggest that individuals sharing household with a patient not reaching glycemic control could be a target group for screening and prevention of T2D in settings with limited availability of diagnostic tools.

Supported By: Novo Nordisk Foundation; Thonvild Madsens Foundation; Aase & Einar Danielsen Foundation; Christian & Otilia Brorsens Rejsielaget.
Factors Involved in Predicting Time to Type 1 Diabetes in Antibody Positive TrialNet Subjects

ALEXANDRA R. FOUTS, LAURA PYLE, LIPING YU, DONGMEI MIAO, AARON W. MICHELS, JEFFREY P. KIRSCHER, JAY M. SOSENKO, PETER A. GOTTIEB, ANDREA K. STECK, TYPE 1 DIABETES TRIALNET STUDY GROUP, Aurora, CO, Tampa, FL, Miami, FL

Relatives of subjects with type 1 diabetes (T1D) positive for islet autoantibodies (Ab) have a high risk of progression to diabetes; however, rate of progression varies significantly. In 1297 TrialNet subjects positive for >1 biochemical Ab (IAA, GADA, IA-2A, ZnT8A), we analyzed new electrochemiluminescence (ECL) assays (ECL-IAA and ECL-GADA) at their initial visit and metabolic markers at baseline; after a median follow-up of 33 months, 184 of these subjects developed T1D. Univariate analyses showed that biochemical Ab, ECL-IAA, ECL-GADA, age, number of positive Ab, presence of HLA DR3/4-DQB genotype, HbA1c and oral glucose tolerance test (OGTT) markers (area under the curve (AUC) glucose, fasting C-peptide, and AUC C-peptide) were all significantly associated with progression to T1D. Four multivariate Cox proportional hazards models were compared, with the base model including age, OGTT markers and number of positive biochemical Ab. The ability to predict time to T1D was improved by adding ECL (but not specific biochemical) Ab to the base model. The model with combined categorical ECL assays (defined as positive if >1 ECL assay was positive) was the best and factors that remained significantly associated with time to T1D were AUC C-peptide, AUC glucose, number of positive biochemical Ab and ECL positivity (Table). In Ab positive subjects, ECL assays improve the ability to predict time to T1D.

Table. Covariate P-value Hazard ratio (95% CI)
Age 0.199 0.99 (0.97-1.01)
AUC glucose <.0001 1.02 (1.01-1.03)
Fasting glucose 0.202 1.15 (0.93-1.42)
AUC C-peptide <.0001 1.03 (1.01-1.06)
Fasting C-peptide 0.094 1.29 (0.96-1.72)
# of positive biochemical Ab <.0001 2 vs. 1: 2.59 (1.52-4.45); 3 vs. 1: 3.30 (1.84-5.10); 4 vs. 1: 3.30 (2.12-4.80)
ECL (GADA or IAA) 0.0003 1.05 (1.01-1.09)

Supported By: American Diabetes Association (1-14-CD-17 to A.K.S.), JDRF (47-2013-581)

Determinants and Prognosis of Early- vs. Late-Onset Islet Autoimmunity

BRIGITTE I. FROHNERT, LISA ODE, ANDREA K. STECK, FRAN DONG, JILL M. NORRIS, MARIAN REWERS, Aurora, CO, Denver, CO

While incidence of islet autoimmunity (IA) peaks in early childhood, little is known about determinants of late-onset IA or its prognosis for future type 1 diabetes (T1D).

This study explored demographic and genetic characteristics, autoantibody appearance and persistence and progression to T1D in early- vs. late-onset IA. Diabetes Autoimmunity Study in the Young (DAISY) followed 2,542 high-risk children for a median of 11 years. IA was defined as persistence of autoantibodies to insulin, GAD, IA-2, or ZnT8. Early-onset IA (<8 years) developed in 142 subjects; late-onset IA was documented in 60. Children with late onset were more likely to be of non-white ethnicity and have no first-degree relatives with T1D. Frequencies of HLA-DR3/4-DQB, PTPN22, INS, CTLA4, and IFIH1 genotypes did not differ between groups.

Late-onset IA presented less often with multiple antibodies. Autoantibodies were more likely to revert to negative and progression to T1D was less frequent. Although followed for shorter time from IA onset, Kaplan-Meier survival analysis with log rank test showed decreased risk of spread to more antibodies (p<.04) or progression to T1D (p=0.003). Late-onset IA may be more frequent than previously appreciated, especially in Hispanics, Blacks and general population families free of T1D. Further follow-up of both early- and late-onset IA subjects is needed to explore implications for development of adult T1D, GDM, LADA and T2D.

Table. Characteristics of Early- vs. Late-Onset Islet Autoimmunity (IA)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Early-Onset (IA &lt;8 y)</th>
<th>Late-Onset (IA ≥8 y)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>52%</td>
<td>45%</td>
<td>ns</td>
</tr>
<tr>
<td>Hispanic or Black</td>
<td>14%</td>
<td>35%</td>
<td>.001</td>
</tr>
<tr>
<td>1st degree relative proband</td>
<td>64%</td>
<td>52%</td>
<td>.10</td>
</tr>
<tr>
<td>Sibling proband</td>
<td>27%</td>
<td>12%</td>
<td>.03</td>
</tr>
<tr>
<td>&gt;1 antibodies at onset</td>
<td>32%</td>
<td>30%</td>
<td>.001</td>
</tr>
<tr>
<td>IAA first</td>
<td>49%</td>
<td>32%</td>
<td>.03</td>
</tr>
<tr>
<td>ZnT8A first</td>
<td>27%</td>
<td>15%</td>
<td>.07</td>
</tr>
<tr>
<td>GADA first</td>
<td>51%</td>
<td>52%</td>
<td>ns</td>
</tr>
<tr>
<td>IA-2A first</td>
<td>20%</td>
<td>15%</td>
<td>ns</td>
</tr>
<tr>
<td>Spreading to other antibodies</td>
<td>60%</td>
<td>47%</td>
<td>.08</td>
</tr>
<tr>
<td>Revert to no IA</td>
<td>35%</td>
<td>57%</td>
<td>.003</td>
</tr>
<tr>
<td>Progression to T1D</td>
<td>47%</td>
<td>13%</td>
<td>.001</td>
</tr>
<tr>
<td>Median follow-up (from 1st antibody)</td>
<td>7.0 yr</td>
<td>4.3 yr</td>
<td>.003</td>
</tr>
</tbody>
</table>

Supported By: National Institutes of Health (DK71293, DK20383, DK250979, 5K2D20394722-D4); JDRF (17-2013-535)

Predictors of Slow Progression to Diabetes in Children with Multiple Islet Autoantibodies

ANDREA K. STECK, FRAN DONG, KATHLEEN C. WAUGH, LIPING YU, JILL M. NORRIS, MARIAN REWERS, Aurora, CO, Denver, CO

Approximately 60% of children with multiple islet autoantibodies (IA) progress to type 1 diabetes (T1D), although rate of progression is variable. The Diabetes Autoimmunity Study in the Young (DAISY) has followed for T1D 118 children with multiple IA. Here, we compare rapid progressors (N=39) who developed T1D in <5 yrs with slow progressors (N=27) who had a diabetes-free follow-up for >10 yrs (eventually developed T1D). Excluded were 25 children diagnosed with T1D within 5-10 yrs and 27 children diabetes-free followed for <10 yrs. Gender, ethnicity, family history of T1D and HLA DR3/4-DQB were not significantly different between the two groups. Slow progressors had later onset of IA (5.8 vs. 4.0 yrs, p=0.03) and fewer IA (mIAA, GADA, IA2, ZnT8, electrochemiluminescence (ECL) IAA, ECL-GAD) at the initial positive visit than rapid progressors (1.6 vs. 3.0, p=0.002). Antibody levels (mean ± SD) were also lower in slow progressors (Table). Of 25 non-HLA SNPs associated with T1D and previously analyzed in DAISY, only r1998760 minor allele G (IFIH1) was less frequent in the slow progressors (30% vs. 49%, p=0.04). In multivariate analyses including age at seroconversion, HLA DR3/4 and all mean antibody levels, lower mean ECL-IAA independently predicted slower progression to T1D (OR 0.66, 95% CI 0.46-0.93). In conclusion, later onset of IA and lower IA levels predicted slower progression to diabetes among children with multiple IA.

Table. Variable Rapid Progressors (N=39) | Slow Progressors (N=27) | p-value |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial ECL-IAA</td>
<td>0.09 ± 0.18</td>
<td>0.01 ± 0.02</td>
</tr>
<tr>
<td>Initial mIAA</td>
<td>0.15 ± 0.40</td>
<td>0.01 ± 0.02</td>
</tr>
<tr>
<td>Initial IA-2</td>
<td>0.17 ± 0.35</td>
<td>0.02 ± 0.07</td>
</tr>
<tr>
<td>Initial GAD65</td>
<td>0.12 ± 0.27</td>
<td>0.02 ± 0.08</td>
</tr>
<tr>
<td>Mean ECL-IAA</td>
<td>0.10 ± 0.17</td>
<td>0.01 ± 0.02</td>
</tr>
<tr>
<td>Mean mIAA</td>
<td>0.12 ± 0.18</td>
<td>0.01 ± 0.02</td>
</tr>
<tr>
<td>Mean ZnT8</td>
<td>0.16 ± 0.21</td>
<td>0.06 ± 0.10</td>
</tr>
</tbody>
</table>

Supported By: American Diabetes Association (1-14-CD-17 to A.K.S.); National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases (R01DK23493)

Glycemic Control and Acute Diabetes Complications during Transition from Pediatric to Adult Care

JENNIFER HUYNH, TAMARA SPAIC, JEFFERY L. MAHON, CHERIL CLARSON, LONDON, ON, Canada

Transition from pediatric to adult diabetes care is a high risk period marked by increased rates of disengagement from care and diabetes-related complications. We conducted a population based cohort from 2007-2014 using...
Epidemiology—Type 1 Diabetes

The Haptoglobin 2 Allele Is Associated with Increased Urinary 15-isoprostane F2t Concentrations Over Time among Adults with Type 1 Diabetes

TINA COSTACOU, ROBERT W. EVANS, ROBERT E. FERRELL, TREVOR J. ORCHARD, Pittsburgh, PA

We have previously shown that the Haptoglobin (Hp) 2 allele is a significant predictor of coronary artery disease risk in type 1 diabetes, potentially due to the decreased antioxidative potential associated with Hp 2. We, thus, assessed whether urinary 15-isoprostane F2t (IsoP) concentrations are a biomarker of oxidative stress and lipid peroxidation, differ by Hp genotype in adults with type 1 diabetes.

Urinary IsoP were measured at three time points during 20 years of follow up in a cohort of childhood onset type 1 diabetes (n=456, baseline mean age 28 and diabetes duration 19 years). Analyses were first conducted to evaluate differences in IsoP levels at the first time point of measurements (considered the baseline for this analysis). Mixed models were further constructed to assess the association between the repeated measures of urinary IsoP and Hp, after adjustment for diabetes duration and univariately significant risk factors.

No significant differences across Hp genotypes were observed at baseline with the exception of a trend toward higher IsoP concentrations with the number of Hp 2 alleles (p=0.02). In multivariable regression analyses allowing for diabetes duration, gender, smoking status, HbA1c, pulse, HDL and non-HDL cholesterol, glomerular filtration rate, WBC count, fibrinogen, hsCRP, adiponectin and e-tocopherol, Hp 2-2 was associated with higher IsoP compared to Hp 1-1 (β=0.14, p=0.04). Non-significantly greater urinary IsoP concentrations were also observed in Hp 2-1 carriers (β=0.08, p=0.06) and Hp 2-2 (β=0.11, p=0.02) were associated with elevated IsoP concentrations over the 20 year follow-up compared to Hp 1-1 carriers.

In this study of adults with type 1 diabetes, the Hp 2 allele is associated with greater IsoP concentrations over 20 years of follow-up, providing further, novel, evidence that the antioxidative capacity of Hp 2 is inferior to that of the Hp 1 allele.

Supported By: National Institutes of Health (DK034818-21)

Association of Continuous Subcutaneous Insulin Injection Pumps with Lower HbA1c and Mortality in Type 1 Diabetes of Chronic Duration

DAVID M. POBER, HILLARY A. KEENAN, MOGHIR KHAMAISI, STEPHANIE M. HASTINGS, STEPHANIE D’ETON, LIANE J. TINSLEY, GEORGE L. KISS, BOSTON, MA

Continuous subcutaneous insulin infusion pumps (CSII) may improve HbA1c and quality of life relative to the use of multiple daily injections (MDI) in individuals with type 1 diabetes (T1D), yet there is limited information about the relationship of CSII to mortality. The 50-Year Medalist Study provides a unique opportunity to investigate in 944 individuals with more than 50y of T1D (mean duration=53y, HbA1c=7.1%, age=65y, age at onset=11y, daily insulin dose=0.43 u/kg, 59% use CSII, 48% for 10y or longer). Medalists using CSII have lower HbA1c (7.1% vs. 7.3%, p<0.01), are less likely to have detectable serum C-peptide (29% vs. 42%, p<0.01), are younger (64y vs. 68y, p<0.01), have shorter duration of disease (54y vs. 56y, p<0.01), have less cardiovascular disease (CVD) (37% vs. 45%, p<0.01), have higher eGFR (71 vs. 67 ml/min/1.73m2, p<0.01), are more likely to use statins (72% vs. 66%, p<0.05) and aspirin (53% vs. 43%, p=0.01), and are similar in use of antihypertensives (65% vs. 64%, p=0.90). We investigated the influence of CSII on mortality by Cox proportional hazards regression. Since 2003, 94 (10%) participants have passed away, 32 (3%) in CSII and 62 (16%) in MDI; 44% from CVD, 10% from cancer, 7% from direct complications of diabetes, and 7% due to accidents. Mean age at death was 77y; CSII use was associated with reduced mortality (hazard ratio (HR)=0.42, 95% CI: 0.27, 0.65) during a mean follow-up of 5y. Models adjusted for baseline characteristics and stratified by CSII show hazard increases by 1.09 for each unit (%) change in HbA1c for MDI compared to 1.30 for CSII. Among Medalists who use CSII HbA1c has a larger role in risk for mortality than among those who use MDI. For Medalists using MDI additional factors of C-peptide, antihypertensive use, and duration of disease influenced mortality risk. CSII may reduce HbA1c and mitigate other risk factors, reducing mortality among individuals with chronic duration of T1D.

Supported By: JDRF (17-2013-310) National Institutes of Health-DP-3K08X43-01; Iacocca Family Foundation (to D.M.P.)
1729-P 
Hemoglobin A1c and Mortality in Adults with Type 1 Diabetes: Updated Analysis from the Pittsburgh Epidemiology of Diabetes Complications (EDC) Cohort
TREVOR J. ORCHARD, RACHEL G. MILLER, TINA COSTACOU, Pittsburgh, PA
A recent report from Sweden has suggested that individuals with type 1 diabetes who have an updated (over, on average, the prior 8 years) mean HbA1c <7.0 or 7.8-8.4% have a 2.36- and 2.38-fold increase in mortality compared to the background population. The EDC study of childhood onset type 1 diabetes has previously reported a similar pattern of little association across the bottom 2 quintiles of updated (over 22 years mean HbA1c <7.8 and 7.8-8.4%). In the current analyses, in order to reflect more contemporary experience, we consider only recent data (from 1996 to 2011). N = 4,400; mean age=37 years, duration=29 years; 66 deaths; and compare mortality to the background [Allegheny County] population. Comparing those with HbA1c <7.0 and 7.0-7.8% at baseline (1996-98), the age adjusted SMRs are 1.85 (95% CI 0.75, 3.90) and 1.80 (0.84, 3.40) respectively while for the updated mean HbA1c the corresponding SMRs are 1.98 (0.92, 3.76) and 1.54 (0.68, 3.06). However, if the same groupings are based on the most recent HbA1c, the age adjusted SMR for <7.0 is 1.12 (0.49, 2.22) while for 7.0-7.8% it is 2.84 (1.44, 5.60). While these results thus confirm the shallow gradient of mortality risk by mean HbA1c below 7.8% seen in Sweden, there is also, albeit based on a small sample size, suggest that mortality may be comparable to that of the general population for those with a most recent HbA1c <7.0%. These findings should be examined in other cohorts.
Supported By: R01DK34819

1730-P 
Glycemic Control Is Worse in the U.S. Compared with Germany/Austria among 33,258 Pediatric Patients with Type 1 Diabetes
STEPHANIE N. DUBOSE, JULIA M. HERMANN, DAVID M. MAHHS, SABINE E. HOFER, ROY W. BECK, RENHARD W. HOFER, Tampa, FL; Bethesda, MD; Seattle, WA; Aurora, CO; Augusta, GA; Turku, Finland; Munich, Germany; Malmö, Sweden; Gainesville, FL; Dresden, Germany
Little is known about the effects of the variable presence of islet autoantibodies on the risk of type 1 diabetes (T1D); remissions may be true remission of autoimmune, humoral markers only or just assay variability. This study assessed autoantibody expression to further clarify the natural progression of the disease and identify factors associated with different progression rates in The Environmental Determinants of Diabetes in the Young (TEDDY) Study of genetically high-risk children. Eligible subjects were <10 years of age screened more than once for mIAA, GADA, and IA-2A. Persistent autoantibody was defined as an autoantibody present on ≥2 consecutive visits and confirmed in two reference laboratories. Remission was defined as ≥2 consecutive negative visits post visit persistence. There were 568/8503 (6.7%) children who developed a persistent autoantibody (mIAA 424 GADA, and IA-2A, 247 IA-2A). Autoantibody remission <12 months, 12-24 months and ≥24 months post persistence was 27.7, 10.1, and 60 per 100 person-years for mIAA, 171, 6.3, and 1.7 person-years for GADA, and 3, 1.3, and 1.0 for IA-2A. Higher initial autoantibody levels decreased the risk of remission (mIAA: HR 0.85, 95%CI (0.77-0.94), p=0.002; GADA, HR 0.35, 95%CI (0.25-0.49), p<0.001; and IA2A: HR 0.55, 95%CI (0.35-0.87), p=0.01), all per 1 standard deviation. Gender, family history of T1D, country and age at seroconversion did not predict GADA or IA-2A remission. However, mIAA were more likely to remit in children with HLA-DR3/3 compared to HLA-DR4/4 (HR 2.21, 95%CI (1.24, 2.0), p=0.02). Of those that remitted, 25% mIAA, 15% GADA and 50% IA-2A reverted back to persistence. After adjusting for baseline level, GADA remission (HR 2.8, 95%CI (1.7-4.8), p=0.001), but not mIAA (HR 0.9, 95%CI (0.6-1.4), p=0.55) or IA2A remission (HR 1.0, 95%CI (0.9-1.1), p=0.38) predicted T1D. The predictive value of remission on risk of T1D appears to vary by autoantibody.
Supported By: National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development; National Institute of Environmental Health Sciences; JDRF; Centers for Disease Control and Prevention

1731-P 
GAD Autoantibody Remission Associated with Risk of Type 1 Diabetes: TEDDY Study
KENDRA VEHK, KRISTIAN LYNCH, BEENA AKOLKAR, WILLIAM A. HAGOPIAN, MARIAN REWERS, JIN-XIONG SHE, OLLI G. SIMEL, JORMA TOPPARI, ANNETTE G. ZIEGLER, AKE LERNMARK, DESMOND SCHATZ, EZIO BONIFICIO, JEFFREY P. KRISCHER, THE TEDDY STUDY, Tampa, FL; Bethesda, MD; Seattle, WA; Aurora, CO; Augusta, GA; Turku, Finland; Munich, Germany; Malmö, Sweden; Gainesville, FL; Dresden, Germany
Two recent studies showed that the incidence of type 1 diabetes (T1D) is increasing worldwide by 2-5%, making the epidemiology of T1D of particular research interest. Potential risk factors under study include age, gender, location, race, genetics and environmental factors. Location is of particular interest since the rate at which incidence is increasing varies with region. Although T1D incidence has been difficult to study in the U.S. due to lack of population databases, the SEARCH study showed increasing incidence in U.S. non-Hispanic whites.
Residents in a Midwestern county in the U.S. receive virtually all medical care in the county. Medical encounters are indexed and linked to medical records, allowing rigorous study of epidemiology of diseases. Residents with T1D were found by searching multiple databases and participation in prior studies. Initially, a broad search based on diagnosis codes was used to identify potential cases between 1994-2010. Clinical charts were reviewed to accurately capture all incident cases. Incidence rates were directly standardized to the 2000 U.S. white population, and trends in incidence for age, gender and calendar time were analyzed with Poisson regression. Charts were also reviewed for biopsy proven celiac disease diagnosis. There were 233 new cases with an age and gender-adjusted annual incidence rate of 9.2 (95% CI, 8.0-10.4)/100,000 population. In reference to a younger population of age<30 years, the rate of T1D was 17.0 (95% CI, 14.5-19.5)/100,000 person-years, based on 177 cases. Average annual incidence rates were higher in males than females (10.5 vs. 7.7)/100,000, across all ages; P=0.015 and decreased with older age (R=0.001). There was no significant linear trend in T1D incidence (P=0.45), as incidence appeared to increase from 1994-2002 and decrease after 2002. Among 109 T1D cases tested for celiac disease, 12% had celiac disease, higher compared to prior reports.
For author disclosure information, see page A810.
1733-P
Nuclear Magnetic Resonance-determined Lipoprotein Subclasses and Carotid Intima-Media Thickness in Type 1 Diabetes: A Prospective Study
APRITA BALDI, ALICIA JENKINS, YING ZHANG, JUDE STONER, RICHARD KLEIN, MARIA F. LÓPEZ-VIRELLA, W. TIMOTHY GARVEY, TIMOTHY J. LYONS, THE DCCT/EDIC RESEARCH GROUP, Stillwater, OK, Sydney, Australia, Oklahoma City, OK, Charleston SC, Birmingham, AL

We investigated the prospective associations of nuclear magnetic resonance-determined lipoprotein subclass profiles (NMR-LSP) with carotid intima-media thickness (IMT) in type 1 diabetes. NMR-LSP were measured in an available subset of Diabetes Control and Complications Trial (DCCT) participants (n=455; men=246; women=209) at study entry (‘baseline’, 1983-89), and were related to carotid IMT determined by ultrasoundography during the observational follow-up of DCCT, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, in EDIC year 1 (1994-96), year 6 (1998-2000), and year 12 (2004-2006). Associations between NMR-LSP and IMT were examined by multiple linear regression stratified by gender and following adjustment for weighted mean HbA1c, albumin excretion rate, DCCT randomization group, ultrasoundography devices, and IMT reader.

In men, we observed significant positive associations of DCCT baseline NMR-based LDL subclasses (total and small LDL) with common and internal carotid IMT, at EDIC years 1, 6, and 12. Significant inverse associations of mean HDL diameter with common and internal carotid IMT were also observed in men at similar time points. Furthermore, associations of HDL subclasses (large (negative), medium (negative) and small (positive)) with common and/or internal carotid IMT were noted at one or more EDIC time points. Finally, small VLDL particles were positively associated with common carotid IMT, but only at EDIC year 1 in men (all p<0.05). No significant associations were observed in women.

We observed associations of LDL subclasses and HDL particle size with IMT that persisted throughout the EDIC observational phase. These data suggest that NMR-LSP can reveal some associations of lipoprotein characteristics with future disease with regard to common and internal carotid IMT in men.

Supported By: National Institutes of Health

1734-P
Determinants of Change of sAF over 4 Years of Follow-up in Type 1 Diabetes
KALINA SALAOBELENA, CATHERINE HELMER, SOVANDANY NOV, BLANDINE FARGES, ELISA MAURY, CONCEPCION GONZALEZ, HENRI GIN, VINCENT RIGAL-LEAU, Bordeaux, France

Skin Autofluorescence of sAF is a non-invasive marker of the long-term accumulation of Advanced Glycation End products (AGEs) in tissues, implicated in complications of diabetes. Our study aimed to identify factors associated with the progression of sAF during 4 years of follow-up of subjects with type 1 diabetes.

In this prospective study, 159 patients with type 1 diabetes underwent two measurements of sAF with AGE Reader (Diagnostica: one at inclusion (T0, 2009) and one at follow-up 4 years later (T4). At these time points, the variables reported to influence the accumulation of AGES in transversal studies was recorded: age, sex, smoking, duration and control (HbA1C) of diabetes, and renal function (estimated glomerular filtration rate eGFR by EPI-CKD equation). The associations between sAF at T4 as dependent variable and measurements at T0, at mean and variance of the T0 and T4 measurements of HbA1c and eGFR were studied in multivariate linear regression analysis adjusted on age, sex, baseline sAF at T0, body mass index, smoking status, and duration of diabetes.

At inclusion, the 159 patients were 51±15 years old, 39.3% women, BMI 25.0±3.9, duration of diabetes 23±14 years, HbA1c 7.7±1.0%, eGFR 89.5±21.9 mL/min/1.73 m². The mean initial sAF was 2.13±0.56 AU (Arbitrary Unit), but significantly increased at T4: 2.48±0.68 (p<0.0001), whereas the mean HbA1c (7.6±0.8%) and eGFR (89.5±21.3 mL/min/1.73 m²) were stable at T4. In multivariate analyses sAF at T4 was associated with sAF at T0 (β=0.75; 95% CI = [0.55 , 0.95], p<0.0001), eGFR at T0 (β=0.07; 95% CI = [-0.12 ; -0.02], p=0.007), mean eGFR (β = -0.07; 95% CI = [-0.13 ; -0.02], p=0.006), and to the variance of HbA1c (β = 0.09; 95% CI = [0.03 , 0.15], p=0.006).

In conclusion, we found that South Asians with T1D presented at a later age, and had more significant macrovascular risk factors than white Caucasians. Interestingly, there was no difference in glycaemic control or prevalence of microvascular complications. As for T2D, these findings have important implications for service delivery and personalized healthcare.

1735-P
The Incidence of Type 1 Diabetes Mellitus in Romanian Children Aged 0-14 Years Increased Constantly
ADRIAN VLAD, VIOREL SERBAN, BOGDAN TIMAR, ALEXANDRA SIMA, MIHAELA VLAD, LAURA DIACONU, DANA ALBASCI, ALIN ALBASCI, ROMULUS TIMAR, ONROCAD STUDY GROUP, Timişoara, Romania

The aim of this work was to analyze the evolution of the incidence of type 1 diabetes mellitus (T1DM) in children aged 0-14 years from Romania, starting year 1996. The primary source for incidence cases was the Romanian Childhood Diabetes Register. The secondary source was represented by the medical records from “Cristian Serban” Medical Center from Buzias, a reference center for pediatric diabetes. The incidence was calculated in the age groups 0-4, 5-9, 10-14, and 0-14 years.

A number of 4,546 new cases of T1DM (2,346-51.6% boys, and 2,200-48.4% girls), aged less than 15 years, were found by both sources. The overall level of ascertainment was 96.8%. The estimated average incidence of T1DM during the studied interval was 7.06/100,000/year (95% CI 6.34 – 7.79). It was similar in boys (7.13/100,000/year, 95% CI 6.83 – 7.43) and in girls (6.99/100,000/year, 95% CI 6.25 - 7.73). The incidence in children aged 0-14 years raised extremely significant (p<0.0001) during the studied interval, being more than double in 2013 (8.71/100,000/year) than in 1996 (4.37/100,000/year), with a mean annual increase of 7.2% (Figure). This trend was noticed for all the age subgroups.

Romania is a country with an intermediate incidence of T1DM in children that showed a continuous increase over the studied interval.
1737-P

ECOLOGICAL STUDY BETWEEN THE INCIDENCE OF TYPE 1 DIABETES AND GEOCHEMICAL DATA IN SARDINIA: NEGATIVE CORRELATION WITH ZINC AND COPPER

MARCO SONGINI, CLARA TARTHERGHTA, CARLA MANNU, ALESSANDRO SANNA, MARIAN J. REWERS, GRAZIELLA BRUNI, PAOLO VALERA, PATRIZIA ZAVATTARI, Cagliari, Italy; Aurora, CO, Terra, Italy

Sardinia has the second highest T1D incidence rate (45/100,000, 0-14 years, 1989-2009) in the world, with an annual increase of 2.2%. The aim of this study was to explore the possibility that exposure to environmental elements (As, Be, Cd, Co, Cu, Mn, Ni, Pb, Sb, Se, Sn, Th, Ti, U, V, Zn) could explain previously reported geographical clustering of T1D in Sardinia. The measurements showed they were mainly derived from stream sediment samples of the Geochemical Strategic Prospecting of Sardinia. Lithological formation threshold values were determined for each element. The formations covered by such data were individually considered, while the others were pooled with formations of the same age and lithology. Sampling units included lithologically homogeneous municipal territories. T1D incidence data for 1989-2009 normalized for the size of each municipality were used. T1D and geochemical data were geo-referenced with a Geographic Information System (GIS) and analysed using correlation matrices. Significant negative correlations were found between T1D incidence and Cu (r=-0.35, p=0.0022) and Zn (r=-0.31, p=0.001), but not the other elements.

These preliminary data may suggest a protective role of environmental exposure to Cu and Zn and development of T1D. It is biologically plausible given the role of Zn in regulation of insulin secretion and in cellular processes of homeostasis and signalling. This ecological study must be validated in a prospective study including individual assessment of zinc and copper content in foods of children developing T1D.

1738-P

PULMONARY FUNCTION AND GLYCEMIC CONTROL

GREGORY L. KINNEY, RYAN W. GAN, LINDSEY DUCA, JOHN E. HOKANSON, MARIAN J. REWERS, JANET K. SNELL-BERGEON, GARY LEBOVICS, ZENOBIA DOTIWALA, CHENGHUI LI, ALAN SCHORR, IFTEKHAR KALSEKAR, TAISIA ISUPOV, ALEX BRUN, PRAVEEN DHANKHAR, AR Langhorne, PA

Reduced pulmonary function has been consistently observed in individuals with type 1 diabetes (T1D) and the mechanism is likely complex. Hyperglycemia has been shown to be associated with reduced pulmonary function but it is not clear whether this reduction is progressive across the range of HbA1c. We examined the association between HbA1c and pulmonary function derived through spirometry.

We performed spirometry on participants in the Coronary Artery Calcification in type 1 diabetes (CACTI) study and calculated the Forcible Expiratory Volume at 1 second % predicted (FEV1pp) and the Forced Vital Capacity % predicted (FVCpp) in controls and those with T1D so models were stratified. Two control participants with type 2 diabetes were excluded. General Linear Models were used to assess the relationship between HbA1c and the outcomes adjusting for SMOKE in all models and diabetes duration in the T1D adults.

121 participants completed spirometry; 47 T1D and 74 Controls. Participants did not differ by sex, asthma or smoking status but differed in HbA1c (T1D 7.7 ± 0.9, Control 5.5 ± 0.4) and race (p=0.01). Participants with T1D had lower FEV1pp (86%, 95%CI 82-90% vs. 98%, 95-100%, p<0.001) and lower FVCpp (89%, 95%CI 82-92% vs. 89%, 95-101%, p<0.001) compared to controls. HbA1c was associated with reduced FVCpp in controls; 14% reduction for every 1% increase in HbA1c (p=0.006) but not with FEV1pp (p=0.08). In T1D participants HbA1c was not associated with FVCpp (p=0.3) or FEV1pp (p=0.9).

1740-P

COMPARISON OF COMORBIDITIES AND RESOURCE USE BETWEEN PRAMLINTEIDE USERS AND GENERAL TYPE 1 DIABETES MELLITUS POPULATION INITIATED ON MEALTIME INSULIN

GARY LEBOVICS, ZENOBIA DOTIWALA, CHENGHUI LI, ALAN SCHORR, JITEKHAR KALSEKAR, TAISIA ISUPOV, ALEX BRUN, PRAVEEN DHANKHAR, White Plains, NY, Indianapolis, IN

Baseline comorbidity burden and resource use in type 1 diabetes mellitus (T1DM) were compared between patients identified as Pramlintide users and those who were not using Pramlintide. Patients with T1DM aged ≥ 18 years of age were identified between January 2010 and September 2013 in MarketScan national claims database. The index date was the date of the first pramlintide prescription claim or, for non-users, the date of the first mealtime insulin prescription. Patients were required to have continuous enrolment during the 12 months before the index date (“pre-index period”). Severity and comorbidity burden were defined by diabetes related comorbidities, Charlson Comorbidity Index, Psychiatric Diagnostic Groupings, and Diabetes Complication Severity Index. Resource use included hospitalizations, emergency room and outpatient visits and related costs (all-cause and DM related). Resource use and disease burden in the pre-index period were compared between the cohorts.

Pramlintide patients with T1DM were older than mealtime insulin initiated T1DM patients (46% vs. 25% above 45 years for T1DM). Pramlintide users had a higher rate of DM related complications (37% vs. 10%). Pramlintide users had more DM related outpatient visits (99% vs. 73%). Mean pre-index DM related total cost was 2.5 times higher in Pramlintide-users than non-users ($8,767 vs. $3,489). Among pramlintide users, there was greater pre-index presence of depression (10% vs. 5%), hypoglycemia (16% vs. 6%).
Clinical and Genetic Predictors of Residual Insulin Secretion in New-Onset Type 1 Diabetes

Paula Jossan, Noah Zaitlen, Srinath Sanda, Type 1 Diabetes TrialNet STUDY GROUP, San Francisco, CA

Type 1 diabetes (T1D) patients experience variable rates of loss of residual endogenous insulin secretion after diagnosis but determinants remain poorly defined. Since several studies have described the impact of variants in beta cell genes on insulin secretion in control populations, we sought to mathematically model both genetic and clinical data to determine factors important to rate of loss of insulin secretion in new onset T1D patients.

A total of 167 patients with T1D within 100 days of diagnosis (age 16.86 ± 8.77 y) who had participated in the placebo arms of several intervention trials conducted through the Type 1 Diabetes TrialNet consortium from 2008-2011 were genotyped for ~200,000 single nucleotide polymorphisms (SNPs) related to metabolic and cardiovascular disease using the Illumina Cardio-MetaboChip. All patients had longitudinal insulin secretion assessed with mixed meal tolerance tests. A total of 344 variants were selected based on their pathway association with insulin secretion and beta cell development. Linear models were constructed to test the effect of these variants on insulin secretion patterns while accounting for clinical parameters such as sex, age, baseline BMI, and baseline HbA1c. All results were corrected for multiple comparisons using the Bonferroni method to determine significance.

No genetic variant or clinical parameter significantly influenced baseline AUC C-peptide. However, both age and genotypy of RBPJ rs3109841 (A/C), a gene involved in beta cell differentiation, were significantly associated with rates of decline in insulin secretion (defined as the change in AUC C-peptide between month 0 and month 6). The addition of each dominant allele (C) significantly reduced the rate of decline in insulin secretion over the first 6 months after diagnosis (p=1.49x10^-4). This data defines novel parameters significantly reduced the rate of decline in insulin secretion over the first 6 months after diagnosis (p=1.49x10^-4). This data defines novel parameters.

Supported By: Hellman Fellows Fund

Meta-GWAS Identifies a Second Locus Associated with Skin Intrinsic Fluorescence

Delnaza Roshandel, Ronald Klein, Barbara E.K. Klein, John MYNARV, Patricia A. CLEARLY, Barbara H. BRAFFETT, Karen M. ENY, David R. SELL, Vincent M. MONNIER, Shelley B. BULL, Andrew D. PATRONS, WESDOR and DCT(UC/EDEC) RESEARCH GROUPS, Toronto, ON; Canada Madison, WI; Albuquerque, NM; Rockville, MD; Cleveland, OH

Skin intrinsic fluorescence (SIF) is a non-invasive marker of advanced glycation end products (AGEs) and an indicator of long-term diabetic complications. AM12 has been identified as a major locus influencing SIF. Here, we aim to identify additional genetic loci influencing SIF in type 1 diabetes (T1D) subjects.

We performed meta-analyses of 2 GWAS in T1D subjects, Epidemiology of Diabetes Interventions and Complications (EDIC) and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) (n=1081 and 278, respectively). Ungeno-tify additional genetic loci influencing SIF in type 1 diabetes (T1D) subjects. Identification of a disease-causing mutation would provide insights into the pathogenesis of rare monogenic diabetes as well as common polygenic diabetes.

The Japanese family contained 9 members and 4 of them had been diagnosed with T1D. The 4 affected members had been diagnosed with diabetes at between the age of 15 and 55, all of them had absolute insulin deficiency (fasting serum C-peptide < 0.1nmol/L). We performed WES in the 4 affected members as well as 2 unaffected family members using the Agilent SureSelect Human All Exon V5 kit and an Illumina HiSeq sequencer.

We predicted the familial aggregation of diabetes was caused by a rare non-synonymous variant. WES identified 439 non-synonymous variants present in all 4 affected members and absent in 2 unaffected members. All cases used common variants with minor allele frequency (MAF) of <1% in the 1000 genomes project or in a Japanese exome database, we selected 18 candidate variants that are predicted to be “disease mutations” by MutationTaster. Then we genotyped all family members and 105 Japanese normoglycemic controls for the 18 variants using Taqman method, and 16 of the candidate variants were rare (MAF <1%) in the controls. Among them 2 mutations (p.R608H in ARHGEF11, p.R656C in UASH2) were confirmed in all 18 affected members and were absent in all 5 unaffected family members. The ARHGEF11 gene has been implicated to be involved in glucose metabolism in genetic association studies.

Accordingly, the R608H mutation in the ARHGEF11 gene might be a mutation for susceptibility to T1D. Family-based comprehensive WES is a promising strategy to elucidate the complex genetic background of diabetes.

Whole Exome Sequencing in a Family with Multiple Cases of Type 1 Diabetes Reveals a Candidate Susceptibility Mutation

Byambatsereen Jambaljav, DaiSuke Tanaka, Kazuki Nagashima, Norio Harada, Nobuya Inagaki, Kyoto, Japan

Familial aggregation of diabetes is frequently observed, however the disease-causing genetic variants in numerous families remain obscure. The aim of this study was to investigate the genetic background of a family with multiple cases of type 1 diabetes (T1D) using whole exome sequencing (WES). Identification of a disease-causing mutation would provide insights into the pathogenesis of rare monogenic diabetes as well as common polygenic diabetes.

The Japanese family contained 9 members and 4 of them had been diagnosed with T1D. The 4 affected members had been diagnosed with diabetes at between the age of 15 and 55, all of them had absolute insulin deficiency (fasting serum C-peptide < 0.1nmol/L). We performed WES in the 4 affected members as well as 2 unaffected family members using the Agilent Sure-Select Human All Exon V5 kit and an Illumina HiSeq sequencer.

We predicted the familial aggregation of diabetes was caused by a rare non-synonymous variant. WES identified 439 non-synonymous variants present in all 4 affected members and absent in 2 unaffected members. All cases used common variants with minor allele frequency (MAF) of <1% in the 1000 genomes project or in a Japanese exome database, we selected 18 candidate variants that are predicted to be “disease mutations” by MutationTaster. Then we genotyped all family members and 105 Japanese normoglycemic controls for the 18 variants using Taqman method, and 16 of the candidate variants were rare (MAF <1%) in the controls. Among them 2 mutations (p.R608H in ARHGEF11, p.R656C in UASH2) were confirmed in all 18 affected members and were absent in all 5 unaffected family members. The ARHGEF11 gene has been implicated to be involved in glucose metabolism in genetic association studies.

Accordingly, the R608H mutation in the ARHGEF11 gene might be a mutation for susceptibility to T1D. Family-based comprehensive WES is a promising strategy to elucidate the complex genetic background of diabetes.

Can Genomic Information Aid in Establishing Aetiology of Young Adult Onset Diabetes?

Fotini K. KAVOUDRA, Loukas Moutsianas, Amanda J. BENNETT, Anubha MAHALJAN, Neil ROBERTSON, N. William RAYNER, Christopher J. GROVES, Katharine R. OWEN, Mark I. MCCARTHY, Oxford, United Kingdom

Establishing aetiology for young adult onset diabetes can be a challenge. We assessed if individual genetic risks using known type 1 (T1D) and type 2 diabetes (T2D) risk variants offer useful diagnostic discrimination between major diabetes subtypes. North European subjects (n=715) with diabetes onset -45 years were provisionally classed as T1D (n=293), T2D (n=370) and LADA (n=52), based on pancreatic antibodies, time to insulin use from diagnosis, and c-peptide level. We used common risk variants for T1D (47 variants) and T2D (65 variants), plus high risk and protective variants for T1D in the MHC (23 variants) to calculate weighted Genetic Risk Scores (GRS) for T1D (T1DGRS) and T2D (T2DGRS). Differences in GRS between clinical parameters or diabetes subtypes were estimated with ANOVA or Wilcoxon signed rank test. The area under the receiver operator curve (AUC) was calculated for discriminating T1D and T2D using T1DGRS and T2DGRS.

Higher T1DGRS was associated with diagnosis <18 years (p=2x10^-1), undetectable c-peptide (p=2x10^-4) and insulin as initial or current treatment vs. tablets (both p<1x10^-2). Lower T2DGRS was observed with insulin therapy at diagnosis vs. diet (p=0.002) or tablet use (p=0.04) and with current oral therapy (p=0.0002). The difference in T1DGRS and T2DGRS between T1D vs. T2D cases was highly significant (both p<1x10^-2), and significantly different between T2D vs. LADA subjects (p<0.02 and p=0.001 respectively). Non-T1D cases starting insulin within 1 year of diagnosis had higher T1DGRS compared to the remainder (p=0.0004), thus estimating T1DGRS at diagnosis could aid in tailoring management. The AUC for clinically defined T1D and T2D patients using the T1DGRS and T2DGRS were 79.9% and 63.8%, respectively.

GENETICS—TYPE 1 DIABETES

Guided Audio Tour: Clinical Translation of Novel Genetic Findings (Posters: 1741-P to 1748-P) see page 15

Guided Audio Tour poster ADA-Funded Research

GENETICS—TYPE 1 DIABETES

For author disclosure information, see page A810.

For author disclosure information, see page A810.

For author disclosure information, see page A810.

For author disclosure information, see page A810.

For author disclosure information, see page A810.
Genetic Risk Scores correlate with traditional diabetes classification parameters and differ between clinically defined diabetes subtypes. Genomic information could be a useful adjunct in the differential diagnosis and management of young adult onset diabetes from diagnosis.

Supported By: UK National Institute for Health Research; Oxford Biomedical Research Centre

**1745-P**

**A Novel, Inexpensive Test Can Discriminate between Type 1 and Type 2 Diabetes**

RICHARD A. ORAM, ANITA HILL, TIMOTHY J. MCDONALD, KASHYAP A. PATEL, ANGUS G. JONES, ANDREW T. HATTERSLEY, MICHAEL N. WEEDON, Edmonton, AB, Canada; Exeter, United Kingdom

Background: Rising obesity rates make it more difficult to distinguish between type 1 and type 2 diabetes in young adults. Autoantibodies are positive in ~80% of T1D and diminish over time. There is strong genetic predisposition for T1D that can be measured by Single Nucleotide Polymorphism (SNP) genotyping which is rapid, inexpensive, and stable over time.

Aim: To determine whether a genetic risk score (GRS) generated from common T1D risk SNPs could be used to predict insulin deficiency.

Methods: We developed a GRS from published T1D associated SNPs. We tested the ability of the score to distinguish clinically defined T1D and T2D in the Wellcome Trust Case Control Consortium (WTCCC, n=3887), and to identify progression to insulin deficiency (C-peptide negative > 3yrs post-diagnosis) in a cohort of 198 individuals diagnosed between 20-40 years where diagnostic uncertainty is common.

Results: The GRS was highly discriminative of T1D and T2D in the WTCCC (ROC-AUC=0.87, R0.0001). A low score was indicative of T2D (GRS>0.28, 95% specific, 41% sensitive). A high score was indicative of T1D (GRS>0.33 score <0.28 and negative genetic test were similar to monogenic patients. Conversely, 65/107 patients with diabetes (9.5% vs. 0.4%, p<0.0001), less syndromic presentation (14% vs. 35%, p<0.0001), had higher birth weight (2.8 vs. 2.5 kg, p<0.0001), higher autoimmune diseases (22% vs. 18%, p<0.0001), higher C-peptide level, we quantified miRNA levels in HepG2 cells with si-RNA knockdowns of HNF1A or HNF1B. We identified 4 miRNAs that were significantly differentially expressed between HNF1A and HNF1B.

In conclusion, GRS is a useful tool to differentiate monogenic diabetes from T1D. Using it identified 7% neonatal diabetes patients ~6months with very early onset T1D that should be excluded from further in-depth genetic analysis to identify novel monogenic cause of diabetes.

Supported By: Diabetes UK

**1746-P**

**Type 1 Diabetes Genetic Risk Score—A Novel Tool to Differentiate Monogenic Diabetes from T1D**

KASHYAP A. PATEL, MICHAEL N. WEEDON, SIAN ELLARD, RICHARD A. ORAM, ANDREW T. HATTERSLEY, Exeter; United Kingdom

Identifying the novel monogenic causes of young-onset diabetes is greatly facilitated if patients with polygenic type 1 diabetes (T1D) can be robustly excluded. We aimed to assess whether T1D genetic susceptibility can be used to differentiate patients with monogenic diabetes from T1D. Genetic susceptibility was captured using weighted genetic risk score (GRS) based on 33 T1D associated common genetic risk variants. The GRS was validated in known monogenic MODY (m.843) and T1D (n=1636) patients where it showed excellent discrimination (mean score ±SD, 0.23±0.03 vs. 0.28±0.03, ROC-AUC 0.87, p<0.0001). 50% T1D and only 6% MODY patients scored >0.28 whereas 52% MODY and only 5% T1D patients had score >0.23. Odds Ratio for monogenic cause with a score >0.23, 0.24-0.27 and >0.28 was 83, 7 and 1 respectively.

Next, we compared the utility of GRS against a genetic test for all 23 causative genes in MODY. Genetic test confirmed monogenic etiology in 90% (241/267) patients with a score >0.23, 85% (222/261) with a score 0.24-0.27 and only 40% (29/71) with a score >0.28. Only 6% confirmed monogenic patients had a score >0.28. These results suggest that 42/107 patients with score >0.28 and negative genetic test were likely to have T1D rather than a novel genetic cause. In keeping with this, these patients presented older (13 vs. 6 wk, p<0.0001), had higher birth weight (2.8 vs. 2.5 kg, p<0.0001), higher autoimmune disease (9.5% vs. 0.4%, p<0.0001), less syndromic presentation (14% vs. 35%, p=0.004) and less consanguineous parents (9.5% vs. 25%, p=0.03) compared to confirmed monogenic diabetes patients. Conversely, 65/107 patients with score <0.28 and negative genetic test were similar to monogenic patients.

In conclusion, GRS is a useful tool to differentiate monogenic diabetes from T1D. Using it identified 7% neonatal diabetes patients ~6months with very early onset T1D that should be excluded from further in-depth genetic analysis to identify novel monogenic cause of diabetes.

Supported By: ADA-Funded Research

**1747-P**

**Monogenic Diabetes in Slovakia—Results of the Slovak Nationwide Survey Carried Out over the Years 2004-2014**

DANIELA GASPERSKIOVA, JURAJ STANKI, LUCIA VALENTINOVA, MIROSLAVA HUCKOVA, DANIELA STANKOVA, DANIEL DANIS, MARTINA SKOPKOVÁ, THE SLOVAK MONOGENIC DIABETES STUDY GROUP, IWAR KLUMES, Bratislava, Slovakia

Maturity Onset Diabetes of the Young (MODY) is a heterogeneous group of monogenic diabetes with early onset, familiar appearance, and autosomal dominant inheritance. The aim of this study was to identify the etiology of the Slovakian families with the clinical suspicion on the monogenic diabetes by the DNA analysis of the known MODY genes.

Methods: 933 patients from 409 families were recruited from the diabetes outpatient clinics throughout Slovakia during the last decade (2004-2014). Relevant genes responsible for monogenic diabetes (GCK, HNF1A, HNF1B, HNF4A, NEUROD1, KCNJ11, insulin, and ABC2B) were sequenced and MLPA analyzed. The m.3243A>G mutation responsible for MODY (maternally inherited diabetes and deafness) syndrome was analyzed using real-time PCR.

Results: patients from 119 families had a mutation in one of the target genes: 72 probands and their 105 family relatives had a mutation in the GCK gene, 32 probands and their 40 family relatives had a mutation in the HNF1A gene. 4 probands and 2 family relatives had a mutation in the HNF4A gene, one proband had a mutation in the insulin gene, 2 probands had a HNF1B whole gene deletion and 8 probands with 10 relatives were carriers of m.3243A>G mutation. No KCNJ11, ABC2B and NEUROD1 gene mutation carriers were found.

Conclusions: Out of 933 patients from 409 families with clinical suspicion for monogenic diabetes, the diagnosis was confirmed in 276 patients from 119 families, which represents 29% from referred probands. 69 different mutations (from which 25 are novel) were found in 4 out of 8 analyzed genes. The minimal prevalence for MODY is estimated to be 55 cases per million of inhabitants and represents 0.08% of all diabetic patients. The most prevalent MODY subtype in Slovakia is GCK-MODY representing 63% of all MODY.

This is consistent with data from Poland, Germany and Czech Republic, where predominantly the pediatric population is analyzed. Opposite exists in UK, where the recruitment of rather adult patients is taking place.

Supported By: APVV10-12

**1748-P**

**Differential Expression of microRNA in MODY**

WOJIECH FENDLER, KASHYAP PATEL, JUSTYNA JANKIEWICZ, MACIEJ BOROWIEC, JOANNA MADZIO, MACIEJ T. MALECKI, MAGDALENA SZOPA, PRZEMYSŁAW JAROSZ-GHOBIOT, MAŁGORZATA MYSŁIWIEC, ANDREW T. HATTERSLEY, AGNIESZKA DZIBRZYNN, SIAN ELLARD, WOJIECH MIYNIŃSKI, Łódź, Poland; Exeter; United Kingdom; Warsaw; Poland; Kraków; Poland; Katowice; Poland; Gdansk, Poland.

Transcriptional regulation of miRNAs coded by non-intronic genomic sequences is unclear and we hypothesized that transcription factors may be implicated in this process. This may result in altered profiles of serum miRNAs in forms of MODY caused by mutations of transcription factor genes.

The study was performed on two groups of subjects. The Polish cohort (N=60) consisted of 11 patients with HNF1B-MODY, 17 with HNF1A-MODY, 11 with GCK-MODY, an HbA1c-matched type 1 diabetes (T1DM) group (n=30) and 10 healthy controls. As a validation group, 61 clinically matched British patients were used mirroring the groups in the Polish one. The Polish group underwent miRNA serum levels profiling with qPCR arrays (Exiqon, Denmark) to identify differentially-expressed miRNAs. Validation was performed using qPCR. To determine whether serum expression reflects alterations at cellular level, we quantified miRNA levels in HepG2 cells with siRNA knockdowns of HNF1A or HNF1B.

Significant differences (adjusted p<0.05) were noted for 11 miRNA. Six of them differed between HNF1A-MODY and HNF1B-MODY, 11 with GCK-MODY, an HBA1c-matched type 1 diabetes (T1DM) group (n=30) and 10 healthy controls. As a validation group, 61 clinically matched British patients were used mirroring the groups in the Polish one. The Polish group underwent miRNA serum levels profiling with qPCR arrays (Exiqon, Denmark) to identify differentially-expressed miRNAs. Validation was performed using qPCR. To determine whether serum expression reflects alterations at cellular level, we quantified miRNA levels in HepG2 cells with siRNA knockdowns of HNF1A or HNF1B.

In summary, we identified 4 miRNAs that seem to be specifically dependent on HNF1B-transcriptional control.

For author disclosure information, see page A810.
Epidemiology/ Genetics

Unmasking Genes Controlling How CD4+ T-Cells Pathogenically Activate Type 1 Diabetes-inducing CD8+ T-Cells

CHENG YE, BRITTNEY NEWBY, CLAYTON E. MATTHEWS, JOHN P. DRIVER, Gainesville, FL

Most beta-cell destruction in type 1 diabetes (T1D) is due to the cytotoxic effects of autoreactive CD8+ T-cells that rely on CD4+ T-cell help for their activation. Here we report that this process is in part controlled by our previously described T1D susceptibility locus on distal chromosome 11 (Idd32), discovered through a first-backcross between diabetes-susceptible NOD mice and diabetes-resistant C57BL/6 (B6) mice congenic for the NOD-derived H2Kb MHC haplotype (B6.H2Kb). In adoptive transfer studies we found that lymphopenic recipients injected with CD8+ T-cells transgenically expressing the diabetogenic A4 TCR were completely resistant and susceptible to T1D when co-injected with CD4+ T-cells from donors respectively expressing heterozygous (Idd32<sup>2Kb</sup><sup>B6</sup>) or homozygous (Idd32<sup>B6</sup><sup>B6</sup>) B6 alleles at Idd32. Diabetogenic Idd32<sup>B6</sup> CD4+ T-cells required CD40-CD40L interactions to pathogenically activate A4 T-cells. Surprisingly, protective Idd32<sup>2Kb</sup><sup>B6</sup> CD4+ T-cells inhibited A4 T-cell activation through a mechanism that requires interferon-γ (IFNγ), suggesting a pro-inflammatory role. In support that our findings are clinically significant, pre-activation with IFNγ reduced the cytotoxicity of human diabetogenic CD8+ T-cells used in a cell-mediated lympholysis assay. Our results are important for addressing how CD4+ T-cells control when tissue-specific CD8+ T-cells, which harmlessly circulate in most individuals, sometimes become pathogenically activated. They are also important for interventions to block this disease-critical process.

Supported By: American Diabetes Association (11-14-BS-051 to J.P.D.)

Immunological Characteristics of Patients with Type 1 Diabetes (T1D) from Sao Paulo City in South America


Genetic factors influence autoimmune manifestations of T1D. T1D incidence is low in South America where few data are known. To analyze the autoimmune manifestations of 865 T1D patients and 787 health controls attended in a city with high ethnic admixture, insulin and extra-pancreatic autoantibodies (Abs) were analyzed: glutamic acid decarboxylase (GAD65), tyrosine phosphatase IA2, insulinoma associated protein-2 antibody (IA-2A), insulin autoantibody (IAA) and zinc transporter 8 antibody (ZnT8A) were detected by radio-immunoprecipitation assay (RIPA). The results indicated that the distribution of allele and genotype frequencies of AFF3 gene polymorphisms did not exhibit significant difference between T1D patients and healthy controls (p>0.05). However the distribution of alleles rs10865035 in AFF3 differed between T1D and healthy controls (p=0.034). We also found that the results of the allele G and genotypes AG/GG of SNP rs10865035 revealed an association with T1D risk (p=0.05). Furthermore, AFF3 rs10865035 polymorphisms allele frequency of T1DM patients was related with the positive rate of any islet autoantibodies (2Ab) (p=0.32, p=0.037). In conclusion, AFF3 polymorphisms may influence T1DM developing, but do not seem to be associated with T1D in Chinese population.

Supported By: National Natural Science Foundation of China (30973398, 81101466), Jilin University (2012214)

Association of AFF3 rs10865035 Polymorphisms with the Risk of Type 1 Diabetes Mellitus and Autoimmune Thyroid Disease in a Chinese Population

LIRAN XIE, YU LIU, SHUHAN MENG, MAOGUANG YANG, YAN CHENG, Changchun, China

AFF3/FMR2 family, member 3 (AFF3) encodes a tissue-restricted nuclear transcriptional activator that may function in lymphoid development, and thus influence immunologic response. There were several studies reported AFF3 gene associated with the incidence of type 1 diabetes mellitus (T1DM) in Caucasian, and we hypothesize that single-nucleotide polymorphisms (SNPs) within AFF3 may also be some autoimmune diseases susceptibility loci. So the aim of this study was to investigate the association of rs10865035 polymorphisms with the two autoimmune diseases - type 1 diabetes mellitus (T1DM), autoimmune thyroid disease (AITD) susceptibility in Chinese population. We enrolled 246 children and adolescents with T1DM, 135 patients with AITD and 252 healthy individuals of China origin. The AFF3 gene polymorphisms was genotyped by PCR-direct sequencing, and the serum levels of glutamic acid decarboxylase 65 antibody (GADA), insulinoma associated protein-2 antibody (IA-2A), insulin autoantibody (IAA) and zinc transporter 8 antibody (ZnT8A) were detected by radio – immune precipitation assay (RIPA). The results indicated that the distribution of allele and genotype frequencies of AFF3 gene polymorphisms did not exhibit significant difference between AITD patients and healthy controls (p>0.05). However the distribution of alleles rs10865035 in AFF3 differed between T1DM and healthy controls (p=0.034). We also found that the results of the allele G and genotypes AG/GG of SNP rs10865035 revealed an association with T1DM risk (p=0.05). Furthermore, AFF3 rs10865035 polymorphisms allele frequency of T1DM patients was related with the positive rate of any islet autoantibodies (2Ab) (p=0.32, p=0.037). In conclusion, AFF3 polymorphisms may influence T1DM developing, but do not seem to be associated with AITD in Chinese population.

Supported By: National Science Center of Poland (2012/05/EN29/02330), Ministry of Science and Higher Education of Poland (IP2011 054571)
1753-P

Epigenomic Profiling of Primary Human T Cells Reveals Enhancers Associated with Type 1 Diabetes Susceptibility

PENG GAO, SARAH E. SALAMATI, YASIN UZUN, BING HE, EVA TSALIUKAN, JUILE COFFEY, KAI TAN, Iowa City, IA

Genome-wide association studies have so far revealed more than 90 genomic regions that are associated with an increased risk of type 1 diabetes (T1D). But very few successful findings of actual etiologic SNPs were reported. The noncoding region represents 98.5% of the genome. Given the abundance of functional non-coding sequences in the genome, many SNPs, if they contribute to disease, likely impact by activating the noncoding genome and being involved in a regulatory function. Here, we present an integrative approach to rapidly and successfully screen candidate causal SNPs that reside in gene-distal enhancers. Using ChiP-Seq and primary T lymphocytes from subjects with T1D and healthy controls, we have generated genome-wide location maps of three histone modification marks, H3K4me1, H3K4me3, and H3K27Ac. We identified many genomic loci with altered epigenetic modification states between T1D subjects and healthy controls. Using histone modification signature, we identified a large compendium of transcriptional enhancers in both cell types. The enhancer compendium is enriched for GWAS SNPs associated with T1D and other autoimmune diseases. By linking enhancers and their target genes using our published algorithm, we were able to construct and compare the transcriptional regulatory networks (TRNs) in T1D patients and healthy controls. Using the disease-specific TRNs, we prioritized multiple GWAS SNPs that are high-confidence causal variants associated with T1D. Our study also led to new insights into how genetic and epigenetic factors work together to modulate enhancer activities and how environmental factors influence the pathogenesis of T1D.

Supported By: National Institutes of Health

1753A-P

STAT3 Signaling, But Not Fast-acting Neurotransmitter Release, Is Required For Leptin Action On Euglycemic Restoration In Type 1 Diabetes

YUANZHONG XU, MARTIN G. MYERS, QINGCHUN TONG, Boston, TX, Ann Arbor, MI

Abundant evidence demonstrated that central leptin administration is sufficient for normalizing blood glucose in insulin-deficient type 1 diabetes mellitus (T1DM). Yet, due to the wide distribution of leptin receptor-expressing (LepR) neurons, where and how leptin action in the brain underlies the euglycemia reversal effects remain largely unknown. To address this elusiveness, different mouse models with streptozotocin (STZ)-induced T1DM were treated with intracerebroventricular (i.c.v.) leptin infusion by using osmotic pumps. Despite being required for normal body weight regulation, release of fast-acting neurotransmitter GABA, glutamate or GABA and glutamate from LepR neurons was not required for mediating leptin’s action on euglycemia restoration in STZ-induced diabetic mice. Concurrent with full reversal of euglycemia, normalization of both plasma glucose levels and food intake was induced by i.c.v. leptin treatment in T1DM mice with specific disruption of GABA, glutamate, or GABA and glutamate release from LepR neurons. Interestingly, specific inactivation of signal transducer and activator of transcription-3 (STAT3) signaling in LepR neurons prevented the euglycemia restoration by i.c.v. leptin treatment in T1DM mice, but had no effects on normalization of food intake that was normally associated with euglycemia restoration. We conclude that, in the absence of insulin, functional STAT3 signaling but not release of fast-acting neurotransmitter of LepR neurons, is required for mediating leptin’s antidiabetic action.

Supported By: JDRF

GENETICS—TYPE 2 DIABETES

Guided Audio Tour: Genome-Wide Association Studies and Their Follow-up (Posters: 1754-P to 1761-P), see page 13.

1754-P

Trans-Ethnic Genome-Wide Association Meta-analysis for Glycated Haemoglobin Levels in 159,940 Individuals of European, African American, South and East Asian Ancestry

MARIE-FRANCE IVERT, ELEANOR WHEELER, WANG XIU, WAYNE SHEU, RONA STRAWBRIIDGE, AUDREY Y. CHU, WEIJI HUANG, JAEYOUNG HONG, CHING-TI LIU, MAGIC, AAGILE, AGENT, TAICHI, Boston, MA, Cambridge, United Kingdom, Singapore, Singapore, Taichung, Taiwan, Stockholm, Sweden, London, United Kingdom

Glycated haemoglobin (A1C) is widely used to monitor glucose control and for type 2 diabetes diagnosis. So far, ethnic-specific meta-analyses in exclusively European or East-Asian populations have revealed 17 loci associated with A1C. We investigated genetic determinants of A1C in individuals from four ethnic backgrounds. We combined genome-wide (GW) and Metabochip (Mc) array data available in up to 159,940 non-diabetic participants from cohorts of European (EA: 28 GW, 20 Mc), African American (AA: 9 GW), East Asian (EA: 12 GW, 1 Mc) and South Asian (EAA: 5 GW, 1 Mc) ancestry in an overall trans-ethnic and in ethnic specific meta-analyses. Each cohort performed quality control and imputation according to common standards. GW and Mc results were combined within each ancestry group using a fixed-effects meta-analysis in METAL. We used MANTRA to combine meta-analysis results from all four ancestries. We considered genome-wide level significance when p-value <5x10^-8 in AA or <5x10^-8 in other ancestries in METAL or Bayes factor>5 in MANTRA.

We found 42 novel loci associated with A1C. 38 loci in our trans-ethnic MANTRA analysis, 3 in EA-only, 1 in EAA-only. We also confirmed the 17 known loci and found independent secondary signals at 5 of these loci. Functional enrichment analysis of A1C loci found significant enrichments in blood cell types, as well as fetal development of muscle and intestines. Cross-trait look-ups revealed that many A1C loci were associated with glycemic traits, others with erythrocytic traits, while some are associated with neither, suggesting that biologic determinants other than glucose and erythrocytes contribute to A1C variation.

The novel loci identified expand our understanding of genetic and biologic determinants of A1C variation. The ability to examine interethnic differences in the allelic architecture of A1C is particularly relevant to the use of A1C as a global diagnostic test for diabetes.

Supported By: 2R01DK078616

1756-P


NISA M. MARUTHUR, MAGGIE C. NG, MAN LI, CHING-TI LIU, EDWARD KABAGAMBE, SRIDHARAN RAGHAVAN, STEPHEN RICH, Y-IDA CHEN, JAMES B. MEIGS, ASSOCIATION OF GENETIC DETERMINANTS OF FASTING GLUCOSE AND INSULIN WITH OTHER METABOLIC TRAITS IN THE AFRICAN-AMERICAN GLUCOSE AND INSULIN GENETIC EPIDEMIOLOGY (AAIGLE) CONSORTIUM, Baltimore, MD, Winston-Salem, NC, Boston, MA, Nashville, TN, Charlottesville, VA, Los Angeles, CA

Understanding the genetics of diabetes-related traits in populations of African ancestry (AA) may help elucidate biological contributing to ethnic differences in diabetes outcomes. We evaluated whether SNPs associated with fasting glucose (FG) and BMI-adjusted fasting insulin (FIB) are also associated with other metabolic traits in a multi-ethnic consortium (European ancestry (EA), N=58,074 (FG) and 51,950 (FIB); AA, N=20,209 (FG) and 17,873 (FIB)). We tested cross-trait associations with 30 SNPs: 1) 4 SNPs (1 FG, 3 FIB) with Bayes’ Factor α6 from discovery/replication using Meta-Analysis of Trans-ethnic Association studies (MANTRA) and 2) 26 SNPs transferable to AA in our sample (glucos <0.05) selected from established EA loci (15 FG, 11 FIB). In AA subjects from additional cohorts (N=19,052 to 39,144), 14/30 SNPs were associated with other metabolic traits in the multi-ethnic consortium (European ancestry (EA), N=58,074 (FG) and 51,950 (FIB); AA, N=20,209 (FG) and 17,873 (FIB)). We tested cross-trait associations with 30 SNPs: 1) 4 SNPs (1 FG, 3 FIB) with Bayes’ Factor α6 from discovery/replication using Meta-Analysis of Trans-ethnic Association studies (MANTRA) and 2) 26 SNPs transferable to AA in our sample (glucos <0.05) selected from established EA loci (15 FG, 11 FIB). In AA subjects from additional cohorts (N=19,052 to 39,144), 14/30 SNPs were associated with other metabolic traits in the multi-ethnic consortium (European ancestry (EA), N=58,074 (FG) and 51,950 (FIB); AA, N=20,209 (FG) and 17,873 (FIB)). We tested cross-trait associations with 30 SNPs: 1) 4 SNPs (1 FG, 3 FIB) with Bayes’ Factor α6 from discovery/replication using Meta-Analysis of Trans-ethnic Association studies (MANTRA) and 2) 26 SNPs transferable to AA in our sample (glucos <0.05) selected from established EA loci (15 FG, 11 FIB). In AA subjects from additional cohorts (N=19,052 to 39,144), 14/30 SNPs were associated with other metabolic traits in the multi-ethnic consortium (European ancestry (EA), N=58,074 (FG) and 51,950 (FIB); AA, N=20,209 (FG) and 17,873 (FIB)).

We present evidence suggestive of pleiotropic effects of FIB SNPs in AA subjects. Our results confirm the association of rs6717858 with adiposity-related traits and suggest loci to inform the pathophysiology, including insulin resistance, of metabolic disease in persons of African ancestry.

For author disclosure information, see page A810.
Transcriptional Profiles of Adipose and Muscle Tissue Are Associated with Insulin Sensitivity and Influenced by Genetic Variation in African Americans

NEERAJ K. SHARMA, SATRIA SAJUTHI, JEFF CHOU, LIJUN MA, JORGE CALLES, JAMELH DEMONS, SAMANTHA ROGERS, DAVID MCWILLIAMS, JOHN BEAL, MARY COMEAU, NICOLETTE D. PALMER, LATA MENON, ETHEL IKUBA, DONNA DAVIS, JOYCE BYERS, MARIE BURRIS, SARAH J. BEVLY, LINDA EASTE, DONALD W. BOWDEN, BARRY I. FREEMAN, CARL D. LANGEFELD, SWAPAN K. DAS, Winston-Salem, NC, Cleveland, OH

African Americans (AAs) are more insulin resistant than a higher insulin secretion response to glucose, when compared to age, sex, and BMI matched European Americans. Mechanisms explaining these unique features of AAs are unknown. Transcriptional profiling (Illumina HT12-V4) was performed on subcutaneous adipose and skeletal muscle from 256 fasting non-diabetic AAs (age 18-60 yrs; BMI 19-42 kg/m²) to identify mechanisms associated with insulin sensitivity (SI), evaluated by FSIVGT and glucose homeostasis-related phenotypes. Regression analysis (age, sex and admixture-adjusted) identified positive (1169) and negative (1043) associations of adipose transcripts with S (FDR<1%). Compared to adipose, fewer transcripts were positively (56) and negatively (89) associated with S. Genes positively associated with S were enriched for eIF2, eIF4, p70S6K, and mTOR signaling (p=0.013-2x10⁻¹⁴) in both tissues. Adipose transcripts positively associated with S were enriched for isoleucine and valine degradation (p=0.002); while negatively associated transcripts were enriched for leucokocyte extravasation and toll-like receptor signaling (p=0.002). S associated transcripts were enriched (p=2.5x10⁻¹⁰-2x10⁻¹⁴) for oxidative phosphorylation, with expression in adipose positively associated with S (41 genes) and muscle negatively associated (9 genes). S associated co-expressed transcript modules were also enriched for these pathways. Integration of genotype data (Illumina Onom+Exome) identified cis-regulatory SNPs (FDR<1%) for 83 and 42 S associated transcripts in adipose and muscle, respectively. The TNP7 gene (p=3x10⁻⁶) in adipose and the SEC25 gene (p=2x10⁻⁹) in muscle were the strongest cis-eQTLs among S associated transcripts. This study identified genetic regulatory mechanisms of insulin sensitivity that may explain distinctive physiologic features of glucose homeostasis in AAs.

Supported By: National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases (R01DK090011)
**GENETICS—TYPE 2 DIABETES**

### 1760-P

**KLF14, a Susceptibility Gene of Type 2 Diabetes, Is an Age-related Epigenetic Biomarker in Human and Mice**

Tatsuya Shimizu, Hideyuki Taniyama, Junya Akiyama, Masahiro Ueda, Yutaka Sato, Yuko Suetsugu, Ryoichi Tateishi, Masahiro Hata, Shoichi Yamada, Shigeru Yasui, Yosuke Kaneki, Hidekazu Tanihara, Shun-ichi Washio, Takao Kohno

**Abstract**

KLF14 (Kruppel-like factor 14) is one of the top-down type 2 diabetes (T2D) loci. We previously found that KLF14 expression was increased in aging adipose tissues and aortic arch arteries. In this study, we aimed to reveal whether KLF14 expression is significantly associated with T2D and whether the expression change is caused by DNA methylation alterations. We first tested whether KLF14 expression and DNA methylation status were associated with age and T2D by gene expression microarray analysis and pyrosequencing on the promoter region of human KLF14. We then included these methylation sites and expression changes in a prediction model to examine the impact on the risk of T2D. Finally, we also analyzed whole blood DNA methylation and KLF14 expression in the ADO family, a general population in Japan. Our results indicate that higher KLF14 expression is associated with DNA hypomethylation and that the expression change is consistent with the DNA methylation change. These data suggest that KLF14 expression and DNA methylation status are significantly associated with T2D. Further studies are required to elucidate the mechanisms underlying the association between KLF14 expression and DNA methylation status.

---

**1761-P**

**Gene Editing of the Key Genomic Element within TCF7L2 Using the CRISPR/Cas9 System Reveals an Impact on Gene Expression and Splice Isoform Repertoire**

Qianghua Xia, Sumei Lu, Brian T. Johnston, Matthew E. Johnson, Kevin J. Basile, Struan F.A. Grant, Coleen M. Damcott, Richard B. Horenstein, Braxton Mitchell, Fasil Tekola-Ayele, Adebowale Adeyemo, the AADM Study Investigators, Charles N. Rotimi, Bethesda, MD

**Abstract**

TCF7L2 (transcription factor 7-like 2) is a key gene involved in glucose metabolism and has been associated with type 2 diabetes (T2D) risk. We recently identified a naturally occurring single nucleotide polymorphism (SNP) rs7903146, which successfully removed a 1.4-kb genomic fragment. In order to study the role of this key genomic element within an intron of the CRISPR/Cas9 system to conduct precise gene editing in HCT116 cells in vivo, we generated constructs through leveraging of short guide RNAs (sgRNAs) targeting the 1.4-kb upstream region of rs7903146, which showed significance change in human population samples. Mice were dissected at the age of 4 weeks (young) or 50 weeks (aged), and the expression of KLF14 was reduced in the aged group. In addition, the corresponding protein level was also found to be lower by Western blot analysis. As such, our gene editing data suggest that this genomic element within TCF7L2 is not only susceptibility gene of T2D but also epigenetic biomarker of T2D in the hematological tissues.

**Supported By:** Japan Ministry of Education, Culture, Sports, Science and Technology (22J13003)

---

**1762-P**

**Whole-Exome Sequencing in Multiplex Families Identifies NLRP9 as a Novel Gene for Type 2 Diabetes**

Basil Tekola-Ayele, Adebowale Adeyemo, the AADM Study Investigators, Charles N. Rotimi, Bethesda, MD

**Abstract**

Type 2 diabetes (T2D) is results from the interaction of genetic and environmental factors. Despite the high heritability (30-70%) of T2D, genome-wide association study (GWAS) loci explain less than 10% of the genetic variance of T2D. Moreover, most of the GWAS loci in T2D are non-coding SNPs which make designing experiments for functional validation challenging. Family-based studies facilitate discovery of loci that segregate in multi-generational pedigrees with multiple affected individuals, and whole exome sequencing (WES) approaches are important to identify protein coding variants that may be validated with functional experiments and geared to clinical translation. In the present study we take advantage of these strengths of linkage studies and WES to identify coding variants of deleterious effect using 15 multi-generational African ancestry pedigrees with multiple T2D affected members. A total of 63 individuals with T2D and 26 controls from the 15 pedigrees were genotyped on the Illumina Omni 2.5M array for linkage analysis. In addition, 41 out of the 63 T2D individuals across the 15 pedigrees, and 10 unrelated controls were whole exome sequenced. Genomic regions showing linkage peaks, and screening criteria including deleteriousness, conservation, absence in controls, raresness in human population samples, and presence in at least two T2D affected pedigrees were used to prioritize variants. We found a total of 13 linkage peaks (LOD >1.5), of which one overlap with a shared missense coding variant chr19:6041404 C>T in the NLRP9 gene that shows segregation with T2D in two pedigrees. Two FLNB variants (chr3:58055718 G>C and chr3:58064830 G>C) segregated with T2D in two pedigrees. NLRP9 is a member of the inflammasome complex and is located near a cluster of zinc finger protein genes. In conclusion, our findings suggests that the NLRP9 inflammasome is involved in T2D through detection of metabolic stress and release of proinflammatory cytokines leading to insulin resistance.

---

**1763-P**

**Genetic Variant (R27S) in Insulin-like Peptide 5 Is Associated with Increased Insulin Sensitivity**


**Abstract**

INSLS is an orexigenic peptide secreted by L-cells in the colon. Furthermore, the Rdp4-null mouse, which lacks a receptor for Insl5, exhibits a lean phenotype. To investigate the peptide's role in human biology, we searched for genetic variants in the INSLS gene. Using an exome chip to assess genotypes, we identified a nonsynonymous SNP (R27S; rs148856578) in the INSLS gene with a minor allele frequency of 0.12 in the Old Order Amish, representing a 30- to 1000-fold enrichment relative to non-Amish European populations. A positively charged, basic amino acid (R or K) is evolutionarily conserved at position 27, the 5th amino acid in the B-chain of INSLS. The R27S substitution is predicted to damage protein function, based on in silico predictions by SIFT and GERP++. The R27S allele is associated with fasting insulin levels (2.9±2.2 for S27R-heterozygotes, and 10.7±2.3 mU/L for R27-homozygotes; p=0.004). Moreover, there is a progressive decrease of ~1.2 cm in height for each copy of the S27-allele (p=0.00046), and a trend toward decreased body weight (p=0.08), with S27-homozygotes (N=19) weighing on average 8.2 kg less than heterozygotes (N=35) and 9.4 kg less than R27-homozygotes (N=273). [Statistical analyses for insulin levels and height were carried out using an additive model with corrections for age, gender, and family structure. Data on body weight were analyzed using a recessive model.] These data are consistent with what one would predict for a loss-of-function mutation in an orexigenic peptide. This experiment of nature supports the hypothesis that INSLS has a physiologically relevant role in regulating food intake in humans. Studies are underway to replicate the observed phenotype-genotype associations. For author disclosure information, see page A810.
1765-P

Genetics of Fructosamine and Glycated Albumin in Adults without Known Diagnoses

NISA M. MARUTHUR, MAN LI, JAMES PANKOW, KARI E. NORTH, HAO MEI, AL-ANNA C. MORRISON, ERIC BOERWINKLE, ELIZABETH SELVIN, ANNA KOTTGEN, Baltimore, MD; Minneapolis, MN; Chapel Hill, NC; Jackson, MS; Houston, TX; Freiburg, Germany

Fructosamine (FA) and glycated albumin (GA) reflect average blood glucose over 2-4 weeks. We evaluated genetic determinants of these markers to 1) identify loci unrelated to glucose that may impact their interpretation and 2) to further characterize previously-identified HBA1C and fasting glucose (FG) loci from GWAS in European ancestry (EA) populations in African Americans (AA). For 1), we conducted genome-wide association analyses of serum FA and GA in 7,955 participants of European ancestry (EA) without diabetes in the Atherosclerosis Risk in Communities Study. For 2), we evaluated prior HBA1C and FG SNPs were associated with glycemic markers in our sample of EA (n=7,950) and AA (n=2,171) subjects. 1) Intronic rs10419198 in RCN3 was significantly associated with FA (p=5.6E-10), and nominally associated with GA (p=4.1E-06, with lower FA and GA% per copy of the minor T allele; Table). 2) Rs1402837 (GSPC2) was associated at study-wide significance with GA% and nominally with FA in the EA sample (Table). Variation in RCN3 was previously associated with serum total protein and albumin in East Asian populations. Neither of these loci was previously known to be associated with FA or GA% in EA or AA. While the genome-wide significant association of FA with RCN3 likely due to a non-glycemic effect, the association between GSPC2 and GA% likely represents a glycemic locus, consistent with prior HBA1c findings in EA.

Table. Associations of rs10419198 and rs1402837 with glycemic markers.

<table>
<thead>
<tr>
<th>Gene</th>
<th>rs10419198</th>
<th>rs1402837</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCN3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSPC2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minor allele – European ancestry</td>
<td>T/C</td>
<td>T/C</td>
</tr>
<tr>
<td>1 frequency – European ancestry</td>
<td>0.28</td>
<td>0.22</td>
</tr>
<tr>
<td>1 frequency – African ancestry</td>
<td>0.78</td>
<td>0.31</td>
</tr>
<tr>
<td>1 for (fructosamine)</td>
<td>p value</td>
<td>0.13, 9.6E-10</td>
</tr>
<tr>
<td>1 for (glycated albumin)</td>
<td>p value</td>
<td>0.08, 1.2E-03</td>
</tr>
<tr>
<td>1 for (hemoglobin A1c)</td>
<td>p value</td>
<td>0.04, 4.3E-06</td>
</tr>
<tr>
<td>1 for (fructosamine)</td>
<td>p value</td>
<td>0.063, 1.9E-03</td>
</tr>
<tr>
<td>1 for (hemoglobin A1c)</td>
<td>p value</td>
<td>0.002, 3.2E-01</td>
</tr>
<tr>
<td>1 for (fasting glucose)</td>
<td>p value</td>
<td>0.017, 4.2E-01</td>
</tr>
</tbody>
</table>

Finding from GWAS in EA (p<5E-08 significant).
Study-wide significant (p<7E-04) finding from evaluation of prior hemoglobin A1c and fasting glucose SNPs.

Supported By: R01DK089174

1766-P

Extensive Targeted Next Generation Sequencing Yields a High Diagnosis Rate in Monogenic Diabetes

VALENCIA SCHWITZGEBEL, FEDERICO SANTONI, JEAN-LOUIS BLOUIN, Geneva, Switzerland

Background: Monogenic diabetes represents a heterogeneous group of metabolic disorders resulting from defects in single genes. Defects are categorized primarily into two groups: disruption of beta cell function or a reduction in the number of beta cells. Monogenic diabetes remains undiagnosed in over 90% of subjects, mainly because the access to genetic testing is not available. The aim of our study was to screen a cohort of individuals with suspected monogenic diabetes.

Methods: The selection criteria for testing were the following: neonatal diabetes, syndromic diabetes with extra-pancreatic features, auto-antibody negative type 1 diabetes, type 2 diabetes diagnosed before the age of 30 years or before the age of 40 years without metabolic features. Genetic analysis was performed by high throughput sequencing (all coding and splicing regions of 323 potential diabetes genes). The most prominent variants were confirmed by Sanger sequencing.

Results: We have analyzed 95 diabetic individuals with suspected monogenic diabetes and found variants in 72% of the subjects, in 21% no variants could be detected, in 7% the sequencing has to be repeated. The different genetic results are depicted in Fig. 1.

Conclusions: This testing approach shows a high yield of positive results and could possibly be used as a diagnostic test. Some of the variants have not been published so far and need functional validation.
GENETICS—TYPE 2 DIABETES

The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH): Genomic Risk Scores (GRS) to Predict the Response to Type 2 Diabetes Medications

MARLENE FERNANDEZ, NATALIA COLÓMO, AYESHA MUHAMMAD, LAUREN DEVITA, NICOLE LANDA, SHYLAJA SRINIVASAN, JENNIFER TODD, GEOFFREY A. WALTER, MARÍD HUDSON, ALISON B. GOLDFINE, JOSE C. FLOREZ, SUGAR-MGH, BOSTON, MA

There has been a recent explosion of published genetic associations with glycemic traits. For most of these discoveries, however, the biochemical, functional and clinical relevance are unknown. SUGAR-MGH perturbs different arms of the glucose homeostasis system in humans to uncover the physiology of genetic variants for which no mechanism is known, and also aims to explore if there is a genetically determined response to glipizide or metformin. Participants (n=667) not taking anti-diabetic medications underwent a sulfonylurea challenge, where they received glipizide 5 mg in the fasting state and have blood drawn at regular time intervals. They then take a total of 2000 mg of metformin over the course of 2 days and return for blood draws and an OGTT.

We genotyped variants previously associated with glycemic traits, and constructed 3 GRSs: for fasting glucose (FG), fasting insulin (FI) and β-cell function (HOMA-B). The GRS for each trait was constructed by assigning 0, 1 or 2 at each locus according to the number of trait-raising alleles present at the locus, and summed to provide the overall genetic risk for each diabetes-related phenotype. The median (range) for FG, FI and HOMA-B GRS was 33 (24–49), 23 (12–33), and 23 (15–30), respectively. The 3 GRSs showed the expected associations with their respective baseline traits. During the glipizide challenge, the FI GRS was significantly associated with glucose trough (β=−0.4163, SE=0.119, P=0.00303), and remained significant after adjusting for age, sex, BMI, race/ethnicity and baseline FG (β=−0.2219, SE=0.1033, P=0.03). The FI and HOMA-B GRSs were not significantly associated with selected pharmacogenetic endpoints. None of the GRSs was significantly associated with metformin response.

In this interim analysis, SUGAR-MGH shows there is a genetically determined response to glipizide beyond FG levels, which might help predict hypoglycemia to a sulfonylurea.

Supported By: Swiss National Science Foundation

1768-P

Population-based Linkage Analysis Reveals a Major Locus for Triglycerides in a Founder Population at High Risk for Type 2 Diabetes

WEN-CHI HSUEH, ANUP K. NAIR, SAYUKO KOBES, LESLIE J. BAER, ROBERT L. HANSON, PHOENIX, AZ

Population-based linkage study offers an efficient way to identify quantitative trait loci (QTL) in founder populations, including loci with multiple and/or rare variants that are harder to detect in association studies. We used this method to identify QTLs for lipid measures in Pima Indians, who are at high risk for type 2 diabetes (T2D). Measures of total cholesterol, HDL-C, and triglycerides (TG) were obtained from 1,024 Pima Indians (mean age=42±12 years, 55% females, and 46% with T2D) with genome-wide SNP data. The percentage of identical by descent allele sharing (%IBD) for all ~800,000 pairs of subjects was estimated based on ~400,000 SNPs with Beagle.

We conducted genome-wide linkage analyses, adjusting for age, sex, T2D status and a population stratification estimate from our GWAS. We identified 2 linkage signals with LOD > 3 (LOD=3.9) for TG on chr. 11q and 4.1 for HDL-C on chr. 1p explaining 10.8% and 7.9% of total trait variance respectively. Power analyses indicated 85% power to detect a QTL accounting for 10% of variance; thus, we focused on TG for subsequent analyses. Conditional measured genotype analyses identified 3 independent variants that explained nearly the entire linkage signal for TG. The SNP with the strongest association (rs147210663, β=−1.5*10E-13) reduced the LOD from 9.3 to 2.2, and explained 6.9% of variance in TG. This SNP predicts a functional A43Thr in PPARA3, the Thr allele is rare in most global populations but occurs in ~5% of Pimas. The association of this SNP with TG was replicated in a second sample of 1,863 Pimas (p=2.7*10E-17, and p=7.9*10E-39 for 2 samples combined). Carriers of the Thr allele had, on average, a >40% reduction in TG levels compared to non-carriers (85.7±59.2 vs. 149.2±116.5mg/dl) with no interaction with T2D (p=0.90). In summary, we identified two major QTLs for lipids in Pima Indians. One mapped to APOC3 and functional variation at this locus may reduce TG levels in diabetic and nondiabetic individuals.

For author disclosure information, see page A810.
of Type 2 Diabetes

GENETICS—TYPE 2 DIABETES

1772-P

Genetic Variants in the Lanosterol Synthase Gene Are Associated with Type 2 Diabetes

NAOKI KANEMASU, KOU KAMOTO, KENJIRO HONDA, AKIRA SAITO, MIHO TAKIZAWA, MAKIKO OGATA, KAZUKI YASUDA, TORBEN HANSEN, OLUF PEDERSEN, OTAKA YOKO, KYONG SOD PARK, WEIPING JIA, CHENG HU, YASUKO UCHIGATA, KATSUSHI TOKUNAGA, Tokyo, Japan; Copenhagen, Denmark; Seoul, Republic of Korea, Shanghai, China

Based on the results of genome-wide linkage analysis of T2DM in Japanese and fine mapping of the candidate region on chromosome 21q (Diabetes 52:209, 2003), we identified a statistically significant association between the single nucleotide polymorphism rs2075906 in the lanosterol synthase (LSS) gene and T2DM which was further replicated in Koreans (rs2075906 P=1.3 x 10^{-8}; odds ratio=2.1, 95% CI: 1.1-4.0). In Europeans, the T allele of rs7282252 which is in perfect LD with rs2075906 showed no significant association with T2DM. However, the DIAGRAM investigators did find a weak association signal (rs2399329: P=4.9 x 10^{-8}, located 30 kb downstream from LSS in C2orf56; replication of this association was not observed in Japanese (control genotypes 2.695/45630; cases, 2.212/39331; Pallele=0.01, OR=1.06). The most significant SNP, rs2075906 in Asians, was located in the Y1 motif of the LSS protein, and the risk genotype was associated with increased LSS expression in mononuclear cells in healthy individuals. In conclusion, we identified a novel T2DM susceptibility gene, LSS, in Asian populations and increased expression of this gene increased risk of T2DM.

Supported By: Japan Ministry of Education, Culture, Sports, Science and Technology

1773-P

Functional Investigations of the Monogenic Diabetes Gene HNF1a Identify Rare Variants as Risk Factors for Type 2 Diabetes in a General Population

LAENA A. NAJMI, INVIGL AUKRUST, JASON A. FLANNICK, JANNE MOLNES, NUNU BURTT, ANDERS MOLNES, LIF GROUP, STEFAN JUHANSSON, DAVID M. ALSTHUER, LISE BJORKHAUG GUNDESEN, PÅL NUBLUSTAD, Bergen, Norway; Boston, MA, Malmt, Sweden

The role of rare genetic variants in common disease is currently not well known. In a previous study, we found that a significant fraction of individuals from the Framingham and Jackson Heart Studies carry rare protein damaging variants in one of seven monogenic diabetes genes although most individuals were euuglycemic. To investigate whether functional characterization of such variants can improve disease risk prediction, we studied all non-synonymous coding variants in the most common of the seven monogenic diabeties genes, HNF1a, identified among 4,033 individuals in the Framingham and Jackson Heart Studies. Of 27 rare HNF1a variants, in silico prediction tools reported four variants as putative pathogenic but nondiabetes related diabetes was detected. All variants were functionally investigated focusing on effect on HNF-1a transcriptional activity (luciferase reporter assay in HeLa cells), DNA binding (Electrophoretic Mobility Assay) and subcellular localization (immunofluorescence). By functional investigation, eight variants were characterized as functionally damaging based on the mutant proteins demonstrating impaired HNF-1a function (reduced DNA binding and/or transcriptional activity, <50%, or reduced nuclear translocation). Moreover, the clinical phenotype of carriers with functionally affected variants was significantly associated with diabetes (p=8.1 x 10^{-4}, OR=6.33; CI 2.22-18.1). Thus, functional evaluation of rare variants in individuals carrying rare HNF1a variants needed an estimaterisk of developing type 2 diabetes.

Supported By: National Institutes of Health (1ZIAHG200362, 3T37TW00041-032), National Center for Research Resources; National Human Genome Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases (DK-54003).

1774-P

WITHDRAWN

Polymerisms in the ESRR1 and ESRR2 Genes Are Associated with Type 2 Diabetes in Females of Mexican-American Families

MANU MAMTANI, HEMANT KULKARNI, SATISH KUMAR, THOMAS D. DYER, LAURA ALMASY, MICHAEL C. MANHANE, RAVIDRANATH DUGIRGALA, ANTHONY DOMUZZIE, JOHN BLANGERO, JOANNE E. CURRAN, Hartiggen, TX; San Antonio, TX

Increasing evidence suggests a potential role of two estrogen receptors (ERα and ERβ) in the causative web of type 2 diabetes (T2D). We probe whether single nucleotide polymorphisms (SNPs) within 10 kb of the ESRR1 and ESRR2 genes (which encode ERα and ERβ, respectively) are associated with T2D in females.

We used the rich data from the San Antonio Family Heart Study of Mexican-Americans. We included 327 and 165 SNPs around the ESRR1 and ESRR2 genes, respectively. Analysis was done in three steps: i) measured genotype analyses (MGA) implemented in SOLAR software for T2D as a discrete trait; ii) construction of gene-specific propensity scores using the allele dosages and the regression coefficients from MGA; and iii) testing association of the propensity scores with T2D. All models were adjusted for age, baseline waist circumference, serum triglycerides, systolic and diastolic blood pressure, top four principal components reflecting population ancestry and use of anti-hypertensive and lipid lowering drugs. Clinical utility was evaluated with integrated discrimination improvement (IDI) and net reclassification improvement (NRI).

We studied 827 women, 21% of whom had T2D (31% had T2D at baseline and 80 developed T2D during 6,897 person-years of follow-up). Thirty two (9.8%) and 12 (7.2%) SNPs in ESRR1 and ESRR2 were significantly associated with T2D. Propensity scores for both ESRR1 and ESRR2 were significantly associated with T2D (p<2.7x10^{-10} and 3.6x10^{-7}, respectively). The IDI and NRI values for ESRR1-specific score were 0.0563 and 0.4584 (p=5.6x10^{-10} and 1.2x10^{-8}, respectively) while those for ESRR2-specific score were 0.1917 (p=1.7x10^{-5} and 1.8x10^{-7}), respectively. Thus, strong evidence for the association of ESRR1 and ESRR2 with T2D in Mexican-American females was found. Additional studies using gene expression, hormonal levels and their interactions are warranted. If substantiated, our results provide new drug targets for T2D treatment in females.

Supported By: National Institutes of Health (R01DK028210, R01DK079168, R01DK045522, R37M095498).

1775-P

Identification of Novel Genes Contributing to Autosomal Dominant Diabetes by Whole-Exome Sequencing

PRAPPARN JUNTRAJKORN, PATNUTI BURANASUPAKIJORN, TIMOTHY HASTINGS, JUN SHIRAKAWA, MARCUS PEZZOLESI, CHRISTINE MENDONCA, ROHIT N. KULKARNI, ALESSANDRO DORIA, Boston, MA

A total of 13 genes for maturity-onset diabetes of the young (MODY) have been identified to date. However, additional causative genes still remain unknown for >15% of MODY cases and for almost all of the other forms of autosomal dominant diabetes presenting at an older age than MODY. To identify these genes, we conducted a whole exome sequencing (WES) study in 52 multigenerational families with autosomal dominant diabetes and without evidence of mutations in known MODY genes. The mean age at diagnosis was <25, 25-35, and >35 years in 15, 26, and 11 of the families, respectively. After applying QC and frequency filters, candidate causative mutations (i.e., rare variants segregating with diabetes and predicted to have a functional impact) were identified in a total of 82 genes. Among these were mutations in 3 genes that had an established role in β-cell function and/or had been previously implicated in neonatal diabetes. These included G182E in HGF (Hepatocyte Growth Factor), P778S in RXFB (Regulatory Factor X B), and 3850G in SLCA192 (Solute Carrier Family 19 [Thiamine Transporter Member 2]). HGF is a growth factor promoting β-cell proliferation. Based on in silico modeling, the G182E mutation creates new H-bonds with surrounding amino acids, potentially altering HGF conformation. RXFB and SLCA192 were recently described as the causes of syndromic forms of neonatal diabetes - the Mitchell-Riley and the
thiamine-responsive megaloblastic anemia (TRMA) syndromes, respectively. This preliminary WES analysis points to mutations in H67F, RRX6, and 3LC1H42 as contributing to the etiology of autosomal dominant diabetes risk due to known MODY genes. In vitro experiments are in progress to determine the functional impact of these mutations as well as those identified by WES in genes with less obvious links to glucose homeostasis.

Supported By: National Institutes of Health (R01DK55253)

177-P Variants Associated with HDL-C Levels: Assessment for Association with Type 2 Diabetes in American Indians

ANUP K. NAIR, NELLIE MCLEAN, PAOLO PAOGLI, MANNEET KAUR, WEN-CHI HSUEN, SAYUKO KOBES, WILLIAM C. KNOWLTON, CLINTON BOGDARUS, ROBERT L. HANSON, LESLIE J. BAIR, PHENIX, AZ

Previous epidemiological studies in Pima Indians have identified a protective role for higher HDL-C against the onset of T2D in women. In this study, we analyzed 35 SNPs from established HDL-C loci for association with HDL-C, T2D and related traits. Genotyping and analysis of these SNPs in 2,717 full-heritage Pima Indians informative for T2D status and lipid levels identified a significant association (P<0.05) for 14 SNPs with HDL-C. An un-weighted multiallelic genetic risk score analysis (GRS) including the 35 SNPs was significantly associated with HDL-C (P=5.0×10⁻¹⁰), however the 21 SNPs not associated with HDL-C did not have any effect on HDL-C levels even in combination (GRS [21 SNPs], P=0.08). Therefore, only 14 SNPs were further genotyped in 4,993 American Indian samples informative for T2D (2,777 informative for lipid levels) and analyzed for association with HDL-C, T2D and related traits in the combined sample. In this analysis, 6 of the 14 SNPs at the CETP, PONP, PPARδ2, ABCG1, APOA1-C3-A4-A5 and ABCA1cis reaches genome wide significance (P<4.0×10⁻⁵) for HDL-C association. The GRS analysis including the 14 loci in the combined samples negatively correlated with HDL-C levels (β=-0.02/dL, P=3.1×10⁻⁶) and had a strong positive correlation with insulin resistance as estimated by homeostasis assessment (HOMA-IR, β=0.015/dL, P=0.015). The GRS correlated positively with T2D (P=0.007, OR=1.03), but there was no interaction with gender (P=0.74). When analyzed individually, SNPs at the CETP, HMG4, and KLF4 loci significantly associated with type 2 diabetes only in female subjects (3.2×10⁻⁵ to 7.7×10⁻⁶) such that the HDL-C lowering allele increased the risk for T2D. The T2D risk loci for the SNPs at the CETP and KLF4 loci were associated with increased insulin resistance in females as estimated by HOMA-IR (P=0.05). In conclusion, our studies suggest a modest effect of the genetic predisposition for lower HDL-C on the risk for T2D in American Indians.

177-P Genetic Architecture of Fasting Plasma Glucose in Pregnancy

MARYSA LEYA, JACKY KARBAN, MICHAEL NODZENSKI, LOREN ARMSTRONG, MARGRET IURBADEN, LYNNE P. LOWE, BOYD E. METZGER, DENISE SCHOLZEN, GREGG GARRETT, WILLIAM L. LOWE, CHICAGO, IL

Pregnancy is characterized by metabolic adaptations that include a decline in fasting plasma glucose (FPG) in the setting of increasing insulin resistance. In non-gravid populations, FPG is heritable and associated with more than 50 genetic loci. Whether the genetic architecture of maternal FPG is similar or different than the non-gravid state is unknown. To address this, we examined the heritability of maternal FPG and 50 genetic regions associated with FPG in non-gravid populations in mothers who participated in the Hyperglycemia and Adverse Pregnancy Outcome (HAPPO) Study. FPG was determined at ≥28 weeks gestation in 1367 European ancestry (EU), 1178 Thai (TH), 1075 Afro-Caribbean (AC) and 817 Mexican-American (MA) mothers. Genome-wide SNP data were obtained using illumina chips and imputation to ~2 million SNPs using HapMap3 reference panels. Heritability of FPG was estimated separately in each of the populations using genome-wide complex trait analysis (GCTA). In a meta-analysis across the 4 populations, heritability was 60 ± 17% (P = 5.8×10⁻⁶), similar to what has been demonstrated in non-gravid populations. For each of the previously-reported 50 genetic loci associated with FPG, we examined association of the lead literature SNP and SNPs in linkage disequilibrium (r²>0.8) with maternal FPG within each ancestry group using linear regression analyses with an additive genotype variable, adjusting for population substructure and other covariates. Meta-analysis was conducted across ancestry groups under a fixed-effects model. To adjust for testing 50 LD blocks, p < 0.001 was considered significant. Five gene regions (PCSK1, MTRNR1B, PPARδ2, G6PC2, GCKR) were associated with FPG in the meta-analysis. In addition to the above genes, in ancestry group-specific analyses, IGFBP2 was associated with FPG in AC mothers. These data demonstrate that FPG is heritable during pregnancy with both overlap and, possibly, differences in genes region that account for the heritability compared to non-gravid populations.

Supported By: National Institutes of Health (R01DK097534)

Epidemiology/Posters

177-P Rs10401670 was Identified as a Possible Functional Variant Affecting Circulating Resistin by a Genome-Wide Search in Japanese

RYOICHI KAWAMOTO, YASHURO TABARA, MIYOHISA IGASE, AKIKO TSUKADA, YASUNORI TAKATA, RYUICHI KAWAMOTO, ISAO SAITO, HIROSHI ONUMA, KATAHIRO KATO, KATSUKIKO KOHARA, HARUHIKO OSAWA, Eshime, Japan; Kyoto, Japan; Nagano, Japan; Tokyo, Japan. Resistin is a cytokine causing insulin resistance. We reported that G/G genotype of single nucleotide polymorphism (SNP) at -420 (rs1826513) in the human resistin gene (RETN) increased susceptibility to type 2 diabetes. SNP-358 (rs2191795) as well as SNP-420, both located in the promoter of RETN was tightly correlated with circulating resistin via a cis-acting effect. Circulating resistin was also affected by tag SNPs around the human decorin gene, identified as a possible resistant receptor, via a trans-acting effect. To identify major quantitative trait loci for circulating resistin, we performed a genome-wide association study of 5708071 SNPs directly genotyped or imputed using references from the 1000 Genome Project in 448 general Japanese subjects. The peak of -logP was found on the chromosome 19 where RETN was located. Previously, the top SNP was SNP-358, followed by rs1423096, SNP-420, and rs10401670 (P<10⁻¹⁴, <10⁻¹⁴, <10⁻¹⁴, and <10⁻¹⁴ respectively). Rs1423096 and rs10401670 were located at 5 kb and 8.5 kb, respectively, downstream from the translation initiation site of RETN and were in the same linkage disequilibrium block. The associations between circulating resistin and these 4 SNPs were replicated in other 2 general Japanese populations (both n=2,000) and meta-analysis (SNP-358, P<10⁻⁵; SNP-420, P<10⁻⁴; rs1423096, P<10⁻⁴; rs10401670, P<10⁻⁴). The analysis of haplotypes showed circulating resistin was associated with rs10401670 independent of SNP-358 and SNP-420, although SNP-420/GSNP-358 A haplotype had the strongest effect. Functionally, nuclear proteins specifically recognized T but not C at rs10401670 in electrophoretic mobility shift assay. The promoter with T at rs10401670 showed lower luciferase activity than that with C in THP-1 cells. Therefore, rs10401670 was identified as a possible functional variant affecting circulating resistin by a genome-wide search in Japanese.

178-P Application of Two-Point Linkage and Association Analysis to Elucidate Genetic Signals of Glucose Homeostasis

JACKLYN N. HELLWEGE, NICOLETHET D. PALMER, LATCHEZAR DIMITROV, JULIE ZIEGLER, CARLOS LORENZO, JILL NORRIS, KENT TAYLOR, RICHARD N. BERGMAN, JEROME ROTTER, CARL D. LANGLEFELD, LYNN E. WAGENKNECHT, DONALD W. BOWDEN, WINSTON-SALEM, NC, SAN ANTONIO, TX, DENVER, CO, TORANCE, CA, LOS ANGELES, CA.

Combining two-point linkage and association analysis provides multi-dimensional support for the relationship of a single variant to a trait of interest, even when the variant does not yield striking results from either analytical method alone. This has been applied to sophisticated measures of glucose homeostasis from the Insulin Resistance Atherosclerosis Family Study using genetic data from the Illumina OmniExpress and HumanExome arrays. Genetic variants contributing to acute insulin response (AIR), insulin sensitivity index (SI), disposition index (DI) and metabolic clearance rate of insulin (MCRI) were evaluated by two-point linkage and association analysis performed for each trait across 750,317 variants in a sample of 1634 Hispanic-American (HA) families. Overall, there were 820 variants with LOD>1 and P<0.05 and 38 variants with LOD>2 and P<0.001. Of the 38, half were contributed by AIR association and linkage from at least 13 independent loci. DI and SI, each contributed eight variants representing 6 and 5 loci, respectively. Some signals of note include MTNR1B (AIR, P=7.60E-05 and LOD=2.05), CAACNA1D (P=4.04E-05 and LOD=2.05), PDE2C (P=2.05E-05, LOD=2.02), and ESRRG (AIR, P=2.05E-05, LOD=3.15). CAACNA1D is a calcium channel involved in insulin release, while PDE2C is a calcium-sensitive phosphodiesterase involved in aural insulin signaling. Several previously implicated diabetes-related loci were represented among those with nominal linkage and association evidence (P<0.05 and LOD>1). Namely, JAZF7 was represented by 5 SNPs with LODs up to 3.38 and p-values as low as 1E-04, and CDK4/1 with LOD scores of up to 2.78 and p-values of 6E-05. Other known loci represented include PPARG, CDKN1A, ADAMTS9, ADR1S, GSU2, ST6GAL1, WWDOX, CAACNA1D, UNCG2, and HMG242, among others. These novel and known signals demonstrate that incorporating two-point linkage analysis can identify meaningful signals that impact glucose homeostasis traits, often in the absence of striking association alone.

Supported By: R01HG007112, R01DK085757
Polygenic Risk Scores in Type 2 Diabetes and Depression

The underlying pathogenesis of the link between type 2 diabetes (T2DM) and depression is complex and to arise from interactions between genetic and environmental factors. Both T2DM and depression are considered polygenic traits and genome-wide association studies (GWAS) allow us to examine overlap in their genetic underpinnings. Polygenic risk scores can be calculated from single nucleotide polymorphisms that each captures modest effects of a trait. The aim of this study is to test whether genetic susceptibility to T2DM is significantly associated with depression status using polygenic risk scores. T2DM polygenic risk scores were derived from the association summary statistics of Diabetes Genetic Replication And Meta-analysis Consortium (34,840 cases and 114,961 controls), at various thresholds of association p-values. Logistic regression was used to test for association between T2DM polygenic risk score and depression status in the RADIANT-UK study (1,624 cases and 1,588 controls) using PRSice software (http://prsice.info). T2DM polygenic risk scores were not significantly associated with depression status (p=0.62; Figure 1). The sample size of RADIANT-UK (n=3,212) may be underpowered to detect true effect. In conclusion, T2DM polygenic risk scores may not be a major contribution to depression genetic susceptibility in this cohort.

Figure 1. Contribution of T2DM polygenic risk score to depression status.

Supported By: European Commission (FP7-27917-1)

A Variant of PSMD6 is Associated with the Therapeutic Efficacy of Oral Antidiabetic Drugs in Chinese Type 2 Diabetes Patients

CHENG HU, MIAO CHEN, RONG ZHANG, WEIPING JIA, TAOUA, PEDRO JARES, RAMON GOMIS, CHRISTOPHE NORMAND, SARA HAYDAR, MEDIGENE CONSORTIUM, Montpellier, France, Ufa, Russian Federation, Barcelona, Spain

The definitive success of GWAS (genome wide association studies) is pending on the ability to control population stratification. The MEDIGENE program was launched among Mediterranean countries for the study of metabolic syndrome (MetS) with the aim to find new population models. Among 6505 DNA samples, 475 samples from lean normal individuals were geographically located by birthplace 2 generations upstream, genotyped with 650,963 SNPs (EUR Chip) and analyzed by Principal Component Analysis (PCA) with SMARTPCA program. A MEDISCOPE micro-array chip was designed containing besides EUR SNPs 107,260 additional SNPs for MetS, including 40 prioritized genes at 10,000 genome or HapMap density while 3898 SNPs were dedicated to anthropological features, including Neandertahl genome. Genotyping with EUR SNPs revealed an extraordinary correlation between of the geographic coordinates for birthplace and PCA eigenvectors. On West side, the most distant were Basque while on the East side the Turkish populations (closed to Turkic-speaking Karachays, Kymys eand Balkars in Russia). Lithuanians and North Africans defined other clusters. While hundreds of SNPs differentiated these clusters, top 10 SNPs were defined for comparative pairs. Between French and Romans 4 genes were different, including interleukin receptor (IL23R). French were also different from Catalans (Spain) by 8 genes, including protein kinase C theta (PRKCQ) while another 9 genes differentiate from North African Tunisians and Algerians, including tumor protein p63 (TP63). These data showed a sufficient genetic distance in Southern Europe and a strong genetic barrier over the Mediterranean Sea to propose new models for GWAS, not only based on autosomal SNPs but also taking the advantage of 1000 times more density. We conclude that considering anthropological markers GWAS will enter in a new era of an extraordinary opportunity to unravel culprit genes in complex disorders.

Supported By: National Basic Research Program of China (2011CB804001, 2012CB945701, 2012CB945702), Shanghai Young Medical Expert of Shanghai (YY20201041), Shanghai Talent Development (2012041), National Young Top Talent Supporting Program
A Genetic Risk Score of 96 Variants Linked with Type 2 Diabetes and Cardiometabolic Risk Traits Is Associated with Cardiovascular Mortality in 29-Years Follow-up of the Framingham Heart Study (FHS)

MARCIO DAURIZ, BLANCA C. PORNEALA, JOSEF DUPUIS, JOANNE M. MURABITO, ADRIENNE L. CUPPLES, JOSE C. FLOREZ, JAMES B. MEIGS, Verona, Italy; Boston, MA

Cardiovascular diseases (CVD) are a major cause of death and are often associated with type 2 diabetes (T2D). Genome-wide studies (GWAS) identified loci associated with T2D, CVD and traits leading to early death. We investigated whether these loci in aggregate carry a higher risk of all-cause and CVD mortality in the FHS. We computed an unweighted genetic risk score (GRS) of 96 variants selected by effect-size within respective GWAS to represent the top 25% of GWAS variants for the following traits: T2D, coronary artery disease, myocardial infarction (MI), stroke, sudden cardiac death, heart rate, long QT-interval, heavy smoking and 15-years-all-cause mortality. We used pooled logistic regressions with genetic-only (GRS adjusted for sex) and full CVD risk factors adjusted models (sex, age, smoking, prevalent non-fatal CVD) to test the association of 96-GWS with all-cause and MI/stroke mortality in 3,426 FHS participants across 29 years follow-up (p=0.025; p=0.052) for significance. Prevalence of non-fatal CVD, T2D and smoking was 7.6, 6.1 and 26.4% at baseline and 18.5, 15.9 and 13.2%, respectively, at the beginning of the last period considered. Cumulative incidence of fatal MI/stroke and all-cause mortality was 5.1 and 22.5%, respectively. The 96-GRS was associated with MI/stroke mortality in both genetic-only (OR95% CI): 1.04[1-1.1], p=0.006) and fully adjusted model (1.04[1-1.1], p=0.009). Association with all-cause mortality did not reach our statistical significance criteria (1.01[1-1.03], p=0.029, genetic-only: 1.02[1-1.03], p=0.034, fully adjusted). An aggregate burden of 96 GWAS variants with the largest effect size on cardiometabolic traits is predictor of MI/stroke death in longitudinal analysis of a large population of European ancestry. Further studies need to specify the impact of cardiometabolic disease genetics on current mortality prediction models.

Supported By: R01DK79616

Prediction of Incident Type 2 Diabetes with Genetic and Nongenetic Risk Factors in Multiple African-American Populations

JILL LAYTON, XIAOCHEN D. CHANG, YU HU, MARY K. DE GROOT, ADOLFO CORREA, LESLIE LANGE, JENNIFER WESSEL, Indianapolis, IN; Jackson, MS; Chapel Hill, NC

The prevalence of type 2 diabetes (T2D) in African Americans (AA) is twice that of European-Americans. Impaired glucose homeostasis is influenced by beta-cell dysfunction (BCD) and insulin resistance (IR). The relationship between genetic risk variants associated with glucose homeostasis and T2D risk has yet to be fully explored in AA populations. We hypothesized that genetic variants in the pathways involved in β-cell dysfunction, insulin resistance or both may improve predictive ability beyond the established demographic and clinical risk factors, and that this relationship is modified by obesity (defined as ≥25% body mass index). To test our hypotheses we pooled data from four population-based, prospective studies (n=5,488 AA) free of T2D at baseline. There were 821 incident T2D cases for a cumulative incidence of 5.9% over 25 years. The BCD GRS and the BCD/IR GRS were significantly associated with increased T2D risk; each risk allele increased T2D risk by 3.7% [HR=1.037, 95% CI: 1.005, 1.070] and 2.9% [HR=1.029, 95% CI: 1.002, 1.056].

For author disclosure information, see page A810.
Epidemiology/Genetics POSTERS

1790-P Comprehensive Second Generation Genetic Diagnosis of Maturity Onset Diabetes of the Young
AARON CHAPA, MUHAN JAMRAJULAM, DENY VARSHNEE, MANIKA VARSHNEY, DODDABEVALANGALU MURTHYUNJAYA MAHESH, FELIX JEBASINGH, MOHAMMED AZHARUDDIN KO, HESARGHATTA SHYAMASUNDER ASHA, SARAH MATHAI, THOMAS V. PAUL, NIKHIL J. THOMAS, Vellore, India

Maturity Onset Diabetes of the Young (MODY) is a monogenic disorder, caused due to a mutation in one of the 13 MODY genes which are primarily involved in β cell development and functioning. Utilizing our previously established cost-effective Second Generation Genetic Diagnosis of MODY (2G-MODY) protocol with the 10 gene panel, a wide spectrum of mutations were identified in 15% of the clinically diagnosed MODY subjects. In the present study we aimed to further develop the 2G-MODY protocol to screen all the known 13 MODY genes. We utilized our improvised 14 multiplex PCRs for gene enrichment followed by sequencing on Ion Torrent Personal Genome Machine (PGM). The 59kb target was sequenced at mean coverage depth of at least 20x and 99% of the target bases were sequenced with a minimum coverage of 20x. We identified mutations in 21% (13/60) of the young onset diabetes subjects screened (mutation Table). These finding were confirmed by Sanger sequencing and the novel mutations were absent in 100 control subjects. This is a first report of a novel KLF11 gene mutation and also two novel digenic mutations involving HFNF4A, HFNF1A and ABCC8 genes from India. The 2G-MODY protocol on Ion Torrent PGM is a flexible, scalable, cost effective, sensitive and specific genetic screening approach in a heterogeneous disorder like MODY.

Table.

<table>
<thead>
<tr>
<th>SNO</th>
<th>Sex</th>
<th>Age</th>
<th>BMI</th>
<th>Acarthritis</th>
<th>DKA</th>
<th>GAD</th>
<th>ADR</th>
<th>GENE</th>
<th>DNA Change</th>
<th>Amino acid Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>38</td>
<td>28.4</td>
<td>AB</td>
<td>AB</td>
<td>AB</td>
<td>3G</td>
<td>*HFNF1A</td>
<td>c.906C&gt;A</td>
<td>p.R302C</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>33</td>
<td>27.1</td>
<td>A</td>
<td>AB</td>
<td>AB</td>
<td>3G</td>
<td>*ABCC8</td>
<td>c.2781G&gt;C</td>
<td>p.R931S</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>31</td>
<td>29.7</td>
<td>A</td>
<td>AB</td>
<td>AB</td>
<td>2G</td>
<td>*HFNF1A</td>
<td>c.895G&gt;A</td>
<td>p.R299G</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>28</td>
<td>27.4</td>
<td>AB</td>
<td>AB</td>
<td>AB</td>
<td>3G</td>
<td>PDX1</td>
<td>c.752C&gt;T</td>
<td>p.R251L</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>32</td>
<td>28.2</td>
<td>A</td>
<td>AB</td>
<td>AB</td>
<td>AB</td>
<td>PDX1</td>
<td>c.675C&gt;A</td>
<td>p.E226K</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>26</td>
<td>22.6</td>
<td>P</td>
<td>AB</td>
<td>AB</td>
<td>3G</td>
<td>*HFNF1B</td>
<td>c.578T&gt;C</td>
<td>p.M193T</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>33</td>
<td>21.3</td>
<td>A</td>
<td>AB</td>
<td>AB</td>
<td>2G</td>
<td>*NEUROD1</td>
<td>c.757C&gt;G</td>
<td>p.R253S</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>17</td>
<td>27.8</td>
<td>A</td>
<td>AB</td>
<td>AB</td>
<td>AB</td>
<td>*NEUROD1</td>
<td>c.757C&gt;G</td>
<td>p.R253S</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>29</td>
<td>28.4</td>
<td>A</td>
<td>AB</td>
<td>AB</td>
<td>3G</td>
<td>*KLF11</td>
<td>c.529C&gt;T</td>
<td>p.R177X</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>29</td>
<td>28.1</td>
<td>A</td>
<td>AB</td>
<td>AB</td>
<td>AB</td>
<td>PDX1</td>
<td>c.529C&gt;T</td>
<td>p.R177X</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>35</td>
<td>23.8</td>
<td>A</td>
<td>AB</td>
<td>AB</td>
<td>2G</td>
<td>*ABCC8</td>
<td>c.979T&gt;C</td>
<td>p.R329W</td>
</tr>
</tbody>
</table>

*Novel mutation, AB - Absent, P - Present, ADHF - Autosomal dominant family history, G-Generation.

Supported By: Council of Scientific and Industrial Research; India Ministry of Science & Technology (to N.J.T.)

1791-P Familial Renal Glucosuria in a Family with Impaired Glucose Control
PETTER VIKMAN, EMILIA UTTOSSON-LAASKONEN, MONIKA GULLSTRÖM, PER-HENRIK GROOUP, LEIF GROOUP, Malmi, Sweden, Närpes, Finland Helsinki, Finland

Background and Aims: Renal glucosuria is a condition where glucose is excreted in the urine despite normal blood glucose levels. A majority of the familial renal glucosuria cases are caused by deleterious mutations in SLC5A2, a gene coding for the SGLT2 transporter responsible for 90% of the glucose reuptake in the kidney. We aim to characterize the underlying genetic cause of glucosuria in a family with renal glucosuria and impaired fasting glucose/impaired glucose tolerance (IGT/IGT) or diabetes and to explore whether glucosuria protects from deterioration of glucose tolerance.

Materials and Methods: We performed exome sequencing of 23 family members, 8 with renal glucosuria. Of the 8 affected individuals, 5 were diagnosed with IGF/IGT or diabetes. Change in glucose tolerance was tested as change in area under the glucose curve (AUCGTT).

Results: A total of 5 variants were found in the sequenced region of SLC5A2, 4 SNVs and one 6 bp deletion. Both snpEff and SIFT ranked the deletion as deleteriously detrimental. The 6 bp deletion removes 4 coding and 2 intronic bases which causes a frame shift and splice site mutation in the third exon with a high probability of functional consequences on the protein. The deletion was seen in 9 individuals, 6 with glucosuria and 3 without, and significantly associated with glucosuria (p=0.023). Of the nine carriers of the deletion, five had IGF/IGT/diabetes; 3 of them also had glucosuria. There was no significant difference in change in AUCGTT over time between carriers and non-carriers of the deletion.

Conclusion: Glucosuria in this family is most likely caused by a deletion in the SLC5A2 gene. The data do not provide any support for the view that increasing glucose excretion in the urine would protect from diabetes.

Supported By: VR, ERC

1792-P Investigation of Novel Type 2 Diabetes QTL in an N20 x DBA/2J Backcross
NICOLE L. HALLAHAN, ANNE KAMITZ, RALPH BURKHARDT, HANS-GEORG JOOST, ANNETTE SCHÜRMANN, Nuthetal, Germany, Leipzig, Germany

The New Zealand Obese (NZO) mouse, a model of human obesity and type 2 diabetes (T2D), was used in the past to identify various quantitative trait loci (QTL) and subsequently pathogenic genes, eg. H202b and Tbc1d1. By backcrossing the NZO mouse with the lean and diabetes-susceptible DBA/J we aim to identify novel T2D genes.

Several metabolic traits of an N20 x DBA/J2 backcross (N2) population were characterized on a high-fat diet (45% fat) and QTL were identified by linkage analysis. Gene expression as well as sequencing data of parental N2O and DBA mice were overlaid with QTL. Recombinant congenic strains (RCS) have been generated through repeated backcrossing of DBA x N2O progeny with selected genotypes to NZO. N4 RCS have been extensively phenotyped by weekly blood glucose and body weight measurements, oral glucose tolerance tests, computed tomography and metabolomics profiling. Pancreata have been additionally analyzed by microarray and immunohistochemistry.

Diabetogenic QTL were identified on chr. 1, 2, 4, 6, 9, 11, 13, 17, 18 and 19. Our data revealed that the strongest T2D QTL (Nidd/DBA) with a LOD score of 9 was on chr. 4. NZ mice containing Nidd/DBA developed a more severe hyperglycemia, accompanied with hypoinsulinaemia and a loss of adipose tissue. Ongoing analysis of RCS has revealed two interesting loci between 88 - 93 and 107 - 141 Mbp on chr. 4. Through transcriptomics we could determine that in the more proximal locus DBA confers 26 unique missense variants, including 3 frameshift and 4 stop-codon mutations. Additionally, 16 genes contain regulatory region variants that correspond to a differential mRNA expression in peripheral tissues and/or pancreatic islets. Within the distal locus, 90 missense variants are conferred by DBA including 8 frameshift and 7 stop-codon mutations. 175 genes contain regulatory region variants that correspond with differential genetic expression. By repeated backcrossing and characterization of RCS we aspire to narrow down these loci and discover novel T2D susceptibility variants.

1793-P Large-Scale Evaluation of 59 GWAS-Identified Type 2 Diabetes Risk Variants in Adult Chinese
WEI GAN, FIONA BRAGG, IDONA Y. MILLWOOD, ROBIN G. WALTERS, YU GUO, LIMING LI, MARK I. MCCARTHY, ZHENMING CHEN, Oxford, United Kingdom, Beijing, China

Few studies have examined the effects of known T2D risk variants, either individually or collectively using genetic risk scores (GRS), on T2D risk in the Chinese population. We addressed this using data from 82,477 unrelated genotyped participants in the prospective China Kadoorie Biobank (CKB) of 0.5 million adults (http://www.ckbiobank.org) that recoded 4,998 prevalent T2D cases at baseline and 1,412 incident T2D cases over ~7 years of follow-up. Since both impaired β-cell function and insulin resistance (IR) contribute to T2D etiology, we also explored their genetic effects separately by constructing GRS for β-cell dysfunction (GRSβ) and IR (GRSIR).

Of the 59 known T2D risk variants (as genotyped in CKB by Oct 2012), 55 variants showed directionally consistent associations with combined (prevalent + incident) T2D, 36 of them nominally significant (p<0.05). Our study confirmed for the first time the association of ADCY5 rs11708067 with T2D in East Asians (p=0.0046) showing a higher effect size (OR [95% CI]: 1.78 [1.19-2.64] vs. 1.12 [1.00–1.15]), F for difference 0.02, in Chinese than Europeans (MAFs, 0.003 [Chinese] vs. 0.226 [European]). Variants at 7 loci
GENETICS—TYPE 2 DIABETES

[THADA, MAEA, CDKAL1, CDK2A2, TCF7L2, KCNQ1]rs2237892, DUSP9 were associated with incident T2D (P=0.05).

An overall T2D-GRS constructed from 53 variants (GRS_t53) genotyped in the majority of subjects (>80% of subjects) was strongly associated with combined T2D (OR 1.07[1.06–1.08], P=1.3x10^-10). The GRS (25 variants) had a stronger effect than GRS_t6 (6 variants) (OR 1.09[1.08–1.10] vs. 1.05[1.03–1.08], P=0.01). Moreover, both GRS_t53 and GRS_t6 were strongly associated with incident T2D [HR 1.04[1.02–1.05], P=2.1x10^-8; HR 1.05[1.04–1.07], P=5.5x10^-4 respectively]. In summary, our results not only confirmed the associations of most of the previously GWAS-identified loci with T2D but also provided insights into the value of T2D-related GRS with respect to risk stratification in the Chinese population.

Supported By: UK Wellcome Trust; UK Medical Research Council; British Heart Foundation; Cancer Research UK; China IIMT

1794-P

Next Generation Sequencing Methylation Profiling Interactions with Genetic Variation from Lean and Obese Subjects

SAMANTHA E. DAY, JIYON KIM, RICARDO I. COLETTA, LATOYA E. CAMPBELL, LORI R. ROUST, VALENTIN DINU, LAWRENCE J. MANDARINO, DAWK K. COLETTA, TEMPE, AZ; SCOTSDALE, AZ

Obesity has become a critical health concern. Insulin resistance is an underlying metabolic consequence of obesity and type 2 diabetes. The development of insulin resistance has both genetic and environmental components. The role of epigenetic factors, such as DNA methylation, which is the addition of a cytosine-guanine dinucleotide, can cause variations in the genome. When SNPs are present, they can alter gene expression and protein function. Vastus lateralis muscle biopsies were taken in the postabsorptive state, and next-generation sequencing reduced representation bisulfite treatment was performed on the DNA isolated from obese (n=16; BMI=32.9±7.0 kg/m2) and lean (n=12; BMI=23.4±0.7 kg/m2) subjects. From sequencing analysis, over a million methylation sites were captured and of these sites, 1,015 were associated with a SNP. DNA methylation was significantly different (A/A 0±0, A/G 0.37±0.2, G/G 0.78±0.3; P<0.001) at a known site of genetic variation rs7349166 for calpain 10 (CAPN10), which has previously been associated with susceptibility to type 2 diabetes. SNP genotyping was performed for CAPN10 on all subjects, which resulted in lean genotypes 2-A/A, 5-S/A, 5-G/G, and obese genotypes 5-A/A and 5-S/G. The allele was associated with increased blood pressure (A/A 125/78, A/G 123/78, G/G 114/63 mmHg; P=0.05) and trended towards an association with BMI (A/A 30.3±5.3, A/G 28.3±3.5, G/G 23.0±3.2 kg/m2; P=0.08) however, larger cohort studies are necessary to capture all possible associations. This study provides evidence that SNP sites that create an available cytosine allow methylation, and that the SNP rs7349166 may be associated with metabolic disease. This interaction may be the link for further understanding how SNPs act as biomarkers for susceptibility for certain diseases.

Supported By: National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases

1795-P

The DNA Methylation of Single Nucleotide Polymorphism (SNP) -420 in RETN Affects Plasma Resistant in Addition to Its Genotype

HIROSHI ONUMA, YASUHARU TABARA, RYOICHI KAWAMURA, YASUNORI TAKATA, JUNO HASHI, RYUICHI KAWAMOTO, KATSUHIKO KOHARA, TETSURO HIROSHI ONUMA, YASUHARU TABARA, RYUICHI KAWAMURA, YASUNORI THADA, MAEA, CDKAL1, CDK2A2, TCF7L2, KCNQ1

We previously reported that SNP-420 [rs1862513] in the promoter region of the human resistin gene (RETN) was associated with type 2 diabetes (T2D) [Am J Hum Genet 2004]. Plasma resistin was highest in G/G genotype, followed by C/G, and C/C. A cytosine-guanine dinucleotide “CG6” is a possible methylation site of DNA. SNPs affecting Cp6 sequences could affect gene expression. SNP-420 is expected to be this type of Cp6 SNP. The aim of this study is to examine whether methylation at -420 affects plasma resistin.

We analyzed plasma resistin and methylation at -420 in RETN in 2,078 Japanese subjects. The methylation at -420 was highest in C/C genotype, followed by C/G, and C/G. Multiple regression analyses were performed involving plasma resistin as a dependent variable, and age, sex, BMI and hscRP as independent variables in each of SNP-420 genotypes. Methylation at -420 was inversely associated with plasma resistin in C/C and C/G genotype (standardized regression coefficient [β]= -0.24499, P= 0.0001; and β= -0.1247, P= 0.0001, respectively). No association was found in G/G genotype. The multiple regression analyses involving methylation at -420 as a dependent variable and age, sex, BMI, SNP-1093, SNP-537, SNP-420, SNP-358, SNP-157, SNP-299, and SNP+1263 as independent variables revealed that SNP-420 and SNP+1263 were responsible for the methylation. The C-C haplotype defined by SNP-420 C-G and SNP+1263 C-G showed lower methylation than the reference C-G haplotype (P=0.78%, P= 0.00221) suggesting that in addition to SNP-420, SNP+1263 was responsible for the methylation at -420.

In conclusion, whereas plasma resistin was mainly determined by the SNP-420 genotype itself, methylation at -420 could have an additional effect. SNP+1263 also could have the effect on methylation at -420.

1796-P

Genome-Wide Gene-Gene Interaction with Insulin Secretion Loci Reveals Novel Loci Contributing to Type 2 Diabetes Etiology in African Americans

JACOB M. KEATON, MAGGIE C. NG, NICOLETTE PALMER, JAMES PANKOW, MYRIMAN FORMANNE, JAMES G. WILSON, ADOLFO CORREA, LAURA J. RASMUS-SEN-TORVIK, JEROME I. ROTTEN, STEPHEN S. RICH, LINNYE W. WAGENKNEITCH, BARRY I. FREEDMAN, DONALD W. BOWDEN, WINSTON-SALEM, NC; MINNEAPOLIS, MN; HOUSTON, TX; JACKSON, MS; CHICAGO, IL; TORRANCE, CA; CHARLOTTESVILLE, VA

Type 2 diabetes is the metabolic result of defects in insulin secretion and insulin sensitivity, yet most of the −70 genetic loci associated with T2D risk map to insulin secretion/beta cell biology. We hypothesized that insulin resistance loci contribute to T2D risk whilst preserving insulin secretion. The biological interaction between diabetes and insulin resistance loci contributes to T2D risk; however, the genetic interaction between these loci is yet to be determined. To this hypothesis SNPs associated with acute insulin response to glucose (AIR), a dynamic measure of first-phase insulin secretion, in African Americans (AfA) from the IRAS Family Study (n=692 subjects) were tested for genome-wide interaction. Significantly, multiple SNPs in each cohort using logistic regression modeling T2D as the outcome and insulin secretion as a dependent variable and age, sex, BMI, SNP-1093, SNP-537, SNP-420, SNP-358, SNP-157, SNP-299, and SNP+1263 as independent variables resulted in loss of association in the novel AIR interaction tests, while top signals in the established T2D interaction tests were robust against this adjustment (-log(P) mean difference = 2.45 vs. 0.48). Overall the biology of loci interacting with the test SNPs were consistent with their being good candidates for further analysis of their relationship with insulin resistance.

Supported By: National Institutes of Health (R01DK086358)

1797-P

Renal Risk Genotype in APO1L Protects against Diabetes and Diabetic Nephropathy

CHARLES N. ROTTIMI, DANIEL SHIRNER, ADEBOWALE ADEYEMO, BARRY I. FREEDMAN, THE AADM STUDY INVESTIGATORS, BERKELEY, CA; WINSTON-SALEM, NC

In individuals with African ancestry, the recessive genotype G at rs73865319 and the homoyzygous deletion at rs71756713 in the gene APO1L confer increased risk for chronic kidney disease (CKD) and several forms of end-stage kidney disease, but not diabetic nephropathy. We conducted a study to determine why APO1L risk variants for end-stage kidney disease do not associate with diabetic nephropathy. Study samples include African Americans enrolled in the Howard University Family Study (HUFs) - a cross-sectional population-based study (n=988); the Atherosclerosis Risk in Communities Study (ARIC) - a prospective population-based study (n=2,523); the Natural History of APO1L-associated Nephropathy Study (INHANS) - a prospective study of first-degree relatives of patients with non-diabetic end-stage kidney disease (n=882); and West Africans enrolled in the Africa America Diabetes Mellitus Study (AADM) - a cross-sectional case-control study of type 2 diabetes (T2D; n=1,011). We found that the GG genotype was associated with protection against T2D (odds ratio of 0.59), whereas the homoyzygous deletion was not associated with T2D (odds ratio of 1.002). Among individuals with the GG genotype, we observed significant but incomplete protection against...
1798-P **Insights from Functional Analysis of the TCF7L2 locus: PARP-1 Inhibition Rescues Glucose-induced Shortened Lifespan in Caenorhabditis elegans**

Sumei Lu, Shana E. McCormack, Qianghua Xia, Marni J. Falk, Struan F.A. Grant, Philadelphia, PA

**T2D** is one of the most strongly associated type 2 diabetes loci reported to date, although the pathophysiological mechanism by which variation within this gene modulates risk remains poorly understood. It was previously reported that the most abundant specific protein factor to bind across the presumed causal lesion at this locus, rs7903146, was poly (ADP-ribose) polymerase type 1 (PARP-1). This finding was suggestive that PARP-1 activity may influence glucose regulation. Here, we investigated whether targeted PARP-1 inhibition with Olaparib could restore animal health in the setting of hyperglycemia. High glucose concentrations progressively shorten the lifespan of the nematode, *C. elegans*, in part by altering insulin signaling pathways that are well-conserved from *C. elegans* to mammals. We evaluated the lifespan of wild-type (N2 Bristol) animals grown in 16mM or 25mM glucose, levels that would correspond to an estimated HbA1c of 11.7% or 17.3% in human patients, respectively, either alone or in the presence of 100μM Olaparib. Interestingly, significant rescue from glucose-induced short lifespan was achieved with Olaparib. In contrast, Olaparib had no beneficial effect on rescuing animal lifespan in hyperglycemic conditions in a knock-out strain harboring a deletion of the PARP-1 homolog, pme-1.

In summary, these data show that direct PARP-1 inhibition specifically rescues longevity under hyperglycemic stress in *C. elegans*. These findings are suggestive that PARP-1 modulation offers a novel therapeutic approach in the treatment of type 2 diabetes.

---

**1799-P Assessing Pathophysiologic Effects of Genetic Variants Associated with Type 2 Diabetes and Related Traits by Leveraging Compartamental Modeling**

Richard M. Watanabe, David Conti, Anny H. Jiang, Hoodman Allayee, Thomas A. Buchanan, Los Angeles, CA, Pasadena, CA

Little is known about how loci underlying type 2 diabetes (T2D) risk or variation in related traits influence T2D pathogenesis. We used a compartmental model-based (CM) approach to dissect the biology underlying genotype-phenotype relationships and interpret their pathogenic effects. The CM links validated models of glucose (GLU) and insulin kinetics into a single construct able to simulate GLU and insulin profiles from clinical protocols, e.g., oral glucose tolerance test (OGTT). Each parameter in the CM denotes a specific biologic function, thus one or more “genes” can be assigned to one or more model parameters, and simulations performed to assess genetic effects on glucose regulation. Simulations were performed in which the PPARG P12A variant was imposed on a parameter (p3) determining insulin signaling transduction. Genotype-specific p3 values were drawn from a literature-derived population distribution, constrained by gene frequencies, and assuming an additive genetic model. 1000 OGTTs were simulated by randomly selecting a p3 value from the population distribution. Resultant OGTT GLU profiles for the AA genotype tightly clustered in the normal range while GLU profiles for PA and PP genotypes show considerable variability; 3% of PA and 11% of PP genotypes have 2-hour GLU >140 mg/dl. Power analysis based on 3000 replicates of 1000 OGTTs showed 60 min GLU having maximum power to detect association with P12A. We validated the CM-based simulation results by testing the association between P12A and OGTT GLU, adjusting for covariates, in T2D related individuals from the BetaGene study. OGTT 60 min GLU showed strongest evidence for association with P12A (p=0.036), compared to fasting (p=0.55), 30 (p=0.10), 90 (p=0.06) or 120 min (p=0.39), consistent with the model-based power analysis. This study demonstrates that a physiologically-based CM can be used to better understand the pathophysiological implications of genetic variation.

For author disclosure information, see page A810.